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Abstract 
 
Infant rotavirus vaccines have led to substantial reductions in rotavirus gastroenteritis (RVGE) 
hospital admissions and costs, but some studies have reported an elevated risk of 
intussusception, a rare bowel disorder, in vaccinated infants. The aim of this thesis is to 
quantify the potential mortality benefits and intussusception risks of alternative rotavirus 
vaccination schedules in 135 low- and middle-income countries (LMICs). 
The thesis begins with an introduction to the topic and background to the literature and 
concludes with some final reflections on the research and its relevance for informing national 
decisions about vaccine safety and optimal scheduling of rotavirus vaccines. The main body 
of the thesis includes a series of research papers which address specific topics relevant to the 
estimation of mortality benefits and intussusception risks. These include methods for 
estimating: RVGE deaths <5 years of age; RVGE age distributions <5 years; vaccine coverage 
and timeliness; rotavirus vaccine efficacy and waning; and, intussusception incidence, age 
distributions, and case fatality ratios in children <5 years of age. The final research paper 
brings together this evidence and uses a national-level vaccine decision support model to 
estimate the potential rotavirus mortality benefits (averted RVGE deaths <5 years of age) and 
risks (excess intussusception deaths <5 years of age) of 18 possible vaccination schedules in 
135 LMICs. Scenarios with and without age restrictions are evaluated.  
Rotavirus vaccines are found to have a favourable benefit-risk profile in LMICs. Mortality 
benefits and intussusception risks are estimated to vary considerably by country and choice of 
rotavirus vaccination schedule. Schedules involving birth and booster doses could further 
increase benefits and reduce risks, but more research is needed to assess their feasibility, safety 
and impact.  
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1.0 Chapter 1 – Introduction 
 
1.1 Benefits and risks of live oral rotavirus vaccines 
 
Rotavirus is an important cause of gastroenteritis (GE) in children aged <5 years 
globally (1). Two oral rotavirus vaccines (Rotarix® - GlaxoSmithKline, and 
RotaTeq® - Merck & Co.) became available in 2006, and have been introduced in 
over half the countries of the world (2). Many have introduced with donor support 
from the GAVI Alliance, a public-private partnership which provides vaccine finance 
to the world’s poorest countries (3). Post-licensure studies have shown substantial 
reductions in GE hospital admissions (4) but some studies have reported an elevated 
risk of intussusception, a rare bowel disorder, in vaccinated infants (5, 6).  
 
In 2012, my colleagues and I estimated the potential mortality benefits and 
intussusception risks of introducing live oral rotavirus vaccines into the national 
immunization programmes of 158 countries (7). Benefits were estimated in terms of 
averted numbers of rotavirus gastroenteritis (RVGE) deaths aged <5 years. Risks were 
estimated in terms of excess numbers of vaccine-related intussusception deaths aged 
<5 years. This analysis provided a reassuringly favourable benefit-risk profile for 
rotavirus vaccines. It also informed a WHO recommendation to remove age 
restrictions for vaccination (first dose before age 15 weeks, last dose before age 32 
weeks) given that the benefits of preventing additional rotavirus mortality from later 
vaccination greatly exceeded the intussusception risks (8). Since our 2012 analysis, 
estimates of the number of RVGE deaths aged <5 years (without vaccination) have 
decreased considerably from ~450,000 in 2008 to ~200,000 in 2015 (1). The evidence 
for several other inputs has also been significantly strengthened. Consequently, there 
has been a need to update the analysis so that decision makers in low- and middle-
income countries (LMICs) can use the best available evidence to determine whether 
the benefit-risk profile in their country is still in favour of rotavirus vaccine 
introduction and the removal of age restrictions.  
 
1.2 Optimising rotavirus vaccination schedules 
 
Mortality benefits and intussusception risks will be influenced by the choice of 
national rotavirus vaccination schedule. For programmatic and economic reasons 
rotavirus vaccines are currently co-administered with Diphtheria-Tetanus-Pertussis 
(DTP)-containing vaccines in the first six months of life. Most countries recommend 
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two doses of Rotarix® with DTP1 and DTP2, or three doses of RotaTeq® with DTP1, 
DTP2, and DTP3 as per current WHO recommendations. The actual age of 
administration varies between countries due to differences in national schedules 
(target ages for DTP) and differences in the timeliness of vaccination (9). The standard 
infant schedules recommended by WHO have demonstrated high and durable efficacy 
in low mortality countries but modest efficacy in higher mortality settings (10). This 
has stimulated interest in the potential value of a booster dose given with the first dose 
of measles-containing vaccine (MCV1, referred to hereafter as Meas1)(11) or a birth 
dose given at the same time as Bacillus Calmette-Guérin (BCG)(12). A birth dose has 
the potential to prevent disease that occurs very early in life, while a booster dose has 
the potential to mitigate the effects of waning rotavirus vaccine protection, a 
phenomenon observed in several high mortality settings (10). Birth doses also have 
the potential to reduce the number of excess (vaccine-related) intussusception cases 
by administering the first dose earlier in life, when the background risk of 
intussusception is lower. The optimal number and timing of doses (concurrent with 
different combinations of BCG, DTP1, DTP2, DTP3 and Meas1) will depend on 
several criteria, including the balance of benefits to risks i.e. number of RVGE deaths 
averted per excess intussusception death. 
 
1.3 Scope of the thesis 
 
The aim of this thesis is to quantify the potential mortality benefits (averted RVGE 
deaths <5 years of age) and risks (excess intussusception deaths <5 years of age) of 
alternative rotavirus vaccination schedule options in LMICs. The World Bank defines 
low- and middle-income as any country with a GNI per capita below $12,236 in the 
2018 fiscal year (13). The scope is LMICs because the overwhelming majority of 
RVGE deaths and intussusception deaths occur in these countries. In high income 
countries, other factors such as healthcare treatment costs and cost-effectiveness 
become more influential. These factors were beyond the scope of this thesis. 
 
1.4 Style and structure of thesis 
 
Chapter 2 provides an overview and background to the literature on rotavirus, 
rotavirus vaccines, intussusception and benefit-risk modelling. The main body of the 
thesis then includes a series of research papers which address specific topics relevant 
to the estimation of mortality benefits and intussusception risks. These include 
estimation of: RVGE deaths aged <5 years (Chapter 4); RVGE age distributions <5 
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years (Chapter 5); vaccine coverage and timeliness (Chapter 6); rotavirus vaccine 
efficacy and waning (Chapter 7); and, intussusception incidence, age distributions and 
case fatality ratios - CFRs (Chapter 8). The final research paper (Chapter 9) brings 
together this evidence and uses a national vaccine decision support model to estimate 
the potential rotavirus mortality benefits and intussusception risks of 18 possible 
rotavirus vaccination schedules in 135 LMICs. The thesis concludes with some final 
reflections on the research and its relevance for informing national decisions about 
vaccine safety and optimal scheduling of rotavirus vaccines (Chapter 10). 
This is a research-paper thesis rather than the conventional book style. Six of the 
chapters are full research papers. Two have been published in peer-reviewed journals 
(Chapters 4 & 6) and the remaining four (Chapters 5, 7, 8 and 9) have been prepared 
for submission. For consistency between published and unpublished research papers, 
references are listed at the end of each chapter, and the numbering of tables and figures 
is restarted at the beginning of each chapter. Each research-paper chapter begins with 
a short section describing how the paper contributes to the overall aim and objectives 
of the thesis. I have also described my independent academic contribution to each 
paper. This is important to clarify because all papers include contributions from 
others. Relevant funding and ethical approvals are also described. 
Appendices to Chapters 5, 8 and 9 are included at the end of each chapter for ease of 
referencing. Other appendices are included at the end of the thesis, either because they 
contain optional background material (Appendices 1-5, 10), or because they describe 
analyses that were primarily done by others (Appendices 6-9). 
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2.0 Chapter 2 – Review of the literature 
 
2.1 Rotavirus gastroenteritis 
 
Gastroenteritis (GE), characterised by diarrhoea, abdominal cramps, nausea and 
sometimes vomiting, is usually diagnosed when a child experiences three or more 
loose stools, or vomiting, within a 24-hour period (1). Without adequate fluid 
replenishment GE can quickly lead to dehydration, electrolyte imbalance, metabolic 
acidosis, shock and death (2). Descriptions of GE exist as far back as the earliest 
records of human civilisation (3) and its role in child mortality is well documented -  
described in 1940s London as “one of the most fatal diseases of infancy in our 
capital”(4).  
 
In 1973 Ruth Bishop, Geoffrey Davidson, Ian Holmes and Brian Ruck identified a 
high volume of particles of a new virus in the faeces of children admitted to the Royal 
Children’s Hospital (RCH) in Melbourne, Australia. The wheel-like structure seen 
under an electron microscope was the inspiration for the name rotavirus (rota is latin 
for wheel) (5). Prior to this discovery, the causative agents of GE were poorly 
understood. Rotavirus has since been detected in numerous studies around the world 
and is now recognised as a leading global cause of GE hospitalisations in children 
aged <5 years (6).  
 
Rotavirus is detected by testing stool samples, typically with commercially available 
enzyme immunoassays (EIAs). EIAs have proven to be highly sensitive and specific 
and have been the standard test used to detect rotavirus in randomised controlled trials 
(RCTs). Several different strains of rotavirus can cause infection and disease in 
humans. The outer shell of the rotavirus particle contains two important proteins that 
determine the strain; a glycoprotein (G-type) and a protease-sensitive protein (P-type). 
G-types can be reliably identified using EIAs and are known as serotypes. EIA 
serotyping is less reliable for P-types, so these are often determined using a molecular 
technique called Polymerase Chain Reaction (PCR). P-types are also referred to as 
genotypes [represented in square brackets] (7). In 2010, the most common strains 
identified by the Rotavirus WHO surveillance network were G1P[8], G2P[4], G3P[8], 
G4P[8] and G9P[8] with wide variations in strain mix across countries and seasons 
(8). Rotavirus has a clear seasonal pattern in most high income countries, but seasonal 
peaks are less evident in lower income settings, where many countries experience 
year-round disease (9). 
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Following a brief period of protection from maternal antibodies, almost every child in 
the world, irrespective of where they live, will be infected with rotavirus at least once 
before their fifth birthday. The mode of transmission is thought to be faecal-oral, and 
the incubation period (interval between exposure and onset of symptoms) is usually 
less than 48 hours (2). Natural or wild type rotavirus infections (asymptomatic or 
symptomatic) have been shown to provide some protection against subsequent 
moderate-to-severe disease. Important birth cohort studies have been conducted in 
Mexico and India. In Mexico, two prior infections provided complete protection 
against subsequent moderate-to-severe disease (10). In India however, two infections 
provided only 57% protection (and only 79% after three) (11). In both settings, natural 
infections provided limited protection against subsequent asymptomatic infections 
and mild disease. Thus frequent reinfections are probably very common and provide 
the basis for continued circulation. A study in England detected rotavirus in the stools 
of healthy individuals in all age groups (12).  
 
Two point scoring systems have been used to determine the severity of RVGE in 
randomised controlled trials (RCTs), the 20-point ‘Vesikari’ system and the 24-point 
‘Clark’ system (13). Points are awarded for the presence and severity of different 
symptoms e.g. duration of vomiting, duration of diarrhoea, rectal temperature, signs 
of dehydration etc. Nearly all RCTs of rotavirus vaccines define severe RVGE as 11-
20 points on the Vesikari scale. Some older trials use a Clark score of 16-24 points. 
These two scores have been shown to correlate poorly with one another when 
estimating the proportion of RVGE episodes defined as severe (13, 14).  
 
In the scientific literature, the most commonly reported rotavirus disease burden 
indicator is the rotavirus-positive proportion among GE hospital admissions aged <5 
years. Some studies have also reported the rotavirus-positive proportion among cases 
of moderate-to-severe diarrhoea (MSD)(15). Definitions of MSD vary but typically 
the symptoms include three or more loose or liquid stools per day and ‘some’ 
dehydration, defined by WHO as having two or more of the following signs: 
restlessness/irritability; sunken eyes; and thirsty/drinks eagerly. Signs of more severe 
dehydration include lethargy, unconsciousness and a skin pinch that goes back very 
slowly (≥ 2 seconds). Rehydration treatment involves dissolving an inexpensive 
sachet of oral rehydration salts/solution (ORS) in drinking water or making an 
equivalent home preparation (six teaspoons of sugar, half a teaspoon of salt and one 
litre of drinking water). However, because RVGE is often associated with explosive 
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vomiting and diarrhoea, intravenous rehydration (IV) is required in more serious cases 
(16). 
 
Estimates of the number of RVGE deaths <5 years of age vary from ~120,000 to 
~215,000 in the year 2015 (6). Most of these deaths were in Sub-Saharan Africa and 
South Asia, where many children are not promptly or adequately rehydrated. The 
incidence of symptomatic RVGE episodes is thought to be similar across the world, 
and largely unaffected by living standards or hygiene. A meta-analysis of studies 
conducted between 1977 and 2003 estimated 0.24 episodes of RVGE (of any severity) 
per person-year of observation among children aged less than 2 years worldwide (17). 
Assuming most cases occur in the first two years of life, this is roughly equivalent to 
every child in the world having a symptomatic episode of RVGE at least once before 
their fifth birthday. Consequently, large numbers of children require medical 
attention, with potentially significant costs to both households and Governments. A 
study by Clark et al estimated a cost to the English National Health Service (NHS) of 
over £11 million each year (18).  
 
2.2 Rotavirus vaccination 
 
In 1987, Albert Kapikian and colleagues at the US National Institutes of Health (NIH) 
developed RotaShield® (Wyeth-Ayherst), a live attenuated, or weakened, oral 
vaccine based on a human-rhesus (monkey) combination of rotavirus strains. This was 
licensed for use in the USA in 1998 for administration in three doses at 2, 4 and 6 
months of age, but withdrawn in 1999 following association with intussusception, a 
rare but potentially fatal bowel disorder (19).  
 
In 2006, two second generation live attenuated oral vaccines were licensed for use in 
the USA following large-scale efficacy and safety trials (20, 21). The first vaccine, 
Rotarix ® (GlaxoSmithKline) was developed by Richard Ward and David Bernstein 
at the Cincinnati Children’s Hospital and is based on a G1P[8] human strain (22), the 
most common strain in circulation globally (8). This is a two-dose vaccine 
administered at 2 and 4 months of age. The second vaccine, Rotateq ® (Merck), was 
developed at the Wistar Institute and Children’s Hospital of Philadelphia by Fred 
Clark, Paul Offit and Stanley Plotkin. In this vaccine, four human G-types (G1, G2, 
G3, G4) and one human P-type (P[8]) were each combined with a bovine (cow) 
rotavirus strain (WC3) to produce a pentavalent vaccine with five reassorted human-
bovine strains (23). This vaccine is given in three doses at 2, 4 and 6 months of age.  
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A good deal of pre- and post-licensure evidence has now been accumulated on the 
efficacy and safety of Rotarix® and RotaTeq®. Both vaccines have demonstrated 
>90% efficacy against severe RVGE episodes in low mortality settings. However, the 
combined estimate of efficacy from higher mortality countries (Bangladesh, Vietnam, 
Ghana, Kenya and Mali) is only around 67% in the first year of life and 34% in the 
second year of life (24). The reason for lower and less durable efficacy in these 
settings is unclear but has been linked to factors including poorer nutritional status 
and more frequent exposure to a wider range of enteric pathogens (25). Both vaccines 
have demonstrated clinical cross-protection to the major strains not included in the 
vaccines (26), and thus similar efficacy in different settings. It is difficult to compare 
the two vaccines directly as different case definitions and severity scales were used in 
some trials (13) and the two vaccines have never been directly compared in a head-
to-head RCT within the same study population.  However, the post-licensure 
experience of countries that have used both Rotarix® and RotaTeq® does not suggest 
any material difference in impact (27). 
 
In recent years, several manufacturers have emerged from LMICs. In China, LLR® 
(Lanzhou lamb rotavirus vaccine - Lanzhou Institute of Biological Products) is based 
on a single G10P[12] lamb rotavirus strain, and has been sold in the private market 
since 2000. A case control study of LLR® in China reported effectiveness of 43% for 
a single dose administered between 2 and 35 months of age (28). In Vietnam, 
Rotavin® (POLYVAC-Vietnam) is based on an attenuated human G1P[8] strain 
isolated from a Vietnamese child. This vaccine was licensed for use after 
demonstrating comparable immunogenicity to Rotarix® among Vietnamese infants 
(29). In India, two vaccines have been developed. ROTAVAC® (Bharat Biotech 
International, India) was recently WHO pre-qualified for global use (30). This is based 
on a naturally attenuated human-bovine (cow) strain (II6E) isolated from an Indian 
infant by Maharaj K Bahn and colleagues at the All India Institute of Medical Sciences 
(AIIMS) in Delhi (31). This vaccine demonstrated 54% efficacy against severe RVGE 
in Indian infants and is priced at less than $3 per three-dose course. This is 
considerably lower than the price of Rotarix® and RotaTeq®. A bovine-human 
reassortant pentavalent rotavirus vaccine (BRV-PV) called ROTASIIL® (Serum 
Institute of India) is also licensed for use in India. This has demonstrated 38% efficacy 
against severe RVGE in India, and 65% efficacy in Niger (32, 33). This vaccine may 
also be WHO pre-qualified for global use soon.  
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Several others rotavirus vaccines are also in the pipeline, including neonatal and non-
replicating injectable vaccines (34, 35). An oral neonatal vaccine, RV3-BB (Murdoch 
Children’s Research Institute - MCRI, Australia) has shown to be efficacious in 
Indonesia when administered as a three-dose series (36). This has the potential to 
increase vaccination coverage and potentially reduce vaccine-related intussusception 
events by allowing the first dose to be administered earlier in life when the 
background rate of intussusception is low. Other vaccines in the pipeline include non-
replicating injectable vaccines (35). These could prove to be safer and more 
efficacious than existing live oral vaccines, but more clinical evidence will be needed 
to confirm this. 
 
2.3 Rotavirus vaccination and intussusception 
 
Intussusception is the main cause of bowel obstruction in children aged <5 years. It 
occurs when a segment of the intestine telescopes or folds back on itself (43). This 
blocks the passage of food and liquid through the intestine and restricts the supply of 
blood to the affected area. Some cases of intussusception will spontaneously resolve 
without treatment, but delayed diagnosis can lead to perforation and infection in the 
lining of the abdominal cavity: peritonitis. Peritonitis can cause severe abdominal 
pain, fever, shock and death (44). In high income countries most children are 
diagnosed quickly with ultrasound or radiograph and the bowel will return to normal 
after injecting a liquid or gas into the rectum (enema). In more severe cases surgery 
is usually very successful. However, in parts of Africa and other high mortality 
settings, enemas are less common due to a lack of imaging equipment and expertise, 
and because many children will present very late to hospital in a severe condition (37). 
In these cases, surgery is often the primary method of diagnosis and treatment, leading 
to death in ~10% of African children that reach hospital (45). The cause of 
intussusception is usually unclear, but infections that cause swelling in the bowel wall 
may be associated (46). 
 
Intussusception occurs naturally in the absence of vaccination, but the risk appears to 
be slightly elevated shortly after rotavirus vaccination in some studies. The first 
rotavirus vaccine, RotaShield® (Wyeth-Ayherst) was voluntarily withdrawn from the 
market in 1999 when an elevated risk of intussusception was detected among 
vaccinated infants in the USA (19). The risk was equivalent to one additional case in 
every 5,000-10,000 vaccinated infants. There is now enough accumulated evidence 
from post-licensure studies to suggest that both Rotarix® and RotaTeq® are also 
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associated with an increased risk of intussusception in some settings (38, 39). While 
the scale of risk associated with Rotarix® and RotaTeq® is believed to be smaller 
than the risk observed for RotaShield®, a true comparison is not possible because 
both vaccines have been administered within age windows designed to avoid the 
background peak age of intussusception. Many of the vaccines administered in the 
RotaShield® programme were administered as part of a catch-up campaign, so were 
administered to older infants when the background incidence of intussusception was 
high (40). To limit the scale of potential vaccine-related intussusception cases the two 
major vaccine manufacturers have recommended different age restrictions tailored to 
their own vaccines. The aim of these age restrictions is to ensure the vaccine is 
administered earlier in life, when the background incidence of intussusception is 
lower. The WHO harmonised the different manufacturers’ age restrictions and 
recommended administration of the first dose before 15 weeks of age and the final 
dose before 32 weeks of age (24). Following a modelling analysis in 2012, the WHO 
revised their recommendation to allow countries to remove age restrictions in 
countries where the benefits of later vaccination would greatly exceed the risks (24, 
41). 
 
An excess or vaccine-related case of intussusception is defined by WHO as an adverse 
event following immunization (AEFI). Intussusception is a ‘serious’ adverse event 
because it has the potential to lead to hospitalisation and death. Serious adverse events 
are included within the wider spectrum of all severe adverse events (SAE). SAEs also 
include severe reactions that are not life-threatening. The distinction between 
‘serious’ and ‘severe’ is important; serious is a regulatory term whereas severe is not 
(42). 
 
Different study designs have been used to detect any potential relative risk of 
intussusception following vaccination, but because intussusception is such a rare 
event, these studies are often not powered for reliable detection of an increase in risk. 
The self-controlled case series (SCCS) methodology is considered to be relatively 
reliable and has been widely used (5). In this method, children with intussusception 
act as their own controls. The risk of intussusception is calculated for the period of 
hypothesised elevated risk (i.e. 21 days following vaccination) and then compared to 
the risk of intussusception in all other periods, with appropriate adjustment for age 
(43). Intussusception risk is expressed as the relative incidence (RI) or relative risk 
(RR) compared to the expected background incidence in the absence of vaccination. 
A meta-analysis of Rotarix® studies by Stowe et al found pooled RI estimates of 2.4 
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(95% confidence interval 1.5 - 3.8) and 1.8 (1.3 - 2.4) in the 21 day period after the 
first and second doses, respectively (44). Similar risks have also been reported for 
RotaTeq® in the USA (39) and Australia (38).  The estimates for Rotarix® and 
RotaTeq® in Australia were equivalent to one additional case in every 14,000-20,000 
vaccinated infants, but studies from other settings have reported a lower level of risk, 
and none have reported a risk as high as RotaShield® (one in every 5,000-10,000 
vaccinated infants). Encouragingly, a recent SCCS study of Rotarix® in Africa found 
no elevated risk of intussusception in the first 1-7 days after dose 1 (RI 0.30, 95% CI 
0.0 - 1.0) or dose 2 (RI 0.8, 95% CI 0.2 – 1.7) and no elevated risk 8-21 days after 
dose 1 (RI 1.0, 95% CI 0.3 – 2.3) or dose 2 (RI 0.7, 95% CI 0.4 – 1.2). This was a 
multi-site study including infants from seven countries (Ethiopia, Ghana, Kenya, 
Malawi, Tanzania, Zambia, and Zimbabwe) (45).  
 
2.4 Published studies evaluating the benefits and risks of rotavirus vaccination 
 
In 2012, Patel et al estimated the potential mortality benefits and intussusception risks 
of introducing live oral rotavirus vaccines into the 2010 birth cohort of 158 countries 
(24). This study updated an earlier analysis conducted in 2009 based on 117 countries 
(46). The 2012 study found that with full adherence to the manufacturers’ age 
restrictions, universal introduction of rotavirus vaccination would prevent 156,000 
RVGE deaths and cause 253 deaths (benefit-risk ratio of ~600:1). Without age 
restrictions, rotavirus vaccines were estimates to prevent 203,000deaths and cause 547 
deaths (benefit-risk ratio of ~370:1). The study therefore found that removing age 
restrictions from a standard infant schedule co-administered with DTP would prevent 
an additional ~47,000 RVGE deaths and potentially cause an additional ~300 
intussusception deaths each year (incremental benefit-risk ratio of 154:1)(24). This 
study informed a WHO recommendation to remove the manufacturers’ age 
restrictions for vaccination given that the benefits of preventing additional rotavirus 
mortality from later vaccination greatly exceeded the intussusception risks (41). The 
2012 publication (Appendix 1) and WHO position paper (Appendix 2) are available 
in the list of appendices.  
 
Several other benefit-risk analyses have also been published. A multi-country analysis 
for all countries in Latin America estimated a benefit-risk ratio of 395:1 (47), while 
in a study in Brazil and Mexico the estimate was 260:1 (48). The benefit-risk ratio 
was estimated to be 88:1 in England (18), 273:1 in France (49), 77:1 in the USA (50) 
and  366:1 in Japan  (51). Other high income countries have calculated benefits and 
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risks for hospitalisations, but not mortality (38). In higher income countries, mortality 
from both rotavirus and intussusception is very rare, and other criteria become more 
important. In England, Clark et al estimated that Rotarix® would cause one additional 
intussusception admission in every 18,551 vaccinated English infants (5th and 95th 
percentiles, 6,728 - 93,952), equivalent to 35 additional intussusception admissions 
each year. In contrast, it was estimated that each year the vaccine prevented three 
rotavirus deaths, 13,000 rotavirus admissions, 27,000 rotavirus emergency visits and 
74,000 rotavirus GP consultations in children aged <5 years, with lead to annual 
savings of over £11 million. There were 375 fewer RVGE admissions for every 
additional intussusception admission (18).  
 
All studies evaluating the benefits and risks of rotavirus vaccination have used a 
relatively simple and conservative modelling approach, excluding any estimation of 
the indirect effects of vaccination. Most of the studies have justified this on the basis 
that if the benefit-risk profile is favourable without herd effects, then it would only be 
more so if those additional benefits were included. Not all studies have captured the 
potential risk in the 1-7 day, 8-21 day windows following administration of both of 
the first doses, and not all studies have presented probabilistic uncertainty intervals 
around their central estimates. All studies have assumed that the relative risks do not 
vary with age, implying that the absolute number of excess cases is heavily dependent 
on the background incidence of intussusception at the time of vaccine administration. 
 
2.5 Modelling considerations for predicting the benefits of rotavirus vaccination 
 
There are several aspects of a model’s structure or design which, if excluded, could 
lead to incorrect assessment of the scale of vaccination impact. Several systematic 
reviews have evaluated the different characteristics of rotavirus vaccine impact 
models in the context of economic evaluations and cost-effectiveness analysis (CEA). 
A review of economic evaluations by Bilcke and Beutels identified 17 unique models 
globally, of which only ten (59%) included a realistic RVGE age distribution, nine 
(53%) included partial vaccine protection, seven (41%) included waning duration of 
protection and none (0%) accounted for transmission dynamics, e.g. herd effects (52). 
A subsequent review of models in developing countries by Tu et al identified 15 
models of which only two (13%) included partial immunity acquired from wild-type 
(natural) infections and none (0%) accounted for herd immunity effects (53). Another 
review (Aballea et al, Sanofi Pasteur) identified 68 studies (15 unpublished). 
Seasonality was included in five (7%) of the studies, but was shown to have a minimal 
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influence on vaccine impact estimates. In contrast, waning duration of protection was 
shown to have an important influence in some of the analyses. Only one (2%) of the 
models explicitly modelled the natural history of disease and associated herd effects 
(54). Postma et al compared estimates from three models and attributed differences in 
results to assumptions about dose-specific vaccine efficacy, waning duration of 
protection and the level of immunity acquired from natural infections (55). The 
timeliness of vaccination was shown to be influential in a cost-effectiveness study by 
Clark et al in Peru. This analysis showed that ignoring delays and assuming ‘on-time’ 
vaccination would over-estimate health benefits by 4% (56). An analysis of delays in 
45 other countries by Clark and Sanderson showed that Peru’s immunization 
programme is relatively timely compared to others, so this error is likely to be greater 
in countries with more pronounced delays (57).  
 
Unlike static cohort models, transmission dynamic models are able to predict the 
number of susceptible, infectious and immune individuals over time. These models 
are also able to capture the interplay between immunity acquired from vaccination 
and immunity acquired from repeated natural (wild type) infections. Models of this 
kind typically require assumptions to be made about the number of individuals 
exposed by each infectious individual (also known as the basic reproductive number 
or R0), the duration of immunity acquired from natural infections, and further 
assumptions about who acquires infection from whom (WAIFW). Pitzer et al 
described five rotavirus transmission dynamic models that were each calibrated to the 
same age-specific RVGE incidence data from England and Wales (58). All five 
models simulated the flow of groups of individuals into different compartments 
(health states) over time using differential equations. A pivotal study by Velasquez et 
al was used to inform estimates of protection from 1 up to 4 natural infections against 
subsequent infections and disease episodes (10). Estimates of R0 varied considerably 
between the five models, ranging from ~1 to 26 secondary exposures per infectious 
individual. Discrepancies between the model predictions reflected uncertainties in the 
age-specific risk of RVGE infections, and the duration of natural and vaccine-induced 
immunity. However, over the long-term (5 years post-vaccination), all of the models 
predicted impact among children aged <5 years that was broadly similar to what 
would have been predicted by direct effects alone, based on a simple multiplication 
of age-specific disease, vaccine coverage and efficacy. Park et al subsequently 
evaluated the potential impact of ROTASIIL® vaccination in Niger using the same 
set of transmission models that were compared by Pitzer et al. An ensemble approach 
with Bayesian averaging was used to give greater weight to model structures with a 
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better fit to the local data. The authors found a marginal role for herd effects in 
explaining overall impact (~1% of the total long-term impact in children aged <5 
years) (59). This is consistent with the findings of a study by Rose et al in India (60). 
In this study a sophisticated individual-based transmission dynamic model was 
developed, and informed by data from a pivotal birth cohort study by Gladstone et al. 
Using this data, the model accounted for protection from 1 to 4 natural infections 
against subsequent infections and disease episodes (11), and predicted that 
introduction of ROTAVAC ® would lead to a 35% reduction in rotavirus deaths aged 
<5 years. This was almost identical to the impact estimated by two much simpler 
models, leading the authors to conclude that simpler approaches would be adequate 
for estimating the potential impact on mortality among children aged <5 years in this 
setting. 
 
Real-world post-licensure studies have produced conflicting results about the level of 
impact among unvaccinated children. While there is evidence of short-term herd 
effects in high income settings, evidence from LMICs is relatively sparse (61). Short-
term decreases in RVGE hospital admissions have been observed among children too 
old to be vaccinated in El Salvador (62), Ghana, Moldova (63) and Rwanda (64). 
However, no substantial herd effect was observed in Malawi (65), South Africa (2), 
Tanzania (63) or Zambia (66), and even where studies have reported short-term 
indirect benefits, uncertainties remain about whether these will be sustained over the 
longer-term.  
 
2.6 Ethical considerations in the context of rotavirus vaccination 
 
When the first rotavirus vaccine (RotaShield®) was voluntarily removed from the 
market in the USA, ethicists argued that “the future of a potentially lifesaving vaccine 
for developing countries has been imperilled by its recent withdrawal”. A central 
argument was that inaction was not a morally neutral state, and that “if one is culpable 
for vaccine related deaths, then one is also culpable for deaths caused by withholding 
the vaccine.” (67). This concept is akin to a well-known thought experiment in ethics 
known as the trolley or tram problem  (68).  In this experiment a tram is about to kill 
five people, but pulling a lever can divert the tram on to another track where only one 
person will be killed.  
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Graphical depiction of the trolley problem 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Source: https://i0.wp.com/moralarc.org/wp-content/uploads/2015/04/trolley-problem.jpg?w=620 
 
Another variation is that a person is pushed from a bridge into the path of the tram, 
again saving five lives at the expense of one. The moral dilemma is a choice between 
inaction and intervention. Utilitarianism (the greatest good for the greatest number) 
would favour intervention (69). In the context of rotavirus vaccination this would 
mean favouring schedule options that maximise the net number of deaths prevented, 
irrespective of whether large number of intussusception deaths are caused in the 
process. This raises important ethical considerations and is contrary to the public 
health principle ‘first do no harm’ (67). It also fails to consider uncertain 
consequences that could be associated with taking action. For example, an increase in 
high profile legal challenges and anti-vaccine sentiment could have an adverse effect 
on the coverage of rotavirus vaccines, and potentially other vaccines. In England, 
concerns about the safety of whole-cell pertussis and MMR (measles mumps and 
rubella) vaccines have previously led to substantial short-term declines in coverage 
(65). There is also some evidence that a death caused by action/intervention may be 
perceived by individuals as worse than a death caused by inaction (70, 71). 
 
Herbert Simon made a distinction between substantive rationality, choosing the 
outcome with the maximum mathematical utility, and procedural rationality, allowing 
decision makers to reject options that do not meet minimum standards (72). In terms 
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of rotavirus vaccination, this would imply a maximum level of acceptable risk, above 
which the vaccination programme would not be socially acceptable. The risk 
associated with RotaShield® in the USA (more than one excess intussusception cases 
in every 10,000 vaccinated infants) provides an important psychological benchmark 
for what might be considered a maximum level of acceptable risk. Fine and Clarkson 
have argued that the level of acceptable risk will differ depending on whether the 
choice is made by individuals (more likely to choose lower uptake) or public health 
decision-makers representing the community as a whole (more likely to choose higher 
uptake) (73). Another benchmark that could be used to inform a socially acceptable 
risk for rotavirus vaccines is the level of risk that has been accepted for other vaccines. 
However, combining this evidence is not straightforward. The WHO provides 
reported reaction rates for each vaccine formulation but the spectrum of possible 
adverse effects is broad and the uncertainty intervals around the risks are wide. For 
BCG vaccine, the risk of disseminated BCG disease (fatal in 50% of cases) is reported 
to be less than one in every 200,000 vaccinated infants. For the first dose of oral polio 
vaccine (OPV) the risk of vaccine associated paralytic poliomyelitis (VAPP) is one in 
every 750,000 vaccinated infants. For Measles and DTP vaccines, rates of febrile 
seizures are relatively common (one in every ~3000 doses) but these are rarely fatal 
(42, 74). Resnik has argued that the maximum level of acceptable risk should not 
exceed the maximum risk of death for high risk forms of paid labour, such the 
mortality risks among fishermen, loggers and extraction workers. He went on to 
suggest this as one possible approach for determining the maximum acceptable risk 
among paid volunteers in clinical trials. The maximum acceptable risk of a serious 
adverse event could then be derived by combining the maximum acceptable mortality 
risk with the CFR for the serious adverse event in question (75). This approach has 
obvious limitations if applied to the example of rotavirus vaccination because the 
focus is on adults and paid participation.  
 
For rotavirus vaccination, the maximum acceptable risk will be inextricably linked to 
the scale of potential benefits and for this reason, it would be very difficult for national 
decision-making committees to set universal thresholds for maximum acceptable risk. 
A minimum threshold for the balance of benefits to risks (minimum benefit-risk ratio) 
could however be developed, and may lead to more consistent decision-making across 
vaccines. The Global Advisory Committee on Vaccines Safety (GACVS) and 
Strategic Advisory Group of Experts (SAGE) are the principal advisory groups to 
WHO on issues around the safety and acceptability of rotavirus vaccines, and 
ultimately the committee members will have to make value judgements and 
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recommendations informed by the best available evidence on benefits and risks, as 
well as other criteria including costs, cost-effectiveness and operational feasibility 
(76). 
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3.0 Chapter 3 - Aim and objectives of thesis 
 
3.1       Aim 
 
The aim of this thesis is to estimate the potential mortality benefits (averted RVGE 
deaths aged <5 years of age) and risks (excess intussusception deaths <5 years of age) 
of alternative rotavirus vaccination schedules in LMICs. 
 
3.2  Objectives 
 
The objectives are: 
 
1. To review national estimates of RVGE deaths <5 years of age, in the absence of 
rotavirus vaccination, in LMICs (Chapter 4); 
2. To estimate the age distribution of RVGE cases, outpatient visits, hospitalisations 
and deaths <5 years of age in the absence of rotavirus vaccination and extrapolate 
to LMICs without data (Chapter 5); 
3. To estimate the timeliness of BCG, DTP1, DTP2, DTP3 and Meas1 vaccination 
in countries with household surveys, and extrapolate to LMICs without data 
(Chapters 6 and 9); 
4. To estimate the efficacy of rotavirus vaccination by duration of follow-up and 
type of setting (Chapter 7); 
5. To estimate the incidence, age distribution and case fatality of intussusception 
hospital admissions in children <5 years of age, and establish methods to 
extrapolate to LMICs without data (Chapter 8); 
6. To estimate the relative risk of intussusception in the 1-7 day and 8-21 day period 
following administration of the first two doses of rotavirus vaccination, and 
generate pooled estimates for use in benefit-risk analysis (Chapter 9); and, 
7. To develop a transparent static cohort model to simulate the experience of infants 
born in the 2015 birth cohort in 135 LMICs. The model will be used to estimate 
the number of RVGE deaths, intussusception cases and intussusception deaths in 
each week of age between birth and age 5.0 years, with and without rotavirus 
vaccination, for 18 alternative schedule options (Chapter 9). 
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4.0 Chapter 4 - Estimation of rotavirus deaths in children aged <5 years 
 
4.1 Contribution of paper to the aim and objectives of the thesis 
 
Estimates of the number of rotavirus deaths in the absence of vaccination are needed 
as a basis for predicting the potential mortality benefits of rotavirus vaccination. Three 
prominent research groups (WHO/CDC, CHERG/MCEE and GBD/IHME) have 
published global estimates of the number of RVGE deaths aged <5 years, but there 
are substantial differences in these estimates. The paper identifies reasons for the 
differences in estimates and some important limitations. In particular, acute watery 
diarrhoea may be responsible for a higher proportion of diarrhoeal hospital admissions 
than diarrhoeal deaths. Thus, applying rotavirus-positive proportions among 
hospitalisations to deaths could lead to over-estimates of RVGE deaths aged <5 years. 
Each group has subsequently shared updated estimates for the year 2015. The three 
updated estimates were used to calculate a mean and 95% confidence interval for each 
country in the benefit-risk analysis (Chapter 9). 
 
4.2 Independent academic contribution 
 
I was asked to chair a WHO working group to bring together the three groups, 
compare approaches and propose improvements for future estimates. My task was to 
compare the publicly available spreadsheet estimates of national, regional and global 
rotavirus mortality estimates, review the documented methods, explain the reasons for 
differences and propose improvements for future estimates. I gathered the datasets, 
ran the statistical analysis for the comparison exercise and wrote the first draft of the 
paper. In addition to my analysis, several gaps in the evidence were identified at an 
early stage in the process, and new analyses were done by others to help bridge these 
gaps. This included estimating the proportion of diarrhoea deaths and admissions due 
to acute watery diarrhoea, estimating the rotavirus attributable fraction among 
rotavirus hospitalisations, and the extent to which this varies depending on the type 
of diagnostic test used. The analyses done by others involved new analysis of the 
Global Enteric Multicenter Study (GEMS) database, the WHO Global Rotavirus 
Surveillance Network (GRSN) database, and other datasets.   
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4.3 Ethical approval 
 
Appendix 3 (Chapter 4, S1 Table, Information about the data used for new analyses) 
describes the ethical approvals obtained by all collaborators/co-authors involved in 
this work. I did not seek LSHTM ethical approval for my contribution to the paper 
because my analysis was based on publicly available datasets and published papers in 
the public domain. I had no access to files with patient identifiable data and did not 
analyse or have access to any primary databases.  
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Abstract
Background
Rotavirus is a leading cause of diarrhoeal mortality in children but there is considerable dis-
agreement about how many deaths occur each year.
Methods and findings
We compared CHERG, GBD and WHO/CDC estimates of age under 5 years (U5) rotavirus
deaths at the global, regional and national level using a standard year (2013) and standard
list of 186 countries. The global estimates were 157,398 (CHERG), 122,322 (GBD) and
215,757 (WHO/CDC). The three groups used different methods: (i) to select data points for
rotavirus-positive proportions; (ii) to extrapolate data points to individual countries; (iii) to
account for rotavirus vaccine coverage; (iv) to convert rotavirus-positive proportions to rota-
virus attributable fractions; and (v) to calculate uncertainty ranges. We conducted new anal-
yses to inform future estimates. We found that acute watery diarrhoea was associated with
87% (95% CI 83–90%) of U5 diarrhoea hospitalisations based on data from 84 hospital sites
in 9 countries, and 65% (95% CI 57–74%) of U5 diarrhoea deaths based on verbal autopsy
reports from 9 country sites. We reanalysed data from the Global Enteric Multicenter Study
(GEMS) and found 44% (55% in Asia, and 32% in Africa) rotavirus-positivity among U5
acute watery diarrhoea hospitalisations, and 28% rotavirus-positivity among U5 acute
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watery diarrhoea deaths. 97% (95% CI 95–98%) of the U5 diarrhoea hospitalisations that
tested positive for rotavirus were entirely attributable to rotavirus. For all clinical syndromes
combined the rotavirus attributable fraction was 34% (95% CI 31–36%). This increased by a
factor of 1.08 (95% CI 1.02–1.14) when the GEMS results were reanalysed using a more
sensitive molecular test.
Conclusions
We developed consensus on seven proposals for improving the quality and transparency of
future rotavirus mortality estimates.
Introduction
Rotavirus is a leading cause of diarrhoeal mortality in children less than five years old (U5),
but there is considerable disagreement about how many rotavirus deaths occur each year.
Recent estimates from different sources range from ~120,000 to ~215,000 [1–3]. Accurate
rotavirus mortality estimates help governments and donors prioritise public health interven-
tions and provide a basis for assessing the impact of immunization on mortality rates. Conflict-
ing estimates from different sources create confusion and can delay the introduction of
important diarrhoea mortality prevention measures, such as rotavirus vaccines.
In recent years, three groups have produced estimates of rotavirus deaths:
1. CHERG—the Child Health Epidemiology Reference Group of the World Health Organiza-
tion (WHO) and UNICEF. CHERG is now referred to as MCEE—the Maternal and Child
Epidemiology Estimation group;
2. GBD—the Global Burden of Disease Study, a collaboration led by the Institute for Health
Metrics and Evaluation (IHME); and,
3. WHO/CDC—the WHO and Centers for Disease Control and Prevention (joint estimates).
A meeting coordinated by WHO (Geneva, March 2015) facilitated the initial discussions on
the differences between the currently available rotavirus mortality estimates. This work builds
on a previous assessment of differences between CHERG and GBD estimates of all-cause U5
diarrhoea deaths [4]. Several gaps in the evidence were identified at an early stage in the pro-
cess, and one important task was to conduct new analyses to help bridge these gaps. First, rota-
virus is not associated clinically with acute bloody (dysenteric) diarrhoea and rarely with
persistent diarrhoea (of 14 days duration or more). As a result, many of the rotavirus-positive
proportions reported in hospital surveillance networks, and in the literature, exclude these
cases, and simply report the rotavirus-positive proportion among hospitalised children with
acute watery diarrhoea. If this proportion is applied to all episodes of diarrhoea resulting in
hospitalisation, it will result in overestimates. Second, there is very limited evidence to inform
whether the distribution of clinical syndromes for U5 diarrhoea hospitalisations (% acute
watery, % acute bloody, % persistent) is similar to, and thus a reasonable proxy for, the distri-
bution of clinical syndromes for U5 diarrhoea deaths. Most approaches assume that rotavirus-
positivity among diarrhoea hospitalisations is a reasonable proxy for rotavirus-positivity
among diarrhoea deaths. However, the two proportions are rarely reported in the same study
population. Third, to date there has been no explicit quantification of the rotavirus attributable
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fraction among U5 diarrhoea hospitalisations, or the extent to which that varies depending on
the type of diagnostic test used.
The aim of this manuscript is to compare the existing rotavirus mortality estimates, explain
the reasons for differences, provide evidence to inform key areas of uncertainty, and propose
improvements for future estimates.
Methods
We used a range of methods and sources of data. First, we compared existing estimates of U5
rotavirus deaths at the global, regional and national level and identified key differences in the
approaches used. Second, we used data from a large number of hospitals to estimate the pro-
portion of U5 diarrhoea hospitalisations that were acute watery, acute bloody and persistent.
Third, we used data from verbal autopsy studies to estimate the proportion of U5 diarrhoea
deaths that were acute watery, acute bloody and persistent. Fourth, we calculated the propor-
tion of U5 diarrhoea hospitalisations and U5 diarrhoea deaths that were rotavirus-positive in
each of the African and Asian sites included in the Global Enteric Multicenter Study (GEMS).
Fifth, we used data from GEMS to estimate the proportion of rotavirus-positive U5 diarrhoea
hospitalisations that were entirely attributable to rotavirus, and quantified the increase in the
rotavirus attributable fraction when a more sensitive molecular test was used to determine
rotavirus-positivity.
All data used in this study were anonymized prior to access and analysis. Please see support-
ing information (S1 Table) for details about institutional ethical approvals, and how and where
the data were collected.
U5 rotavirus deaths: Comparison of estimates from GBD, CHERG and
WHO/CDC
An independent reviewer (AC) compared the methods and data files published by the Global
Burden of Disease 2013 Study (GBD 2013) [1, 5], CHERG [2, 6] and WHO/CDC [3, 7]. GBD
provided a data file with country specific estimates of U5 rotavirus deaths [8].
We compared global, regional and national estimates of U5 deaths, U5 diarrhoea deaths
and U5 rotavirus deaths for the year 2013 using a standard list of 186 countries (S1 File).
CHERG did not report country estimates of U5 rotavirus deaths, so we multiplied country
estimates of U5 diarrhoea deaths for the year 2013 by regional estimates of the proportion of
U5 diarrhoea deaths due to rotavirus, as reported by CHERG for the year 2010. We removed
two countries from the GBD list (Taiwan, Palestine) and seven from the WHO/CDC list
(Cook Islands, Monaco, Nauru, Niue, Palau, St Kitts and Nevis, San Marino, Tuvalu) because
they did not appear in both GBD and WHO/CDC datasets. GBD, CHERG and WHO/CDC
used different classifications for grouping countries. For the purpose of this comparison exer-
cise, all countries were grouped using the WHO classification system i.e. AFRO, AMRO,
EMRO, EURO, SEARO, WPRO [9].
Clinical syndromes of U5 diarrhoea hospitalisations: Acute watery, acute
bloody, persistent
To estimate the proportion of U5 diarrhoea hospitalisations that were acute watery, acute
bloody and persistent, we used data from 84 hospitals in 9 countries:
1. 50 hospitals (5 in Indonesia, 42 in Rwanda and 3 in Zambia) from the WHO-coordinated
Global Sentinel Site Rotavirus Surveillance Network—GRSN [10];
Estimating rotavirus deaths in children aged <5 years
PLOS ONE | https://doi.org/10.1371/journal.pone.0183392 September 11, 2017 3 / 18
2. 7 hospitals from the Indian National Hospital Rotavirus Surveillance Network—NRSN
(Delhi, Hyderabad, Kolenchery, Ludhiana, Tirupati, Trichy and Vellore); and;
3. 27 hospitals included in the Global Enteric Multicenter Study—GEMS (1 in Bangladesh, 4
in India, 6 in Gambia, 10 in Kenya, 6 in Mozambique). Methods for recruiting and enroll-
ing moderate-to-severe diarrhoea (MSD) cases in GEMS have been described in detail else-
where [11]. We included 5 of the 7 GEMS sites in this particular analysis. Mali and Pakistan
were excluded because they rarely hospitalised children [12].
To be included, sites had to be major paediatric hospitals or district hospitals with100
children aged<5 years hospitalised for diarrhoea. For GEMS sites, inpatients included chil-
dren with inpatient status at enrolment as well as children who were admitted after enrolment.
Data had to be available for the full 12 months of the year (to account for rotavirus seasonality)
and obtained before the introduction of rotavirus vaccination. Diagnoses were grouped into
acute watery, acute bloody and persistent diarrhoea based on coding systems in place in the
country and site. Acute syndromes were<14 days in duration, and persistent were14 days.
All GRSN, NRSN and GEMS sites excluded patients who were defined as “persistent” at the
time of enrolment, but included patients who became persistent after enrolment. Paediatric
logbooks were reviewed in the Indian NRSN sites and Indonesian GRSN sites. Cases were
excluded (2% in India, 8% in Indonesia) if there was not enough information in the logbook to
categorise them. Electronic discharge data were used in Rwanda and Zambia so all cases had
to be coded into a category.
The Stata 14 command metaprop was used for meta-analysis of the proportion of U5 diar-
rhoea hospitalisations associated with acute watery diarrhoea (AWD), with random effects
and exact confidence intervals [13].
Clinical syndromes of U5 diarrhoea deaths
The clinical syndromes for U5 diarrhoea deaths were assessed using published verbal autopsy
data from 5 demographic surveillance sites in Bangladesh, Ethiopia, Pakistan, Tanzania and
Uganda [14] and verbal autopsy data from 4 sites in Cameroon, Malawi, Niger and Nigeria
(Henry Kalter personal communication). The data came from investigation of child deaths
identified in a household survey, including deaths in the community or a health facility, using
the birth history method with follow-up questions to family members of the deceased child
(S1 Table). All data sources included children aged<5 years and covered a period of at least
12 months, so they reflect all seasons.
The Stata 14 command metaprop was also used for meta-analysis of the proportion of U5
diarrhoea deaths associated with AWD, with random effects and exact confidence intervals
[13].
Rotavirus-positive proportion in U5 diarrhoea hospitalisations and U5
diarrhoea deaths in GEMS
We calculated the rotavirus-positive proportions among MSD cases aged<5 years who were
admitted to hospital in 6 of the 7 country sites included in GEMS, using the conventional EIA
(Enzyme immunoassay) test results. We excluded Mozambique because there was an unusu-
ally high number of positive samples in healthy controls, and only 55% of the rotavirus-
positive cases and 7% of the rotavirus-positive healthy controls were shown to be rotavirus-
positive on retesting with a different EIA test kit.
We calculated rotavirus-positive proportions separately for acute watery diarrhoea and all
clinical syndromes combined (acute watery, acute bloody and persistent cases). In GEMS, if
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more than 9 children with MSD were identified in a fortnight, only the first 9 children were
enrolled and tested for rotavirus; the remainder were recorded on a log and assumed to have
the same rotavirus-positive proportion as enrolled cases that were identified in the same fort-
night, age stratum (0-11m, 12-23m, 24-59m) and diarrhoea syndrome (acute watery, acute
bloody, persistent).
We also calculated the proportion of U5 deaths that: a) tested positive for rotavirus within 7
days of death; and, b) had diarrhoea coded as the first or second cause of death on their verbal
autopsy (VA) report. Rotavirus-positive children with a missing VA report (~20%) were
assumed to have the same cause-of-death breakdown as rotavirus-positive children with a VA
report.
For completeness, we also calculated the rotavirus-positive proportion among healthy con-
trols as well as MSD cases that were not admitted to hospital.
Proportion of rotavirus-positive U5 diarrhoea hospitalisations attributable
to rotavirus in GEMS
GEMS tested for a wide range of enteric pathogens in the stools of MSD cases and healthy
community controls without diarrhoea matched to cases by age, gender, and residence; con-
trols were enrolled within 14 days of the index case. GEMS also included information about
whether MSD cases were admitted to hospital or not.
We used multiple conditional logistic regression to calculate the odds ratio of rotavirus EIA
positivity in hospitalized MSD cases vs matched healthy controls adjusted for the presence of
other pathogens. All syndromes of diarrhoea were included. We then calculated the attribut-
able fraction (AF) as described by Bruzzi et al [15]. These methods were the same as those used
to estimate attributable fractions in the main GEMS analysis [12, 16]. However, we restricted
the analysis to hospitalised cases, thought to be a better proxy for estimating rotavirus-
attributable mortality than all MSD cases. We excluded Mozambique from all AF analyses due
to concerns about the quality of the EIA testing, and did not estimate individual AFs for Mali
and Pakistan because hospitalisation for diarrhoea was very rare in these sites.
Using these attributable fractions, which represent the fraction of hospitalised MSD cases
with disease attributable to rotavirus, we calculated the attributable fraction among the
exposed (AFe). The AFe represents the fraction of rotavirus positive cases who have disease
caused by rotavirus. The rotavirus-positive proportions used to derive the AF and AFe were
based only on the children with MSD that were tested for rotavirus. These were age-specific
(0-11m, 12-23m, 24-59m) and did not involve extrapolation to non-enrolled MSD cases.
Finally, we used previously described methods [17] to calculate the rotavirus attributable
fraction based on quantitative Polymerase Chain Reaction (qPCR). We restricted the analysis
to a subset of 721 hospital cases and matched controls, and calculated the AF for all country
sites combined, excluding Mozambique. To quantify the test performance of EIA compared to
qPCR, we repeated this analysis for EIA test results, and calculated the ratio between the two
attributable fractions. All syndromes of diarrhoea were included. Confidence intervals were
calculated by bootstrapping with 1000 iterations.
Results
Comparison exercise
GBD produce their own estimates of U5 deaths [18], whereas CHERG and WHO/CDC use
U5 deaths from the UN Inter-agency Group for Child Mortality Estimation (IGME)[19]. Both
GBD and IGME estimate approximately 6.3 million U5 deaths globally in 2013 (Table 1) but
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some important differences exist at country/regional levels e.g. ~739,000 (GBD) vs ~845,000
(IGME) in the Eastern Mediterranean Region (EMRO). The main methodological differences
between GBD and IGME have been described in detail elsewhere and include the choice of
data points selected (vital registration, census and household surveys) and fitting methods
used [20].
GBD and CHERG produce their own estimates of the proportion of U5 deaths due to diar-
rhoea [5, 6]; WHO/CDC use the CHERG estimates. GBD and CHERG estimated that 8–9% of
U5 deaths were caused by diarrhoea at the global level in the year 2013 (Table 1). Differences
in GBD and CHERG estimates for the South East Asia (SEARO) region (6% vs 10%) are driven
by differences in estimates for India (6% vs 10%) where U5 diarrhoea deaths are ~80,000 vs
~140,000 respectively (Table 1). In other regions there is more agreement. Estimates for the
African (AFRO) region are consistent overall (10% vs 10%) but there are still large differences
at country level e.g. Zimbabwe (Fig 1).
Methodological differences between GBD and CHERG have been described in detail else-
where [4]. In brief, CHERG excluded verbal autopsy studies that only investigated a single
cause of death and data points from incomplete vital registration systems in higher mortality
Table 1. Comparison of CHERG, GBD and WHO/CDC estimates of U5 deaths, U5 diarrhoea deaths and U5 rotavirus deaths in the year 2013 by
WHO region, and for selected large countries.
GLOBAL AFRO AMRO EMRO EURO SEARO WPRO Bangladesh DR
Congo
India Indonesia
U5 deaths
UN (IGME) used by
CHERG
6,282,254 2,977,576 227,475 845,286 136,850 1,700,178 394,889 129,433 319,977 1,340,055 136,371
GBD 6,271,643 3,164,861 248,643 738,702 130,573 1,604,028 384,836 128,228 340,416 1,249,673 148,807
WHO/CDC - - - - - - - - - - -
Proportion of U5 deaths
due to diarrhoea
CHERG 0.09 0.10 0.04 0.10 0.04 0.10 0.06 0.06 0.11 0.10 0.06
GBD 0.08 0.10 0.05 0.12 0.03 0.06 0.02 0.01 0.17 0.06 0.06
WHO/CDC - - - - - - - - - - -
U5 diarrhoea deaths
CHERG 577,508 293,289 9,297 84,592 5,689 162,298 22,344 8,298 33,730 140,451 7,505
GBD 519,485 312,297 11,923 88,071 3,694 94,574 8,926 1,715 57,344 80,188 8,694
WHO/CDC 577,508 293,289 9,297 84,592 5,689 162,298 22,344 8,298 33,730 140,451 7,505
Proportion of U5
diarrhoea deaths due to
Rotavirus
CHERG 0.27 0.27 0.23 0.31 0.26 0.26 0.33 0.26 0.27 0.26 0.26
GBD 0.24 0.24 0.18 0.18 0.26 0.27 0.42 0.12 0.13 0.26 0.37
WHO/CDC 0.37 0.39 0.26 0.36 0.31 0.35 0.43 0.33 0.40 0.34 0.50
U5 rotavirus diarrhoea
deaths
CHERG 157,398 78,601 2,176 26,477 1,473 41,386 7,284 2,116 9,040 35,815 1,914
GBD 122,322 73,758 2,178 15,984 976 25,637 3,790 202 7,523 21,205 3,176
WHO/CDC 215,757 115,023 2,455 30,577 1,752 56,287 9,664 2,723 13,526 47,082 3,771
Region and global estimates may differ from official WHO/CDC, CHERG and GBD estimates because a standard set of countries and regions was used and
no rounding was done prior to aggregation.
https://doi.org/10.1371/journal.pone.0183392.t001
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settings. GBD included these data points and adjusted for missing data. GBD also included
unpublished data points obtained under third party data use agreements whereas CHERG
only use publicly available data points [21].
All three groups produce their own estimates of the proportion of U5 diarrhoea deaths that
are attributable to rotavirus. For the year 2013, the global proportions were 24% (GBD), 27%
(CHERG) and 37% (WHO/CDC). These correspond to 122,322 (GBD), 157,398 (CHERG)
and 215,757 (WHO/CDC) U5 rotavirus deaths (Table 1). Fig 2 shows the extent of variation in
the fraction of diarrhoea deaths attributed to rotavirus across countries within each WHO
region. There are large differences in some countries; for example, in DR Congo the propor-
tions are 13% (GBD), 27% (CHERG) and 40% (WHO/CDC).
The three groups used different methods to:
1. select data points (rotavirus-positive proportions);
2. extrapolate data points to individual countries;
3. account for rotavirus vaccine coverage;
4. convert rotavirus-positive proportions to rotavirus attributable fractions; and,
5. calculate uncertainty ranges.
A more detailed description of these differences can be found in the supporting informa-
tion (S1 Appendix).
Fig 1. Country-level differences in GBD vs CHERG estimates of the proportion of U5 deaths due to
diarrhoea in the year 2013 by WHO region.
https://doi.org/10.1371/journal.pone.0183392.g001
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Clinical syndromes for U5 diarrhoea hospitalisation
Table 2 shows the distribution of clinical syndromes for U5 diarrhoea hospitalisations for vari-
ous sites in Africa and Asia. A meta-analysis including data from all GRSN, NRSN and GEMS
sites suggests that acute watery diarrhoea was associated with 87% (95% CI 83–90%) of U5
diarrhoea hospitalisations (Fig 3) but there was substantial evidence for heterogeneity (I-
squared 99.08%, p = 0.00) between the studies. The GEMS site in Bangladesh (Mirzapur) had a
very high rate of acute bloody diarrhoea for reasons that are not clear.
Clinical syndromes for U5 diarrhoea deaths
Table 2 shows the distribution of clinical syndromes for U5 diarrhoea deaths. A meta-analysis
suggests that acute watery diarrhoea was associated with 65% (95% CI 57–74%) of U5 diar-
rhoea deaths (Fig 4) but again there was substantial evidence for heterogeneity between the
studies (I-squared 92.06%, p = 0.00). In four of the nine countries with verbal autopsy data, the
clinical syndromes of diarrhoea deaths were compared for those who died in any type of health
facility and those who died in the home, as reported by the family respondent. Most of deaths
were in the home (Cameroon 70%, Malawi 50%, Niger 86% and Nigeria 78%) but the distribu-
tion of acute watery, acute bloody and persistent diarrhoea was similar irrespective of the place
of death (Kalter, personal communication).
Rotavirus-positive proportion in U5 diarrhoea hospitalisations and U5
diarrhoea deaths in GEMS
For all GEMS sites combined (excluding Mozambique), rotavirus was detected (EIA-positive)
in 44% of acute watery U5 diarrhoea hospitalisations (55% in Asia, and 32% in Africa)
Fig 2. Country-level variation in the fraction of U5 diarrhoea deaths due to rotavirus in the year 2013
by source of estimates and by WHO region.
https://doi.org/10.1371/journal.pone.0183392.g002
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Table 2. Number and proportion of acute watery, acute bloody and persistent cases among U5 diarrhoea hospitalisations and U5 diarrhoea deaths
in various settings before rotavirus vaccine introduction.
Source Study
location
Study type Study
period
Diarrhoea
outcome
Age TotalΔ
n
Acute
Watery
n
Acute
Bloody
n
Persis-tent*
n
Acute
Watery
%
Acute
Bloody
%
Persis-tent
%
Clinical syndromes of U5 diarrhoea hospitalisations
GRSN Indonesia Surveillance
hospitals (n = 5)
2014–15 Inpatients <5yrs 1840 1695 110 35 92% 6% 2%
Rwanda Surveillance
hospitals (n = 42)
2012 Inpatients <5yrs 9097 8878 199 20 98% 2% 0.2%
Zambia Surveillance
hospitals (n = 3)
2009–11 Inpatients <5yrs 4381** 3761 15 - 86% 0.3% -
NRSN India Surveillance
hospitals (n = 7)
2013–14 Inpatients <5yrs 5156 4940 196 20 96% 4% 0.4%
GEMS Bangladesh Case control study
hospitals (n = 1)
2007–10 Inpatients <5yrs 337 171 154 11 51% 46% 3%
India Case control study
hospitals (n = 4)
2007–10 Inpatients <5yrs 437 411 17 10 94% 4% 2%
Gambia Case control study
hospitals (n = 6)
2007–10 Inpatients <5yrs 440 397 14 28 90% 3% 6%
Kenya Case control study
hospitals (n = 10)
2007–10 Inpatients <5yrs 175 129 3 44 74% 1% 25%
Mozambique Case control study
hospitals (n = 6)
2007–10 Inpatients <5yrs 633 579 6 48 91% 1% 8%
Clinical syndromes of U5 diarrhoea deaths
Verbal Bangladesh Demographic
surveillance (16)
2003–11 Deaths 1-
59m
59 43 7 9 73% 12% 15%
autopsy
studies
Pakistan Demographic &
Health Survey (16)
2006–7 Deaths 1-
59m
318 213 22 83 67% 7% 26%
Cameroon Subnational
household
survey***
2006–10 Deaths 1-
59m
166 125 20 22 75% 12% 13%
Ethiopia Demographic
surveillance (16)
2003–12 Deaths 1-
59m
60 19 6 35 32% 10% 58%
Malawi Subnational
household
survey***
2008–11 Deaths 1-
59m
149 118 18 13 79% 12% 9%
Niger Demographic &
Health Survey***
2006–10 Deaths 1-
59m
160 104 32 24 65% 20% 15%
Nigeria Demographic &
Health Survey***
2009–13 Deaths 1-
59m
537 435 70 32 81% 13% 6%
Tanzania Demographic
surveillance (16)
2000–11 Deaths 1-
59m
80 48 13 19 60% 16% 24%
Uganda Demographic
surveillance (16)
2007–10 Deaths 1-
59m
77 37 9 31 48% 12% 40%
ΔTotals for GEMS sites do not sum exactly due to rounding
*GRSN, NRSN and GEMS persistent cases include only those children who progressed to ‘persistent’ status (14+ days duration) after acute admission
** 605 cases in Zambia were classified as ‘non-infectious diarrhoea’, which is likely to include persistent cases as well as other cases that could not be
classified as acute watery or acute bloody diarrhoea.
*** Henry Kalter, personal communication
https://doi.org/10.1371/journal.pone.0183392.t002
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Fig 3. Meta-analysis showing the proportion of U5 diarrhoea hospitalisations associated with acute
watery diarrhoea (AWD) for selected sites in Africa and Asia.
https://doi.org/10.1371/journal.pone.0183392.g003
Fig 4. Meta-analysis showing the proportion of U5 diarrhoea deaths associated with acute watery
diarrhoea (AWD) for selected sites in Africa and Asia.
https://doi.org/10.1371/journal.pone.0183392.g004
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(Table 3). When all clinical syndromes of diarrhoea were included, the rotavirus-positive pro-
portion was 38% (44% in Asia; 30% in Africa).
Rotavirus was detected (EIA-positive) in 32% (12/37) of children aged<5yrs that died
within 7 days of enrolment at any type of health facility with acute watery MSD. Seven of the
rotavirus-positive children that died had a VA report, and 6 of these children (86%) had diar-
rhoea coded as a primary or secondary cause of death. Assuming that children with rotavirus
who lacked a VA report died from diarrhoea at the same rate as those with a report, the frac-
tion of U5 diarrhoea deaths that were rotavirus-positive was estimated to be 28% (10/37)
(Table 3). It was not possible to consider all syndromes because there were very few acute
bloody diarrhoea deaths (n = 3) and no persistent cases were eligible for inclusion in this anal-
ysis due to the short 7-day follow-up period.
The rotavirus-positive proportion was 3% in healthy controls. The rotavirus-positive preva-
lence in MSD inpatients was approximately double the rotavirus-positive prevalence in MSD
outpatients. 10% (147/1438) of inpatients and 20% (1782/8832) of outpatients had no detected
pathogen using conventional testing methods.
Table 3. Number and proportion of rotavirus infections in healthy controls and different types of diarrhoea cases aged <5yrs in GEMS.
Bangladesh India Pakistan ASIA Gambia Kenya Mali AFRICA TOTAL
Controls Number positive 74 42 66 182 42 39 43 124 306
Number tested 2465 2014 1838 6317 1569 1883 2064 5516 11833
% Positive 3% 2% 4% 3% 3% 2% 2% 2% 3%
All
syndromes
MSD Number positive 23 292 187 502 208 250 573 1031 1533
Not hospitalised Number tested 741 1398 902 3041 1038 1644 3109 5791 8832
% Positive 3% 21% 21% 17% 20% 15% 18% 18% 17%
MSD Number positive 111 233 2 346 152 40 5 197 543
Hospitalised Number tested 337 437 8 782 440 175 41 656 1438
% Positive 33% 53% 25% 44% 35% 23% 12% 30% 38%
Acute
watery
MSD Number positive 0 284 125 409 198 207 515 920 1329
Not hospitalised Number tested 2 1315 485 1802 899 1258 2657 4814 6616
% Positive 0% 22% 26% 23% 22% 16% 19% 19% 20%
MSD Number positive 93 230 0 323 141 33 5 179 502
Hospitalised Number tested 171 411 3 585 397 129 35 561 1146
% Positive 54% 56% 0% 55% 36% 26% 14% 32% 44%
Deaths Number positive 4 0 0 4 1 2 5 8 12
(within 7 days of
enrolment)
Number VA adjudicated 4 0 0 4 0 1 2 3 7
Number VA confirmed as
diarrhoea
4 0 0 4 0 0 2 2 6
% VA confirmed as
diarrhoea
100% - - 100% - 0% 100% 67% 86%
Number positive (adjusted
for VA)
4 - - 4 - 0 5 5 10
Total deaths 5 0 1 6 12 12 7 31 37
% Positive * * * * * * * * 28%
*proportion positive not reported at country-level due to small numbers.
VA = verbal autopsy.
https://doi.org/10.1371/journal.pone.0183392.t003
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Proportion of rotavirus-positive U5 diarrhoea hospitalisations attributable
to rotavirus in GEMS
The AFe value (equivalent to the rotavirus attributable fraction among rotavirus-positive U5
diarrhoea hospitalisations) was 0.97 (95% CI 0.95–0.98) for all included GEMS sites (Table 4)
and all diarrhoea syndromes combined.
Using qPCR instead of EIA for rotavirus detection increased the AF by a factor of 1.08
(95% CI 1.02–1.14).
Proposed improvements
We propose a number of improvements for consideration by all groups involved in the devel-
opment of future rotavirus mortality estimates.
Reporting a standard set of minimum variables to describe all input data
points
Previous comparison exercises have stressed the need for input data points to be made avail-
able at the time estimates are published [4, 20]. Recent Guidelines for Accurate and Transpar-
ent Health Estimates Reporting (GATHER) have recommended publication of a spreadsheet
table with details about the data points used to inform estimates [22]. These guidelines do not
provide explicit guidance on the variables that should be reported. We suggest that the follow-
ing standard set of minimum variables should be reported: (a) author/reference; (b) country;
(c) sub-national location; (d) data collection period; (e) age range; (f) type of study; (g) type of
diagnostic test; (h) number of enteric pathogens tested; (i) inpatient/outpatient; (j) pre/post
Table 4. Rotavirus positive proportion, attributable fraction (AF) and attributable fraction in the exposed (AFe) for MSD cases <5yrs that were hos-
pitalised with all syndromes of diarrhoea in GEMS*.
Rotavirus positive proportion (includes extrapolation to
MSD cases that were not enrolled)
Value
Rotavirus positive proportion
(enrolled MSD cases only)**
Value
AF AFe
Value 95% CI Value 95% CI
Bangladesh 0.33 0.35 0.34 (0.30,
0.38)
0.96 (0.94,
0.98)
India 0.53 0.48 0.47 (0.42,
0.52)
0.99 (0.97,
1.00)
Pakistan 0.25 0.22 *** *** *** ***
ASIA 0.44 0.40 0.39 (0.36,
0.42)
0.97 (0.95,
0.98)
Gambia 0.35 0.29 0.28 (0.23,
0.33)
0.98 (0.96,
1.00)
Kenya 0.23 0.21 0.19 (0.13,
0.26)
0.91 (0.82,
0.99)
Mali 0.12 0.18 *** *** *** ***
AFRICA 0.30 0.26 0.24 (0.20,
0.29)
0.95 (0.91,
0.99)
ALL SITES 0.38 0.35 0.34 (0.31,
0.36)
0.97 (0.95,
0.98)
* Includes all syndromes of diarrhoea i.e. acute watery diarrhoea, acute bloody diarrhoea, and acute watery cases that became persistent after enrolment.
** These values were based on the children that were enrolled i.e. tested for rotavirus. Age-specific presentations of these values (0-11m, 12-23m, 24-59m)
were used in the calculation of AF and AFe.
*** Rotavirus-positive hospitalisation was rare in Mali (n = 5) and Pakistan (n = 2) so country-specific AF and AFe are not reported. The data for these
countries are included in the estimates for ASIA, AFRICA and ALL SITES.
https://doi.org/10.1371/journal.pone.0183392.t004
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implementation of rotavirus vaccine in the public sector, or preferably a more precise estimate
of rotavirus vaccine coverage with details about the source of sub-national or national coverage
data used; (k) type of clinical syndrome e.g. acute watery, all syndromes; (l) included/excluded
in final estimates; (m) justification if excluded; (n) rotavirus-positive proportion (unadjusted);
(o) rotavirus-positive proportion (adjusted); and, (p) description of adjustment applied. Inclu-
sion and exclusion criteria should be clearly documented, and any exclusions applied after
data extraction should be justified using a clearly defined framework for evaluating data qual-
ity and outliers.
Annual online publication of WHO surveillance data points in
spreadsheet format
A spreadsheet table should be published annually on the WHO web site to allow for potential
inclusion of GRSN data by all groups in future estimates. At a minimum, rotavirus-positive
proportions <5 years should be made available by country (aggregated across sub-national
sites) and by calendar year. The standard set of recommended variables described above
should be reported for each data point. To ensure the integrity and confidentiality of country
surveillance data and to protect the ownership of those who collect the data, this and similar
surveillance data should be aggregated and proper attribution should be given to countries
that share this data. Data for sub-national sites should be provided where possible and where
appropriate to do so. Given its importance to global estimates, efforts should also be made to
routinely publish the sub-national Indian NRSN data points in an accessible spreadsheet for-
mat, with data points presented by sub-national location and data year. Other partners and
networks that generate rotavirus-positive proportions are also encouraged to share their data
in an accessible format, wherever possible.
Extrapolation of data points to country-level estimates using methods
that appropriately capture between-country variation
Statistical regression modelling or finer levels of stratification than geographical region should
be used when and where possible to extrapolate sub-national data points to different countries.
The source of all sub-national, national and supranational indicators used to inform statistical
regression models (e.g. GDP per capita) should be clearly defined. Care should be taken to
ensure the coverage and impact of rotavirus vaccination is consistently captured at all levels of
the analysis, including U5 deaths, the proportion of U5 deaths due to diarrhoea, and the pro-
portion of U5 diarrhoea deaths due to rotavirus. Where possible, groups should extract and
test the importance of other potentially influential sub-national characteristics e.g. private/
public hospital, secondary/tertiary hospital, under-five mortality rate, proportion of patients
from rural areas etc. If it is not feasible to collect this information from all sites, then a more
detailed review of the GRSN dataset could be informative, and would allow comparison of sev-
eral sub-national sites within the same countries. Input data points should be disaggregated
into individual years of data collection to capture changes in the rotavirus-positive proportion
over time at country level; covariates linked to period effects (e.g. GDP per capita, under-five
mortality rate) should be carefully selected on the basis of their ability to reproduce observed
trends in the rotavirus-positive proportion.
Separation of the clinical syndromes of U5 diarrhoea hospitalisations
Rotavirus is not associated clinically with acute bloody or persistent diarrhoea, two diarrhoeal
syndromes that may also be proximal or distal causes of death. Rotavirus-positive proportions
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derived exclusively from acute watery U5 diarrhoea hospitalisations should be adjusted to
account for the proportion of total U5 diarrhoea hospitalisations that are acute watery. If the
rotavirus-positive proportion (r) is not reported for all clinical syndromes combined, then the
equation r = ab + c(1 − b) can be used, where a is the rotavirus-positive proportion among
acute watery U5 diarrhoea hospitalisations, b is the proportion of total U5 diarrhoea hospitali-
sations that are acute watery, and c is the rotavirus-positive proportion among acute bloody
and persistent U5 diarrhoea hospitalisations combined. In the absence of local data to inform
parameter b, our analysis shows that acute watery diarrhoea is likely to be responsible for no
more than 87% (95% CI 83–90%) of U5 diarrhoea hospitalisations. The true value of b is likely
to be lower because all data points included in the meta-analysis under-estimated the role of
persistent diarrhoea. Given that rotavirus is not associated clinically with acute bloody or per-
sistent diarrhoea, the value of parameter c is likely to be at least ~3% based on the rotavirus-
positivity observed in healthy controls in GEMS.
Accounting for uncertainty in the steps used to convert rotavirus-positive
proportions into rotavirus-attributable fractions
The frequent asymptomatic carriage of many pathogens in the stools of healthy controls neces-
sitates the calculation of attributable fractions. To estimate the proportion of rotavirus-positive
cases that are attributable only to rotavirus, the population attributable fraction estimated by
the equation r × AFe can be used, where r is the rotavirus-positive proportion reported among
U5 diarrhoea hospitalisations (all syndromes combined), and AFe is the rotavirus-attributable
fraction among rotavirus-positive U5 diarrhoea hospitalisations (all syndromes combined).
Because it is rare for diarrhoea surveillance studies to include diarrhoea-free controls, very few
studies allow calculation of AFe. GEMS does include diarrhoea-free controls so permits this
calculation; our new analysis of GEMS calculated the AFe to be 0.97 (95% CI 0.95–0.98). This
value was relatively consistent across all GEMS sites where it could be reported (Bangladesh,
India, Gambia, Kenya). This suggests that rotavirus is the attributable cause in almost all U5
rotavirus-positive diarrhoea hospitalisations. In a separate, related analysis, the rotavirus
attributable fraction was shown to increase by a factor of 1.08 (95% 1.02–1.14) when the more
sensitive qPCR test was used. This is similar (albeit slightly larger) than the adjustment made
to r to account for AFe, so both adjustments could reasonably be excluded, and this would
have a limited impact on central estimates of U5 rotavirus deaths. However, adjustments
applied to some pathogens and not others, would lead to inconsistent reporting of central esti-
mates (and uncertainty intervals) across enteric pathogens. These adjustments, and their
uncertainty, should therefore be reflected in future estimates for all enteric pathogens, includ-
ing rotavirus.
Further research into the clinical syndromes of U5 diarrhoea deaths, and
the real-world impact of rotavirus vaccines on those deaths
To date, all groups have assumed that the proportion of U5 diarrhoea hospitalisations caused
by rotavirus is a reasonable proxy for the proportion of U5 diarrhoea deaths caused by rotavi-
rus. This approach has been taken because hospitalisation is thought to be a good proxy for
diarrhoea that is sufficiently severe to lead to death. Two aspects of our analysis suggest this
assumption may lead to over-estimates of the number of U5 rotavirus deaths. First, we esti-
mate that acute watery diarrhoea is associated with 87% of diarrhoea hospitalisations but only
65% of U5 diarrhoea deaths. Higher case fatality ratios (CFR) have been reported for acute
bloody and persistent diarrhoea than acute watery diarrhoea [23] but more evidence on the
fatality of different syndromes is needed to corroborate this. In addition, the analysis of
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diarrhoeal deaths relied on verbal autopsy reports which may be prone to recall bias, and our
analysis of diarrhoea hospitalisations only included those that became persistent after admis-
sion. Second, rotavirus was detected in a higher proportion of U5 acute watery diarrhoea hos-
pitalisations than U5 acute watery diarrhoea deaths in GEMS (44% vs 28%). Thus, among
children that had access to treatment, rotavirus was estimated to be less fatal than other causes
of acute watery diarrhoea. However, more evidence is needed on the effect of treatment on the
proportion of acute watery diarrhoea deaths due to rotavirus; in communities without access
to treatment services, rotavirus may represent a larger proportion of acute watery diarrhoea
deaths. Another explanation for the lower rotavirus-positivity among U5 acute watery diar-
rhoea deaths, is that the number of deaths captured in the 7 days after enrolment (n = 37) were
too few to make a reliable assessment. Longer follow-up periods allow more deaths to be
included but it then becomes increasingly difficult to ascertain whether children who were
rotavirus-positive at the time of enrolment were still rotavirus-positive at the time of death,
and whether cases that were negative at enrolment had a new rotavirus episode prior to death.
Further evidence is needed from other geographical locations on the distribution of clinical
syndromes among U5 diarrhoea hospitalisations and deaths. This should include a more accu-
rate assessment of the role of persistent diarrhoea among U5 diarrhoea hospitalisations. More
importantly, efforts should be made to accurately capture the real-world impact of rotavirus
vaccines on U5 diarrhoea deaths in early introducing countries. This will provide critical
insights into the true contribution of rotavirus to U5 diarrhoea deaths in different locations.
Presenting and incorporating the uncertainty in parameters used to
derive U5 rotavirus deaths
The uncertainty interval around the central estimates of U5 rotavirus deaths should be explic-
itly defined (e.g. the type of confidence or prediction interval) and should incorporate uncer-
tainty in each of the three core parameters (number of U5 deaths, % due to diarrhoea, % due
Fig 5. Global estimates of the number of rotavirus deaths <5 years in the year 2013 by source of
estimates.
https://doi.org/10.1371/journal.pone.0183392.g005
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to rotavirus) as well as any other parameters used to adjust the original input data points e.g.
the parameters used to convert rotavirus-positive proportions into rotavirus-attributable
fractions.
Conclusion
There is considerable disagreement between global estimates of U5 rotavirus deaths, but it is
encouraging to note that estimates are converging over time, at least in absolute terms (Fig 5).
The aim of this analysis was not to recommend a single set of best estimates, but rather to
explain the reasons for differences, provide evidence to inform key areas of uncertainty, and
propose improvements for future estimates. Updates to GBD [24] and CHERG (now MCEE)
estimates were already well advanced during the course of this comparison study, and further
convergence is expected. The suggested improvements presented in this manuscript should be
incorporated, as far as possible, into future rotavirus mortality estimates. This is likely to be an
iterative and evolving process as new evidence emerges over time.
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5.0 Chapter 5 - Estimation of rotavirus age distributions in children aged <5 years 
 
5.1 Contribution of paper to the aim and objectives of the thesis 
 
This analysis involved fitting parametric curves to available data on age distributions. 
This allows estimation of RVGE hospital admissions by week of age between birth 
and age 5.0 years. This level of granularity is important for assessing the potential 
benefits of alternative rotavirus vaccination schedules. Many country datasets are 
analysed, and these provide a critical input to the benefit-risk analysis (Chapter 9). 
For countries without data, methods of extrapolation are proposed based on under-
five mortality strata. There is considerable variation between countries in the median 
age of RVGE hospital admission. Countries in high mortality settings have a much 
lower median age than countries in lower mortality settings. 
 
5.2 Independent academic contribution 
 
I was the LSHTM principle investigator and senior author of the paper. I was 
responsible for the main statistical analysis (fitting of age distributions) and worked 
on this independently. I wrote the R code, ran the statistical analysis and wrote the 
first draft of the paper. The regression models were done by Colin Sanderson. The 
systematic review and data gathering were done by the first two authors. I helped to 
develop the methodology for the systematic review and used Distiller software to 
resolve any conflicts between the two systematic reviewers.  
 
5.3 Ethical approval 
 
This study was approved by the ethical committee (Ref 14398) of the London School 
of Hygiene and Tropical Medicine (LSHTM).  
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Abstract 
 
Background: The impact of live oral rotavirus vaccines could be improved by adjusting the 
schedules, but in published age distributions of rotavirus gastroenteritis (RVGE) the age bands 
are too broad to allow a detailed investigation of the potential gains.  
 
Methods: We sought datasets that could provide age distributions of rotavirus-positive 
community cases, clinic visits, hospital admissions, emergency visits and deaths among 
children <5 years of age, before the introduction of rotavirus vaccines. We analysed the WHO 
Global Rotavirus Surveillance Network (GRSN) database and conducted a systematic 
literature review (January 1990 to February 2017) to identify other relevant datasets. We 
contacted study investigators to obtain more granular age distributions than were originally 
published. We used a robust statistical approach to fit parametric age distributions to each 
country dataset and mortality stratum. We calculated the median age, and cumulative 
proportion of RVGE events expected to occur at specific ages between birth and 5.0 years.  
 
Findings: We identified 117 pre-vaccination datasets with rotavirus-positive events among 
children aged <5 years. The median age of rotavirus-positive hospital admissions was 38 
weeks (inter-quartile range IQR: 25-58) in countries with very high child mortality and 65 
weeks (IQR: 40-107) in countries with low/very low child mortality. In countries with very 
high child mortality 69% of rotavirus-positive admissions <5 years were in the first year of 
life, with 3% by 10 weeks, 8% by 15 weeks and 27% by 26 weeks of age.  
 
Conclusions: The median age of rotavirus disease in children aged <5 years varies between 
and within countries but tends to be younger in higher mortality settings. The age distributions 
presented in this paper provide information that is critical for assessing the potential benefits 
of alternative rotavirus vaccination schedules in different countries, and for monitoring 
programme impact.
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Introduction 
 
Rotavirus gastroenteritis (RVGE) is estimated to cause around 200,000 child deaths each year 
(1). Over half of the countries in the world now include live oral rotavirus vaccines in their 
national immunization programmes (2). There are three vaccines licensed for global use 
(Rotarix® - GSK, RotaTeq® - Merck & Co., and ROTAVAC® - Bharat Biologicals), others 
for national use (e.g. in Vietnam, China and India) and several others in the pipeline, including 
neonatal and non-replicating injectable vaccines (3). Randomised controlled trials (RCTs) 
have reported high vaccine efficacy (~90%) against severe RVGE in low mortality countries 
but modest efficacy (~50%) in higher mortality settings (4). Alternative schedules are being 
considered to increase their impact. A neonatal vaccine has had promising results in 
Indonesia(5), and some studies have evaluated the potential of a booster dose given at around 
9-12 months of age (6, 7). Several studies and surveillance systems have collected information 
on RVGE age distributions but much of it is unpublished or has been published in age bands 
that are too broad to allow a detailed assessment of the potential impact of alternative rotavirus 
vaccination schedules. More granular age distributions would also help to quantify the number 
of RVGE cases expected to occur at specific ages, so that changes can be monitored after 
vaccination. More generally, there is a need to update the global evidence on RVGE age 
distributions, compare them between countries and regions, and establish a reliable method 
for extrapolating them to countries without data. An unpublished review was conducted in 
2012 (8) but this did not include the large multi-country Global Rotavirus Surveillance 
Network (GRSN) database (9), and several pivotal multi-country studies have also been 
published since (10-12). 
 
In this paper we aim to estimate granular age distributions of rotavirus disease outcomes in 
children aged <5 years by type of RVGE presentation, country and mortality level, before the 
introduction of rotavirus vaccines.  
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Methods 
 
Ethical Approval 
This study was approved by the ethical committee of the London School of Hygiene and 
Tropical Medicine (LSHTM); ethics reference 14398. All authors and countries gave their 
consent to analyse and publish the data. 
 
Search strategy and study selection 
We sought country datasets containing counts of rotavirus-positive disease in children aged 
<5 years before the introduction of rotavirus vaccines. A country dataset is defined as a dataset 
derived from a single study (e.g. hospital surveillance, case-control, cohort etc.) within a single 
country, reporting on a single rotavirus-positive outcome/presentation (community cases, 
clinic visits, emergency visits, hospitalisations, deaths). If a dataset contained multiple sub-
national locations and/or multiple calendar years, then these were aggregated, and any relevant 
exclusion criteria were applied to the aggregated dataset. When studies reported multiple 
rotavirus-positive presentations then each presentation was considered to be a distinct dataset. 
Pre-vaccine datasets only included data for years prior to rotavirus vaccine introduction.  
 
First, we analysed the WHO GRSN database, which contains information about hospital 
admissions among children <5 years from surveillance sites in 69 countries (9). In these sites, 
rotavirus-positivity is determined by enzyme immunoassay (EIA). We applied the definition 
described above and aggregated sub-national locations and multiple calendar years to create 
unique pre-vaccine introduction GRSN country datasets. The year of rotavirus vaccine 
introduction was determined by WHO/UNICEF Estimates of National Immunization 
Coverage (WUENIC)(13). If a country dataset did not have data of hospital admissions by 
day of age, then we used month of age. Admissions recorded as aged zero days were removed 
for face validity (inconsistent with the rotavirus incubation period). 
 
Second, we conducted a systematic literature review adhering to Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify other relevant 
rotavirus studies. A full description of the search strategy is provided in the supplementary 
appendix (Appendix). In brief, we searched for papers published between January 1990 and 
February 2017 and publications in English, French, Spanish and Polish. We excluded studies 
in which rotavirus positivity was not determined by EIA or quantitative polymerase chain 
reaction (qPCR); non-human studies; nosocomial infection studies; studies without 
information on individuals aged less than 5 years old; special populations such as HIV-
infected patients; meta-analyses and systematic reviews reporting regional or global age 
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distributions; and, papers without an accessible full text link. Two independent reviewers 
(MHA, CL) screened abstracts and any ambiguity was resolved by a third reviewer (AC). A 
letter was sent by email to the investigators of all studies identified in the systematic review. 
Investigators were asked to provide anonymised data or complete a standard data extraction 
table with counts by week of age up to 5.0 years. If the investigators did not respond before 
the end of August 2017 and no other study was available for that country, we extracted the 
age distribution reported in the publication. We included all country datasets that were 
obtained from a previously unpublished literature and database search conducted by 
Sanderson et al in 2012(8). This included articles published between 1990 and 2011. 
 
All country datasets were combined into a central database with a standard format and list of 
variables and analysed together with the GRSN datasets. We cross-checked datasets identified 
through the literature search and GRSN to avoid data duplication. Prior to analysing the 
datasets, we excluded studies that included fewer than 35 RVGE events, had known concerns 
about EIA quality, had fewer than three age bands <1 year of age and did not capture cases 
from birth. We designed a tool to assess the risk of bias in RCTs and observational studies 
and assigned very low, low or medium risk of bias to each country dataset. The risk of bias 
was scored against a list of five criteria (Appendix).    
 
Data analysis 
 
We fit a range of parametric distributions (Gamma, Weibull, Lognormal, Log Logistic, Burr) 
to several GRSN datasets that were reported by day of age, and that represented the extreme 
range of younger and older age distributions globally. We fit age distributions using Maximum 
Likelihood Estimation (MLE). The best-fitting distribution was chosen by comparing 
goodness of fit statistics (Kolmogorov-Smirnov; Cramer-von Mises; Anderson-Darling) and 
goodness of fit criteria (Akaike's Information Criterion, Bayesian Information Criterion). For 
each country dataset, we calculated the best-fitting parameters of the chosen distribution. We 
generated summary tables with the median age, interquartile age range, and the cumulative 
proportion of RVGE cases aged <5 years that were estimated to occur at different granular 
ages between birth and age 5.0 years. We reported the Root Mean Squared Error (RMSE) and 
Mean Absolute Error (MAE) for the parametric distribution fitted to each country dataset. All 
analyses were conducted using R v.3.4.1 using the following packages: polspline, nloptr, zoo, 
MASS, fitdistrplus, actuar and mutil. 
 
We assigned each of the 201 countries in the world to an under-five mortality quintile (very 
low, low, medium, high and very high) using 2010-2015 estimates of under-five mortality as 
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reported by the UNPOP 2017 Revision(14). We grouped all datasets according to the under 5 
mortality quintile of the country concerned, and calculated the median age and median best-
fitting parameters for each stratum. We also ran a series of regression analyses to explore 
which combinations of variables would best predict the median age and parameters of the 
chosen parametric distribution. To compare differences in rotavirus disease presentations we 
plotted the full set of median ages reported for a given presentation against their respective 
2010-2015 under-five mortality rates. We fit a least-squares line of best fit for each 
presentation, reported the R-squared value and compared the best-fitting lines. 
 
We used ArcGIS mapping software to display the median age of rotavirus hospitalisation 
estimated for each country in the world. If more than a single dataset was available for a 
country, we calculated the median age and median best-fitting parameters of all datasets for 
that country. If no dataset was available, we assigned the median age of the country’s 
corresponding mortality stratum. 
 
Results 
 
We identified 117 pre-vaccination datasets with rotavirus-positive events among children <5 
years of age (6 datasets with community cases, 12 with clinic visits, 7 with emergency visits, 
92 with hospital admissions and 0 with deaths) (Table 1, Figure 1).  Around half of the country 
datasets (51/117) were rotavirus-positive cases identified through hospital-based sentinel site 
surveillance from the GRSN (35 reported by day of age and 16 reported by month of age). 
The other half (66/117) were identified from the systematic literature review (n=61) or 
obtained from the previously unpublished review (n=5). The 117 pre-vaccination datasets 
were taken from 47 studies with very low (n=24), low (n=12) and medium (n=11) risk of bias.  
 
Log Logistic age distributions had favourable goodness of fit statistics and criteria (Appendix 
Figures S1 and S2) so were used to generate summary statistics on the age distribution of 
hospital admissions aged <5 years (Appendix Tables S2 and S3). The median age of RVGE 
hospital admission was 38 weeks (inter-quartile range IQR: 25-58) in countries with very high 
child mortality, 43 weeks (IQR: 28-68) in countries with high child mortality, 46 weeks (IQR: 
29-72) in countries with medium child mortality and 65 weeks (IQR: 40-107) in countries 
with low/very low child mortality (Figure 2). We collapsed the low and low child mortality 
strata because they had a very similar age profile (67 weeks for very low and 63 weeks for 
low). In countries with very high child mortality 69% of rotavirus-positive admissions in 
children <5 years were in the first year of life, with 3% by 10 weeks, 8% by 15 weeks and 
27% by 26 weeks. There was considerable variation within each child mortality stratum. For 
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example, in the very high child mortality stratum, the median age ranged from 29 weeks (IQR: 
19-46) in Zambia to 50 weeks in Ethiopia (IQR: 30-81). Similarly, in the low/very low 
mortality stratum, the median age ranged from 35 weeks (IQR: 19-64) in France to 101 weeks 
(IQR: 65-157) in Ukraine.  
 
Globally, most countries with a low median age were in Africa (Figure 3). In general, the 
median age of rotavirus-positive hospital admissions decreased as child mortality increased 
(one-way ANOVA, p<0.0001), but there were notable outliers such as France and The 
Netherlands where the median age was exceptionally low (35 and 48 weeks respectively) and 
Mauritius and Ukraine where the median age was exceptionally high (84 and 101 weeks 
respectively). Regression models with more variables provided no substantive advantage over 
the simple stratification by under-five mortality quintile (Appendix Tables S4 and S5). 
 
There were relatively few global datasets with age distributions for community cases, clinic 
visits and emergency visits, and none for RVGE deaths that met our inclusion criteria. The 
median age for RVGE emergency visits was around 10 weeks younger than the median age 
for RVGE hospital admissions.  The median age for RVGE clinic visits was around 5 weeks 
older than the median age for RVGE hospital admissions (Appendix Tables S6-S8).  This 
pattern was consistent across settings with different under-five mortality rates (Appendix 
Figure S3).  
 
Discussion 
 
We have gathered and synthesised a large amount of evidence on rotavirus age distributions 
globally. To our knowledge this is the first systematic global study to estimate granular age 
distributions by country, mortality stratum and level of care sought. We use statistically robust 
and standard methods to provide reproducible parametric age distributions for each country. 
We show that the median age of rotavirus disease varies between and within countries but 
tends to occur at a much younger age in higher mortality settings. We hypothesise that this is 
probably due to a higher force of infection and shorter intervals between repeat infections in 
these settings. There could also be important age-specific differences in the early management 
and treatment of RVGE in higher mortality settings. Birth cohort studies have shown a peak 
age of infection at around 20 months of age in Mexico (medium mortality) (15) compared to 
5.5 months in India (high mortality) (16). RVGE age distributions were similar in these 
studies, probably because natural infections were less protective in India leading to more cases 
in older ages; consistent with rotavirus vaccination doses being less protective in high 
mortality settings (17). However, this comparison included cases that were not hospitalised. 
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Our analysis relies heavily on the WHO GRSN database which may include sentinel sites that 
are not fully representative of the country concerned. Importantly, healthcare seeking 
behaviour varies by country and age and this may help to explain heterogeneities observed 
within each mortality stratum. For example, in some settings with high rates of private 
healthcare, children aged <1 year may be more likely to be treated outside of the regular 
sentinel surveillance system. In Hungary, Slovenia and Ukraine the median age of rotavirus-
positive hospital admissions was 86, 88 and 101 weeks respectively. This high median age 
might simply be a characteristic of rotavirus in Central and Eastern Europe or may reflect 
other surveillance peculiarities e.g. under-recruitment of younger patients or over-recruitment 
of mild RVGE cases. We analysed the very low and low mortality strata without Ukraine but 
that did not change the median age of 65 weeks. In other datasets, there may be a bias to 
younger ages. For example, we found a surprisingly low median age of hospital admission 
from multiple datasets in France (median age 27-41 weeks) for reasons that are not clear.  
 
We chose to fit parametric distributions, rather than report the actual age distributions 
observed in each study. This required an assumption to be made about the standard functional 
form of the distribution.  However, our parametric fitting approach: a) provides a function that 
can be easily reproduced by others; b) avoids the issue of heaping i.e. the tendency to report 
cases at exactly 1.0 years, 2.0 years etc., an issue that has been evident in many of the datasets 
because of a reporting artefact; c) smooths distributions based on small (noisy) samples; and, 
d) allows standard reporting of the proportion of RVGE cases that occur at specific ages e.g. 
the proportion of cases occurring before the first dose of rotavirus vaccine at 6 weeks, or 
before vaccine age restrictions are applied at 15 weeks. We also explored non-parametric 
smoothing approaches. We used Kernel Density Estimation (KDE), with default Gaussian 
smoothing.  However, heaping was evident in some of the datasets and areas of density below 
zero were common. One way to avoid this is to truncate the density at zero, but this introduces 
a bias in the distribution and creates an implausible cliff-edge at zero in some datasets. Another 
way to avoid this is to use Logspline Density Estimation, with the lower bound set to zero. 
This worked well for some datasets but not others and required manual adjustment to the 
number and location of knots so was not practical as a standardised approach.  
 
We obtained many datasets on rotavirus-positive hospital admissions but few on other 
presentations. No datasets with rotavirus-positive deaths met our inclusion criteria because 
they had fewer than 35 deaths and it was very difficult to ascertain whether the deaths were 
entirely attributable to rotavirus. Compared to hospital admissions, we found a higher median 
age for clinic visits and a younger median age for emergency visits, but this was based on very 
few data points.  
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Conclusion 
The median age of rotavirus disease in children aged <5 years varies between and within 
countries but tends to be younger in higher mortality settings. The age distributions presented 
in this paper should provide information that is critical for assessing the potential benefits of 
alternative rotavirus vaccination schedules in different countries, and for monitoring the 
impact of rotavirus vaccines. 
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Table 1.  Number of country datasets containing RVGE age distributions before the 
introduction of rotavirus vaccination, by type of presentation and under-five mortality 
quintile 
 
Quintile 
for 2010-
2015 
under-five 
mortality 
rate 
Number of country datasets (Number of rotavirus-positive cases) 
Hospital 
admissions 
Emergency 
visits Clinic visits 
Community 
cases Total 
Very Low 13 (31,211) 3 (10,467) 3 (1,552) 0 (0) 19 (43,230) 
Low 8 (10,348) 2 (179) 1 (41) 0 (0) 11 (10,568) 
Medium 14 (13,990) 0 (0) 1 (224) 1 (89) 16 (14,303) 
High 31 (23,557) 2 (167) 3 (461) 4 (536) 40 (24,721) 
Very High 26 (26,142) 0 (0) 4 (1,066) 1 (71) 31 (27,279) 
Total 92 (105,248) 7 (10,813) 12 (3,344) 6 (696) 117 (120,101) 
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Figure 1. Flowchart of the study selection process and data extraction. 
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Figure 2. Age distributions of rotavirus-positive hospital admissions by under-five mortality strata 
 
Very Low / low mortality Medium mortality
High mortality Very high mortality
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Figure 3. Estimated and extrapolated pre-vaccination median age of rotavirus-positive hospital 
admissions <5 years by country.  
 
 
Lighter red represents younger median age and darker red represented older median age. If more than 
one study was conducted within a country, the median of median ages was used. If no data were 
available for a country, the median age was extrapolated (indicated by diagonal shading) using the 
median age of the under-five mortality stratum. 
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Appendix to: 
 
Global review of the age distribution of rotavirus disease in children aged <5 years 
before the introduction of rotavirus vaccination.  
 
Mateusz Hasso-Agopsowicz, Chandresh Nanji Ladva, Benjamin Lopman, Colin Sanderson, 
Adam L. Cohen, Global Rotavirus Surveillance Network, Rotavirus Age Distribution 
Collaborators, Jacqueline E. Tate, Ximena Riveros, Ana Maria Henao-Restrepo, Andrew 
Clark 
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Search strategy 
 
a) Search Terms 
1. rotavir* 
2. Rotavirus Infections/ or Rotavirus 
3. 1 or 2 
4. incidence 
5. hospital* 
6. case* 
7. visit* 
8. admission* 
9. death* 
10. surveill* 
11. Fetal Mortality/ or Child Mortality/ or Infant Mortality/ or Hospital Mortality/ or 
Mortality/ 
12. Mortalit* 
13. Diarrh* 
14. Diarrhea/ or Diarrhea, Infantile/ 
15. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
16. 3 and 15 
17. limit 16 to (humans and yr="1990 -Current" and ("all infant (birth to 23 
months)" or "all child (0 to 18 years)" or "newborn infant (birth to 1 month)" or 
"infant (1 to 23 months)" or "preschool child (2 to 5 years)") and (english or 
french or polish or spanish)) 
 
b) Limits:  
• English, French, Spanish, Polish,  
• Humans  
• Year 1990- current 
• Yr 0-5 
 
c) Search engines (with modified search terms where appropriate): 
• EMBASE 
• Cochrane 
• Medline 
• Chinese citation database 
 
d) Exclusion Criteria 
• Rotavirus Not Reported 
• Age Information Not Reported 
• No Cases <5 Years 
• EIA/ELISA or PCR Not Used or Diagnostic Not Specified 
• Hospital Acquired (Nosocomial) Infection 
• Comorbidities (Other Medical Conditions) in Cases 
• Systematic Review/Meta-Analysis 
• In vitro or animal study 
• Full-Text Not Found 
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Risk of bias assessment tool 
 
When reviewing studies, we expanded the exclusion criteria to exclude highly biased studies 
(see Methods: Literature Review). Additionally, following a consultation with Cochrane we 
designed a custom tool to assess the risk of bias in the remaining observational studies. We 
checked each study for the following criteria:  
 
i) whether participants were representative of the general population;  
ii) whether participants’ characteristics were reported; 
iii) whether surveillance methods and outcomes were the same for all participants; 
iv) whether study assessors were blinded at outcome assessment; and, 
v) whether drop-outs, withdrawals and missing data were described?  
 
Each answer was given a score: 0 for “No”, 1 for “Unclear”, and 2 for “Yes”. The total score 
was calculated and studies with a score of 0-1 were considered to have a very low risk of bias; 
2-4 low risk of bias; and 5-7 medium risk of bias (Appendix Table S1).
70 
 
 
 
Appendix Table S1: Assessment criteria and scores for risk of bias in studies with rotavirus disease age distributions in children aged <5 years  
 
 Selection Bias Baseline Confounding Outcome Measurement 
Blinding at Outcome 
Assessment Description of Missing 
     
Ref 
Are participants 
representative of 
the general 
population? 
Are characteristics of 
participants reported? 
Are surveillance and 
measurement of 
outcomes the same for 
all participants? 
Are study assessors 
blinded at outcome 
assessment? 
Are drop-outs, 
withdrawals and 
missing data 
described? 
Total 
"Y" 
Total 
"U" 
Total 
"N" Score Risk of Bias 
(18) Y Y Y U Y 4 1 0 1 VERY LOW 
(19) Y Y Y U Y 4 1 0 1 VERY LOW 
(10) Y Y N Y N 3 0 2 4 LOW 
(20) Y Y Y U Y 4 1 0 1 VERY LOW 
(21) Y Y Y U Y 4 1 0 1 VERY LOW 
(12) Y Y Y Y N 4 0 1 2 LOW 
(22) Y N Y U N 2 1 2 5 MEDIUM 
(23) Y Y Y U Y 4 1 0 1 VERY LOW 
(11) Y Y Y U Y 4 1 0 1 VERY LOW 
(24) Y N Y U N 2 1 2 5 MEDIUM 
(25) Y N Y U N 2 1 2 5 MEDIUM 
(26) Y Y Y U Y 4 1 0 1 VERY LOW 
(27) Y Y Y U Y 4 1 0 1 VERY LOW 
(28) Y Y Y U N 3 1 1 3 LOW 
(29) Y Y Y U N 3 1 1 3 LOW 
(30) Y Y Y U Y 4 1 0 1 VERY LOW 
(31) Y N Y U N 2 1 2 5 MEDIUM 
(32) Y N Y U N 2 1 2 5 MEDIUM 
(33) Y Y Y U Y 4 1 0 1 VERY LOW 
(34) Y Y Y Y Y 5 0 0 0 VERY LOW 
(35) Y Y Y U Y 4 1 0 1 VERY LOW 
(36) Y Y Y U N 3 1 1 3 LOW 
(37) Y Y Y U N 3 1 1 3 LOW 
(38) Y Y Y U Y 4 1 0 1 VERY LOW 
(39) Y Y Y U Y 4 1 0 1 VERY LOW 
(40) Y Y Y U Y 4 1 0 1 VERY LOW 
(41) Y N Y U Y 3 1 1 3 LOW 
(42) Y Y N U Y 3 1 1 3 LOW 
(43) Y N Y U N 2 1 2 5 MEDIUM 
(44) Y Y Y U Y 4 1 0 1 VERY LOW 
(45) Y N Y U N 2 1 2 5 MEDIUM 
(46) Y Y Y U N 3 1 1 3 LOW 
(47) Y Y Y U N 3 1 1 3 LOW 
(48) Y Y Y U N 3 1 1 3 LOW 
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(49) Y Y Y U Y 4 1 0 1 VERY LOW 
(50) Y Y Y U Y 4 1 0 1 VERY LOW 
(51) Y Y Y U Y 4 1 0 1 VERY LOW 
(52) Y N Y U N 2 1 2 5 MEDIUM 
(53) Y Y Y U Y 4 1 0 1 VERY LOW 
(54) Y N Y U N 2 1 2 5 MEDIUM 
(55) Y N Y U N 2 1 2 5 MEDIUM 
(56) Y Y Y U Y 4 1 0 1 VERY LOW 
(57) Y Y Y U Y 4 1 0 1 VERY LOW 
(58) Y Y Y U N 3 1 1 3 LOW 
(59) Y N N U N 1 1 3 7 MEDIUM 
(15) Y Y Y U Y 4 1 0 1 VERY LOW 
(9) Y Y Y U Y 4 1 0 1 VERY LOW 
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Justification for choosing the Log Logistic age distribution  
 
We fitted a range of parametric distributions to all cases identified in the GRSN that were 
reported by day of age. This dataset was used to identify the best-fitting parametric 
distributions because it had finest age granularity and covered a wide range of countries. 
Importantly, it also included a country dataset very skewed to younger ages (Zambia) and a 
country dataset very skewed to older ages (Ukraine) and represented the full range of age 
distributions identified in our search.  We fitted separate parametric distributions to the 
aggregated global dataset, each WHO region, Zambia and the Ukraine. The Log Logistic 
distribution had the lowest (most favourable) goodness of fit statistics (Kolmogorov-Smirnov, 
Cramer-von Mises, Anderson-Darling) for Zambia, WHO regions AFR, SEAR, WPR and the 
global dataset (Appendix Figures S1 & S2). The Lognormal distribution had marginally better 
goodness of fit statistics than Log Logistic in the Ukraine.  The Burr distribution had 
marginally better goodness of fit criteria than Log Logistic for most datasets (Akaike's 
Information Criterion – AIC, Bayesian Information Criterion - BIC) but had much worse 
goodness of fit statistics. In the interests of using a flexible, defensible and standardised fitting 
approach, we used the Log Logistic distribution to fit curves to all datasets. 
 
The Log Logistic age distribution is defined by a scale (α) and a shape (β) parameter. The 
scale parameter is conveniently the same as the median age. The proportion of rotavirus 
disease within each week of age is calculated by the following equation, where 𝑥𝑥 represents 
the age at the beginning of each week of age 
 (β/α)(𝑥𝑥/α)𝛽𝛽−1(1 + (𝑥𝑥/α)𝛽𝛽)2  
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Appendix Figure S1: Age distribution of rotavirus-positive hospital admissions aged <5 
years for all countries included in the WHO GRSN database with data reported by day 
of age, before the introduction of rotavirus vaccination: comparison of alternative 
fitted parametric distributions 
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Appendix Figure S2: Age distribution of rotavirus-positive hospital admissions aged <5 
years for selected countries and WHO regions included in the WHO GRSN database 
with data reported by day of age, before the introduction of rotavirus vaccination: 
comparison of fitted parametric distributions 
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Appendix Table S2. Age distributions for rotavirus-positive hospital admissions aged <5 years before the introduction of rotavirus vaccination: 
median, interquartile range and cumulative age distribution 
Study characteristics Median (IQR) Proportion of RVGE hospital admissions expected to occur by specific ages 
Ref Country n 50th pc. 
25th 
pc. 
75th 
pc. 6w 2m 10w 14w 15w 4m 6m 9m 12m 24m 36m 48m 60m 
(41) Australia 44 67 42 108 0·4% 0·9% 1·2% 2·6% 3·1% 4·2% 10·1% 22·3% 35·9% 73·5% 87·6% 93·2% 95·8% 
(57) Bulgaria 2197 65 40 105 0·5% 1·0% 1·4% 3·0% 3·5% 4·8% 11·3% 24·1% 37·9% 74·6% 88·1% 93·4% 95·9% 
(52) Chile 942 49 29 81 1·0% 2·3% 3·1% 6·2% 7·2% 9·6% 20·3% 38·0% 53·4% 83·8% 92·6% 95·9% 97·4% 
(23) China, Hong Kong SAR 13147 69 41 116 0·5% 1·2% 1·6% 3·2% 3·6% 4·9% 10·9% 22·6% 35·1% 70·5% 85·0% 91·3% 94·4% 
(42) China, Hong Kong SAR 123 84 53 133 0·2% 0·4% 0·6% 1·3% 1·6% 2·2% 5·6% 13·6% 23·9% 62·4% 81·5% 89·8% 93·7% 
(10) France 8035 43 23 80 3·0% 5·6% 7·1% 12·2% 13·6% 16·9% 29·4% 46·0% 58·6% 82·8% 90·8% 94·2% 96·0% 
(40) France 473 27 15 49 6·1% 11·3% 14·2% 23·5% 25·9% 31·2% 48·9% 66·8% 77·3% 92·4% 96·2% 97·7% 98·5% 
(9) Georgia 110 67 42 107 0·4% 0·9% 1·2% 2·6% 3·0% 4·2% 10·1% 22·3% 35·9% 73·8% 87·8% 93·4% 95·9% 
(10) Hungary 1820 86 52 142 0·3% 0·7% 0·9% 1·8% 2·1% 2·9% 6·8% 15·1% 25·0% 60·4% 78·8% 87·5% 91·9% 
(22) Italy 1002 77 46 128 0·4% 0·9% 1·2% 2·5% 2·9% 3·9% 8·8% 18·8% 30·1% 65·7% 82·1% 89·5% 93·3% 
(59) Italy 2434 62 33 119 1·9% 3·4% 4·3% 7·4% 8·2% 10·3% 18·6% 31·2% 42·5% 70·6% 82·7% 88·6% 91·9% 
(37) Japan 58 73 48 113 0·2% 0·4% 0·6% 1·5% 1·7% 2·5% 6·7% 16·7% 29·4% 70·8% 87·2% 93·4% 96·1% 
(10) Netherlands 710 48 25 92 3·0% 5·4% 6·8% 11·3% 12·6% 15·5% 26·5% 41·6% 53·6% 78·7% 87·9% 92·2% 94·5% 
(39) New Zealand 555 55 35 87 0·4% 1·1% 1·5% 3·4% 4·0% 5·5% 13·6% 29·7% 46·1% 82·2% 92·6% 96·2% 97·7% 
(9) Oman 728 53 35 78 0·3% 0·7% 1·0% 2·5% 3·1% 4·5% 12·6% 30·5% 49·2% 86·7% 95·2% 97·8% 98·8% 
(54) Russian Federation 819 58 36 95 0·6% 1·4% 1·9% 3·9% 4·5% 6·1% 14·0% 28·8% 43·6% 78·7% 90·2% 94·6% 96·7% 
(9) Seychelles 123 62 38 102 0·6% 1·3% 1·8% 3·7% 4·3% 5·8% 13·0% 26·6% 40·5% 75·7% 88·3% 93·4% 95·9% 
(10) Slovenia 2224 88 58 134 0·1% 0·2% 0·3% 0·8% 0·9% 1·3% 3·8% 10·4% 19·8% 60·6% 81·8% 90·6% 94·5% 
(9) Sri Lanka 153 65 46 93 0·1% 0·2% 0·3% 0·8% 1·0% 1·6% 5·4% 16·8% 32·9% 80·8% 93·7% 97·3% 98·6% 
(36) Switzerland 586 64 38 107 0·6% 1·4% 1·8% 3·7% 4·3% 5·7% 12·6% 25·6% 39·0% 73·8% 87·1% 92·6% 95·3% 
(9) Ukraine 5276 101 65 157 0·1% 0·2% 0·3% 0·7% 0·8% 1·2% 3·2% 8·3% 15·8% 51·7% 74·8% 86·0% 91·5% 
Very low / low mortality (median) 728 65 40 107 0·4% 1·0% 1·4% 3·0% 3·5% 4·8% 11·3% 24·1% 37·9% 73·8% 87·8% 93·4% 95·9% 
(9) Armenia 781 76 52 113 0·1% 0·2% 0·3% 0·9% 1·0% 1·5% 4·7% 13·2% 25·4% 70·4% 88·1% 94·3% 96·9% 
(9) China 1078 52 33 81 0·5% 1·2% 1·7% 3·9% 4·6% 6·4% 15·6% 33·4% 50·4% 84·8% 93·8% 96·8% 98·2% 
(9) Egypt 666 34 22 53 1·1% 2·8% 4·0% 9·0% 10·6% 14·7% 32·8% 58·1% 74·4% 94·5% 98·0% 99·0% 99·5% 
(46) Iran 275 47 30 74 0·7% 1·6% 2·3% 5·0% 5·9% 8·1% 19·1% 38·6% 55·8% 87·1% 94·8% 97·3% 98·4% 
(47) Iran 88 50 28 89 1·6% 3·2% 4·2% 7·8% 8·8% 11·3% 21·8% 38·0% 51·7% 80·4% 90·0% 94·0% 96·0% 
(9) Iran 958 46 29 72 0·7% 1·7% 2·4% 5·3% 6·2% 8·6% 20·1% 40·2% 57·5% 87·9% 95·1% 97·5% 98·5% 
(9) Jordan 337 32 21 50 1·6% 3·8% 5·3% 11·4% 13·2% 17·9% 37·1% 61·4% 76·3% 94·7% 98·0% 99·0% 99·4% 
(28) Kazakhstan 2023 46 29 72 0·7% 1·6% 2·3% 5·1% 6·0% 8·3% 19·7% 39·8% 57·2% 87·9% 95·1% 97·5% 98·6% 
(9) Mauritius 355 84 54 132 0·2% 0·4% 0·5% 1·2% 1·5% 2·1% 5·4% 13·3% 23·6% 62·8% 82·0% 90·2% 94·1% 
(9) Mongolia 1424 38 26 55 0·4% 1·3% 1·9% 5·1% 6·1% 9·1% 24·7% 52·0% 71·6% 95·1% 98·5% 99·3% 99·7% 
(9) Syria 1157 35 23 53 0·8% 2·3% 3·3% 7·8% 9·2% 13·0% 30·8% 57·1% 74·3% 94·9% 98·2% 99·2% 99·5% 
(9) Tunisia 118 40 26 61 0·8% 2·0% 2·9% 6·5% 7·6% 10·7% 25·2% 48·7% 66·4% 92·1% 97·0% 98·6% 99·2% 
(27) Venezuela 102 42 27 66 0·9% 2·2% 3·0% 6·6% 7·7% 10·5% 23·9% 45·5% 62·5% 89·9% 95·9% 97·9% 98·8% 
(9) Vietnam 4628 52 35 76 0·2% 0·6% 0·9% 2·3% 2·8% 4·1% 12·2% 30·7% 50·3% 88·1% 95·9% 98·2% 99·0% 
Medium mortality (median) 724 46 29 72 0·7% 1·7% 2·4% 5·2% 6·2% 8·8% 21·0% 40·0% 57·3% 88·0% 95·5% 97·7% 98·7% 
(9) Azerbaijan 643 71 45 113 0·3% 0·7% 0·9% 2·1% 2·4% 3·4% 8·4% 19·4% 32·3% 71·2% 86·6% 92·8% 95·6% 
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(19) Bangladesh 297 35 19 65 3·8% 7·2% 9·2% 15·7% 17·4% 21·5% 36·4% 54·5% 66·9% 87·7% 93·7% 96·2% 97·4% 
(10) Bangladesh 191 53 39 73 0·0% 0·2% 0·3% 0·9% 1·2% 1·9% 7·5% 25·1% 47·8% 91·2% 97·7% 99·2% 99·6% 
(33) Bangladesh 2021 45 33 61 0·1% 0·3% 0·5% 1·5% 1·9% 3·2% 12·3% 37·4% 62·5% 95·2% 98·8% 99·6% 99·8% 
(56) Bangladesh 4787 48 36 63 0·0% 0·1% 0·2% 0·8% 1·0% 1·8% 8·4% 31·2% 58·5% 95·6% 99·1% 99·7% 99·9% 
(9) Cambodia 2094 48 33 70 0·2% 0·6% 0·9% 2·4% 2·9% 4·4% 13·5% 34·5% 55·5% 90·9% 97·1% 98·8% 99·4% 
(9) Eritrea 110 67 42 107 0·4% 0·9% 1·2% 2·6% 3·0% 4·2% 10·1% 22·3% 35·9% 73·8% 87·9% 93·4% 96·0% 
(24) Guatemala 91 47 28 78 1·2% 2·7% 3·6% 7·1% 8·2% 10·8% 22·3% 40·4% 55·6% 84·5% 92·8% 96·0% 97·5% 
(10) India 173 52 38 70 0·0% 0·1% 0·2% 0·8% 1·0% 1·8% 7·4% 26·2% 50·6% 92·9% 98·3% 99·4% 99·7% 
(34) India 704 43 27 69 1·0% 2·3% 3·1% 6·6% 7·7% 10·5% 23·2% 43·9% 60·6% 88·7% 95·3% 97·5% 98·5% 
(44) India 52 54 38 78 0·1% 0·4% 0·6% 1·6% 2·0% 3·0% 9·7% 27·0% 47·0% 88·0% 96·2% 98·4% 99·2% 
(48) Indonesia 88 48 32 73 0·4% 1·1% 1·6% 3·8% 4·5% 6·4% 16·6% 36·5% 54·9% 88·2% 95·6% 97·9% 98·8% 
(9) Indonesia 711 60 39 94 0·3% 0·8% 1·1% 2·5% 3·0% 4·2% 10·8% 25·0% 40·7% 79·6% 91·5% 95·7% 97·5% 
(9) Iraq 1786 32 19 52 2·3% 5·2% 7·0% 13·8% 15·7% 20·5% 39·1% 61·5% 75·3% 93·6% 97·3% 98·6% 99·1% 
(43) Kenya 429 41 28 60 0·5% 1·3% 1·9% 4·7% 5·7% 8·3% 22·2% 47·1% 66·7% 93·4% 97·8% 99·0% 99·5% 
(45) Kenya 232 26 17 40 2·5% 6·1% 8·4% 17·6% 20·2% 26·7% 50·1% 73·4% 85·0% 97·0% 98·9% 99·4% 99·7% 
(51) Kenya 195 33 22 49 0·9% 2·4% 3·5% 8·4% 10·0% 14·2% 33·7% 60·9% 77·6% 95·9% 98·6% 99·4% 99·7% 
(53) Kenya 587 42 29 61 0·3% 0·9% 1·4% 3·8% 4·6% 6·9% 19·7% 44·9% 65·6% 93·7% 98·0% 99·1% 99·6% 
(9) Kenya 634 39 25 63 1·2% 2·8% 3·8% 8·1% 9·4% 12·7% 27·3% 49·3% 65·6% 90·6% 96·2% 98·0% 98·8% 
(9) Lao 482 56 39 81 0·1% 0·4% 0·6% 1·5% 1·9% 2·8% 9·0% 24·9% 43·9% 86·2% 95·4% 98·0% 99·0% 
(9) Libya 717 38 24 58 1·0% 2·4% 3·4% 7·6% 8·9% 12·3% 28·1% 52·1% 69·2% 92·8% 97·3% 98·7% 99·2% 
(9) Madagascar 58 38 26 55 0·4% 1·3% 2·0% 5·1% 6·2% 9·1% 25·0% 52·3% 71·9% 95·2% 98·5% 99·3% 99·7% 
(25) Morocco 582 36 22 60 2·1% 4·5% 6·0% 11·6% 13·2% 17·1% 33·1% 54·1% 68·7% 90·7% 95·9% 97·7% 98·6% 
(9) Morocco 450 43 26 73 1·6% 3·3% 4·5% 8·6% 9·9% 12·9% 25·7% 44·8% 59·8% 86·4% 93·7% 96·5% 97·8% 
(9) Myanmar 919 50 35 70 0·1% 0·4% 0·6% 1·7% 2·2% 3·4% 11·3% 31·8% 53·9% 91·5% 97·5% 99·0% 99·5% 
(9) Nepal 536 38 21 68 3·3% 6·2% 8·0% 13·9% 15·5% 19·3% 33·6% 51·7% 64·5% 86·7% 93·3% 95·9% 97·3% 
(9) Senegal 228 42 23 75 2·8% 5·3% 6·8% 11·9% 13·3% 16·7% 29·7% 47·1% 60·2% 84·5% 92·0% 95·1% 96·7% 
(55) South Africa 216 27 18 41 2·0% 5·0% 7·0% 15·4% 17·9% 24·1% 47·8% 72·5% 84·8% 97·1% 99·0% 99·5% 99·7% 
(9) Tajikistan 1395 42 30 59 0·2% 0·6% 0·9% 2·6% 3·3% 5·2% 16·9% 43·2% 66·0% 94·9% 98·6% 99·4% 99·7% 
(28) Uzbekistan 1081 50 32 77 0·5% 1·2% 1·8% 4·0% 4·7% 6·6% 16·4% 35·1% 52·7% 86·3% 94·6% 97·3% 98·4% 
(9) Yemen 1068 37 25 57 0·8% 2·2% 3·1% 7·1% 8·4% 11·8% 27·8% 52·6% 70·1% 93·5% 97·6% 98·9% 99·4% 
High mortality (median) 536 43 28 68 0·5% 1·3% 1·9% 4·7% 5·7% 8·3% 22·2% 43·9% 60·6% 90·9% 97·1% 98·6% 99·2% 
(9) Afghanistan 4628 36 24 55 0·9% 2·4% 3·4% 7·9% 9·3% 12·9% 29·8% 54·8% 71·9% 93·9% 97·8% 98·9% 99·4% 
(9) Benin 125 37 28 50 0·1% 0·5% 0·8% 2·7% 3·5% 5·7% 21·2% 54·3% 77·3% 97·7% 99·5% 99·8% 99·9% 
(9) Cameroon 1263 31 20 48 1·8% 4·2% 5·9% 12·6% 14·6% 19·5% 39·7% 64·0% 78·3% 95·2% 98·2% 99·1% 99·5% 
(9) Central African Republic 293 31 21 44 0·7% 2·2% 3·4% 8·7% 10·5% 15·3% 37·9% 67·4% 83·0% 97·5% 99·3% 99·7% 99·8% 
(9) Côte d'Ivoire 82 37 26 53 0·4% 1·2% 1·9% 5·0% 6·1% 9·1% 25·6% 54·0% 73·7% 95·8% 98·7% 99·5% 99·7% 
(21) DR Congo 272 36 26 51 0·3% 1·0% 1·5% 4·4% 5·4% 8·4% 25·3% 55·5% 75·9% 96·7% 99·1% 99·6% 99·8% 
(9) DR Congo 1750 33 23 48 0·5% 1·5% 2·3% 6·3% 7·7% 11·6% 31·5% 61·8% 79·8% 97·1% 99·2% 99·7% 99·8% 
(9) Ethiopia 518 50 30 81 0·9% 2·1% 2·8% 5·7% 6·6% 8·9% 19·3% 37·0% 52·6% 83·7% 92·7% 96·0% 97·5% 
(10) Gambia 86 50 34 74 0·3% 0·7% 1·0% 2·7% 3·2% 4·8% 13·5% 32·9% 52·5% 88·6% 96·1% 98·2% 99·0% 
(9) Ghana 1133 39 25 61 1·0% 2·5% 3·5% 7·6% 8·9% 12·2% 27·3% 50·3% 67·1% 91·8% 96·8% 98·4% 99·1% 
(9) Guinea-Bissau 443 40 25 63 1·0% 2·5% 3·5% 7·5% 8·8% 11·9% 26·5% 48·8% 65·5% 91·0% 96·4% 98·2% 98·9% 
(9) Lesotho 86 38 26 57 0·5% 1·5% 2·2% 5·4% 6·5% 9·5% 24·8% 51·0% 70·1% 94·3% 98·1% 99·2% 99·6% 
(31) Malawi 807 31 21 48 1·3% 3·2% 4·7% 10·6% 12·4% 17·2% 37·7% 63·8% 79·0% 95·9% 98·6% 99·3% 99·6% 
(49) Nigeria 49 40 26 62 0·8% 2·0% 2·8% 6·4% 7·5% 10·5% 24·7% 47·8% 65·5% 91·7% 96·9% 98·5% 99·1% 
(9) Nigeria 1336 39 27 58 0·5% 1·3% 2·0% 5·0% 6·0% 8·8% 23·5% 49·2% 68·7% 94·0% 98·0% 99·1% 99·5% 
(9) Pakistan 3276 37 21 63 2·4% 5·0% 6·6% 12·3% 13·9% 17·8% 33·2% 53·3% 67·2% 89·4% 95·1% 97·2% 98·2% 
(9) Rwanda 123 47 31 72 0·5% 1·2% 1·8% 4·1% 4·9% 6·9% 17·6% 37·9% 56·2% 88·6% 95·7% 97·9% 98·8% 
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(9) Sierra Leone 74 39 24 63 1·4% 3·2% 4·4% 8·9% 10·3% 13·7% 28·5% 50·0% 65·8% 90·2% 95·9% 97·8% 98·7% 
(9) Sudan 4077 39 25 59 0·8% 2·1% 3·0% 6·9% 8·1% 11·4% 26·6% 50·6% 68·1% 92·7% 97·3% 98·7% 99·2% 
(9) Swaziland 138 35 22 56 1·4% 3·4% 4·7% 10·0% 11·5% 15·6% 32·7% 56·1% 71·8% 93·0% 97·2% 98·6% 99·2% 
(9) Tanzania 66 37 26 53 0·4% 1·3% 2·0% 5·2% 6·3% 9·4% 25·9% 53·9% 73·4% 95·6% 98·7% 99·4% 99·7% 
(9) Togo 293 36 23 58 1·5% 3·4% 4·6% 9·7% 11·2% 15·0% 31·3% 54·0% 69·7% 92·1% 96·8% 98·3% 99·0% 
(20) Uganda 263 41 29 58 0·2% 0·6% 1·0% 2·9% 3·6% 5·7% 18·4% 45·6% 68·0% 95·3% 98·7% 99·5% 99·7% 
(9) Uganda 211 44 30 63 0·2% 0·7% 1·1% 3·0% 3·7% 5·6% 17·0% 41·5% 63·1% 93·4% 98·0% 99·2% 99·6% 
(9) Zambia 2149 29 19 46 1·9% 4·6% 6·5% 13·7% 15·9% 21·3% 42·5% 66·9% 80·5% 95·8% 98·4% 99·2% 99·6% 
(9) Zimbabwe 2601 39 25 60 0·9% 2·2% 3·2% 7·1% 8·4% 11·6% 26·7% 50·2% 67·5% 92·2% 97·1% 98·5% 99·2% 
Very high mortality (median) 293 38 25 58 0·8% 2·1% 2·9% 6·6% 7·9% 11·5% 26·5% 52·1% 69·2% 93·7% 97·9% 99·0% 99·4% 
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Appendix Table S3.  Goodness of fit statistics, goodness of fit criteria and best-fitting parameters of Log Logistic age distributions fitted to age 
distributions for rotavirus-positive hospital admissions <5 years in different countries 
 
 
Study characteristics Period Shape Scale COR Goodness of fit statistics and criteria 
 Ref Country 
Age 
grps. 
(n) 
Fro
m To Est. L95 U95 Est. L95 U95 
RM 
SE MAE KS CV AD AIC BIC 
Very low / low mortality                 
(41) Australia 31 1984 1985 2·31 1·71 2·91 66·87 52·71 80·99 0·0953 5% 4% 0·14 0·17 1·72 468 472 
(57) Bulgaria 44 2005 2011 2·27 2·19 2·35 64·64 62·56 66·71 0·0442 2% 1% 0·06 1·17 11·61 23250 23262 
(52) Chile 95 2007 2010 2·17 2·05 2·29 48·82 46·35 51·33 0·0464 3% 2% 0·05 0·50 4·13 9530 9539 
(23) Hong Kong 60 1997 2011 2·14 2·11 2·17 69·28 68·31 70·24 0·0428 2% 2% 0·06 4·89 66·91 142364 142379 
(42) Hong Kong 56 2014 2015 2·40 2·04 2·76 84·17 73·51 94·86 0·0419 2% 2% 0·07 0·05 0·86 1357 1362 
(10) France 100 2007 2016 1·77 1·73 1·80 42·74 41·82 43·66 0·0618 3% 2% 0·05 5·88 56·62 81992 82006 
(40) France 20 1997 2000 1·83 1·70 1·97 26·65 24·38 28·92 0·0253 3% 3% 0·06 0·25 2·33 4389 4397 
(9) Georgia 74 2012 2012 2·33 1·97 2·68 66·68 57·29 76·11 0·0326 5% 3% 0·08 0·10 0·73 1170 1176 
(10) Hungary 100 2006 2016 2·19 2·11 2·28 85·82 82·69 88·93 0·0570 3% 2% 0·08 1·41 15·58 20349 20360 
(22) Italy 98 2009 2016 2·16 2·05 2·27 76·90 73·09 80·72 0·0654 2% 2% 0·07 0·85 8·84 11013 11023 
(59) Italy 99 2013 2016 1·70 1·64 1·76 62·12 59·63 64·64 0·0928 4% 3% 0·08 3·97 40·34 26657 26668 
(37) Japan 32 2004 2006 2·54 2·00 3·08 73·43 60·36 86·47 0·0360 3% 2% 0·10 0·07 0·46 620 624 
(10) Netherlands 95 2007 2016 1·68 1·57 1·78 47·72 44·16 51·28 0·0756 4% 3% 0·07 0·92 10·73 7432 7441 
(39) New Zealand 57 1998 2000 2·44 2·27 2·61 55·47 52·20 58·74 0·0410 3% 2% 0·10 0·51 5·02 5631 5640 
(9) Oman 51 2008 2010 2·75 2·59 2·92 52·59 50·20 54·99 -0·0222 5% 3% 0·10 0·64 3·46 7208 7218 
(54) Russia 98 2005 2007 2·25 2·12 2·38 58·26 55·20 61·33 0·0122 3% 2% 0·04 0·22 2·57 8540 8550 
(9) Seychelles 85 2013 2016 2·19 1·87 2·51 61·97 53·24 70·71 0·0123 3% 2% 0·06 0·06 0·45 1308 1314 
(10) Slovenia 99 2007 2016 2·64 2·55 2·73 88·33 85·94 90·72 0·0424 2% 2% 0·06 0·73 12·08 24287 24299 
(9) Sri Lanka 90 2014 2016 3·10 2·69 3·51 65·40 59·56 71·24 -0·0358 4% 3% 0·08 0·18 1·08 1548 1554 
(36) Switzerland 96 2002 2006 2·14 2·00 2·29 64·09 59·95 68·26 0·0352 1% 1% 0·05 0·17 2·85 6260 6269 
(9) Ukraine 258 2012 2016 2·52 2·46 2·57 101·17 99·26 103·08 0·0538 4% 3% 0·09 6·84 55·95 59369 59382 
Medium mortality                 
(9) Armenia 193 2012 2012 2·80 2·64 2·97 76·32 72·98 79·66 0·0056 2% 1% 0·04 0·17 1·77 8244 8254 
(9) China 180 2014 2016 2·46 2·33 2·58 51·68 49·56 53·84 0·0446 3% 2% 0·05 0·75 6·82 10792 10801 
(9) Egypt 35 2008 2010 2·57 2·41 2·74 34·36 32·60 36·11 0·0227 1% 1% 0·06 0·37 2·42 6095 6104 
(46) Iran 33 2008 2010 2·42 2·18 2·66 47·21 43·25 51·15 0·0033 1% 1% 0·05 0·12 1·07 2729 2736 
(47) Iran 34 2008 2009 1·94 1·59 2·28 50·22 41·01 59·45 0·0349 2% 2% 0·10 0·11 0·93 919 924 
(9) Iran 47 2008 2010 2·42 2·29 2·55 45·92 43·85 47·98 -0·0049 3% 2% 0·07 0·42 2·68 9466 9476 
(9) Jordan 34 2008 2012 2·45 2·23 2·67 32·26 29·84 34·69 0·0349 2% 1% 0·07 0·25 1·78 3068 3075 
(28) Kazakhstan 98 2007 2009 2·44 2·35 2·54 46·19 44·78 47·59 0·0344 2% 1% 0·05 1·21 9·24 19849 19860 
(9) Mauritius 174 2010 2014 2·44 2·24 2·66 84·02 77·80 90·25 0·0348 2% 2% 0·06 0·17 1·77 3896 3904 
(9) Mongolia 138 2013 2016 2·94 2·81 3·07 37·97 36·82 39·14 0·0433 2% 1% 0·05 0·79 6·10 12914 12925 
(9) Syria 32 2008 2013 2·70 2·56 2·83 35·09 33·79 36·38 0·0274 1% 1% 0·06 0·65 5·69 10512 10522 
(9) Tunisia 31 2008 2010 2·55 2·17 2·93 39·80 34·90 44·71 -0·0177 3% 2% 0·08 0·09 0·53 1123 1129 
(27) Venezuela 57 2003 2003 2·41 2·02 2·80 42·05 36·18 47·94 0·0125 1% 1% 0·04 0·02 0·15 990 995 
(9) Vietnam 232 2012 2016 2·87 2·80 2·94 51·80 50·91 52·70 0·0091 1% 1% 0·02 0·30 4·50 45154 45167 
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High mortality                 
(9) Azerbaijan 206 2012 2016 2·37 2·22 2·52 71·04 66·96 75·09 0·0249 2% 2% 0·05 0·30 2·72 6886 6895 
(19) Bangladesh 35 2012 2012 1·82 1·64 1·99 35·35 31·58 39·12 0·0406 7% 4% 0·12 0·57 3·95 2922 2929 
(10) Bangladesh 57 2007 2010 3·50 3·08 3·92 53·32 49·61 57·02 -0·0004 1% 1% 0·05 0·06 0·40 1811 1817 
(33) Bangladesh 81 2000 2006 3·57 3·44 3·70 45·04 44·09 46·00 0·0103 1% 1% 0·05 0·67 3·80 18307 18318 
(56) Bangladesh 42 2012 2017 3·93 3·84 4·03 47·67 47·08 48·27 0·0207 1% 1% 0·07 2·64 16·03 42899 42912 
(9) Cambodia 178 2013 2016 3·00 2·89 3·10 48·31 47·11 49·50 0·0085 1% 1% 0·02 0·08 0·92 19968 19979 
(9) Eritrea 74 2013 2013 2·33 1·97 2·68 66·67 57·27 76·08 0·0333 5% 3% 0·08 0·10 0·74 1170 1175 
(24) Guatemala 46 2007 2009 2·13 1·76 2·49 46·81 38·99 54·65 0·0885 6% 4% 0·09 0·18 1·43 914 919 
(10) India 55 2007 2010 3·68 3·22 4·14 51·67 48·07 55·28 -0·0167 1% 1% 0·05 0·04 0·29 1615 1621 
(34) India 19 2005 2007 2·34 2·20 2·49 43·28 40·95 45·60 0·0438 3% 2% 0·10 0·94 7·14 6866 6875 
(44) India 28 2011 2012 3·04 2·33 3·76 54·09 46·11 62·06 0·0161 4% 3% 0·09 0·12 0·96 511 515 
(48) Indonesia 27 2013 2013 2·61 2·16 3·07 48·22 41·52 54·91 0·0020 2% 2% 0·08 0·06 0·33 867 872 
(9) Indonesia 175 2014 2016 2·51 2·35 2·66 60·43 57·34 63·50 0·0117 2% 1% 0·03 0·09 1·36 7326 7335 
(9) Iraq 48 2008 2011 2·25 2·16 2·34 31·64 30·51 32·76 0·0001 2% 2% 0·06 0·80 5·31 16585 16596 
(43) Kenya 43 2009 2014 2·81 2·59 3·04 40·63 38·31 42·95 -0·0089 3% 2% 0·08 0·36 2·46 4025 4033 
(45) Kenya 34 2009 2011 2·50 2·22 2·77 25·97 23·70 28·26 -0·0601 3% 2% 0·13 0·63 3·74 2049 2056 
(51) Kenya 61 2005 2007 2·76 2·44 3·09 33·20 30·28 36·10 0·0060 3% 2% 0·07 0·08 0·51 1756 1763 
(53) Kenya 77 2002 2004 2·96 2·76 3·16 41·81 39·84 43·79 0·0262 1% 1% 0·05 0·21 1·27 5439 5448 
(9) Kenya 148 2008 2013 2·34 2·19 2·50 39·50 37·21 41·77 -0·0082 1% 1% 0·03 0·10 0·76 6103 6111 
(9) Lao 137 2013 2016 2·99 2·77 3·21 56·44 53·49 59·40 -0·0164 2% 2% 0·04 0·18 1·26 4755 4763 
(9) Libya 38 2008 2013 2·52 2·37 2·68 37·75 35·85 39·61 0·0120 2% 1% 0·07 0·36 2·43 6732 6741 
(9) Madagascar 38 2013 2013 2·95 2·30 3·60 37·78 32·23 43·33 0·0366 3% 2% 0·09 0·07 0·63 529 533 
(25) Morocco 34 2006 2009 2·15 2·00 2·29 36·10 33·73 38·45 0·0060 3% 2% 0·06 0·26 1·85 5592 5601 
(9) Morocco 38 2008 2009 2·10 1·94 2·26 43·07 39·76 46·36 -0·0029 2% 2% 0·07 0·29 2·12 4502 4510 
(9) Myanmar 143 2014 2016 3·20 3·02 3·37 49·52 47·79 51·24 0·0160 1% 1% 0·03 0·10 0·84 8695 8705 
(9) Nepal 36 2014 2016 1·85 1·71 1·98 37·63 34·68 40·57 0·0517 4% 3% 0·08 0·50 5·21 5303 5311 
(9) Senegal 111 2009 2014 1·84 1·64 2·04 41·51 36·43 46·59 0·0638 4% 3% 0·08 0·24 2·10 2294 2301 
(55) South Africa 20 2003 2004 2·61 2·32 2·90 26·88 24·52 29·25 0·0076 4% 3% 0·08 0·18 1·07 1875 1882 
(9) Tajikistan 156 2012 2014 3·25 3·11 3·40 42·42 41·24 43·60 0·0055 1% 1% 0·03 0·25 1·41 12760 12770 
(28) Uzbekistan 92 2008 2009 2·50 2·38 2·63 49·82 47·78 51·87 0·0333 1% 1% 0·05 0·41 3·44 10716 10726 
(9) Yemen 38 2008 2011 2·61 2·47 2·74 37·48 36·00 38·96 0·0235 2% 2% 0·07 0·59 4·56 9919 9929 
Very high mortality                 
(9) Afghanistan 46 2008 2016 2·59 2·53 2·65 36·19 35·49 36·89 0·0095 3% 2% 0·08 3·12 18·70 42811 42823 
(9) Benin 56 2013 2016 3·66 3·11 4·22 37·21 34·20 40·21 -0·0311 5% 4% 0·09 0·15 1·03 1094 1100 
(9) Cameroon 132 2008 2013 2·45 2·34 2·57 30·85 29·66 32·03 0·0290 2% 1% 0·04 0·42 4·04 11374 11385 
(9) C. Afr. Rep. 74 2011 2016 3·00 2·71 3·29 30·63 28·63 32·63 0·0187 1% 1% 0·05 0·08 0·72 2532 2539 
(9) Côte d'Ivoire 52 2010 2016 3·03 2·48 3·58 37·00 32·43 41·57 0·0446 3% 2% 0·07 0·10 0·57 739 744 
(21) DR Congo 24 2012 2013 3·22 2·90 3·54 36·39 34·09 38·71 0·0433 3% 2% 0·08 0·25 1·94 2395 2402 
(9) DR Congo 123 2009 2016 3·10 2·98 3·22 33·41 32·54 34·28 0·0246 1% 1% 0·03 0·30 3·00 15253 15264 
(9) Ethiopia 49 2008 2013 2·21 2·05 2·37 49·61 46·26 52·95 0·0064 2% 2% 0·04 0·12 1·31 5267 5275 
(10) Gambia 43 2007 2010 2·82 2·31 3·32 50·19 43·73 56·64 0·0419 4% 3% 0·07 0·06 0·54 838 843 
(9) Ghana 145 2009 2011 2·45 2·33 2·57 38·83 37·23 40·42 0·0363 2% 1% 0·04 0·28 3·18 10707 10717 
(9) Guinea-Bis. 120 2010 2013 2·40 2·22 2·59 39·79 37·12 42·47 0·0393 3% 2% 0·04 0·16 1·46 4223 4231 
(9) Lesotho 51 2013 2016 2·83 2·32 3·33 38·47 33·52 43·41 0·0420 2% 2% 0·06 0·06 0·43 793 798 
(31) Malawi 58 1997 2007 2·64 2·48 2·79 31·43 30·01 32·85 0·0320 2% 1% 0·08 0·42 4·28 7169 7178 
(49) Nigeria 19 2012 2013 2·54 1·95 3·13 40·36 32·60 48·12 0·0458 4% 3% 0·11 0·06 0·49 466 470 
(9) Nigeria 152 2010 2016 2·84 2·71 2·97 39·43 38·15 40·71 0·0143 1% 1% 0·03 0·21 1·57 12343 12354 
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(9) Pakistan 53 2008 2016 2·05 1·99 2·10 36·59 35·53 37·66 0·0241 1% 1% 0·05 1·40 11·92 31740 31752 
(9) Rwanda 74 2010 2011 2·59 2·20 2·98 47·20 41·78 52·64 0·0439 3% 2% 0·06 0·13 1·52 1199 1205 
(9) Sierra Leone 26 2013 2013 2·27 1·82 2·71 38·99 32·40 45·58 0·0195 6% 5% 0·12 0·14 0·89 717 722 
(9) Sudan 47 2008 2010 2·56 2·50 2·63 38·65 37·86 39·45 0·0227 2% 1% 0·07 2·49 15·96 38282 38294 
(9) Swaziland 69 2013 2014 2·39 2·05 2·73 35·18 30·95 39·41 0·0606 3% 2% 0·10 0·24 1·46 1284 1290 
(9) Tanzania 45 2009 2012 2·98 2·37 3·60 37·01 31·96 42·06 0·0078 5% 3% 0·09 0·07 0·47 601 606 
(9) Togo 97 2009 2013 2·34 2·11 2·57 36·40 33·38 39·44 0·0341 2% 2% 0·05 0·13 1·57 2759 2766 
(20) Uganda 25 2012 2012 3·24 2·91 3·57 41·19 38·53 43·83 0·0263 3% 2% 0·07 0·18 1·33 2382 2389 
(9) Uganda 84 2015 2016 3·06 2·71 3·41 43·64 40·35 46·94 0·0290 3% 2% 0·05 0·10 0·90 1961 1968 
(9) Zambia 135 2008 2013 2·48 2·39 2·57 29·35 28·49 30·21 0·0490 3% 2% 0·05 1·13 10·37 19026 19038 
(9) Zimbabwe 190 2009 2013 2·51 2·43 2·60 38·86 37·84 39·88 0·0226 1% 1% 0·03 0·37 3·68 24521 24533 
 
 
COR: Correlation coefficient between fitted shape and scale parameters 
 
Goodness of fit statistics and criteria: RMSE = Root Mean Squared Error, MAE = Mean Absolute Error, KS = Kolmogorov-Smirnov statistic; CV= Cramer-von Mises statistic; AD= 
Anderson-Darling statistic; AIC = Akaike's Information Criterion; BIC = Bayesian Information Criterion. 
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Regression models to predict scale and shape parameters of the Log Logistic 
distribution 
 
Independent variables considered 
• 5 mortality strata (v low, low, medium, high, v high) 
• 3 mortality strata (v low and low, medium, high and v high) 
• 2 mortality strata (v low/ + low; medium + high + v high) 
• WHO regions (6) 
• WHO Choice mortality strata/subregions (14) 
• Mid-year of data collection period (1980-1999, 2000-2004, 2005-2009, 2010-2014, 
2015-2018). 
• Presentation: clinic visits, community cases, emergency visits, hospital admissions. 
• Access to skilled delivery: 0-35%, 36-44%, 45-54%, 55-64%, 65-94%, 95-100%. 
• GDP per capita in 2011 
 
 
Datasets considered 
A. all 117 studies 
B. 110 studies excluding 7 of emergency admissions 
C. 106 studies excluding 7 of emergency admissions and 4 with midyear of data 
collection between 1980 and 1999. 
D. 103 studies excluding 7 of emergency admissions, 4 with midyear of data collection 
between 1980 and 1999, and 31  with no data on GDP 
 
 
Appendix Table S4:  Summary of alternative models for the Scale (median age) 
parameter 
 
Model Data Independent variables  df Akaike’s 
Information 
Criterion 
Adjusted 
R2 (Scale)  
1 A 14 WHO Choice mortality sub-regions  13 919.8 41.5% 
2 A 5 mortality strata  4 920.7 36.8% 
3 B 5 mortality strata 4 861.3 40.8% 
4 C 5 mortality strata 4 815.9 47.6% 
5 D 5 mortality strata 5 794.4 43.8% 
6 D 6 WHO regions and 2 mortality strata 6 793.9 45.7% 
7 D 6 WHO regions and 3 mortality strata 7 784.2 50.5% 
8 D 6 WHO regions and 5 mortality strata 9 787.5 49.8% 
9 D 6 WHO regions and 3 mortality strata, 
with interactions 
15 777.0 56.9% 
10 D 5 mortality strata and GDPpc2011 5 784.4 49.5% 
11 D 6 WHO regions & 3 mortality strata 
with interactions, and GDPpc2011 
16 765.4 61.8% 
 
 
                                                 
1 1 study from the Seychelles and 2 from Hong Kong. The Seychelles is the only country in the AFRO 
region in the Low or Very Low mortality strata.  
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By comparing models 2 to 5 in this table it can be seen that selecting less heterogeneous sets 
of studies for analysis resulted in better fits.   
 
Using D, the most restricted dataset, it can then be seen that models 9 and 11 provide the 
best fit, in terms of both AIC and adjusted R-square.  However they involve large numbers 
of predictors relative to the numbers of observations, including one for the mid strata and 
one for the high strata in each region, risking overfitting.  For several combinations of 
stratum and region of the coefficient depends on only one data point, and for 2 combinations 
there is no data point. 
 
Model 5, in which the predicted value of the scale parameter for a country is simply the 
mean of the scale parameters for all studies in that country’s mortality stratum, provides a 
moderately good fit with few predictors, and is worth considering for its simplicity. 
 
Model 7 is superior to model 5 (likelihood ratio test p = 0.1%) and so is Model 10 (LR test p 
= 0.05%).  There is no evidence that model 10 is superior to model 7 in terms of fit (LR test 
p = 12%) but model 10 involves fewer predictors.  
 
For the Shape parameter, restricting the analysis to dataset D again improved the fit for the 
simple mortality strata model in terms of AIC (116.9 for model 5compared to 131.2  for 
model 2) but not in terms of adjusted R-squared (12.8% compared to 15.0%).  However 
none of the models tried was good. For example model 7 gave R-square 16.9% and AIC 
114.8. 
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Appendix Table S5:  Selected regression models for estimating the scale parameter of the Log Logistic age distribution 
 
 
  Model 5   Model 7    Model 10         Model 11 
                                    
R-Sq  46.0%   53.90%   52.00%      R-Sq    67.80%    
adjusted R-sq 43.8%   49.8%   49.5%      adjusted R-sq   61.8%    
AIC  794.4   787.5   784.4      AIC    765.4    
                          
  group n coeff p group n coeff p group n coeff p        
group 
n coeff p 
Constant     70.16 0.000   55.53 0.000   91.09 0.000   Constant       52.82 0.000 
                           
GDP per capita               -0.0006 0.001   GDP       -0.0004 0.001 
                                    
mortality Very low 11 0.00      11 0.00     region/ 
mortality 
AFR Low 0 -   
  Low 8 -6.22 0.234 19 0.00  8 -21.93 0.001    Mid 1 34.76 0.003 
  Mid 15 -22.12 0.000 15 -9.58 0.032 15 -40.15 0.000      High 36 -13.23 0.052 
  High 38 -25.36 0.000 69 -15.31 0.000 38 -45.17 0.000     AMR Low 1 1.83 0.873 
  Very high 31 -31.39 0.000     31 -51.80 0.000      Mid 1 -6.39 0.575 
                     High 2 -0.62 0.947 
region AFR       37 0.00             EMR Low 1 9.97 0.394 
  AMR     4 2.69 0.638           Mid 7 -10.50 0.160 
  EMR     18 -3.92 0.240           High 10 -14.58 0.044 
  EUR     19 14.99 0.001          EUR Low 14 29.17 0.000 
  SEAR     18 6.53 0.035           Mid 2 11.38 0.222 
  WPR     7 6.50 0.183           High 3 2.87 0.734 
                          SEAR Low 2 8.45 0.362 
                Mid 0 -   
                High 16 -5.22 0.452 
               WPR Low 1 39.18 0.002 
                Mid 4 -4.49 0.576 
                 High 2 0.00   
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Appendix Table S6: Age distributions for rotavirus-positive community cases aged <5 years before the introduction of rotavirus vaccination: 
median, interquartile range and cumulative age distribution* 
 
 
Reference Country n 50th pc. 
25th 
pc. 
75th 
pc. 6w 2m 10w 14w 15w 4m 6m 9m 12m 24m 36m 48m 60m 
(12) Bangladesh 143 44 31 61 0·2% 0·5% 0·8% 2·4% 2·9% 4·7% 15·6% 41·1% 64·1% 94·6% 98·5% 99·4% 99·7% 
(12) India 40 43 29 65 0·5% 1·3% 2·0% 4·7% 5·6% 8·0% 20·5% 43·3% 62·3% 91·4% 96·9% 98·5% 99·2% 
(58) India 282 37 19 70 4·4% 7·9% 9·8% 16·2% 17·9% 21·7% 35·6% 52·4% 64·2% 85·4% 92·1% 95·0% 96·5% 
(15) Mexico 89 28 17 46 3·1% 6·7% 9·0% 17·3% 19·6% 25·2% 45·5% 67·4% 79·8% 94·9% 97·9% 98·9% 99·3% 
(12) Nepal 71 50 35 70 0·1% 0·4% 0·6% 1·8% 2·3% 3·6% 11·6% 32·0% 53·8% 91·1% 97·4% 98·9% 99·5% 
(12) Pakistan 71 37 25 56 0·7% 2·0% 2·8% 6·7% 8·0% 11·3% 27·4% 52·7% 70·7% 93·9% 97·9% 99·0% 99·4% 
 Median 80 40 27 63 0·6% 1·7% 2·4% 5·7% 6·8% 9·7% 23·9% 47·9% 64·2% 92·6% 97·6% 98·9% 99·4% 
 
*These age distributions are likely to be biased to younger ages because all of the data used for the fitting was based on children aged <2 years. 
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Appendix Table S7: Age distributions for rotavirus-positive clinic visits aged <5 years before the introduction of rotavirus vaccination: median, 
interquartile range and cumulative age distribution 
 
Reference Country n 50th pc. 25th pc. 75th pc. 6w 2m 10w 14w 15w 4m 6m 9m 12m 24m 36m 48m 60m 
(50) China 224 46 29 72 0·7% 1·8% 2·5% 5·4% 6·4% 8·8% 20·4% 40·6% 57·8% 88·0% 95·1% 97·5% 98·5% 
(11) Gambia 119 54 37 78 0·2% 0·5% 0·7% 1·9% 2·4% 3·6% 10·8% 28·3% 47·8% 87·4% 95·8% 98·1% 99·0% 
(35) Germany 1244 58 33 101 1·1% 2·2% 2·9% 5·5% 6·3% 8·2% 16·8% 31·2% 44·6% 76·2% 87·8% 92·7% 95·2% 
(24) Guatemala 56 55 36 84 0·3% 0·8% 1·2% 2·8% 3·4% 4·8% 12·6% 29·1% 46·4% 83·8% 93·6% 96·9% 98·2% 
(3) Hungary 229 96 57 163 0·3% 0·6% 0·8% 1·7% 1·9% 2·6% 6·0% 12·9% 21·4% 53·9% 73·3% 83·4% 89·0% 
(11) India 222 54 36 79 0·2% 0·5% 0·8% 2·1% 2·5% 3·8% 11·2% 28·7% 47·9% 87·0% 95·5% 98·0% 98·9% 
(11) Kenya 183 40 26 61 0·8% 2·0% 2·8% 6·4% 7·6% 10·6% 25·2% 48·8% 66·6% 92·2% 97·1% 98·6% 99·2% 
(31) Malawi 446 35 25 51 0·5% 1·4% 2·2% 5·7% 7·0% 10·4% 28·3% 57·4% 76·3% 96·3% 98·9% 99·5% 99·8% 
(11) Mali 275 46 31 69 0·4% 1·0% 1·5% 3·7% 4·5% 6·5% 17·4% 38·8% 58·1% 90·1% 96·5% 98·4% 99·1% 
(11) Pakistan 226 37 25 54 0·6% 1·7% 2·5% 6·2% 7·5% 10·8% 27·6% 54·5% 72·9% 95·0% 98·4% 99·3% 99·6% 
(3) Slovenia 79 76 50 116 0·1% 0·3% 0·5% 1·2% 1·4% 2·0% 5·6% 14·7% 26·9% 69·4% 86·8% 93·3% 96·2% 
(30) Thailand 41 54 33 88 0·7% 1·7% 2·3% 4·7% 5·4% 7·3% 16·4% 32·6% 47·9% 81·2% 91·5% 95·3% 97·1% 
 Median 223 54 33 78 0·4% 1·2% 1·8% 4·2% 4·9% 6·9% 16·6% 31·9% 47·9% 87·2% 95·3% 97·7% 98·7% 
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Appendix Table S8: Age distributions for rotavirus-positive emergency visits aged <5 years before the introduction of rotavirus vaccination: median, 
interquartile range and cumulative age distribution 
 
Reference Country n 50th pc. 
25th 
pc. 
75th 
pc. 6w 2m 10w 14w 15w 4m 6m 9m 12m 24m 36m 48m 60m 
(29) France 9127 41 21 78 3·7% 6·6% 8·3% 13·9% 15·3% 18·8% 31·6% 48·0% 60·1% 83·1% 90·7% 94·1% 95·9% 
(18) Israel 1245 43 28 67 0·6% 1·6% 2·3% 5·3% 6·3% 8·9% 21·5% 43·4% 61·5% 90·3% 96·3% 98·2% 99·0% 
(32) Namibia 119 33 18 61 4·4% 8·2% 10·4% 17·5% 19·4% 23·8% 39·2% 57·2% 69·1% 88·6% 94·1% 96·4% 97·6% 
(10) Netherlands 95 58 36 92 0·5% 1·2% 1·7% 3·6% 4·2% 5·7% 13·5% 28·7% 44·0% 79·8% 91·1% 95·2% 97·1% 
(55) South Africa 48 28 16 52 5·5% 10·2% 12·8% 21·5% 23·7% 28·8% 46·0% 64·2% 75·2% 91·6% 95·8% 97·5% 98·3% 
(26) USA 101 63 41 98 0·3% 0·7% 1·0% 2·3% 2·7% 3·9% 9·9% 23·2% 38·1% 77·5% 90·4% 95·1% 97·1% 
(38) USA 78 53 32 87 0·9% 1·9% 2·6% 5·3% 6·1% 8·1% 17·7% 34·3% 49·4% 81·6% 91·5% 95·3% 97·1% 
 Median 101 43 28 78 0·9% 1·9% 2·6% 5·3% 6·3% 8·9% 21·5% 43·4% 60·1% 83·1% 91·5% 95·3% 97·1% 
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Appendix Figure S3: Median age of rotavirus disease before the introduction of 
rotavirus, by type of presentation and national under-five mortality rate 
 
 
 
We did not include community cases in this analysis because the data were only available up 
to two years of age, compared to five years for other presentations. 
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6.0 Chapter 6 - Estimation of rotavirus vaccine coverage and timeliness 
 
6.1  Contribution of paper to the aim and objectives of the thesis 
 
This paper was published prior to registration of the research degree but provides 
important background to the household survey data and survival analysis methods 
used to calculate coverage and timeliness of vaccination in different LMICs. The 
paper was published in the Lancet. As the Lancet is not an open access journal, it is 
included in this chapter in its final draft post-refereeing, rather than in the publisher’s 
final format. The appendix to the paper is also included in this format, at the end of 
the thesis (Appendix 5). 
 
Vaccine timeliness is required to calculate vaccine impact in each week of age. It can 
also be used to calculate the number of new doses administered in each week of age, 
and thus allows for more precise estimation of the potential intussusception risks in 
each week of age.  
 
The survival analysis in the publication was done by Colin Sanderson using USAID 
Demographic and Health Survey (DHS) data. Since this paper was published, Colin 
has expanded the database to include UNICEF Multiple Indicator Cluster Surveys 
(MICs) and has updated the estimates periodically. For the updated benefit-risk 
analysis (Chapter 9), Colin shared estimates of country-specific coverage rates 
derived from survival analysis of 73 nationally representative household surveys. This 
included estimates of coverage at different ages up to age 3.0 years, for the following 
vaccines: BCG; DTP1; DTP2; DTP3; and, Meas1. To accommodate this data into the 
benefit-risk analysis, I fit parametric curves to the age-specific coverage estimates for 
each country/vaccine using maximum likelihood estimation (MLE). This allowed 
calculation of uncertainty intervals and provided a convenient basis for extrapolating 
timeliness curves to countries without household survey data. The methods and 
outputs of this analysis are described in more detail later in the chapter. 
 
6.2 Independent academic contribution 
 
In the published paper, I extracted the datasets, ran the first analysis, wrote the first 
draft and presented the work to WHO’s Strategic Advisory Group of Experts (SAGE). 
Survival analyses were done by Colin Sanderson. For the new benefit-risk analysis 
(Chapter 9), Colin shared updated survival analyses, and I fit parametric curves to 
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these data. For the parametric fitting, I wrote the R code, tested goodness of fit for a 
range of distributions, and developed methods to extrapolate the curves to countries 
without data.  
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Summary 
Background:  Vaccinations are often delayed until well after the recommended ages, leaving 
many children exposed for longer than they should be. We estimated vaccination coverage at 
different ages, and delays in administration, in 45 low-income and middle-income countries. 
Methods:  We used data for 217 706 children from Demographic and Health Surveys between 
1996 and 2005 (median 2002), which provided data for vaccination of children on the basis 
of events recorded on vaccination cards and interviews with mothers, with imputation of 
missing values and survival analysis. We devised an index combining coverage and delay. 
Findings: For vaccinated children, the median of the median delays in the 45 countries was 
2.3 weeks (IQR 1.4-4.6) for bacille Calmette-Guérin (BCG); 2.4 weeks (1.2-3.3) for 
diphtheria, tetanus, and pertussis (DTP1); 2.7 weeks (1.7-3.1) for measles-containing vaccine 
(MCV1); and 6.2 weeks (3.5-8.5) for DTP3. However, in the 12 countries with the longest 
delays for each vaccination, at least 25% of the children vaccinated were more than 10 weeks 
late for BCG, 8 weeks for DTP1, 11 weeks for MCV1, and 19 weeks for DTP3. Variation 
within countries was substantial: the median of the IQRs in the 45 countries for delay in DTP3 
was 10.9 weeks, 7.9 weeks for MCV1, 5.4 weeks for BCG, and 5.3 weeks for DTP1. The 
median of the national coverage rates for DTP1 increased from 57% in children aged 12 weeks 
to 88% at 12 months, and for DTP3 from 65% at 12 months to 76% at 3 years. 
Interpretation: The timeliness of children's vaccination varies widely between and particularly 
within countries, and published yearly estimates of national coverage do not capture these 
variations. Delayed vaccination could have important implications for the effect of new and 
established vaccines on the burden of disease. 
Funding: WHO's Initiative for Vaccine Research. 
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Introduction 
Late administration of vaccines has implications for the success of child immunisation 
programmes. Currently WHO/UNICEF (1) vaccination coverage estimates are based on the 
prevalence of vaccinated children in a given cohort (eg 12-23 months for DTP), or numbers 
of vaccinations in a given year divided by the number of surviving infants (or, for BCG, by 
the number of newborns).  This throws very little light on the extent to which vaccinations are 
administered ‘on time’ (2).  In practice a few children may be vaccinated early but many will 
be vaccinated late (3,4), and for some vaccines programme effectiveness may be reduced if 
children at high risk of exposure are left unprotected (5).  On the other hand vaccination at 
older ages, or increased intervals between doses, can give more durable protection (6-9).  
Booster doses may offset the limitations of early doses in some respects, but at extra cost.  
Thus information about the actual timing of vaccination is needed to help policy makers 
monitor programmes and respond if need be.  Two of the WHO/UNICEF Global 
Immunisation and Vision Strategies (GIVS) are to strengthen monitoring of coverage and 
strengthen the analysis of data (10), and improved surveillance of departures from ‘age-
appropriate’ vaccination has been recommended in both low- and high-income settings (11-
13).   
There are also concerns about using current schedules as the basis for delivering new vaccines.  
For example it is uncertain whether new rotavirus vaccines will provide indirect protection to 
unvaccinated infants, and according to a WHO position paper, “vaccination should not be 
initiated for infants aged more than 12 weeks”(14), because of a potentially higher risk of 
intussusception, a rare bowel disorder.  The implication is that the safety as well as the 
effectiveness of the programme may depend on timely administration. 
Methods 
The Demographic & Health Surveys (DHS)(15) provide representative data on vaccination of 
children, based on events recorded on vaccination cards and interviews with mothers.  There 
were surveys in 52 countries between 1996 and 2005, and the most recent survey for each 
country was used. Seven were excluded, 4 with no data on days of the month of birth, 2 with 
fewer than 250 children with complete and valid data for calculating exact age at each 
vaccination, and 1 with non-standard recording of dates. For the remaining 45 the median 
survey year was 2002, and the median (IQR) national sample size of children less than 3 years 
old at the time of the mother’s interview was 3,952 (3,012 to 6,043), with a range from 1,127 
to 30,666. 
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At the time of these surveys 28 countries used the standard schedule for BCG (birth), 
Diphtheria-tetanus-pertussis vaccine and Oral polio vaccine (DTP/OPV: 6, 10, 14 weeks) and 
Measles-containing vaccine (MCV1: 9 months).  Seven countries in South and Central 
America used birth, 2, 4, 6, and 12 months, and the others used local variants. 
The survey data on child’s month and year of birth were almost complete, but if the day of the 
month of birth was missing it was imputed. Vaccination cards were the primary source for 
vaccination dates.  If the card was not available or a specific vaccination was not recorded, the 
mother was asked whether the child had been vaccinated. Ages at vaccination were imputed 
for cases in which the only evidence for vaccination was mother’s recall, using separate 
regression analyses for each country to identify the necessary predictors. The website gives 
more details on imputation.   
Age-specific coverage rates and delays after target ages were estimated using survival analysis 
methods(16,17) with sampling weights provided in the DHS datasets.  Coverage at different 
ages and delays are closely linked, and a summary index was calculated from the area under 
the cumulative age-at-vaccination curve (the hatched area as a % of the rectangle CDEF in 
Figure 1). This is analogous to the Kaplan-Meier survival curve and indicates mean coverage 
between target age and 24 months, or 36 months for MCV1.   
One way of improving coverage is to take opportunities to give children vaccinations that they 
have missed when they attend for others later in the schedule.  The extent to which 
opportunities were being taken to give missed doses of DTP when children attend for MCV1, 
and vice versa, was examined. An opportunity was defined as, for a child at least 9 months 
old at the time, i) any dose of DTP if they had not yet had MCV1, or ii) MCV1 if they had not 
yet had all doses of DTP, conditional on no dose of DTP in the preceding 4 weeks.  The 
opportunity was ‘taken’ if the child was given doses of DTP and MCV1 on the same date. 
This analysis was based on actual vaccination dates from cards, with no imputation.   
Analyses were carried out using Stata version 10 (Stata Corp, College Station, Texas).  
Role of the funding source 
The World Health Organization’s Initiative for Vaccine Research provided funding and 
comments on an earlier draft. They also suggested the work should be presented to the 
Strategic Advisory Group of Experts (SAGE) whose feedback informed this analysis.   
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Results 
Data quality 
Data quality was examined for all the children covered by the surveys. The older the children, 
the less likely they were to have a card record of their vaccination (Table 1). Also reported 
coverage (card plus mother’s recall) dropped slightly as child’s age at interview increased 
from 2 to 4 years, consistent with lower levels of reporting for more ‘distant’ events. Only 
data for children less than 36 months old when their mother was interviewed were included in 
the main analyses. In children aged 36 to 59 months the percentages of all vaccinations with 
a card date that were given after the age of 36 months were 0.7%, 1.0%, 1.5% and 3.3% for 
BCG, DTP1, DTP3 and MCV1 respectively.   
Ages at vaccination   
Figure 2 gives the distributions of ages at vaccination for the cohorts of children 18 to 35 
months old at the time of the mother’s interview, using card data only.  This provides complete 
‘follow-up’ to age 18 months (c 78 weeks) for all of the children. Each distribution has high 
peaks near or after target ages, followed by long tails to the right, indicating delays in 
vaccination in substantial proportions of children. The different peaks in the distributions for 
DTP and MCV reflect the two main target ages. The results for OPV1-3 were very similar to 
those for DTP1-3. These distributions should be interpreted as broad indicators of the nature 
rather than scale of the problem because each country’s contribution is implicitly weighted by 
the size of its survey sample, and this is only very weakly related to population size. Also the 
data are from a variety of survey years. 
Imputation 
The predictors of delay used in the imputation were rural/urban residence, home or hospital 
birth, mother’s years of education and age at birth, child’s position in birth order and child’s 
age at mother’s interview. Gender was a significant independent predictor in only two 
countries and was not used.  
Age-specific coverage rates 
Table 2 gives medians, 25th and 75th percentiles across countries for coverage rates at different 
ages, and summary indices for different regions, using both card and imputed dates. Overall, 
the median of the country values for BCG coverage increased from 49% at 4 weeks to 89% at 
12 months. Median coverage for DTP1 increased from 57% at 12 weeks to 82% at 6 months 
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and 91% at 3 years. Coverage for DTP3 increased from 65% at 12 months to 76% at 3 years, 
and MCV1 from 54% at 12 months to 82% at 3 years, so in both cases coverage at 12 months 
substantially underestimates final coverage. In general coverage for the 27 countries in the 
WHO AFRO region was lower than for the 9 countries in the AMRO region, although the 
highest 25% of AFRO countries were similar to the lowest 25% of the AMRO group, and 
much better for DTP1. In the other WHO regions the numbers of countries in the analysis 
were small. 
Table 3 gives coverage rates for each national survey. 95% CIs are not shown but the standard 
errors of the percentages in the table can be summarised as follows: for BCG, mean 0.7% 
std 0.2%; for DTP1, mean 0.7% std 0.3%; for DTP3, mean 0.6% std 0.4%; and for MCV1, 
mean 0.5% std 0.5%.  Thus the 95% CIs for the estimates of coverage were typically 1 to 1.5% 
above and below the figures given. Countries with generally very high coverage rates include 
Egypt, Peru, Rwanda and the Kyrgyz Republic. Countries with generally low rates include 
Chad, Nigeria and Yemen.  Some countries had a marked drop-off in coverage between DTP1 
and DTP3, including the Dominican Republic, Gabon, Guinea, Niger, Nigeria and Togo. In 
most countries over 30% of children were vaccinated at more than 12 weeks old, so under the 
existing safety guidelines would have been ineligible for rotavirus vaccine. 
Delays after target ages 
The website gives median, quartiles and inter-quartile ranges (IQRs) for delays for BCG, 
DTP1, DTP3 and MCV1 for each country. In Table 4 these parameters are summarised with 
median values across the 45 countries and 25th and 75th percentiles. For BCG for example, the 
median of the 45 country median delays was 2.3 weeks, the 25th percentile of the country 
medians was 1.4 weeks and the 75th percentile 4.6 weeks (so the median delay was more than 
this in a quarter of the countries). The distributions of median delays for DTP1 and MCV1 
were broadly similar, but the delays for DTP3 were more than twice as long.    
In 75% of the countries a quarter of the children were subject to delays of a week or less for 
DTP1 and MCV1, and just over a week for BCG, and so were vaccinated close to the 
scheduled ages. However the country-specific distributions of ages at vaccination had long 
tails. Thus for BCG the median of the 45 country-specific 75th percentile delays was 6.6 weeks 
compared to 2.3 weeks for the median of medians and 0.7 weeks for the median 25th percentile. 
The corresponding figures for DTP1 and MCV1 were broadly similar, and for DTP3 about 
double. For 25% of the countries surveyed, 25% of the children were at least 10, 8, 11 and 19 
weeks late in being given BCG, DTP1, MCV1 and DTP3 respectively.  
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Opportunistic vaccination 
The percentages of opportunities taken in each country to give DTP when a child was given 
MCV1 or vice versa are shown in the right-hand column of Table 3. These percentages tended 
to be higher in countries with lower coverage, which suggests that in general this strategy is 
making a useful contribution by giving a late boost to coverage rates that would otherwise 
have been even lower. However results from some countries went against this trend. For 
example in Gabon DTP3 coverage at 12m was 33% and opportunities taken 21%; in Nigeria, 
24% and 22%.   
Discussion 
Variation between countries in vaccination coverage rates is widely reported. We have shown 
that coverage at 12 months underestimates final coverage, and that there is substantial 
variation within as well as between countries in adherence to the recommended schedules.    
Our findings are based on survey data. How representative are they?  Consistent DHS 
sampling methods and questionnaires were used in every country, but the survey years varied 
(1996-2005) so country-specific results are not strictly comparable. In terms of completeness 
of reporting, one problem was that there were no data on children that had died before the 
interview.  The proportions of children affected varied from about 5% of children aged less 
than 1 year to about 7% of children aged less than 3 years and of course varied between 
countries.  However it seems unlikely that the children who died will generally have had a 
better vaccination record that those who did not, so we may, if anything, have slightly 
underestimated the delays and overestimated the coverage. Incompleteness of data on 
surviving children is of more concern. Where possible the dates of vaccination were taken 
from record cards.  However for 32% of vaccinations the evidence was mothers’ recall, or a 
card with no information on the date.  We imputed the missing values from the known dates 
of children from the same country survey who were similar in terms of local predictors of age 
at vaccination, in the belief that this would give a more accurate result than assuming that the 
vaccination experience of the children with missing dates was similar to the rest. This will not 
have eliminated information bias altogether, and its extent remains uncertain.   
Our index attempts to capture both coverage and timeliness. The implicit weight given to the 
timeliness element depends on the age range covered; we chose up to 2 years for BCG and 
DTP, and up to 3 years for MCV1, these being the age ranges with a heavy burden of relevant 
mortality in low income countries. In this formulation there is no ‘penalty’ for vaccinating 
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children before target dates, but an adjustment could be made by subtracting the shaded % of 
the rectangle ABCF in Figure 1.   
Countries as diverse as Egypt, Peru, Rwanda and the Kyrgyz Republic all have relatively high 
and timely coverage, and in most countries at least a quarter of the children are vaccinated 
close to the schedule. Prima facie this suggests that delays are not inevitable. However the 
scale of variation within countries is striking. There may be concerns about safety on the part 
of parents or care-givers or both, particularly if the child is unwell at the time the vaccination 
is due(18-19), but in a review of nine surveys ‘lack of parental acceptance of immunisation’ 
was given in a median of 3% of responses and ‘was not an important reason for missed 
opportunities’. There will be accessibility, organisational and cultural factors; in almost all the 
countries in this study delays were more protracted in more rural areas. Coverage may have 
improved since the survey year in some areas, but this does not necessarily mean 
improvements in timeliness. 
Do these delays matter? In principle, if schedules are designed to achieve a balance between 
effective protection at vulnerable ages, durable protection and vaccine safety, then adherence 
to schedules must matter too, but it is difficult to say how much. Others have made the case 
for more timely vaccination against pertussis (21), measles (22) and Haemophilus influenzae 
type b (Hib)(23).  Delays may be unimportant in children protected indirectly by high and 
timely coverage of their contacts, but many children at high background risk of mortality and 
of vaccination delay will not benefit from herd effects of this kind.   
Rotavirus vaccination (RV) is a topical case.  It is currently scheduled with DTP, but in most 
of the countries in our study more than 30% of the children were past the WHO-recommended 
age window for RV when they were given DTP1. This may be a problem in more developed 
countries too, at least in some population groups (24); in a recent study from Philadelphia, 
Pennsylvania the figure was 23% (25).  One possible scenario is strict adherence to the 
recommendation and no improvement in timeliness.  This would compromise the impact of 
the RV programme. However according to the Global Advisory Committee on Vaccine Safety 
strict adherence would be “extremely difficult to implement in the field” in low income 
countries (26), and a more likely scenario is no improvement in timeliness and widespread 
violation of the recommended age window. This may compromise safety, although the 
evidence on level of risk in older children is weak. The WHO recommendation is based on 
experience of an earlier vaccine, RotaShield (Wyeth-Ayerst), now withdrawn, which was 
linked to a rare bowel disorder when the first dose was administered to older infants [Rothman 
K, Young-Xu Y, Arellano F. Age dependence of the relation between reassortant rotavirus 
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vaccine (RotaShield) and intussusception. J Inf Dis 2006; 193: 898-9.]. Safety trials of the 
new vaccines did not address the effects of delayed vaccination, and while the authors of a 
recent study of post-marketing safety monitoring data from the US excluded an overall effect 
on the scale of RotaShield (27), it covered relatively few children with delayed first doses. 
Even if the new vaccines do carry an as yet undetected excess risk in older children, in high 
mortality settings broadening the age restriction may well represent a 'greater good' from a 
utilitarian perspective.  The benefits and risks of decisions of this kind would have to be 
considered carefully and in context by policy makers, as will the implications for informing 
parents.   
Improvement in timeliness on the other hand would improve RV programme effectiveness 
and reduce any residual risks to safety. Introducing RV might stimulate such improvements, 
and the rest of the vaccination programme would benefit. The problem is that the optimal ages 
for different vaccines may differ. Delays for Pneumococcal conjugate vaccine for example 
may be associated with more durable levels of individual protection (28), although the effect 
on programme effectiveness is unclear.  On the other hand coverage and adherence to 
schedules may be improved and family as well as programme costs reduced by vaccinating 
against several pathogens at one visit (29).  In this situation the design of the schedule should 
be based on a detailed assessment of a range of options.  
Assessments of vaccination programmes are generally based on evidence from efficacy trials, 
in which children are vaccinated relatively close to the schedule. Applied to wider populations 
these are likely to be optimistic, and there is little evidence about the relative benefits of 
seeking to improve timeliness rather than say expanding final coverage. One approach might 
be to include different schedules in trials, but this would increase the sample sizes needed and 
there may be ethical issues. A second approach would be to gather data on the effectiveness 
of vaccines in countries (or areas within countries) with contrasting levels of delay. The 
challenge would be to design out or take account of the other factors involved such as 
differences in age-specific patterns of transmission, disease and antibody protection (30). A 
third approach would be to use computer simulation models. Ideally all three approaches 
would be used; they would inform each other and strengthen decision making on vaccine 
policy.  
More generally, there is a need for monitoring and surveillance systems which allow for more 
detailed analyses of timeliness and coverage than are currently available.  
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Table 1: Quality of data on DTP1, by child’s age at interview, for surveys with data on children aged up to 5 years. 
 
DTP1 Child's age at interview (years)
0 1 2 3 4 Overall
% with DTP1 not yet given 35.3% 14.2% 14.3% 15.4% 15.8% 19.1%
% given, recorded on card with date 46.8% 54.0% 44.9% 37.4% 33.0% 43.3%
recorded on card, no date 0.4% 0.8% 0.8% 0.9% 1.0% 0.8%
mother's recall only 12.3% 23.7% 30.9% 36.3% 39.7% 28.4%
% not known 0.2% 0.5% 0.6% 0.8% 1.0% 0.6%
No data1 5.0% 6.7% 8.5% 9.2% 9.5% 7.8%
Total numbers of children surveyed 69,859 67,858 66,713 67,903 66,734 339,067
% of those given DTP1 with card record of date2 78.7% 68.7% 58.6% 50.1% 44.8% 59.7%
Coverage among children with data 62.8% 84.7% 84.3% 82.9% 82.4% 79.10%
 
1.   91% of these were the children who had died before their mother’s interview.  
2.  (number with card date)/(number with card date + card[no date] + mother’s recall) 
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Table 2: Target ages and median, 25th and 75th percentiles for estimated coverage at different ages across 45 countries. 
 
Median 25th 75th Median 25th 75th Median 25th 75th Median 25th 75th
Target (weeks) 0 0 0 6 6 9 3.2 3.2 4 9 9 9
Coverage at 4w 49% 30% 70%
8w 69% 48% 81% 24% 8% 36%
12w 74% 62% 86% 57% 46% 70%
4m 82% 68% 90% 73% 60% 83% 10% 4% 22%
5m 84% 70% 90% 80% 64% 88% 27% 16% 42%
6m 85% 73% 91% 82% 67% 89% 36% 23% 54%
9m 87% 75% 92% 87% 75% 92% 59% 43% 72% 12% 10% 14%
12m 89% 76% 93% 88% 73% 92% 65% 49% 79% 54% 37% 69%
18m 90% 78% 94% 90% 75% 94% 72% 52% 83% 74% 58% 82%
24m 90% 78% 94% 90% 76% 94% 74% 53% 84% 80% 62% 88%
36m 91% 78% 95% 91% 76% 95% 76% 56% 85% 82% 66% 91%
Index All countries 84% 73% 89% 84% 70% 89% 63% 45% 72% 74% 58% 83%
AFRO1 83% 72% 86% 78% 67% 85% 58% 40% 68% 67% 56% 80%
AMRO2 91% 87% 93% 91% 88% 93% 75% 55% 79% 83% 76% 87%
DTP3 MCV1
%iles %iles %iles %iles
BCG DTP1
 
1. 27 countries covered by the WHO Regional Office for Africa    
2.    9 countries covered by the WHO Regional Office for the Americas 
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Table 3: Variation between countries in estimated coverage for BCG, DTP1, DTP3 and MCV1; and in opportunities taken. 
Opps
at 4w at 12w at 6m at 12m Index at 8w at 12w at 6m at 12m Index at 6m at 9m at 12m at 3yrs Index at 9m at 12m at 18m at 3yrs Index taken
Bangladesh 2004 8% 72% 90% 93% 85% 33% 71% 89% 92% 88% 57% 75% 80% 82% 72% 10% 69% 78% 80% 75% 43%
Benin 2001 75% 86% 89% 90% 89% 51% 72% 84% 87% 84% 52% 63% 69% 74% 65% 7% 60% 71% 74% 69% 66%
Bolivia 2003 59% 79% 87% 92% 88% 8% 54% 84% 92% 88% 12% 52% 65% 79% 65% 5% 15% 64% 90% 74% 22%
Brazil 1996 36% 80% 88% 91% 87% 3% 70% 89% 94% 91% 5% 68% 76% 89% 75% 9% 75% 89% 94% 87% 57%
Burkina 2003 42% 66% 72% 77% 73% 10% 43% 67% 73% 70% 30% 44% 50% 62% 48% 12% 47% 58% 67% 58% 37%
Cambodia 2000 19% 43% 56% 64% 59% 17% 35% 53% 61% 58% 23% 33% 38% 51% 38% 9% 39% 48% 62% 51% 62%
Cameroon 2004 49% 72% 80% 85% 80% 41% 61% 74% 80% 77% 48% 56% 60% 68% 57% 16% 58% 66% 71% 65% 53%
Chad 2004 13% 22% 29% 36% 33% 12% 17% 30% 39% 36% 8% 13% 16% 28% 16% 7% 15% 23% 30% 24% 65%
Colombia 2005 73% 88% 93% 96% 93% 5% 69% 92% 96% 93% 19% 72% 80% 89% 79% 44% 54% 86% 96% 89% 45%
Comoros 1996 56% 76% 85% 91% 86% 34% 57% 80% 88% 83% 34% 50% 61% 79% 58% 14% 48% 67% 85% 69% 69%
Congo 2005 65% 86% 89% 89% 87% 14% 61% 82% 84% 82% 55% 63% 66% 70% 63% 12% 59% 66% 73% 67% 20%
Côte d'Ivoire 1998 55% 71% 76% 80% 77% 30% 52% 71% 76% 73% 36% 46% 53% 66% 50% 14% 50% 67% 74% 66% 64%
Dominican Rep. 2002 71% 90% 93% 93% 91% 6% 63% 85% 91% 88% 26% 49% 54% 62% 55% 54% 74% 82% 95% 87% 27%
Egypt 2005 70% 96% 98% 98% 95% 11% 90% 98% 99% 97% 25% 93% 94% 95% 93% 25% 95% 96% 98% 96% 7%
Eritrea 2002 33% 67% 83% 89% 83% 43% 64% 82% 88% 84% 64% 74% 79% 85% 74% 24% 74% 82% 89% 83% 60%
Gabon 2000 56% 76% 84% 88% 84% 24% 41% 57% 63% 59% 23% 28% 33% 39% 30% 11% 46% 58% 66% 57% 21%
Ghana 2003 50% 78% 85% 88% 84% 37% 67% 85% 89% 85% 54% 69% 75% 81% 69% 19% 72% 83% 87% 81% 38%
Guatemala 1998 28% 55% 73% 82% 76% 7% 39% 76% 85% 81% 20% 43% 56% 81% 54% 10% 56% 75% 91% 76% 68%
Guinea 2005 61% 74% 77% 78% 76% 35% 55% 72% 74% 71% 36% 46% 49% 53% 45% 16% 46% 54% 59% 55% 50%
Haiti 2000 34% 56% 64% 69% 65% 28% 50% 66% 73% 70% 24% 35% 42% 56% 39% 10% 37% 52% 75% 57% 72%
Honduras 2005 71% 91% 97% 98% 95% 2% 83% 98% 99% 97% 8% 84% 92% 96% 88% 2% 12% 93% 97% 93% 17%
India 2005 30% 61% 73% 76% 71% 28% 54% 71% 73% 70% 40% 50% 54% 57% 50% 12% 53% 60% 64% 59% 18%
Kenya 2003 49% 77% 85% 87% 83% 48% 72% 86% 88% 86% 61% 68% 71% 74% 67% 20% 67% 74% 80% 74% 40%
Kyrgyz 1997 91% 95% 97% 98% 97% 6% 70% 93% 97% 94% 43% 83% 89% 96% 85% 1% 15% 89% 96% 90% 4%
Lesotho 2004 66% 88% 91% 92% 90% 58% 81% 89% 91% 89% 66% 76% 79% 85% 75% 7% 74% 84% 91% 84% 22%
Madagascar 2003 30% 60% 68% 72% 68% 36% 54% 67% 72% 69% 48% 57% 61% 66% 57% 12% 53% 58% 64% 58% 39%
Malawi 2004 28% 66% 84% 90% 83% 33% 64% 89% 93% 89% 52% 72% 79% 87% 72% 14% 69% 82% 88% 80% 34%
Mali 2001 33% 46% 56% 63% 60% 25% 36% 49% 57% 55% 22% 29% 34% 48% 33% 14% 37% 48% 61% 50% 65%
Mauritania 2000 30% 43% 50% 58% 55% 20% 34% 45% 53% 50% 21% 28% 31% 40% 30% 13% 35% 48% 58% 48% 30%
Morocco 2003 89% 96% 97% 98% 95% 63% 90% 95% 96% 94% 84% 90% 92% 95% 88% 14% 86% 90% 93% 89% 44%
Mozambique 2003 58% 74% 81% 84% 81% 6% 51% 78% 84% 78% 41% 59% 65% 76% 60% 16% 62% 74% 82% 74% 53%
Namibia 2000 79% 89% 90% 90% 89% 68% 82% 90% 91% 89% 65% 73% 76% 82% 72% 14% 74% 81% 89% 81% 42%
Nicaragua 2001 70% 86% 92% 94% 92% 4% 66% 89% 93% 91% 46% 66% 73% 88% 75% 4% 13% 80% 93% 83% 42%
Niger 1998 21% 36% 44% 46% 43% 14% 27% 39% 45% 42% 15% 22% 24% 28% 22% 12% 29% 37% 42% 37% 64%
Nigeria 2003 27% 41% 45% 48% 46% 18% 26% 36% 39% 38% 16% 19% 21% 25% 20% 10% 30% 36% 43% 37% 22%
Peru 2004 79% 94% 95% 96% 94% 3% 80% 95% 97% 95% 72% 80% 83% 88% 81% 1% 13% 83% 89% 83% 17%
Rwanda 2005 71% 94% 95% 96% 93% 62% 91% 95% 96% 94% 81% 86% 88% 89% 84% 10% 81% 87% 90% 85% 43%
Senegal 2005 49% 77% 87% 89% 84% 37% 67% 84% 90% 85% 56% 69% 72% 79% 68% 14% 63% 76% 80% 74% 51%
Tanzania 1999 59% 85% 91% 93% 89% 53% 75% 89% 92% 88% 60% 73% 80% 85% 72% 16% 74% 82% 84% 79% 55%
Togo 1998 48% 65% 73% 76% 73% 31% 49% 63% 69% 66% 28% 36% 42% 49% 39% 11% 36% 46% 52% 46% 55%
Turkey 1998 8% 66% 85% 87% 85% 3% 46% 81% 85% 81% 34% 53% 56% 63% 52% 11% 71% 81% 88% 80% 16%
Uganda 2000 30% 54% 69% 76% 71% 24% 44% 64% 74% 69% 27% 37% 44% 53% 41% 13% 49% 62% 68% 61% 77%
Uzbekistan 1996 90% 94% 95% 96% 95% 6% 48% 84% 94% 90% 40% 61% 73% 93% 72% 12% 63% 87% 99% 86% 19%
Yemen 1997 9% 35% 46% 50% 46% 18% 35% 47% 51% 48% 27% 35% 38% 42% 35% 14% 39% 44% 47% 44% 31%
Zambia 2001 38% 73% 86% 91% 85% 15% 51% 84% 91% 85% 43% 64% 74% 84% 67% 18% 69% 82% 92% 83% 46%
BCG DPT1 DPT3 MCV
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Table 4: Delay in vaccination (weeks): variation between and within countries  
 
25th 75th 25th 75th 25th 75th 25th 75th
Median 2.3 1.4 4.6 2.4 1.2 3.3 6.2 3.5 8.5 2.7 1.7 3.1
25th %ile 0.7 0.3 1.3 0.6 0.3 1.0 2.7 1.4 3.5 0.1 -0.3 0.4
75th %ile 6.6 4.3 10.3 6.3 3.7 8.3 13.5 9.0 19.1 7.6 5.3 11.0
IQR 5.4 3.4 8.6 5.3 3.6 7.1 10.9 8.0 15.6 7.9 5.9 13.9
Across children in 
a country sample
Median %iles Median
across 45 countriesacross 45 countries across 45 countries across 45 countries
%ilesMedian %iles Median %iles
BCG DTP1 DTP3 MCV1
 
Negative values indicate vaccination before target date.   
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Figure 1: The plot of cumulative coverage against child’s age, and calculation of the coverage index 
 
 
 
 
The index is calculated from the shaded area after the target age as a % of the whole area CDEF.   
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Figure 2: Age distributions for administration of BCG, DTP1, DTP3 and MCV1 vaccines, based on card dates only among children aged 18-35.9m 
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6.3  Methods used to fit parametric vaccine timeliness curves in 135 LMICs 
 
The research paper presented in this chapter used information from USAID 
Demographic and Health Surveys (DHS). This database has since been expanded to 
include UNICEF Multiple Indicator Cluster Surveys (MICs). The most recent 
database includes 73 nationally representative household surveys that were conducted 
in the last ten years (2009 or later) in LMICs. To accommodate this data into the 
benefit-risk analysis (Chapter 9), age-specific coverage estimates from survival 
analysis were converted into cumulative age distributions (% of final coverage at 3 
years achieved at different ages) for BCG, DTP1, DTP2, DTP3 and Meas1. 
Parametric curves were then fitted to these cumulative age distributions using R 
version 3.4.0 (packages MASS and fitdistrplus). Fitting parametric timeliness curves 
allowed each country/vaccine to be defined by a small number of parameters (e.g. 
shift, shape and scale) which could then be conveniently varied in scenario analysis 
e.g. to assess earlier or later target ages. It also allowed 95% confidence intervals to 
be calculated for each parameter and provided a convenient basis for extrapolating 
timeliness curves to countries without household survey data (around half of the 135 
LMICs evaluated in the benefit-risk analysis). 
 
For each country/vaccine, goodness of fit was compared for Lognormal, Gamma, 
Weibull and Log Logistic cumulative age distributions, using the Akaike Information 
Criterion (AIC). The Log Logistic distribution generally ranked the highest (had the 
lowest/most favourable AIC scores), so was used to calculate best-fitting shape and 
scale parameters, and their respective 95% confidence intervals, for all 
countries/vaccines (Tables 5-9)1.  
 
The Log Logistic age distribution is defined by a scale (α) and a shape (β) parameter. 
The scale parameter is the same as the median age. The proportion of children 
vaccinated within each week of age is calculated by the following equation, where 𝑥𝑥 
represents the age at the beginning of each week of age 
 (β/α)(𝑥𝑥/α)𝛽𝛽−1(1 + (𝑥𝑥/α)𝛽𝛽)2  
 
                                                          
1 Table numbers start at 5, and Figures at 3, for continuity with the research-paper presented earlier. 
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For countries without a recent household survey the target ages currently 
recommended for BCG, DTP1, DTP2, DTP3 and Meas1 were extracted from the 
official WHO schedules database (1). Parametric timeliness curves were assigned to 
these countries using the median of the Log Logistic scale and shape parameters for 
all other countries with the same schedule. This simple approach was used because 
the 0, 6, 10, 14 and 39-week schedule (for BCG, DTP1, DTP2, DTP3 and Meas1) 
tends to be used in similar (higher mortality) LMICs, whereas the 0, 2, 4, 6, 12-month 
schedule is more commonly used in lower mortality LMICs (Figures 3-7). This was 
also the most practical approach because some children are vaccinated earlier than the 
target age in many countries, making it difficult to standardise different timeliness 
curves to a common starting point, and then average them in a reliable way.  
 
For countries with unique national schedules (target ages) and no household survey 
data, the median parametric timeliness curve for the closest matching target age was 
used for each vaccine. A shift parameter was added (difference between the target age 
of the country and the closest matching target age, in weeks) to ensure that 
extrapolated timeliness curves were aligned with the relevant national schedules.  
 
For the benefit-risk analysis (Chapter 9), the fitted and extrapolated vaccine timeliness 
curves for each country were rescaled to reflect the coverage level estimated by 
WHO/UNICEF in the year 2015 (2). 
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Table 5. Median age (IQR - inter-quartile range) of BCG vaccination in 72 LMICs; fitted Log Logistic shape and scale parameters and AIC rank 
Country Survey Target Sample Shape     Scale (median age, wks) IQR age, wks Log Logistic 
    age (wks) size (n) Mid L95% CI U95% CI Mid L95% CI U95% CI 25th 75th AIC rank 
Afghanistan 2011_MICS4 0.0 1444 1.3 1.2 1.4 3.0 2.8 3.2 1.3 7.0 2 
Algeria 2013_MICS4 0.0 8230 3.9 3.8 3.9 1.1 1.1 1.2 0.9 1.5 1 
Armenia 2010_DHS6 0.0 858 7.7 7.2 8.2 1.0 1.0 1.0 0.9 1.2 1 
Bangladesh 2014_DHS7 0.0 3142 2.9 2.8 3.0 6.6 6.5 6.7 4.5 9.6 2 
Belize 2011_MICS4 0.0 824 1.9 1.8 2.0 3.2 3.0 3.4 1.8 5.7 2 
Benin 2011_DHS6 0.0 3248 2.1 2.1 2.2 1.6 1.6 1.7 1.0 2.7 1 
Bosnia and Herzegovina 2012_MICS4 0.0 1059 2.9 2.7 3.1 1.2 1.2 1.2 0.8 1.8 1 
Burkina Faso 2010_DHS6 0.0 3367 2.1 2.0 2.2 2.1 2.0 2.1 1.2 3.5 2 
Burundi 2010_DHS6 0.0 1309 2.4 2.3 2.5 2.5 2.4 2.6 1.6 4.0 2 
Cambodia 2014_DHS7 0.0 2077 2.6 2.5 2.7 1.2 1.2 1.3 0.8 1.9 1 
Cameroon 2011_DHS6 0.0 1918 1.7 1.7 1.8 2.8 2.7 2.9 1.5 5.3 2 
Central African Republic 2010_MICS4 0.0 1475 1.8 1.7 1.8 2.1 2.0 2.2 1.1 3.8 1 
Chad 2010_MICS4 0.0 842 1.4 1.3 1.5 5.8 5.3 6.3 2.6 12.8 2 
Colombia 2010_DHS6 0.0 7856 3.6 3.6 3.7 1.1 1.1 1.1 0.8 1.5 1 
Comoros 2012_DHS6 0.0 1113 2.4 2.3 2.5 1.4 1.4 1.5 0.9 2.3 1 
Congo 2011_DHS6 0.0 1443 2.0 1.9 2.1 2.0 1.9 2.1 1.2 3.5 2 
Costa Rica 2011_MICS4 0.0 1271 8.1 7.6 8.5 1.0 1.0 1.0 0.9 1.2 1 
Côte d'Ivoire 2011_DHS6 0.0 1395 1.6 1.5 1.7 2.4 2.3 2.6 1.2 4.9 1 
Cuba 2014_MICS5 0.0 3214 10.4 10.0 10.7 1.0 1.0 1.0 0.9 1.1 1 
Democratic Republic of the Congo 2013_DHS6 0.0 847 1.7 1.6 1.8 2.2 2.0 2.4 1.1 4.2 2 
Dominican Republic 2014_MICS5 0.0 8426 2.8 2.7 2.8 1.3 1.3 1.3 0.9 1.9 1 
El Salvador 2014_MICS5 0.0 3804 5.6 5.4 5.8 1.1 1.0 1.1 0.9 1.3 1 
Ethiopia 2011_DHS6 0.0 1521 1.7 1.6 1.8 9.3 8.8 9.8 4.8 17.9 4 
Gabon 2012_DHS6 0.0 1558 2.0 1.9 2.1 2.1 2.0 2.2 1.2 3.6 1 
Gambia 2013_DHS6 0.0 1889 2.5 2.4 2.6 3.1 3.0 3.2 2.0 4.8 1 
Ghana 2016_DHS7 0.0 1454 2.1 2.0 2.2 1.7 1.7 1.8 1.0 2.9 2 
Guatemala 2015_DHS7 0.0 6090 1.7 1.7 1.8 2.3 2.2 2.4 1.2 4.3 2 
Guinea 2012_DHS6 0.0 894 1.9 1.8 2.0 2.0 1.9 2.2 1.1 3.6 1 
Guinea-Bissau 2014_MICS5 0.0 3224 1.7 1.6 1.7 3.2 3.1 3.4 1.7 6.2 2 
Guyana 2014_MICS5 0.0 1718 2.3 2.2 2.4 1.5 1.5 1.6 0.9 2.5 1 
Haiti 2012_DHS6 0.0 1543 1.4 1.3 1.4 4.6 4.3 4.9 2.1 10.1 2 
Honduras 2011_DHS6 0.0 5662 2.4 2.4 2.5 1.3 1.3 1.3 0.8 2.1 1 
Kazakhstan 2015_MICS5 0.0 324 14.3 12.7 15.8 1.0 1.0 1.0 0.9 1.1 1 
Kenya 2014_DHS7 0.0 8479 2.0 2.0 2.0 2.0 1.9 2.0 1.1 3.4 2 
Kyrgyzstan 2012_DHS6 0.0 2359 5.4 5.2 5.6 1.1 1.0 1.1 0.9 1.3 1 
Lao People's Democratic Republic 2012_MICS4 0.0 2501 1.3 1.2 1.3 3.5 3.3 3.7 1.5 8.2 2 
Lesotho 2014_DHS7 0.0 687 2.0 1.8 2.1 1.7 1.6 1.8 1.0 3.0 2 
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Liberia 2013_DHS6 0.0 1099 1.8 1.7 1.9 2.2 2.1 2.3 1.2 4.1 2 
Madagascar 2012_MICS4 0.0 335 1.4 1.3 1.6 4.1 3.6 4.7 1.9 8.9 1 
Malawi 2016_DHS7 0.0 2381 2.0 1.9 2.0 2.1 2.0 2.1 1.2 3.6 1 
Mali 2012_DHS6 0.0 786 1.6 1.5 1.7 4.3 4.0 4.6 2.1 8.7 2 
Mauritania 2011_MICS4 0.0 1383 1.7 1.7 1.8 2.5 2.4 2.6 1.3 4.7 1 
Mexico 2015_MICS5 0.0 3662 2.7 2.6 2.8 1.3 1.3 1.4 0.9 2.0 1 
Mongolia 2013_MICS5 0.0 2479 29.7 28.5 30.9 1.0 1.0 1.0 1.0 1.0 1 
Mozambique 2011_DHS6 0.0 4586 1.8 1.8 1.9 2.0 1.9 2.0 1.1 3.6 1 
Namibia 2013_DHS6 0.0 1011 7.6 7.1 8.1 1.0 1.0 1.0 0.9 1.2 1 
Nepal 2014_MICS5 0.0 1005 1.8 1.7 1.9 3.5 3.3 3.7 2.0 6.4 1 
Nigeria 2013_DHS6 0.0 4470 1.5 1.5 1.6 4.0 3.8 4.1 1.9 8.1 2 
Pakistan 2011_MICS4 0.0 4401 1.7 1.7 1.8 4.0 3.9 4.1 2.1 7.5 2 
Peru 2010_DHS6 0.0 11912 2.4 2.4 2.5 1.5 1.5 1.5 1.0 2.4 1 
Rwanda 2015_DHS7 0.0 2086 3.0 2.9 3.1 1.5 1.5 1.6 1.1 2.2 1 
Sao Tome and Principe 2014_MICS5 0.0 995 3.7 3.5 3.9 1.1 1.1 1.2 0.8 1.5 1 
Senegal 2015_DHS7 0.0 2601 2.0 1.9 2.0 3.0 2.9 3.1 1.7 5.3 2 
Serbia 2014_MICS5 0.0 821 4.2 3.9 4.5 1.1 1.1 1.1 0.8 1.4 1 
Sierra Leone 2013_DHS6 0.0 2148 1.9 1.9 2.0 1.8 1.8 1.9 1.0 3.2 1 
State of Palestine 2014_MICS5 0.0 3900 2.8 2.7 2.8 2.0 2.0 2.1 1.4 3.0 2 
Sudan 2014_MICS5 0.0 2103 1.7 1.6 1.7 6.3 6.0 6.6 3.2 12.2 3 
Swaziland 2014_MICS5 0.0 1349 8.6 8.2 9.1 1.0 1.0 1.0 0.9 1.2 1 
TFYR Macedonia 2012_MICS4 0.0 705 1.8 1.7 1.9 1.8 1.7 1.9 1.0 3.3 1 
Timor-Leste 2009_DHS6 0.0 2430 1.6 1.6 1.7 3.4 3.3 3.6 1.7 6.7 2 
Togo 2013_DHS6 0.0 1380 2.1 2.0 2.2 2.4 2.3 2.5 1.4 4.1 2 
Tunisia 2012_MICS4 0.0 1491 4.2 4.0 4.4 1.1 1.1 1.1 0.8 1.4 1 
Uganda 2011_DHS6 0.0 804 1.6 1.5 1.7 2.6 2.3 2.8 1.3 5.1 2 
United Republic of Tanzania 2016_DHS7 0.0 4523 1.6 1.6 1.7 2.7 2.6 2.8 1.4 5.3 2 
Viet nam 2014_MICS5 0.0 1431 1.8 1.7 1.9 3.1 2.9 3.2 1.7 5.7 2 
Yemen 2010_DHS6 0.0 2357 1.8 1.8 1.9 7.3 7.1 7.6 4.0 13.5 2 
Zambia 2013_DHS6 0.0 5171 1.6 1.6 1.6 3.8 3.6 3.9 1.9 7.4 2 
Zimbabwe 2015_DHS7 0.0 2423 2.6 2.5 2.7 1.4 1.3 1.4 0.9 2.1 1 
Republic of Moldova 2012_MICS4 0.3 266 6.1 5.4 6.8 1.1 1.0 1.1 0.9 1.3 1 
Ukraine 2012_MICS4 0.4 412 4.1 3.7 4.5 1.1 1.1 1.1 0.8 1.4 1 
Tajikistan 2012_DHS6 0.5 2530 1.8 1.8 1.9 1.7 1.6 1.7 0.9 3.1 1 
Egypt 2014_DHS6 1.0 4223 2.7 2.6 2.8 1.8 1.7 1.8 1.2 2.6 1 
             
  Median 0.0   2.00 1.92 2.08 2.05  1.97  2.13  1.2 3.6   
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Table 6. Median age (IQR - inter-quartile range) of DTP1 vaccination in 73 LMICs; fitted Log Logistic shape and scale parameters and AIC rank 
Country Survey Target Sample Shape     Scale (median age, wks) IQR age, wks Log Logistic 
    age (wks) size (n) Mid L95% CI U95% CI Mid L95% CI U95% CI 25th 75th AIC rank 
Afghanistan 2011_MICS4 6.0 1286 1.9 1.8 2.0 12.9 12.2 13.5 7.2 22.9 1 
Armenia 2010_DHS6 6.0 781 3.9 3.7 4.2 13.8 13.3 14.2 10.4 18.2 1 
Bangladesh 2014_DHS7 6.0 3086 6.0 5.8 6.1 8.9 8.9 9.0 7.4 10.8 1 
Benin 2011_DHS6 6.0 2233 4.1 3.9 4.2 8.3 8.1 8.4 6.3 10.8 1 
Burundi 2010_DHS6 6.0 1292 6.4 6.1 6.7 8.1 8.0 8.2 6.8 9.6 1 
Cambodia 2014_DHS7 6.0 1938 6.3 6.0 6.5 7.7 7.7 7.8 6.5 9.2 1 
Cameroon 2011_DHS6 6.0 1834 3.9 3.8 4.1 8.4 8.2 8.6 6.4 11.1 1 
Central African Republic 2010_MICS4 6.0 1292 2.9 2.8 3.1 9.7 9.4 10.0 6.7 14.1 1 
Chad 2010_MICS4 6.0 867 1.8 1.7 1.9 13.1 12.2 14.0 7.0 24.4 1 
Comoros 2012_DHS6 6.0 1045 4.0 3.8 4.2 8.4 8.2 8.6 6.4 11.0 1 
Côte d'Ivoire 2011_DHS6 6.0 1274 3.3 3.1 3.5 9.2 8.9 9.4 6.6 12.8 1 
Democratic Republic of the Congo 2013_DHS6 6.0 873 3.5 3.3 3.7 8.9 8.6 9.2 6.5 12.1 1 
Ethiopia 2011_DHS6 6.0 1580 2.4 2.3 2.5 11.2 10.8 11.6 7.1 17.8 1 
Gabon 2012_DHS6 6.0 586 3.6 3.3 3.8 8.9 8.5 9.2 6.5 12.1 1 
Ghana 2016_DHS7 6.0 1423 5.8 5.6 6.1 8.0 7.9 8.2 6.7 9.7 1 
Guinea 2012_DHS6 6.0 714 3.0 2.9 3.2 9.6 9.2 10.0 6.7 13.7 1 
Guinea-Bissau 2014_MICS5 6.0 3222 3.7 3.6 3.9 9.7 9.6 9.9 7.3 13.0 1 
Haiti 2012_DHS6 6.0 1604 2.5 2.4 2.6 11.4 11.0 11.8 7.3 17.8 1 
Kenya 2014_DHS7 6.0 8275 6.0 5.9 6.1 7.3 7.3 7.3 6.1 8.8 1 
Lao People's Democratic Republic 2012_MICS4 6.0 2462 2.5 2.4 2.5 11.4 11.1 11.7 7.3 17.8 1 
Lesotho 2014_DHS7 6.0 692 8.0 7.5 8.5 7.6 7.5 7.7 6.6 8.7 1 
Liberia 2013_DHS6 6.0 1069 3.9 3.7 4.1 8.8 8.5 9.0 6.6 11.6 1 
Madagascar 2012_MICS4 6.0 437 2.6 2.4 2.8 11.5 10.7 12.2 7.5 17.6 1 
Malawi 2016_DHS7 6.0 2284 6.2 6.0 6.5 8.2 8.1 8.3 6.9 9.8 1 
Mali 2012_DHS6 6.0 715 2.5 2.3 2.6 10.3 9.8 10.9 6.6 16.1 1 
Mauritania 2011_MICS4 6.0 428 2.7 2.5 2.9 10.2 9.5 10.8 6.8 15.2 1 
Mozambique 2011_DHS6 6.0 4396 3.9 3.8 4.0 11.5 11.3 11.6 8.7 15.2 1 
Namibia 2013_DHS6 6.0 929 6.6 6.2 7.0 7.3 7.2 7.4 6.2 8.6 1 
Nepal 2014_MICS5 6.0 977 5.4 5.1 5.7 8.8 8.7 9.0 7.2 10.8 1 
Nigeria 2013_DHS6 6.0 4229 2.7 2.6 2.7 9.8 9.6 9.9 6.4 14.7 1 
Pakistan 2011_MICS4 6.0 4402 3.5 3.4 3.6 10.2 10.1 10.4 7.5 13.9 1 
Rwanda 2015_DHS7 6.0 2016 9.6 9.2 10.0 7.5 7.5 7.6 6.7 8.4 1 
Sao Tome and Principe 2014_MICS5 6.0 954 9.2 8.7 9.8 7.4 7.4 7.5 6.6 8.4 1 
Senegal 2015_DHS7 6.0 2561 4.2 4.1 4.4 9.2 9.1 9.3 7.1 11.9 1 
Sierra Leone 2013_DHS6 6.0 2007 3.4 3.3 3.6 8.2 8.1 8.4 6.0 11.3 1 
Sudan 2014_MICS5 6.0 2161 3.3 3.2 3.4 8.6 8.4 8.7 6.1 12.0 1 
Swaziland 2014_MICS5 6.0 1316 12.9 12.2 13.5 7.1 7.0 7.1 6.5 7.7 1 
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Timor-Leste 2009_DHS6 6.0 2408 3.2 3.1 3.3 9.5 9.3 9.7 6.7 13.4 1 
Togo 2013_DHS6 6.0 1309 5.5 5.3 5.8 8.0 7.9 8.1 6.6 9.8 1 
Uganda 2011_DHS6 6.0 753 4.0 3.7 4.2 9.3 9.0 9.6 7.0 12.3 1 
United Republic of Tanzania 2016_DHS7 6.0 4547 5.6 5.4 5.7 8.0 7.9 8.1 6.6 9.7 1 
Yemen 2010_DHS6 6.0 3015 2.9 2.8 3.0 9.8 9.6 10.0 6.8 14.3 1 
Zambia 2013_DHS6 6.0 5199 3.6 3.5 3.7 9.1 8.9 9.2 6.7 12.3 1 
Zimbabwe 2015_DHS7 6.0 2553 6.5 6.3 6.7 7.3 7.3 7.4 6.2 8.7 1 
Burkina Faso 2010_DHS6 8.0 3039 6.2 6.0 6.4 10.4 10.3 10.5 8.7 12.4 1 
Congo 2011_DHS6 8.0 1059 5.5 5.2 5.7 10.9 10.7 11.1 8.9 13.3 1 
Serbia 2014_MICS5 8.0 1076 7.1 6.7 7.5 11.7 11.5 11.8 10.0 13.6 1 
Belize 2011_MICS4 8.7 775 5.9 5.5 6.3 11.3 11.1 11.5 9.4 13.6 1 
Bosnia and Herzegovina 2012_MICS4 8.7 1021 5.1 4.8 5.3 12.9 12.6 13.1 10.4 16.0 1 
Colombia 2010_DHS6 8.7 7394 5.8 5.6 5.9 10.4 10.3 10.4 8.6 12.6 1 
Costa Rica 2011_MICS4 8.7 1184 8.7 8.3 9.2 9.8 9.7 9.9 8.6 11.1 1 
Cuba 2014_MICS5 8.7 35 1.7 1.2 2.1 18.7 11.5 25.9 9.6 36.3 2 
Dominican Republic 2014_MICS5 8.7 3028 1.6 1.5 1.6 32.3 30.9 33.6 16.2 64.4 4 
Egypt 2014_DHS6 8.7 4613 10.3 10.1 10.6 9.9 9.9 9.9 8.9 11.0 1 
El Salvador 2014_MICS5 8.7 3719 11.5 11.2 11.8 9.7 9.7 9.7 8.8 10.7 1 
Gambia 2013_DHS6 8.7 1673 5.5 5.3 5.7 11.6 11.5 11.8 9.5 14.2 1 
Guatemala 2015_DHS7 8.7 5725 5.5 5.4 5.6 11.3 11.2 11.4 9.3 13.8 1 
Guyana 2014_MICS5 8.7 1685 7.1 6.8 7.4 10.5 10.4 10.6 9.0 12.2 1 
Honduras 2011_DHS6 8.7 5416 11.2 10.9 11.4 9.8 9.8 9.9 8.9 10.8 1 
Kazakhstan 2015_MICS5 8.7 248 4.6 4.1 5.1 11.8 11.2 12.4 9.3 15.0 1 
Kyrgyzstan 2012_DHS6 8.7 2141 5.0 4.8 5.2 10.1 9.9 10.2 8.1 12.5 1 
Mexico 2015_MICS5 8.7 3349 4.1 4.0 4.3 10.5 10.3 10.6 8.0 13.6 1 
Mongolia 2013_MICS5 8.7 2276 14.4 13.9 14.9 9.6 9.6 9.7 8.9 10.4 1 
Peru 2010_DHS6 8.7 12137 7.5 7.4 7.6 10.2 10.1 10.2 8.8 11.8 1 
Republic of Moldova 2012_MICS4 8.7 179 4.6 4.0 5.3 11.3 10.7 11.9 8.9 14.3 1 
State of Palestine 2014_MICS5 8.7 3750 14.0 13.6 14.4 10.4 10.3 10.4 9.6 11.2 1 
Suriname 2010_MICS4 8.7 1051 2.3 2.2 2.5 14.0 13.4 14.6 8.8 22.3 1 
Tajikistan 2012_DHS6 8.7 2396 4.1 4.0 4.2 11.5 11.3 11.7 8.8 15.0 1 
TFYR Macedonia 2012_MICS4 8.7 699 7.1 6.7 7.6 15.1 14.9 15.4 13.0 17.7 1 
Tunisia 2012_MICS4 8.7 1409 7.4 7.1 7.8 10.1 10.0 10.2 8.7 11.8 1 
Ukraine 2012_MICS4 8.7 327 4.2 3.7 4.6 16.4 15.6 17.1 12.6 21.3 1 
Viet nam 2014_MICS5 8.7 74 2.0 1.6 2.4 17.8 13.8 21.8 10.2 30.9 2 
Algeria 2013_MICS4 13.0 7011 7.0 6.9 7.2 15.9 15.9 16.0 13.6 18.6 1 
             
  Median 6.0   3.9 3.7 4.1 8.9 8.8 9.2 6.7 12.0   
  Median 8.0   6.2 6.0 6.4 10.9 10.7 11.1 8.9 13.3   
  Median 8.7   5.5 5.4 5.7 11.3 10.7 11.4 8.9 13.6   
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Table 7. Median age (IQR - inter-quartile range) of DTP2 vaccination in 73 LMICs; fitted Log Logistic shape and scale parameters and AIC rank 
Country Survey Target Sample Shape     Scale (median age, wks) IQR age, wks Log Logistic 
    age (wks) size (n) Mid L95% CI U95% CI Mid L95% CI U95% CI 25th 75th AIC rank 
Afghanistan 2011_MICS4 10.0 1098 3.0 2.8 3.1 17.0 16.4 17.6 11.7 24.6 1 
Bangladesh 2014_DHS7 10.0 2929 7.3 7.0 7.5 14.1 14.0 14.3 12.2 16.4 1 
Benin 2011_DHS6 10.0 2016 4.8 4.6 5.0 13.6 13.4 13.8 10.8 17.1 1 
Burundi 2010_DHS6 10.0 1223 8.8 8.4 9.2 13.1 12.9 13.2 11.5 14.8 1 
Cambodia 2014_DHS7 10.0 1789 6.4 6.2 6.7 13.3 13.1 13.4 11.2 15.7 1 
Cameroon 2011_DHS6 10.0 1688 5.5 5.2 5.7 13.4 13.2 13.6 11.0 16.4 1 
Central African Republic 2010_MICS4 10.0 1008 3.7 3.5 3.8 16.7 16.2 17.2 12.4 22.6 1 
Chad 2010_MICS4 10.0 595 2.4 2.2 2.6 22.4 21.1 23.8 14.2 35.5 2 
Comoros 2012_DHS6 10.0 963 4.5 4.3 4.8 14.6 14.2 14.9 11.4 18.6 1 
Côte d'Ivoire 2011_DHS6 10.0 1108 3.6 3.4 3.8 15.8 15.4 16.3 11.7 21.5 1 
Democratic Republic of the Congo 2013_DHS6 10.0 782 3.9 3.7 4.2 14.4 14.0 14.9 10.9 19.1 1 
Ethiopia 2011_DHS6 10.0 1336 2.9 2.7 3.0 18.4 17.8 19.0 12.6 27.0 1 
Gabon 2012_DHS6 10.0 504 4.0 3.7 4.3 14.5 14.0 15.1 11.0 19.2 1 
Ghana 2016_DHS7 10.0 1346 7.6 7.2 7.9 13.1 13.0 13.3 11.3 15.2 1 
Guinea 2012_DHS6 10.0 570 4.1 3.8 4.4 15.4 14.8 15.9 11.7 20.1 1 
Guinea-Bissau 2014_MICS5 10.0 2880 4.1 3.9 4.2 16.6 16.3 16.9 12.7 21.8 1 
Haiti 2012_DHS6 10.0 1355 3.1 3.0 3.2 19.3 18.7 19.9 13.5 27.5 1 
Kenya 2014_DHS7 10.0 7852 8.4 8.3 8.6 11.8 11.8 11.9 10.4 13.5 1 
Lao People's Democratic Republic 2012_MICS4 10.0 2161 2.8 2.7 2.9 20.9 20.3 21.4 14.1 30.9 2 
Lesotho 2014_DHS7 10.0 655 9.8 9.1 10.5 12.8 12.6 13.0 11.4 14.3 1 
Liberia 2013_DHS6 10.0 928 4.7 4.4 4.9 15.2 14.8 15.5 12.0 19.2 1 
Madagascar 2012_MICS4 10.0 388 3.8 3.5 4.1 18.3 17.5 19.2 13.7 24.5 1 
Malawi 2016_DHS7 10.0 2176 6.8 6.6 7.1 13.4 13.3 13.6 11.4 15.8 1 
Mali 2012_DHS6 10.0 635 3.2 3.0 3.4 16.6 15.9 17.3 11.8 23.5 1 
Mauritania 2011_MICS4 10.0 355 4.0 3.6 4.4 14.6 13.9 15.2 11.1 19.2 1 
Mozambique 2011_DHS6 10.0 3990 4.3 4.2 4.4 18.3 18.1 18.6 14.2 23.7 1 
Namibia 2013_DHS6 10.0 870 9.8 9.2 10.4 11.8 11.7 11.9 10.5 13.2 1 
Nepal 2014_MICS5 10.0 894 7.3 6.9 7.8 13.8 13.5 14.0 11.8 16.0 1 
Nigeria 2013_DHS6 10.0 3679 3.3 3.2 3.4 16.0 15.7 16.2 11.4 22.3 1 
Pakistan 2011_MICS4 10.0 4401 4.3 4.2 4.4 16.3 16.1 16.5 12.6 21.0 1 
Rwanda 2015_DHS7 10.0 1939 12.9 12.5 13.4 11.9 11.9 12.0 11.0 13.0 1 
Sao Tome and Principe 2014_MICS5 10.0 905 8.6 8.1 9.1 12.5 12.4 12.7 11.0 14.2 1 
Senegal 2015_DHS7 10.0 2324 5.0 4.9 5.2 15.1 14.9 15.3 12.1 18.8 1 
Sierra Leone 2013_DHS6 10.0 1832 3.7 3.5 3.8 14.9 14.6 15.3 11.1 20.2 1 
Sudan 2014_MICS5 10.0 1974 3.7 3.6 3.9 14.7 14.4 15.0 11.0 19.8 1 
Swaziland 2014_MICS5 10.0 1278 12.7 12.1 13.4 11.4 11.4 11.5 10.5 12.5 1 
Timor-Leste 2009_DHS6 10.0 2211 4.2 4.0 4.3 14.9 14.6 15.1 11.4 19.4 1 
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Togo 2013_DHS6 10.0 1228 6.2 5.9 6.5 13.3 13.1 13.5 11.1 15.9 1 
Uganda 2011_DHS6 10.0 666 4.5 4.2 4.8 15.1 14.6 15.5 11.8 19.2 1 
United Republic of Tanzania 2016_DHS7 10.0 4241 6.6 6.4 6.7 13.3 13.2 13.4 11.2 15.7 1 
Yemen 2010_DHS6 10.0 2616 3.6 3.5 3.7 16.3 16.0 16.6 12.0 22.0 1 
Zambia 2013_DHS6 10.0 4845 4.4 4.3 4.5 15.2 15.0 15.3 11.8 19.5 1 
Zimbabwe 2015_DHS7 10.0 2415 7.1 6.9 7.4 12.5 12.3 12.6 10.7 14.5 1 
Armenia 2010_DHS6 12.0 716 4.7 4.4 5.0 21.9 21.3 22.5 17.3 27.7 1 
Burkina Faso 2010_DHS6 12.0 2869 7.6 7.4 7.9 15.3 15.2 15.5 13.3 17.7 1 
Congo 2011_DHS6 12.0 968 6.5 6.1 6.8 15.7 15.4 15.9 13.2 18.6 1 
Gambia 2013_DHS6 13.0 1571 5.5 5.2 5.7 18.2 17.9 18.5 14.9 22.2 1 
Kazakhstan 2015_MICS5 13.0 219 6.1 5.4 6.8 17.3 16.7 18.0 14.5 20.7 1 
Mongolia 2013_MICS5 13.0 2148 19.8 19.0 20.5 14.4 14.3 14.4 13.6 15.2 1 
Tajikistan 2012_DHS6 13.0 2229 5.2 5.0 5.4 17.3 17.1 17.6 14.0 21.4 1 
Tunisia 2012_MICS4 13.0 1326 9.3 8.9 9.7 15.4 15.2 15.5 13.7 17.3 1 
Viet nam 2014_MICS5 13.0 57 2.8 2.1 3.6 21.3 17.5 25.1 14.5 31.4 1 
Serbia 2014_MICS5 14.0 1028 7.3 6.9 7.7 18.9 18.6 19.1 16.3 21.9 1 
Kyrgyzstan 2012_DHS6 15.2 1968 7.4 7.1 7.7 18.1 17.9 18.2 15.6 21.0 1 
Algeria 2013_MICS4 17.3 6364 6.9 6.7 7.0 22.5 22.4 22.6 19.2 26.4 1 
Belize 2011_MICS4 17.3 721 7.0 6.6 7.5 20.8 20.4 21.1 17.8 24.3 1 
Bosnia and Herzegovina 2012_MICS4 17.3 973 5.2 4.9 5.5 20.6 20.1 21.0 16.6 25.4 1 
Colombia 2010_DHS6 17.3 6828 7.1 6.9 7.2 20.0 19.9 20.1 17.1 23.4 1 
Costa Rica 2011_MICS4 17.3 1106 16.0 15.2 16.9 18.9 18.8 19.0 17.6 20.2 1 
Cuba 2014_MICS5 17.3 26 5.3 3.2 7.4 20.6 18.0 23.2 16.7 25.4 1 
Dominican Republic 2014_MICS5 17.3 1395 2.4 2.3 2.5 31.2 30.0 32.4 19.8 49.1 2 
Egypt 2014_DHS6 17.3 4335 15.2 14.8 15.6 18.9 18.8 19.0 17.6 20.3 1 
El Salvador 2014_MICS5 17.3 3523 16.4 16.0 16.9 18.8 18.7 18.9 17.6 20.1 1 
Guatemala 2015_DHS7 17.3 5059 6.8 6.6 6.9 21.6 21.4 21.7 18.4 25.4 1 
Guyana 2014_MICS5 17.3 1559 8.9 8.5 9.3 20.1 19.9 20.3 17.7 22.7 1 
Honduras 2011_DHS6 17.3 4967 13.3 12.9 13.6 19.4 19.3 19.4 17.8 21.0 1 
Mexico 2015_MICS5 17.3 2997 4.4 4.2 4.5 20.0 19.7 20.3 15.5 25.7 1 
Peru 2010_DHS6 17.3 11038 8.1 8.0 8.2 20.0 20.0 20.1 17.5 22.9 1 
Republic of Moldova 2012_MICS4 17.3 160 8.1 7.0 9.3 20.7 20.0 21.4 18.0 23.7 1 
State of Palestine 2014_MICS5 17.3 3503 21.2 20.6 21.8 19.3 19.2 19.3 18.3 20.3 1 
Suriname 2010_MICS4 17.3 914 6.6 6.3 7.0 21.5 21.1 21.8 18.2 25.3 1 
TFYR Macedonia 2012_MICS4 17.3 663 7.2 6.7 7.6 22.9 22.5 23.3 19.6 26.7 1 
Ukraine 2012_MICS4 17.3 299 3.0 2.7 3.3 27.6 25.7 29.5 19.2 39.7 2 
             
  Median 10.0   4.4 4.2 4.5 14.7 14.4 15.1 11.4 19.2   
  Median 13.0   5.8 5.3 6.3 17.3 16.9 17.8 14.2 21.1   
  Median 17.3   7.1 6.7 7.5 20.6 20.0 21.0 17.8 24.3   
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Table 8. Median age (IQR - inter-quartile range) of DTP3 vaccination in 73 LMICs; fitted Log Logistic shape and scale parameters and AIC rank 
Country Survey Target Sample Shape     Scale (median age, wks) IQR age, wks Log Logistic 
    age (wks) size (n) Mid L95% CI U95% CI Mid L95% CI U95% CI 25th 75th AIC rank 
Afghanistan 2011_MICS4 14.0 865 2.7 2.6 2.9 28.9 27.7 30.2 19.4 43.2 2 
Bangladesh 2014_DHS7 14.0 2715 7.5 7.3 7.8 19.4 19.2 19.6 16.8 22.4 1 
Benin 2011_DHS6 14.0 1766 4.8 4.6 5.0 19.4 19.1 19.7 15.4 24.4 1 
Burundi 2010_DHS6 14.0 1140 8.6 8.2 9.1 18.4 18.2 18.6 16.2 20.9 1 
Cambodia 2014_DHS7 14.0 1636 6.5 6.3 6.8 18.4 18.1 18.6 15.5 21.7 1 
Cameroon 2011_DHS6 14.0 1497 5.5 5.2 5.7 19.0 18.7 19.3 15.5 23.2 1 
Central African Republic 2010_MICS4 14.0 729 3.7 3.5 4.0 24.7 23.8 25.5 18.4 33.2 1 
Chad 2010_MICS4 14.0 430 3.0 2.7 3.2 28.1 26.5 29.7 19.4 40.7 2 
Comoros 2012_DHS6 14.0 865 4.0 3.8 4.3 21.3 20.7 22.0 16.3 28.0 1 
Côte d'Ivoire 2011_DHS6 14.0 952 4.5 4.2 4.7 21.4 20.9 21.9 16.8 27.4 1 
Democratic Republic of the Congo 2013_DHS6 14.0 675 4.3 4.0 4.6 20.9 20.3 21.6 16.2 27.0 1 
Ethiopia 2011_DHS6 14.0 1121 3.8 3.6 4.0 22.9 22.3 23.5 17.1 30.5 2 
Gabon 2012_DHS6 14.0 414 3.8 3.5 4.2 19.9 19.1 20.8 14.9 26.5 1 
Ghana 2016_DHS7 14.0 1262 7.7 7.3 8.1 18.2 17.9 18.4 15.7 20.9 1 
Guinea 2012_DHS6 14.0 461 4.3 4.0 4.7 21.1 20.3 21.8 16.3 27.2 1 
Guinea-Bissau 2014_MICS5 14.0 2529 4.3 4.1 4.4 23.6 23.2 24.0 18.2 30.6 1 
Haiti 2012_DHS6 14.0 1114 3.0 2.9 3.2 28.2 27.2 29.2 19.5 40.6 1 
Kenya 2014_DHS7 14.0 7248 8.6 8.5 8.8 16.6 16.5 16.7 14.6 18.9 1 
Lao People's Democratic Republic 2012_MICS4 14.0 1802 3.0 2.9 3.1 29.3 28.4 30.1 20.3 42.2 2 
Lesotho 2014_DHS7 14.0 612 8.1 7.5 8.6 18.2 17.9 18.6 15.9 20.9 1 
Liberia 2013_DHS6 14.0 787 4.3 4.1 4.6 22.2 21.5 22.8 17.2 28.5 1 
Madagascar 2012_MICS4 14.0 313 4.5 4.0 4.9 23.7 22.6 24.8 18.5 30.3 1 
Malawi 2016_DHS7 14.0 2035 7.0 6.7 7.2 18.9 18.7 19.1 16.1 22.1 1 
Mali 2012_DHS6 14.0 563 3.6 3.4 3.9 22.2 21.3 23.1 16.4 30.1 1 
Mauritania 2011_MICS4 14.0 294 4.5 4.0 4.9 21.1 20.1 22.0 16.5 26.9 1 
Mozambique 2011_DHS6 14.0 3549 4.3 4.2 4.4 25.7 25.3 26.0 19.9 33.1 1 
Namibia 2013_DHS6 14.0 810 8.4 7.9 8.9 16.4 16.2 16.6 14.4 18.7 1 
Nepal 2014_MICS5 14.0 806 7.7 7.2 8.1 19.0 18.7 19.3 16.5 22.0 1 
Nigeria 2013_DHS6 14.0 3065 3.7 3.6 3.8 21.7 21.3 22.1 16.1 29.2 1 
Pakistan 2011_MICS4 14.0 4344 4.7 4.6 4.8 22.1 21.8 22.3 17.4 27.9 1 
Rwanda 2015_DHS7 14.0 1864 13.3 12.8 13.8 16.5 16.4 16.6 15.2 17.9 1 
Sao Tome and Principe 2014_MICS5 14.0 874 9.0 8.4 9.5 17.6 17.3 17.8 15.5 19.8 1 
Senegal 2015_DHS7 14.0 2058 5.4 5.2 5.6 21.0 20.7 21.2 17.1 25.7 1 
Sierra Leone 2013_DHS6 14.0 1596 4.0 3.9 4.2 21.9 21.4 22.3 16.6 28.7 1 
Sudan 2014_MICS5 14.0 1721 3.8 3.7 4.0 21.4 20.9 21.9 16.0 28.6 1 
Swaziland 2014_MICS5 14.0 1215 10.2 9.7 10.8 16.1 16.0 16.3 14.5 17.9 1 
Timor-Leste 2009_DHS6 14.0 2009 4.7 4.5 4.8 20.9 20.6 21.2 16.5 26.5 1 
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Togo 2013_DHS6 14.0 1101 5.8 5.5 6.1 18.8 18.5 19.1 15.6 22.7 1 
Uganda 2011_DHS6 14.0 581 3.7 3.4 4.0 22.9 22.0 23.8 17.0 30.9 1 
United Republic of Tanzania 2016_DHS7 14.0 3919 6.5 6.3 6.7 18.8 18.6 19.0 15.9 22.3 1 
Yemen 2010_DHS6 14.0 2251 4.2 4.1 4.3 22.4 22.0 22.8 17.2 29.1 1 
Zambia 2013_DHS6 14.0 4384 4.4 4.3 4.5 21.8 21.5 22.0 17.0 27.9 1 
Zimbabwe 2015_DHS7 14.0 2228 6.7 6.4 6.9 17.7 17.6 17.9 15.1 20.9 1 
Burkina Faso 2010_DHS6 16.0 2699 7.2 7.0 7.4 20.8 20.6 21.0 17.8 24.2 1 
Congo 2011_DHS6 16.0 821 7.0 6.6 7.4 21.2 20.8 21.6 18.1 24.8 1 
Gambia 2013_DHS6 17.3 1441 5.6 5.4 5.8 24.4 24.0 24.8 20.0 29.7 1 
Kazakhstan 2015_MICS5 17.3 190 2.8 2.4 3.1 32.1 29.1 35.2 21.7 47.7 2 
Mongolia 2013_MICS5 17.3 1992 18.1 17.4 18.8 19.0 18.9 19.1 17.9 20.2 1 
Tajikistan 2012_DHS6 17.3 2089 5.0 4.8 5.2 23.3 23.0 23.7 18.7 29.0 1 
Viet nam 2014_MICS5 17.3 49 3.1 2.2 4.0 26.2 21.6 30.8 18.5 37.2 1 
Armenia 2010_DHS6 18.0 658 4.8 4.5 5.1 31.1 30.2 32.0 24.7 39.1 1 
Serbia 2014_MICS5 20.0 954 6.9 6.5 7.3 26.2 25.8 26.6 22.3 30.7 1 
Algeria 2013_MICS4 21.7 5751 6.4 6.2 6.5 29.3 29.1 29.5 24.7 34.8 1 
Kyrgyzstan 2012_DHS6 21.7 1863 6.3 6.0 6.5 26.6 26.3 26.9 22.3 31.7 1 
Belize 2011_MICS4 26.0 641 8.1 7.6 8.7 30.1 29.6 30.5 26.3 34.4 1 
Bosnia and Herzegovina 2012_MICS4 26.0 908 5.5 5.2 5.8 30.1 29.5 30.8 24.7 36.8 1 
Colombia 2010_DHS6 26.0 6132 7.4 7.3 7.6 29.5 29.4 29.7 25.5 34.3 1 
Costa Rica 2011_MICS4 26.0 1000 13.6 12.9 14.4 28.3 28.1 28.5 26.1 30.7 1 
Cuba 2014_MICS5 26.0 24 2.6 1.7 3.6 76.2 52.8 99.6 50.2 115.7 4 
Dominican Republic 2014_MICS5 26.0 1065 3.2 3.0 3.3 40.3 38.9 41.7 28.5 57.0 2 
Egypt 2014_DHS6 26.0 3937 19.2 18.7 19.8 27.9 27.8 28.0 26.4 29.6 1 
El Salvador 2014_MICS5 26.0 3278 14.6 14.1 15.0 28.1 28.0 28.3 26.1 30.3 1 
Guatemala 2015_DHS7 26.0 4480 7.0 6.9 7.2 31.8 31.6 32.0 27.2 37.2 1 
Guyana 2014_MICS5 26.0 1409 10.0 9.5 10.5 29.3 29.0 29.5 26.2 32.7 1 
Honduras 2011_DHS6 26.0 4537 12.5 12.1 12.8 29.0 28.9 29.2 26.6 31.7 1 
Mexico 2015_MICS5 26.0 2600 4.2 4.0 4.3 30.0 29.5 30.5 23.0 39.0 1 
Peru 2010_DHS6 26.0 9830 8.1 8.0 8.2 30.0 29.8 30.1 26.2 34.3 1 
Republic of Moldova 2012_MICS4 26.0 129 11.0 9.2 12.9 29.4 28.6 30.2 26.6 32.5 1 
State of Palestine 2014_MICS5 26.0 3175 25.5 24.7 26.3 28.3 28.2 28.4 27.1 29.5 1 
Suriname 2010_MICS4 26.0 827 6.2 5.8 6.6 31.9 31.3 32.5 26.7 38.1 1 
TFYR Macedonia 2012_MICS4 26.0 611 7.5 7.0 8.0 30.8 30.3 31.4 26.6 35.7 1 
Tunisia 2012_MICS4 26.0 1167 10.1 9.5 10.6 28.5 28.2 28.8 25.6 31.8 1 
Ukraine 2012_MICS4 26.0 261 3.0 2.7 3.4 35.0 32.4 37.6 24.4 50.2 2 
             
  Median 14.0   4.5 4.2 4.8 21.1 20.6 21.8 16.4 27.0   
  Median 17.3   5.0 4.8 5.2 24.4 23.0 24.8 18.7 29.7   
  Median 26.0   8.1 7.6 8.2 30.0 29.5 30.2 26.3 34.3   
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Table 9. Median age (IQR - inter-quartile range) of Meas1 vaccination in 73 LMICs; fitted Log Logistic shape and scale parameters and AIC rank 
Country Survey Target Sample Shape     Scale (median age, wks) IQR age, wks Log Logistic 
    age (wks) size (n) Mid L95% CI U95% CI Mid L95% CI U95% CI 25th 75th AIC rank 
Cambodia 2014_DHS7 26.0 1234 9.1 8.6 9.6 42.7 42.3 43.2 37.9 48.2 1 
Congo 2011_DHS6 36.0 746 11.1 10.4 11.8 42.5 42.0 42.9 38.5 46.9 1 
Bangladesh 2014_DHS7 38.0 2078 14.7 14.2 15.3 42.7 42.5 42.9 39.6 46.0 1 
Afghanistan 2011_MICS4 39.0 453 3.4 3.1 3.7 52.2 49.7 54.7 37.7 72.3 1 
Benin 2011_DHS6 39.0 1703 8.3 7.9 8.6 42.8 42.4 43.2 37.4 48.8 1 
Burkina Faso 2010_DHS6 39.0 2151 15.4 14.8 16.0 41.7 41.5 41.8 38.8 44.7 1 
Burundi 2010_DHS6 39.0 815 14.4 13.5 15.3 42.5 42.2 42.8 39.4 45.9 1 
Cameroon 2011_DHS6 39.0 1086 9.4 8.9 9.9 41.7 41.3 42.2 37.1 46.9 1 
Central African Republic 2010_MICS4 39.0 530 5.1 4.7 5.5 46.1 44.7 47.4 37.1 57.2 1 
Chad 2010_MICS4 39.0 405 2.8 2.5 3.0 48.3 45.2 51.3 32.4 71.8 3 
Comoros 2012_DHS6 39.0 665 5.6 5.2 6.0 43.1 42.1 44.1 35.4 52.5 1 
Côte d'Ivoire 2011_DHS6 39.0 682 5.1 4.8 5.5 44.7 43.6 45.8 36.0 55.4 1 
Democratic Republic of the Congo 2013_DHS6 39.0 454 7.4 6.8 8.0 44.5 43.5 45.4 38.3 51.6 1 
Ethiopia 2011_DHS6 39.0 775 6.8 6.3 7.2 42.7 41.9 43.4 36.3 50.2 1 
Gabon 2012_DHS6 39.0 836 6.0 5.6 6.4 45.5 44.6 46.3 37.9 54.6 1 
Gambia 2013_DHS6 39.0 1142 9.4 8.9 9.9 43.7 43.2 44.1 38.9 49.1 1 
Ghana 2016_DHS7 39.0 969 14.8 13.9 15.6 42.7 42.4 43.0 39.6 46.0 1 
Guinea 2012_DHS6 39.0 360 5.7 5.2 6.3 44.7 43.3 46.1 36.9 54.1 1 
Guinea-Bissau 2014_MICS5 39.0 1948 6.8 6.6 7.1 43.9 43.5 44.4 37.4 51.6 1 
Haiti 2012_DHS6 39.0 883 3.4 3.3 3.6 61.5 59.4 63.6 44.7 84.6 1 
Kenya 2014_DHS7 39.0 5026 11.6 11.3 11.9 42.3 42.2 42.5 38.5 46.5 1 
Lao People's Democratic Republic 2012_MICS4 39.0 1457 5.4 5.2 5.7 47.9 47.1 48.6 39.1 58.6 1 
Lesotho 2014_DHS7 39.0 470 11.5 10.5 12.4 43.2 42.6 43.7 39.2 47.5 1 
Liberia 2013_DHS6 39.0 516 7.2 6.6 7.8 44.0 43.1 44.9 37.8 51.3 1 
Madagascar 2012_MICS4 39.0 237 6.1 5.4 6.9 44.8 43.2 46.4 37.5 53.6 1 
Malawi 2016_DHS7 39.0 1543 10.6 10.1 11.1 43.3 43.0 43.7 39.1 48.1 1 
Mali 2012_DHS6 39.0 431 5.4 4.9 5.9 42.3 41.1 43.6 34.6 51.9 1 
Mauritania 2011_MICS4 39.0 422 4.0 3.6 4.3 44.2 42.3 46.0 33.5 58.2 1 
Mongolia 2013_MICS5 39.0 1500 17.5 16.7 18.4 40.9 40.7 41.1 38.4 43.5 1 
Mozambique 2011_DHS6 39.0 3045 6.3 6.1 6.5 44.3 43.9 44.7 37.2 52.8 1 
Namibia 2013_DHS6 39.0 623 5.2 4.8 5.6 41.3 40.3 42.2 33.4 50.9 1 
Nepal 2014_MICS5 39.0 558 6.9 6.4 7.4 45.0 44.1 45.9 38.4 52.8 1 
Nigeria 2013_DHS6 39.0 2252 5.2 5.0 5.4 45.6 45.0 46.2 37.0 56.2 1 
Pakistan 2011_MICS4 39.0 4285 7.5 7.3 7.7 43.3 43.1 43.6 37.4 50.2 1 
Rwanda 2015_DHS7 39.0 483 5.6 5.2 6.0 57.6 55.9 59.3 47.3 70.1 3 
Sao Tome and Principe 2014_MICS5 39.0 763 11.0 10.2 11.7 42.6 42.2 43.0 38.5 47.1 1 
Senegal 2015_DHS7 39.0 1434 9.9 9.5 10.4 43.6 43.3 44.0 39.1 48.8 1 
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Sierra Leone 2013_DHS6 39.0 1165 6.3 5.9 6.6 43.2 42.6 43.9 36.3 51.5 1 
Sudan 2014_MICS5 39.0 1229 3.8 3.6 3.9 38.3 37.4 39.3 28.6 51.3 3 
Swaziland 2014_MICS5 39.0 955 11.6 10.9 12.3 41.8 41.4 42.1 38.0 45.9 1 
Timor-Leste 2009_DHS6 39.0 1480 8.4 8.0 8.8 42.1 41.7 42.5 37.0 48.0 1 
Togo 2013_DHS6 39.0 795 9.5 8.9 10.1 43.5 42.9 44.0 38.7 48.8 1 
Uganda 2011_DHS6 39.0 418 7.0 6.4 7.6 44.2 43.2 45.2 37.8 51.7 1 
United Republic of Tanzania 2016_DHS7 39.0 2897 10.8 10.5 11.2 43.5 43.3 43.8 39.3 48.2 1 
Viet nam 2014_MICS5 39.0 903 10.5 9.9 11.2 44.5 44.0 45.0 40.1 49.4 1 
Yemen 2010_DHS6 39.0 1772 5.0 4.8 5.2 46.4 45.6 47.1 37.2 57.8 1 
Zambia 2013_DHS6 39.0 3364 7.6 7.4 7.9 44.5 44.2 44.9 38.6 51.4 1 
Zimbabwe 2015_DHS7 39.0 1743 9.7 9.3 10.1 42.6 42.3 42.9 38.0 47.7 1 
Algeria 2013_MICS4 47.7 5296 8.8 8.5 9.0 43.9 43.7 44.1 38.7 49.8 1 
Armenia 2010_DHS6 52.0 523 13.7 12.6 14.7 57.6 57.0 58.2 53.1 62.4 1 
Belize 2011_MICS4 52.0 525 7.6 7.0 8.2 57.7 56.7 58.8 49.9 66.8 1 
Bosnia and Herzegovina 2012_MICS4 52.0 737 9.7 9.0 10.3 60.7 59.9 61.5 54.2 68.0 1 
Colombia 2010_DHS6 52.0 4622 9.1 8.8 9.3 59.0 58.7 59.3 52.3 66.6 1 
Cuba 2014_MICS5 52.0 2087 11.2 10.8 11.7 56.4 56.1 56.7 51.1 62.2 1 
Dominican Republic 2014_MICS5 52.0 4368 5.3 5.2 5.5 57.8 57.3 58.3 47.0 71.1 1 
Egypt 2014_DHS6 52.0 233 7.1 6.3 7.9 46.7 45.1 48.2 39.9 54.5 1 
El Salvador 2014_MICS5 52.0 2559 21.6 20.8 22.3 55.9 55.7 56.0 53.1 58.8 1 
Guatemala 2015_DHS7 52.0 3490 11.7 11.4 12.1 58.8 58.5 59.1 53.5 64.6 1 
Guyana 2014_MICS5 52.0 1113 16.9 16.0 17.9 57.0 56.7 57.3 53.4 60.8 1 
Honduras 2011_DHS6 52.0 3565 17.6 17.0 18.1 56.4 56.2 56.6 53.0 60.0 1 
Kazakhstan 2015_MICS5 52.0 149 4.0 3.4 4.6 53.9 50.2 57.5 40.9 70.9 2 
Kyrgyzstan 2012_DHS6 52.0 1351 8.6 8.1 9.0 56.5 56.0 57.1 49.7 64.3 1 
Mexico 2015_MICS5 52.0 2013 6.6 6.3 6.8 61.0 60.3 61.7 51.6 72.1 1 
Peru 2010_DHS6 52.0 7308 10.4 10.2 10.7 59.3 59.1 59.5 53.4 65.9 1 
Republic of Moldova 2012_MICS4 52.0 100 4.8 3.9 5.8 54.6 50.9 58.4 43.5 68.6 1 
Serbia 2014_MICS5 52.0 627 7.7 7.1 8.2 62.4 61.4 63.4 54.1 72.0 1 
State of Palestine 2014_MICS5 52.0 2513 37.1 35.8 38.4 55.8 55.7 55.9 54.2 57.5 1 
Suriname 2010_MICS4 52.0 853 10.3 9.7 11.0 59.2 58.5 59.8 53.2 65.8 1 
Tajikistan 2012_DHS6 52.0 1634 6.2 5.9 6.5 55.7 55.0 56.4 46.6 66.5 2 
TFYR Macedonia 2012_MICS4 52.0 552 8.4 7.8 9.0 56.6 55.7 57.6 49.7 64.5 1 
Tunisia 2012_MICS4 52.0 786 9.0 8.4 9.6 69.3 68.4 70.1 61.4 78.2 1 
Ukraine 2012_MICS4 52.0 185 3.5 3.0 3.9 65.2 60.8 69.6 47.5 89.5 2 
Costa Rica 2011_MICS4 65.0 691 12.6 11.7 13.5 69.6 69.0 70.3 63.8 76.0 1 
             
  Median 39.0   7.0 6.6 7.6 43.6 43.1 44.1 37.8 51.3   
  Median 52.0   9.0 8.4 9.3 57.6 56.7 58.3 52.3 65.9   
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Figure 3. Distributions of the actual age at BCG vaccination in 72 LMICs with median 
distribution for countries with a target age at birth 
 
  
127 
 
Figure 4. Distributions of the actual age at DTP1 vaccination in 73 LMICs with median 
distributions for countries with target ages at 6 weeks and 2 months 
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Figure 5. Distributions of the actual age at DTP2 vaccination in 73 LMICs with median 
distributions for countries with target ages at 10 weeks and 4 months 
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Figure 6. Distributions of the actual age at DTP3 vaccination in 73 LMICs with median 
distributions for countries with target ages at 14 weeks and 6 months 
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Figure 7. Distributions of the actual age at Meas1 vaccination in 73 LMICs with 
median distributions for countries with target ages at 39 weeks and 12 months 
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7.0 Chapter 7 - Estimation of rotavirus vaccine efficacy and waning 
 
7.1  Contribution of paper to the aim and objectives of the thesis 
 
This paper brings together available evidence from RCTs on the efficacy of live oral 
rotavirus vaccines and uses the data to generate pooled estimates of efficacy by 
duration of follow-up and type of setting. These are essential to the estimation of 
rotavirus vaccine impact in each week of age. The pooled estimates from this paper 
are used in the benefit-risk analysis (Chapter 9). Specifically, I used the estimates for 
the medium mortality stratum, high mortality stratum (no India) and for India alone. 
Several possible waning functions were evaluated in this paper. The gamma function 
had the best goodness of fit in the high mortality stratum, so was used in the base case 
estimates of the benefit-risk analysis. However, the power function (the main function 
presented in this paper) estimated less rapid waning and had a better fit in the medium 
mortality stratum. This function was also evaluated in an alternative ‘what-if’ scenario 
to assess the impact of this choice on the benefit-risk ratios. 
 
The paper presented in this chapter also evaluates two schedules that were compared 
in a head-to-head trial in Indonesia (a three-dose neonatal schedule and a three-dose 
infant schedule). In the analysis presented in this paper, the neonatal schedule is 
estimated to have twice the mean duration of protection as the infant schedule. This 
informed a what-if scenario evaluated in the benefit-risk analysis (Chapter 9), where 
all doses administered as part of a neonatal schedule were assumed to have twice the 
mean duration of protection as doses administered as part of an infant schedule.  
 
7.2 Independent academic contribution 
 
I extracted the data from the RCTs and ran initial statistical analyses using Maximum 
Likelihood Estimation (MLE). This involved writing the R code to fit curves to the 
mid-points of the reported durations of follow-up in each trial. Mid-points were used 
rather than the full duration of follow-up in order to approximate instantaneous 
efficacy at specific follow-up durations. I presented the work to the WHO IVIR-AC 
committee and wrote the first draft of the paper.  
 
The analysis was subsequently improved by involving experts in Bayesian meta-
regression (Kevin Van Zandvoort and Stefan Flasche) who recommended a novel 
method for converting cumulative vaccine efficacy into instantaneous efficacy (rather 
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than the crude mid-point approach). Kevin Van Zandvoort ran these subsequent 
analyses and authored Appendices A-D. Kevin was later included as a joint first 
author to recognise his important contribution. Appendices A-D are included at the 
end of the thesis (Appendices 6-9), rather than in the main body of this chapter 
because I had a minor role in their development.  
 
7.3 Ethical approval 
 
This study was approved by the ethical committee (Ref 15829) of the London School 
of Hygiene and Tropical Medicine (LSHTM). 
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Summary 
 
Background  
It has become clear that the duration of protection offered by rotavirus vaccines varies across 
the world, and that this is important to understanding and predicting vaccine impact. There is 
now a large body of evidence on the efficacy of live oral rotavirus vaccines (VE) in different 
settings, but this has never been synthesised to obtain robust estimates of efficacy by duration 
of follow-up by type of setting.  
Methods  
We identified all RCTs of rotavirus vaccines published before March 2018. For all reported 
follow-up periods we extracted the mean duration of follow-up, the number of enrolled infants, 
and case counts for rotavirus-positive severe gastroenteritis (RVGE) in both placebo and 
vaccine arms. We used a Bayesian hierarchical Poisson meta-regression model to estimate 
pooled VE and its waning with time for three mortality strata. We then converted these 
cumulative VE estimates into instantaneous VE (iVE). 
Findings  
In settings with low-mortality (number of studies, n=10) iVE pooled for infant schedules of 
Rotarix® and RotaTeq® was 98% (95% credibility interval: 93-100%) two weeks following 
the final dose of vaccination and 94% (87-98%) after 12 months. In medium-mortality settings 
(n=8), equivalent estimates were 82% (74-92%) and 77% (67-84%). In settings with high-
mortality (n=13), there were five vaccines with observation points for infant schedules. The 
pooled iVE was 66% (48-81%) after two weeks of follow-up and 44% (27-59%) after 12 
months. The data points from India were influential in the high-mortality stratum; iVE pooled 
for ROTAVAC® and ROTASIIL® in India was 54% (-78-88%) after two weeks and 42% (-
128-85%) after 12 months. For RV3-BB in Indonesia, we found more durable efficacy for the 
neonatal schedule than the infant schedule. 
Interpretation 
Rotavirus vaccine efficacy is lower and wanes more rapidly in high mortality settings but the 
earlier peak age of disease in these settings means that rotavirus vaccines are still likely to 
provide substantial benefit. Strategies to improve the level and durability of protection in high 
mortality settings should be explored. 
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Strengths and limitations of this study 
 We use high quality evidence from randomised placebo-controlled trials. 
 We provide statistically robust and novel methods for estimating instantaneous efficacy 
by duration of follow-up. 
 Combining data points for different brands of vaccine and different infant schedules 
enabled us to maximise the number of data points in each stratum.  
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Introduction 
Rotavirus gastroenteritis (RVGE) is estimated to cause around 200,000 child deaths each year 
(1-3) with most deaths occurring in Sub-Saharan Africa and South Asia. Episodes of RVGE 
occur frequently in young children irrespective of living standards and are a major contributor 
to healthcare costs worldwide (4, 5). 
Over half of the countries in the world have introduced rotavirus vaccines into their national 
immunisation programmes (6). Infants typically receive two oral doses of Rotarix® (GSK 
Biologicals) or three oral doses of RotaTeq® (Merck & Co.) in the first six months of life (7, 
8). Both vaccines have demonstrated high and durable efficacy against episodes of severe 
RVGE in high income settings, but lower and less durable efficacy in Sub-Saharan Africa and 
South Asia (9-12). Other live oral rotavirus vaccines are becoming available (ROTAVAC® - 
Bharat Biotech, ROTASIIL® – Serum Institute of India, RV3-BB – MCRI) but these have 
also reported lower and/or less durable efficacy in high mortality settings when used as part 
of a standard infant schedule i.e. India, Indonesia and Niger (13-16). Alternative schedules are 
being considered as one way to improve efficacy in the second year of life. This may involve 
administering the first dose at birth (15) or administering a booster dose at 9-12 months (17). 
Countries considering rotavirus vaccine introduction, global bodies such as the World Health 
Organization (WHO) and donors funding vaccine introduction in resource-poor settings, 
require accurate projections of the potential impact of vaccination. Such projections are also 
useful in post-introduction surveillance, to ensure that the vaccine is performing as expected, 
and to estimate the remaining burden of disease after the vaccine has been introduced. 
Mathematical models can predict the potential impact of rotavirus vaccines but require 
credible estimates of vaccine efficacy by duration of follow-up, in different settings. This 
information is also critical to the evaluation of alternative vaccination schedules. A large body 
of evidence now exists from high quality randomised controlled trials (RCTs) in different parts 
of the world but these data have never been pooled and synthesised to obtain robust estimates 
of vaccine efficacy over time. Combining this evidence is not straightforward. There is 
substantial variation in trial settings, follow-up periods, sample sizes, case definitions, and 
statistical methods used to calculate confidence intervals. In addition, the main outcome 
reported in RCTs is the cumulative efficacy (VE) over a period of many weeks, but if there is 
evidence of vaccine waning, then the cumulative efficacy over the entire follow-up period 
may greatly overestimate the actual instantaneous efficacy (iVE) at the end of the follow-up 
period. 
Our aim is to propose statistically robust and consistent methods for estimating the 
instantaneous efficacy of live oral rotavirus vaccines by duration of follow-up (time since 
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administration of the final dose of rotavirus vaccination). We then apply these methods to the 
entirety of the relevant literature to generate definitive efficacy estimates by mortality setting. 
 
Methods 
Search strategy and selection criteria 
We included all individually randomised placebo-controlled trials that were identified in a 
recent Cochrane systematic review of studies published between May 2012 and March 2018 
(Soares-Weiser et al, forthcoming)(18) and cross-checked the list against the studies identified 
by a recent review by Lamberti et al (19). We excluded trials that were based on special 
populations, trials without an infant schedule and trials without clear reporting of enrolled 
infants and events in different periods of follow-up. The outcome measure was efficacy 
against episodes of severe RVGE, which is the primary endpoint reported in nearly all RCTs 
of rotavirus vaccines. Severe RVGE is defined as 11-20 points on the Vesikari scale (20), or 
for some older trials, 15-24 points on the Clark scale (21). If this outcome was not reported, 
we used the closest available proxy e.g. efficacy against episodes of RVGE that were admitted 
to hospital or the emergency department. In all RCTs rotavirus-positive episodes were 
detected by enzyme immunoassay (EIA). 
Follow-up definition 
We extracted vaccine efficacy for all reported periods of follow-up. We extracted the number 
of infants and number of rotavirus-positive cases in both the placebo and vaccine arms, as well 
as the mean duration of follow-up in months. We extracted according-to-protocol (ATP) 
estimates, which exclude any disease cases that are reported in the first 14 days post-
vaccination and only include infants that received all recommended doses. We added 14 days 
to the reported mean duration of follow-up to calculate the entire period between 
administration of the last dose and the mean age at follow-up. If all infants were followed to 
a specific age (e.g. 12 months) we subtracted the mean age of administration of the final dose 
(or target age if the mean was not reported) from the specific follow-up age. 
Stratification of studies 
To account for heterogeneity between the RCT sites, we grouped all 201 countries in the world 
into quintiles (very low mortality, low, medium, high, very high) using the under-five 
mortality rates reported for the period 2010-2015 in the 2017 Revision of the United Nations 
Population Division (UNPOP) database. We further collapsed the very low and low quintiles 
and the high and very high quintiles to give three mortality strata (low, medium, high). Each 
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RCT was then assigned to a specific stratum. For RCTs with multiple sites across several 
countries, we included each individual country as a separate observation point where this was 
possible. If RCT results were not disaggregated by country, we used the sample size in each 
site to calculate a weighted under-five mortality rate and used this to assign the trial to a 
specific mortality stratum. We restricted the pooled analysis to infant schedules only.  
Recalculating cumulative vaccine efficacy for reported periods of follow-up 
There was substantial variation in the way authors estimated vaccine efficacy and 95% 
confidence intervals. Our pooled analyses (see section below) used case counts and numbers 
reported in trials to generate credible intervals, but to ensure consistent reporting of the 
observed data in the plots we also recalculated VE and 95% confidence intervals using the 
method of Daly and Altman (22, 23). VE was calculated as 1 – RR (relative risk) with zero-
inflation to 0.5 for rotavirus-positive disease events in the vaccine arm (24). 
Efficacy by duration of follow-up and mortality strata 
We used a Bayesian hierarchical meta-regression model to estimate cumulative vaccine 
efficacy by duration of follow-up. We generated separate pooled estimates for RCTs in low, 
medium and high mortality strata. We assumed that the observed number of cases in the 
unvaccinated and vaccinated groups followed a Poisson distribution. The total number of 
cases in the unvaccinated group in study i and period p, Yi,p,u, was estimated as: log (𝑌𝑌𝑖𝑖,𝑝𝑝,𝑢𝑢) = 𝜆𝜆𝑖𝑖,𝑝𝑝 + 𝑃𝑃𝑖𝑖,𝑝𝑝,𝑢𝑢 
Similarly, the total number of cases in the vaccinated group in study i and period p, Yi,p,v, was 
estimated as: log (𝑌𝑌𝑖𝑖,𝑝𝑝,𝑣𝑣) = 𝜆𝜆𝑖𝑖,𝑝𝑝 + 𝑃𝑃𝑖𝑖,𝑝𝑝,𝑣𝑣 + 𝜃𝜃𝑖𝑖(𝑡𝑡𝑖𝑖,𝑝𝑝) 
where λi,p is the baseline rate of becoming infected, Pi,p,* is the total person-months of follow-
up in the respective group, and θi(ti,p) is the cumulative relative risk ratio (RR) in study i, at t 
months of follow-up. Total person-months of follow-up was calculated as the number of 
participants at the beginning of the follow-up period multiplied by the mean reported duration 
of follow-up. The hierarchical component of the model ensured that parameter values of the 
study-specific RR were identical across periods in studies with more than one data point e.g. 
RR for period 1, RR for period 1+2 combined.  
Best-fitting model parameters were estimated using Markov Chain Monte Carlo (MCMC) 
methods. Gibbs sampling was used to draw from posterior distributions. We used non-
informative prior distributions for all parameters. We ran four parallel MCMC chains and 
visually assessed whether chains converged. We reported medians and 95% credible intervals 
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from the posterior distribution of the cumulative vaccine efficacy. In the absence of any prior 
knowledge about the likely shape of waning we explored several functional forms, including 
linear, power law, sigmoid and gamma (Appendix A). Their goodness of fit was assessed 
using the Deviance Information Criterion (DIC), visual assessment, and biological 
plausibility.  
The best-fitting function of cumulative efficacy was used to estimate instantaneous vaccine 
efficacy (iVE) by duration of follow-up using a novel approach, based on Kaplan-Meier 
survival estimates. The instantaneous rate ratio at time t, σ(t), is retrieved using the formula 
below. Here, the instantaneous rate ratio is a function of the cumulative rate ratio at time t, 
θ(t), all instantaneous rate ratios up until time t, σ(x), the baseline rate or force of infection at 
time t, λt, and all baseline rates up until time t, λx: 
𝜎𝜎(𝑡𝑡) = 𝜃𝜃(𝑡𝑡) + � (𝜃𝜃(𝑡𝑡) − 𝜎𝜎(𝑥𝑥))𝑡𝑡
𝑥𝑥=0
𝜆𝜆𝑥𝑥
𝜆𝜆𝑡𝑡
𝑑𝑑𝑥𝑥 
The instantaneous and cumulative rate ratios are identical at time t=1, i.e. σ(1)= θ(1). We then 
solve the integral using an iterative approach. If changes in baseline rates are unknown, they 
can be assumed to be similar over time, and 𝜆𝜆𝑥𝑥
𝜆𝜆𝑡𝑡
 set to 1 or omitted from the equation. iVE at 
time t is then calculated as 1 – σ(t). Extensive details and example simulations of this method 
are given in Appendix B. For each stratum, we reported iVE at standard follow-up times.  
Analyses were done using R version 3.4.3 (25) using the rjags package. 
Head-to-head comparison of efficacy for alternative schedules 
To compare the efficacy and waning associated with different rotavirus vaccine schedules we 
identified RCTs that directly compared different vaccine schedules head-to-head and 
requested more granular unpublished information from the investigators on the number of 
events occurring in each week of follow-up after the last dose was administered. In sites with 
available data, we fitted the same models (Appendix A) as in the pooled analysis, but without 
the hierarchical parameters. Again, cumulative vaccine efficacy was converted to 
instantaneous vaccine efficacy. 
 
Results 
RCTs included in study 
We included 50 observation points from 31 RCTs published before March 2018 in populations 
with low (n=10), medium (n=8) and high (n=13) under-five mortality (Table 1). We excluded 
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trials that specifically evaluated high HIV prevalence populations (26) and trials that only 
presented results for breastfed versus non-breastfed infants (27). We excluded the Finnish 
Extension Trial (FEC)(28, 29) because the results for the extension trial could not be 
disentangled from the European estimate reported in the REST trial. For the pooled analysis 
we focused on infant schedules, so excluded the neonatal RotaShield trial in Ghana (30) and 
the neonatal schedule arm of the RV3-BB trial in Indonesia (15). The neonatal schedule arm 
of the RV3-BB trial was included in a separate head-to-head comparison of the infant and 
neonatal schedule in Indonesia (see below).  
Most of the data points (40/50) were reported using a Vesikari score of 11-20 (V11-20). There 
were 24 data points for Rotarix, 19 for RotaTeq, two for RV-3BB, three for ROTASIIL and 
two for ROTAVAC. More data points (30/50) were based on a three-dose schedule than a 
two-dose schedule (20/50). The mean age of administration for the first dose ranged from six 
to 13 weeks.  
Efficacy by duration of follow-up and mortality strata 
We estimated cumulative and instantaneous vaccine efficacy (median and 95% credible 
intervals) by duration of follow-up (Figure 1, Table 2). In settings with low-mortality iVE 
pooled for infant schedules of Rotarix® and RotaTeq® was 98% (95% credibility interval: 
93-100%) two weeks following the final dose of vaccination and 94% (87-98%) after 12 
months. Equivalent pooled estimates for medium-mortality settings were 82% (74-92%) and 
77% (67-84%). In settings with high-mortality (n=13), there were five vaccines with 
observation points for infant schedules. The pooled iVE was 66% (48-81%) after two weeks 
of follow-up and 44% (27-59%) after 12 months. 
The two large studies in India (ROTAVAC® and ROTASIIL®) were influential, so we ran a 
sensitivity analysis to calculate iVE with and without the Indian data points, and for India 
alone (Figure 2, Table 2). In India, iVE pooled for ROTAVAC® and ROTASIIL® was 54% 
(-78-88%) after two weeks and 42% (-128-85%) after 12 months. When the Indian data points 
were excluded from the high-mortality stratum, iVE was 81% (56-94%) after two weeks and 
36% (5-60%) after 12 months. Thus without the Indian data points, there was higher initial 
efficacy, but more rapid waning. 
A simple power function was fitted in all strata because this required the fewest 
assumptions/parameters and had goodness of fit (DIC scores) that were consistently 
favourable across all strata of interest, compared to other functions (Appendix A). 
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Head-to-head comparison of efficacy for alternative schedules 
There were few RCTs with head-to-head comparisons of different schedules. In Indonesia, a 
three-dose neonatal RV3-BB schedule (0-5 days, 8-10 weeks, 14-16 weeks) was compared to 
a three-dose RV3-BB infant schedule (8-10 weeks, 14-16 weeks, 18-20 weeks)(15). For the 
neonatal schedule, the cumulative efficacy was 94% (55-99%) after ~9 months of follow-up 
and 75% (43-89%) after ~15 months. For the infant schedule, cumulative efficacy was 77% 
(32-92%) after ~8 months and 51% (7-74%) after ~14 months (Table 1). For this trial we were 
able to obtain the number of events in each week of follow-up to better inform estimates of 
instantaneous efficacy over time. For the neonatal schedule, the estimated iVE was 100% (99-
100%) after 2 weeks, 77% (73-81%) after 6 months and 40% (26-53%) after 12 months of 
follow-up. For the standard infant schedule, instantaneous efficacy was 97% (93-99%) after 2 
weeks, 51% (45-57%) after 6 months and 2% (-23-23%) after 12 months of follow-up (Table 
2, Figure 3). Again, a simple power function was used because it required the minimum 
number of assumptions/parameters and had favourable DIC scores (Appendix A). Results for 
alternative functions are shown in Appendix D. 
The only other trial with head-to-head comparison of schedules was a multi-country trial 
comparing infant schedules of Rotarix in South Africa and Malawi. We were unable to obtain 
the underlying dataset for this trial. In both countries, a three-dose schedule (6, 10, 14 weeks) 
had higher cumulative efficacy than the two-dose schedule (10, 14 weeks) but confidence 
intervals were wide (Table 1).  
 
Discussion 
Our analysis shows that live oral rotavirus vaccines provide high and durable protection in 
low and medium mortality settings. Efficacy is lower and wanes more rapidly in high mortality 
settings, but these settings are also associated with higher rates of severe disease and mortality 
earlier in life. Before the introduction of rotavirus vaccines, the median age of severe RVGE 
hospitalisation is estimated to be ~9 months in high mortality settings (Hasso-Agopsowicz et 
al, forthcoming). Thus, live oral rotavirus vaccines are still likely to provide substantial benefit 
in these settings, irrespective of waning.  
The reasons for lower rotavirus vaccine efficacy in resource-poor settings are not well 
understood. Immunogenicity studies have shown much lower Geometric Mean 
Concentrations (GMCs) in resource-poor settings compared to high income settings (31). 
Hypotheses for lower immunogenicity include interference by maternal antibodies, oral polio 
vaccines (OPV), breastfeeding, malnutrition, other enteric co-infections, rotavirus strain 
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diversity and HIV infection. Competition in the gut has also been proposed as a reason for the 
lower performance of OPV in resource-poor settings (32, 33). Research is currently underway 
to assess the role of maternal antibodies and gut microbiota in the immune response to 
rotavirus vaccines in UK, Malawian and Indian infants (34). Two pivotal cohort studies from 
Mexico(35) and India (36) have reported contrasting estimates of the protection conferred by 
natural infections against subsequent disease. In Mexico (medium mortality), two prior 
infections (asymptomatic or symptomatic) conferred 100% protection against subsequent 
moderate/severe RVGE. In India (high mortality), the equivalent protection was 57% after 
two prior infections (and 79% after three prior infections). Thus, if natural infections are less 
likely to protect against moderate/severe RVGE in higher mortality settings, then a live oral 
vaccine mimicking natural infection will also have lower estimated efficacy in these children.  
The reported declines in instantaneous efficacy may not be entirely caused by declining 
vaccine-induced antibodies. Some of the decrease could be explained by higher rates of 
immune-boosting asymptomatic and mild infections among placebo recipients compared to 
vaccine recipients. The risk of severe RVGE in vaccine recipients would then converge with, 
and may exceed, the risk in placebo recipients over time. Our analysis of the infant and 
neonatal schedules for RV3-BB in Indonesia suggested a positive protective effect of the 
vaccine in the first 12 months of follow-up, but extrapolation of the curves suggested a 
negative effect thereafter. This would be consistent with preferential natural boosting among 
placebo recipients, but is speculative, as it involves extrapolating beyond the observed period 
of follow-up in the trial. Re-analysis of RCT data from Bangladesh has allowed these effects 
to be partly disentangled by excluding any children that experienced an episode of non-severe 
RVGE. This explained some but not all of the reduction in vaccine efficacy observed over 
time. However, it was not possible to exclude infants that had prior asymptomatic infections, 
and these may also play an important role (37). 
Head-to-head comparisons of vaccine schedules for the same vaccine were very rare, and more 
evidence is needed from more geographical locations on the relative benefits of one schedule 
over another. In our analysis of RV3-BB in Indonesia, the neonatal schedule provided more 
durable protection than the infant schedule. A neonatal schedule is also likely to result in 
higher and earlier coverage, and fewer vaccine-related intussusception events, so warrants 
serious consideration. A booster dose later in infancy (17, 38) or schedules that use injectable 
non-replicating vaccines (39) could be beneficial, but more evidence is needed on the safety 
and clinical efficacy of both of these options.  
For the pooled analysis, we combined evidence for different vaccine products and different 
infant schedules to avoid small numbers of data points in each stratum. None of the RCTs 
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compared different brands of rotavirus vaccination head-to-head in the same population. There 
were several observations for RotaTeq and Rotarix but the Rotarix sites included data points 
from South Africa, which had higher efficacy and lower child mortality relative to the sites 
evaluated in the RotaTeq trials. Thus, in the absence of head-to-head comparisons from the 
same trial populations, there is currently insufficient evidence to favour one product over 
another in terms of vaccine efficacy and duration of protection. However, the post-licensure 
experience of countries that have used both Rotarix and RotaTeq does not suggest any material 
difference in impact (40).  
Most of the data points were reported against Vesikari 11-20 but some were reported against 
Clark 16-24.  These two scores have been shown to correlate poorly with one another when 
estimating the proportion of RVGE episodes defined as severe (41, 42). However, this bias is 
unlikely to change the conclusion that protection is high and durable in the low mortality 
stratum, where the Clark scale was more commonly used.  
We stratified our results by mortality and presented pooled results with and without data points 
from influential studies. We restricted the analysis to RCTs because they represent the gold 
standard approach for measuring per protocol vaccine efficacy and provide accurate 
information about the mean duration of follow-up. Other designs, such as case controls 
studies, report vaccine effectiveness (1 – odds ratio) rather than vaccine efficacy (1 – relative 
risk) and do not permit precise estimation of the mean duration of follow-up. Some case 
control studies report vaccine effectiveness by age band, so could potentially be used to derive 
the duration of follow-up, but this approach becomes increasingly crude as the width of the 
age band increases. Case control studies are also at risk of bias because vaccinated infants are 
likely to differ from unvaccinated infants for both known and unknown reasons.  
We reported the initial/peak efficacy starting at two weeks of follow-up due to uncertainty 
around the time it may take for antibodies to develop after vaccination. In addition, we had to 
extrapolate our fitted estimated of cumulative vaccine efficacy to periods without empiric data 
e.g. beyond two years of follow-up. The absence of empirical data from RCTs is represented 
by larger credible intervals in these periods. However, this makes comparison of different 
waning functions difficult. Evidence from RCTs with a longer duration of follow-up or high-
quality observational studies is needed to overcome this knowledge gap. 
We used a novel approach to convert estimates from cumulative vaccine efficacy to 
instantaneous vaccine efficacy. Simulations (in Appendix B) showed that this method appears 
to work well and is able to retrieve instantaneous vaccine efficacy by converting cumulative 
vaccine efficacy, and that cumulative efficacy may over-estimate instantaneous efficacy if 
vaccine efficacy wanes. However, there are some limitations in applying this method to the 
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meta-regression used in this study. First, it would be better to use relative rates than relative 
risks. We had to compute relative risks because most of the RCTs only reported observed 
numbers of cases and individuals at a limited number of time follow-up points. However, as 
severe RVGE is a relatively rare outcome, risk and rate ratios are expected to be numerically 
similar, and we assume that this bias is negligible in our study. Second, waning of vaccine 
efficacy (or conversely, waxing of the relative rate) may interact with changes in baseline 
rates. This effect would be relatively small on the estimated cumulative vaccine efficacy but 
may be pronounced when converted to an instantaneous vaccine efficacy. As we had no 
information on changes in the baseline rates in our studies, we assumed that this rate was 
constant over time (an assumption which is often made in survival analyses) and did not 
correct for it. The bias is likely to be in the direction of increasing VE since baseline rates are 
declining, particularly in high mortality settings. Our method should ideally be extended to 
control for different changing baseline-rates across different studies, as would be the case in 
a pooled analysis. However, even uncorrected instantaneous vaccine efficacy should still be a 
better approximation to true instantaneous vaccine efficacy than cumulative vaccine efficacy 
in the case of waning vaccine efficacy.  
 
Conclusion 
Recent reviews of the efficacy, effectiveness and impact of rotavirus vaccines (19, 43, 44) 
have described variation in rotavirus vaccine effects according to under-five mortality and 
geographical region. However, this is the first time all of the available RCT evidence has been 
synthesised to obtain robust estimates of instantaneous efficacy by duration of follow-up. Our 
analysis provides the most comprehensive evidence to date that rotavirus vaccine efficacy is 
lower and wanes more rapidly in high mortality settings. Strategies to improve the level and 
durability of protection in high mortality settings should be explored. 
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Table 1. Observations from published RCTs included in the pooled analysis of infant 
schedules: cumulative efficacy (VE) for reported periods of follow-up (FUP) after two or 
three doses of live oral rotavirus vaccines  
Ref Country Schedule  
Score 
  
FUP 
(m)  
Placebo Vaccine VE 
    
d1 age  
(weeks) Doses Brand Cases N Cases N Mid L95 U95 
High mortality 
(9) Bangladesh 10.0 2d Rotarix V11-20 8.1 35 301 9 292 73% 45% 87% 
(10) Malawi 11.0 2d Rotarix V11-20 7.7 38 483 21 525 49% 15% 70% 
(10) Malawi 11.0 2d Rotarix V11-20 15.6 53 483 38 525 34% 2% 56% 
(11) South Africa* 11.0 2d Rotarix V11-20 7.7 9 408 5 418 46% -60% 82% 
(11) South Africa* 11.0 2d Rotarix V11-20 15.6 13 408 9 418 32% -56% 71% 
(10) Malawi 6.2 3d Rotarix V11-20 7.7 38 483 20 505 50% 15% 70% 
(10) Malawi 6.2 3d Rotarix V11-20 15.6 53 483 32 505 42% 12% 62% 
(11) South Africa* 6.2 3d Rotarix V11-20 7.7 9 408 1 425 89% 16% 99% 
(11) South Africa* 6.2 3d Rotarix V11-20 15.6 13 408 2 425 85% 35% 97% 
(12) Bangladesh 8.3 3d RotaTeq V11-20 8.0 31 565 17 563 45% 2% 69% 
(12) Bangladesh 8.3 3d RotaTeq V11-20 14.7 56 565 33 563 41% 11% 61% 
(45) Ghana 8.4 3d RotaTeq V11-20 8.0 42 1081 15 1081 64% 36% 80% 
(45) Ghana 8.4 3d RotaTeq V11-20 14.5 57 1081 26 1081 54% 28% 71% 
(45) Kenya 7.3 3d RotaTeq V11-20 8.1 12 611 2 610 83% 26% 96% 
(45) Kenya 7.3 3d RotaTeq V11-20 12.3 14 611 5 610 64% 1% 87% 
(45) Mali*** 6.9 3d RotaTeq V11-20 8.5 4 921 4 921 0% -299% 75% 
(45) Mali 6.9 3d RotaTeq V11-20 14.9 58 921 48 921 17% -20% 43% 
(14) Niger 6.8 3d ROTASIIL V11-20 5.6 87 1728 31 1780 65% 48% 77% 
(13) India** 6.9 3d ROTASIIL V11-20 8.3 94 3498 61 3527 36% 11% 53% 
(13) India 6.9 3d ROTASIIL V11-20 20.0 275 3502 171 3533 38% 26% 49% 
(16) India 6.8 3d ROTAVAC V11-20 8.2 64 2187 56 4354 56% 37% 69% 
(16) India 6.8 3d ROTAVAC V11-20 13.4 76 2187 71 4354 53% 35% 66% 
(15) Indonesia$ 9.3 3d RV3-BB V11-20 7.5 17 504 4 511 77% 32% 92% 
(15) Indonesia 9.3 3d RV3-BB V11-20 13.5 28 504 14 511 51% 7% 74% 
Medium mortality 
(46) China 9.6 2d Rotarix V11-20 4.0 32 1573 8 1575 75% 46% 88% 
(46) China 9.6 2d Rotarix V11-20 16.5 75 1573 21 1575 72% 55% 83% 
(47) Latin Am. (n=3) 8.4 2d Rotarix V11-20 7.5 34 454 27 1392 74% 58% 84% 
(48) Latin Am. (n=6) 8.6 2d Rotarix V11-20 7.9 19 2099 7 4211 82% 56% 92% 
(49) Latin Am. (n=10) 8.0 2d Rotarix V11-20 8.8 58 7081 10 7205 83% 67% 91% 
(49) Latin Am. (n=10) 8.0 2d Rotarix V11-20 20.5 161 7081 32 7205 80% 71% 87% 
(50) China 8.5 3d RotaTeq V11-20 9.8 52 1946 11 1930 79% 59% 89% 
(51) Latin Am. (n=5) 9.7 3d RotaTeq Hosp/ED 19.0 10 2237 1 2252 90% 22% 99% 
(52) USA (Navajo) >6 3d RotaTeq C11-24 8.8 37 403 4 392 89% 69% 96% 
(12) Viet nam 9.7 3d RotaTeq V11-20 8.0 7 442 2 446 72% -36% 94% 
(12) Viet nam 9.7 3d RotaTeq V11-20 12.3 15 442 5 446 67% 10% 88% 
Low mortality 
(53) Europe (n=6) 11.5 2d Rotarix V11-20 5.3 60 1302 5 2572 96% 90% 98% 
(53) Europe (n=6) 11.5 2d Rotarix V11-20 17.3 127 1302 24 2572 90% 85% 94% 
(54) Finland 8.3 2d Rotarix V11-20 5.3 5 123 1 245 90% 15% 99% 
(54) Finland 8.3 2d Rotarix V11-20 17.3 10 123 3 245 85% 46% 96% 
(55) Japan 7.7 2d Rotarix V11-20 20.6 12 250 2 498 92% 63% 98% 
(56) SE Asia (n=3) 12.0 2d Rotarix V11-20 7.4 15 5256 0 5263 97% 46% 100% 
(56) SE Asia (n=3) 12.0 2d Rotarix V11-20 31.7 64 5256 2 5263 97% 87% 99% 
(56) SE Asia (n=3) 12.0 2d Rotarix V11-20 19.5 51 5256 2 5263 96% 84% 99% 
(57) USA 13.0 2d Rotarix All RVGE 7.0 18 107 2 108 89% 54% 97% 
(58) Europe (n=5) 10.0 3d RotaTeq C17-24 13.3 43 1188 0 1120 99% 80% 100% 
(58) Europe (n=5)** 10.0 3d RotaTeq C17-24 19.0 61 1155 1 1088 98% 87% 100% 
(51) USA 9.7 3d RotaTeq Hosp/ED 19.0 58 12179 3 12284 95% 84% 98% 
(59) Finland/USA 10.0 3d RotaTeq C17-24 4.4 6 661 0 651 92% -38% 100% 
(55) Japan 7.6 3d RotaTeq C17-24 6.7 10 381 0 380 95% 19% 100% 
(60) USA >8 3d RotaTeq C17-24 5.5 8 183 0 187 94% 1% 100% 
 
* Data only extracted for the South African cohort that was followed for two successive seasons. 
** N values were adjusted to be the same for both follow-up periods in Bayesian meta-regression. 
*** There were surveillance issues in the first year of trial in Mali that have been postulated to contribute to the low efficacy 
in the first period, but we did not adjust for this. 
$ Only shows data from the infant schedule arm of the trial. See Figure 3 for a comparison with the neonatal schedule arm. 
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Table 2. Median instantaneous vaccine efficacy (iVE) and 95% credible intervals by 
duration of follow-up and setting after two or three doses of oral rotavirus vaccination 
(infant schedules only) 
 
Low  
mortality 
Medium 
mortality 
High  
mortality 
High mortality  
(no India) India 
 iVE 95%CI iVE 95%CI iVE 95%CI iVE 95%CI iVE 95%CI 
2w 98% 93-100% 82% 74-92% 66% 48-81% 81% 56-94% 54% -78-88% 
1m 98% 93-100% 81% 74-90% 62% 47-75% 74% 53-88% 52% -89-88% 
2m 97% 93-99% 80% 73-87% 57% 45-67% 66% 50-79% 49% -105-87% 
3m 96% 92-99% 79% 73-86% 54% 44-64% 61% 48-72% 48% -108-86% 
6m 95% 91-98% 78% 71-84% 49% 40-61% 49% 38-64% 45% -115-86% 
9m 95% 89-98% 77% 69-84% 46% 33-60% 42% 22-61% 43% -124-86% 
12m 94% 87-98% 77% 67-84% 44% 27-59% 36% 5-60% 42% -128-85% 
18m 94% 83-97% 77% 63-84% 41% 17-58% 27% -26-59% 41% -135-85% 
24m 93% 79-97% 76% 59-83% 38% 9-58% 19% -54-57% 40% -139-85% 
36m 92% 69-97% 76% 53-83% 35% -4-57% 7% -107-56% 39% -149-85% 
48m 91% 58-97% 75% 48-83% 32% -14-57% -2% -154-56% 38% -154-85% 
60m 91% 48-97% 75% 44-83% 30% -23-57% -10% -200-55% 37% -163-85% 
 
 
 
  
148 
 
Figure 1. Median and 95% credible intervals of cumulative and instantaneous vaccine 
efficacy by duration of follow-up and setting after two or three doses of oral rotavirus 
vaccination (infant schedules only) 
 
 
Note: A simple power function was used to represent vaccine waning over time (Appendix A). See Appendix C 
for equivalent plots based on other potential waning functions. 
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Figure 2. Median and 95% credible intervals of cumulative and instantaneous vaccine 
efficacy by duration of follow-up after two or three doses of oral rotavirus vaccination 
(infant schedules only) in high mortality settings: sensitivity analysis showing results with 
and without the Indian data points, and for India alone 
 
 
Note: A simple power function was used to represent vaccine waning over time (Appendix A). See Appendix C 
for equivalent plots based on other potential waning functions. 
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Figure 3. Median and 95% credible intervals of cumulative and instantaneous vaccine 
efficacy by duration of follow-up and type of schedule (neonatal versus infant) following 
three doses of RV3-BB in Indonesia 
 
 
Note: A simple power function was used to represent vaccine waning over time (Appendix A). See Appendix D 
for equivalent plots based on other potential waning functions. Data points shown on the left panel represent 
observed vaccine efficacies derived from cumulative Kaplan-Meier hazard ratios, and error bars with their 
corresponding 95% confidence intervals. Solid lines (VE) and dashed lines (iVE) represent medians. Shaded 
areas represent 95% credible intervals. 
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Chapter 8 - Estimation of the incidence, age distribution and case fatality of 
intussusception in children aged < 5 years 
 
8.1  Contribution of paper to the aim and objectives of the thesis 
 
This paper provides a comprehensive update of the evidence on intussusception 
incidence rates, age distributions and CFRs in LMICs. This greatly expands the 
quality and depth of evidence that was used in the previous benefit-risk analysis 
(Appendix 1). For example, multiple new studies have been published since the time 
of the last analysis. We also sought more granular data on age distributions than was 
published in the original articles and broadened the scope to include incidence rates 
and age distributions up to age 5.0 years. We found high rates of intussusception in 
the Western Pacific region and very high CFRs in Africa. 
 
8.2 Independent academic contribution 
 
I was the LSHTM principal investigator and first author of the paper. I wrote the R 
code, ran the statistical analysis, presented the work to the WHO IVIR-AC committee 
and wrote the first draft of the paper. The systematic review and data gathering were 
done by others. I resolved conflicts between the two systematic reviewers using 
Distiller software. 
 
8.3 Ethical approval 
 
This study was approved by the ethical committee (Ref 15595) of the London School 
of Hygiene and Tropical Medicine (LSHTM). 
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Abstract 
 
Objective To estimate the incidence, age distribution and case fatality of intussusception 
hospital admissions among children aged < 5 years, before the introduction of rotavirus 
vaccination 
Methods We included all studies published between January 2002 and January 2018. We 
fitted parametric age distributions to estimate the median age, interquartile age range, and 
cumulative proportion of intussusception cases estimated to have occurred by standard ages 
between birth and age 5.0 years. We estimated incidence rates and case fatality ratios (CFRs) 
for children aged <5 years for each country and each WHO region. 
Findings We identified 128 articles containing 227 country datasets (61 age distributions, 71 
incidence rates and 95 CFRs). The median age of intussusception ranged from 29 weeks in 
Africa (83% of cases in the first year of life) to 70 weeks in the Western Pacific region (35% 
of cases in the first year of life). The median (range) annual incidence of intussusception 
hospital admissions per 100,000 aged <1 years ranged from 34 (13-56) in Africa to 90 (9-380) 
in the Western Pacific region. We found extreme differences between the CFRs in Africa (one 
in ten hospital admissions) and the rest of the world (less than one in every 100-2000 hospital 
admissions). 
Conclusion Intussusception epidemiology varies by country and region. Understanding and 
recognising these differences will be important when assessing the potential number of 
intussusception cases associated with rotavirus vaccines. 
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Introduction 
Intussusception is the main cause of bowel obstruction in children aged <5 years. It occurs 
when a segment of the intestine telescopes or folds back on itself (1). This blocks the passage 
of food and liquid through the intestine and restricts the supply of blood to the affected area. 
Some cases of intussusception will spontaneously resolve without treatment, but delayed 
diagnosis can lead to perforation and infection in the lining of the abdominal cavity 
(peritonitis). Peritonitis can cause severe abdominal pain, fever, shock and death (2). In high 
income countries most children are diagnosed quickly with ultrasound or radiograph and the 
bowel will return to normal after injecting a liquid or gas into the rectum (enema). In more 
severe cases surgery is usually very successful. However, in parts of Africa and elsewhere, 
many children will die before reaching healthcare. For those that do reach healthcare, surgery 
is often the primary method of diagnosis and treatment, leading to death in ~10% of cases (3).  
The cause of intussusception is usually unclear, but infections that cause swelling in the bowel 
wall may be associated (4). In some countries that have introduced oral rotavirus vaccines, a 
small but elevated risk of intussusception has been reported in the first few weeks after 
administration of the first and second dose. To limit the scale of potential vaccine-related 
intussusception cases the vaccine manufacturers have recommended administration of the first 
dose before 15 weeks of age (and the final dose before 32 weeks of age) when the background 
rate of intussusception is relatively low (5).  
Published intussusception incidence rates, age distributions and case fatality ratios (CFRs) 
have been reviewed and published by the World Health Organization (WHO) (1960-2002) (2) 
and Jiang et al (2002-2012) (3) but there are a number of reasons why this evidence should 
now be updated. First, many new studies have been published since 2012. Second, age 
distributions and incidence rates were previously restricted to children aged <1 year despite 
many cases being observed between the ages of 1.0 and 5.0 years in some settings (6-8). Third, 
case-fatality ratios (CFRs) were estimated for a variety of age groups rather than a standard 
(e.g. <5 years) making it difficult to compare countries and estimate ratios in countries with 
no data. Fourth, published intussusception age distributions are rarely published by week of 
age. Obtaining data from authors/investigators at this level of age granularity will improve 
precision when estimating the potential number of excess intussusception cases after rotavirus 
vaccine introduction. Other inputs needed for this calculation are already available in weekly 
age units, such as vaccine coverage/timeliness (9) and the relative risk of intussusception after 
each dose of rotavirus vaccine (10). 
In this paper we provide an updated global review of the incidence, age distribution and case 
fatality of intussusception hospital admissions among children aged < 5 years of age, before 
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the introduction of rotavirus vaccination. This will provide an important pre-vaccination 
baseline to compare with evidence from the post-vaccination era. It will also provide inputs 
that are critical for assessing the number of excess intussusception cases that could be 
associated with different rotavirus vaccination schedules in different settings. 
 
Methods 
Search strategy 
We sought information from published research articles on intussusception incidence rates, 
age distributions and CFRs in children aged <5 years, before the introduction of rotavirus 
vaccination. We included all studies published between January 2002 and June 2012 that were 
identified in a previous review by Jiang et al (3). We then added all relevant studies published 
between June 2012 and January 2018, identified from a new global systematic literature 
review. This review used search terms that were consistent with the review by Jiang et al i.e. 
“intussusception” or “intestinal invagination”. It was conducted in accordance with PRISMA 
guidelines. We searched PubMed, EMBASE, MEDLINE and Cochrane Library. We restricted 
the search to articles published in English, French, Spanish and Polish. To increase the 
relevance of our analysis we excluded all studies published before January 2002. We therefore 
excluded all studies from an earlier review by WHO (1960-2002) (2). All titles and abstracts 
identified by the systematic review were screened for inclusion by two reviewers (MHA and 
LS) using Distiller software. Any disagreements were resolved by a third reviewer (AC). 
Articles were excluded if: a) it was not possible to extract data for the years prior to rotavirus 
vaccine introduction; b) the data period ended prior to the year 2000; c) cases were not coded 
as ICD9-560, ICD10-K56.1, Brighton Collaboration Level 1 (BCL1) or defined clinically as 
intussusception; d) there were fewer than 35 cases (for age distribution fitting); e) more recent 
data was published elsewhere for the same population/location (for incidence rates); f) they 
described animal studies; g) they described individual case reports; h) they focused on a 
specific subgroup of cases e.g. follow-up evaluations of chronic or recurrent intussusception;  
i) they were conducted in special populations e.g. HIV positive; or, j) the study had a high risk 
of bias. All remaining studies were assigned very low, low or medium risk of bias (see 
Appendix Table 1).  If information from multiple countries was published as a single data 
point it was included if all countries were from the same WHO region and it was clear that 
none of the country-level data were reported elsewhere.  
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Data extraction 
We compiled a database containing information on intussusception incidence rates, age 
distributions and CFRs in children aged <5 years. For all studies, we extracted the country, 
subnational location, study design, case definition, period of data collection and age range. To 
obtain more granular age distributions we emailed an invitation letter to all authors that were 
listed in the Jiang et al review (2002-2012)(3) and all authors identified in the new systematic 
review (2012-2018). We invited each author to share a spreadsheet table with counts of 
intussusception hospital admissions by week of age up to 5.0 years. If the authors did not 
respond then we extracted the age distributions published in the research article. We also 
extracted the published incidence rate and the number of intussusception cases and deaths. 
A country dataset was defined as any dataset with hospitalised patients before the introduction 
of rotavirus vaccine, taken from a single study in a single country, and reporting on a single 
outcome e.g. age distribution, incidence rate, CFR. If a study included multiple years and 
multiple sites then all pre-vaccination years and subnational sites were aggregated and 
included in the same country dataset. The main outcome/presentation was hospital admissions, 
but we also included emergency room visits if admissions were not reported in the same study. 
Age distribution of intussusception hospital admissions < 5 years 
Age distributions were fitted to all studies that had at least three age bands below the age of 
1.0 year to ensure there was enough information to inform the shape of the age distribution. 
Age distributions that did not capture the entire age range <5 years (e.g. <1 year, <2 years) 
were adjusted to ensure that each country dataset had a realistic right-hand tail prior to fitting. 
To do this we calculated the median cumulative proportion of intussusception cases that were 
reported to have occurred by ages 1, 2, 3, 4 and 5 years in each WHO region, using a subset 
of country datasets that had a full set of counts in each single year of age up to 5.0 years. The 
median proportions in each WHO region were then used to estimate the expected number of 
intussusception cases in each missing single year of age <5 years. 
We fitted a range of parametric age distributions <5 years (Gamma, Weibull, Lognormal, Log 
Logistic, Burr) to each country dataset using Non-linear Least Squares (NLS) and Maximum 
Likelihood Estimation (MLE). Each distribution was compared using the Root Mean Squared 
Error (RMSE), Mean Absolute Error (MAE), goodness of fit statistics (Kolmogorov-Smirnov, 
Cramer-von Mises, Anderson-Darling) and goodness of fit criteria (Akaike's Information 
Criterion, Bayesian Information Criterion).  
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We estimated the median age, interquartile age range, and cumulative proportion of 
intussusception cases estimated to have occurred by standard ages between birth and age 5.0 
years. All analyses were conducted using R v.3.4.1 using the R packages MASS, nloptr, 
fitdistrplus, actuar and mutil. 
Results were stratified by the following WHO regions: the Americas (AMR); Africa (AFR); 
Eastern Mediterranean (EMR); Europe (EUR); Southeast Asia (SEA); and, Western Pacific 
(WPR)(11).  
Incidence of intussusception hospital admissions <5 years 
For country datasets that did not capture the entire age range <5 years (e.g. <1yr, <2yrs) we 
calculated an adjusted incidence rate per 100,000 per year <5 years. First, we estimated the 
expected number of cases in each missing single year of age <5 years using the median 
cumulative proportion of intussusception cases by ages 1, 2, 3, 4 and 5 years in each WHO 
region. These median proportions were based on the entire set of fitted parametric age 
distributions <5 years, so included more studies than those used to adjust the right-hand tails 
of age distributions prior to fitting (see above). Second, we inflated the denominator based on 
the ratio between the size of the population in the reported age group and the under-five age 
group. Ratios were determined using UNPOP population data for ages 0, 1, 2, 3, 4 years in the 
period 2010-2015 (12). Results were stratified by WHO region. 
In-hospital intussusception case fatality ratios <5 years 
We used three alternative approaches to estimate CFRs for each country dataset and each 
WHO region. First, we calculated age unadjusted CFRs by dividing reported deaths by 
reported cases in each country and WHO region. Second, we calculated age unadjusted CFRs 
and 95% confidence intervals for each country and WHO region using meta-analysis. For 
meta-analysis we used the metaprop_one and metareg commands in Stata version 15.1 
(StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp 
LLC). With metaprop_one we chose the logit option, so that binomial distributions were used 
to model within-study variability. Logistic models with random intercepts were fitted, and the 
variability of the random intercepts indicated heterogeneity. We also ran a separate meta-
analysis with results pooled by national under-five mortality quintile. Quintiles were based on 
the 2010-2015 under-five mortality rates published by the UNPOP (2017 Revision)(12). 
Third, we calculated age adjusted CFRs by converting CFRs that did not extend the full 5 year 
age range (e.g. <1yr, <2yrs) into a CFR aged <5 years. To do this we first calculated the 
expected number of intussusception cases in the missing age range (e.g. 12-59 months) using 
the median cumulative proportion of cases expected to occur by each age in each WHO region. 
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These estimates were based on the full set of fitted parametric age distributions <5 years in 
each WHO region. To estimate CFRs in the missing age range, the ratio of difference between 
the CFR in the known and missing age range was assumed to be the same as the ratio of 
difference between the probability of dying from any cause in the known and missing age 
ranges during a single year of life. These probabilities were derived from country-specific life 
tables for the period 2010-2015 (12).  
 
Results 
Search results 
After exclusions, we identified 128 articles (Figure 1). We included 62 articles from the Jiang 
et al review (2002-2012) and 66 articles from the new search (2012-2018). There were 61 
country datasets with age distributions, 71 with incidence rates and 95 with CFRs (Appendix 
Table 1). We obtained additional age granularity from authors in around half (28/61) of the 
country datasets with age distributions. We included post-vaccination age distribution and 
CFR data for one study in Africa (13) because it included high quality prospective data for 
several African countries and found no elevated risk of intussusception. We also included data 
from China and Vietnam despite uncertainties about the level of vaccine use in the private 
market. We included data from four studies that were published after the end date of the 
systematic review (13-16).   
Age distribution of intussusception hospital admissions < 5 years 
Prior to fitting, we used a subset of 31 datasets with complete counts in each single year of 
life between birth and age 5.0 years (Appendix Table 2) to estimate realistic right-hand tails 
in the datasets with incomplete age distributions <5 years. Using MLE, in most of the 61 
country datasets the Burr distribution had the most favourable goodness of fit statistics and 
goodness of fit criteria compared to the Weibull, Lognormal, Gamma and Log Logistic 
distributions. However, the fits based on NLS had a lower overall RMSE and a much better 
visual fit to the data than MLE, particularly around the peak of the age distribution (Figure 2). 
The Burr distribution had more favourable RMSE and MAE statistics than the Log Logistic 
distribution in over 80% of the country datasets, and a better visual fit to distributions with 
long tails. Our preference was to use a standard approach to fitting, summarising, and 
extrapolating curves to countries without data so we fitted the Burr distribution to all 61 
datasets (17) (Figure 3, Appendix Table 3). 
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In the African, Eastern Mediterranean and South East Asian regions ≥80% of intussusception 
hospital admissions were in the first year of life, compared to 63% in the Americas, 54% in 
Europe and 35% in the Western Pacific region (Appendix Table 4). Median (IQR) ages of 
intussusception hospital admissions were: 29 (22-43) weeks in Africa; 30 (22-42) weeks in 
the Eastern Mediterranean; 33 (24-47) weeks in South East Asia; 41 (27-69) weeks in the 
Americas; 47 (29-89) weeks in Europe; and, 70 (42-126) weeks in the Western Pacific region. 
The median proportion of cases occurring by 15 weeks of age ranged from 2.4% in the 
Western Pacific region to 6.8% in the Eastern Mediterranean region (Table 1). There was 
substantial within-region variation in the European and the Western Pacific regions (Appendix 
Table 4).  
Incidence of intussusception hospital admissions <5 years 
The median (range) annual incidence rate of intussusception hospital admissions was 8 (3-14) 
per 100,000 aged <5 years in Africa, 11 (1-34) in the Americas, 19 (13-23) in the Eastern 
Mediterranean region, 14 (4-49) in Europe, 19 (4-61) in South East Asia and 52 (5-196) in the 
Western Pacific region (Figure 4, Table 1). Incidence rates in the Western Pacific region 
ranged from ~5 in Malaysia, to ~200 in Nha Trang, Vietnam. Incidence rates above 70 per 
100,000 per year <5 years were found in Japan, South Korea and Vietnam (Appendix Table 
5). Globally, we found no correlation (R2 = <0.1%) between the adjusted incidence rates <5 
years and the under-five mortality rate for the period 2010-15. Median incidence rates among 
children aged <1 year were above 75 per 100,000 per year in South East Asia and in the 
Eastern Mediterranean and Western Pacific regions (Table 1, Figure 4).  
In-hospital intussusception case fatality ratios <5 years 
Pooled CFRs in each WHO region varied according to the method used (Table 1). The CFR 
(95% CI for each region) based on age unadjusted meta-analysis was 11.5% (7.24- 17.78%) 
in Africa, 0.41% (0.11 – 1.54%) in the Americas, 0.46% (0.02 – 8.74%) in the Eastern 
Mediterranean region, 0.20% (0.05 – 0.89%) in Europe, 0.27% (0.03 – 2.48%) in South East 
Asia, and 0.05% (0.02 – 0.12%) in the Western Pacific region, but there was variation within 
each region (Table 1, Appendix Table 6). We chose to stratify by WHO region rather than 
under-five mortality quintile. Both had similar explanatory power in meta-regression 
(p<0.005) but WHO region was consistent with the stratification used for age distributions 
and incidence rates, and had more favourable between group heterogeneity (p=0.001 vs 
p=0.003). The strongest predictor of CFRs was whether a country was based in the region of 
Africa or not. Stratifying by study age group gave no evidence of heterogeneity (p = 0.7732) 
so CFRs were not adjusted for age in meta-analysis.  
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Discussion 
This analysis provides an important update to the existing global evidence on intussusception 
incidence rates, age distributions and case fatality ratios prior to rotavirus vaccine 
introduction. More than half of the research articles (67/129) included in our analysis were 
published after the previous review by Jiang et al (3). In addition, we have provided incidence 
rates and CFRs that are both unadjusted and adjusted to a standard age group (<5 years), 
allowing the totality of evidence to be included and compared across countries. We have also 
benefited from the generosity of many study investigators, who were able to share more 
precise breakdown of their age data. We fitted standard parametric curves to all datasets using 
statistically robust methods that will allow estimates of intussusception cases in each week of 
age <5 years. 
Our analysis found that the annual incidence of intussusception ranges from 34 (African 
region) to 90 (Western Pacific region) per 100,000 children aged <1 year. The previous review 
by Jiang et al estimated a global incidence of 74 in the same age range (3). Several Western 
Pacific countries reported very high incidence rates. The reason for this is unclear. In one 
study from this region we were able to analyse only the non-recurrent cases, and the median 
age was still high (67 weeks) (16). Globally, recurrent cases represented <15% of total 
intussusception hospital admissions in each of the 32 studies where this proportion was 
reported. In other studies the proportion was not reported or unclear. There were very few 
incidence rate data points from the African region (2 data points) and Eastern Mediterranean 
region (3 data points). Relatively low incidence rates from these regions may simply reflect 
the lack of access to hospitals. For all datasets we accepted the definition of intussusception 
provided by the authors. However, different definitions and coding systems could have led to 
important differences in results. One study in Bangladesh found a very large range of possible 
incidence rates (0-97 per 100,000 per year, <2 years) depending on whether the study was 
retrospective or prospective, and whether cases were probable or confirmed (18). Around one-
third (25/71) of the country datasets with incidence rates were based on studies with a 
prospective design, and most (63/71) used specific ICD codes or BCL case definitions. We 
excluded incidence rates if a more recent data point was reported in the same 
population/location. In England, estimates of the annual incidence of intussusception hospital 
admissions <1 year were 66 for the period 1993-1995 (19), 30 for the period 2002-2012 
[unpublished from (10)] and 24 for the period 2008-2009 (20). In California, the rate declined 
from in 51 in 1985-1997 to 37 in 2000-2005 (21). 
Countries with higher incidence rates tended to have a higher median age. This effect was 
largely driven by countries in the Western Pacific region where high incidence rates and high 
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median ages were commonly reported. Our analysis of age distributions found median ages 
ranging from 29 weeks in Africa (83% of cases in the first year of life) to 70 weeks in the 
Western Pacific region (35% of cases in the first year of life). There was substantial within-
region variation in Europe and the Western Pacific region. The country datasets in Switzerland 
and Germany had a much higher median age of intussusception that the median for the 
European region. In a small number of studies with very high median ages there was some 
evidence of second peak shortly after the first (6, 22-25). The observed decreases in incidence 
<1 year in England and the USA partly reflect a shift in intussusception cases to older age 
groups over time. National Inpatient Survey (NIS) data representing 20% of hospitals in the 
USA has shown that the proportion of under-five intussusception admissions aged <1 year has 
declined from 62% in 1994 to 50% in 2004 and continues to decline in the post-vaccine era 
[unpublished from (26)]. 
We found extreme differences between the CFRs in Africa (one in ten hospital admissions) 
and the rest of the world (less than one in every 100-2000 hospital admissions). This gross 
level of inequality is mainly due to the very high proportion of cases diagnosed and treated 
with high-risk surgery in Africa (27, 28). Strategies are urgently needed to reduce the time 
between onset of symptoms and presentation at hospital. This should dramatically reduce the 
risk of complications and other contraindications that prohibit the use of lower-risk treatment 
options, such as enemas. Investment is also needed to ensure hospitals have the appropriate 
imaging equipment (ultrasound, radiograph) and staff required to implement lower-risk 
treatment (18). We did not formally evaluate the proportion of cases receiving different types 
of diagnostics and treatment in different settings. This would be a worthwhile follow-up 
analysis and would inform estimates of the costs of intussusception treatment in different 
settings. 
Our analysis excludes children without access to hospital. Some access to healthcare 
indicators are reported in household surveys, but these are not available for all countries and 
do not represent care seeking for emergency conditions that may require surgery (29). This 
adjustment will be influential in Africa, leading to much higher CFRs than reported in our 
analysis. Most children with intussusception will die if left untreated, but a proportion will 
spontaneously resolve without treatment e.g. 25% of hospital admissions in Italy (30), 21% in 
Turkey (31), 19% in South Africa (32), 10% in Thailand (33) and 2% in Hong Kong (34). 
Without early intervention, the proportion may be even higher. This suggests that CFRs 
applied to children without access to hospital should probably not exceed ~90% in most 
settings.  
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In the context of rotavirus vaccines, a recent study in Africa encouragingly found no 
intussusception risk associated with a live oral rotavirus vaccine (13), but an elevated risk has 
been found with the same vaccine, and other oral rotavirus vaccines, in other parts of the world 
(35). Our analysis provides inputs that are critical to assess the number of excess 
intussusception cases that could be associated with different rotavirus vaccination schedules 
in different settings. It is important to evaluate this at the national level given the substantial 
country-level variation observed in age distributions, incidence rates and CFRs, as well as 
vaccine schedules, coverage and timeliness (5, 9). Avoiding the peak age of intussusception 
is important for the design of rotavirus vaccination schedules because the absolute risk is 
relative to the background incidence. Our analysis encouragingly found that less than 5% of 
hospital admissions occurred before age 15 weeks (median of all 71 datasets) when the first 
dose is typically administered. If the first dose of rotavirus vaccination could be administered 
at birth (36) this would avoid nearly all of the background incidence. Large scale post-
licensure studies are needed to assess whether this strategy can substantially lower the risk of 
intussusception, without reducing the benefits of rotavirus vaccination. We excluded case 
counts recorded in the first week of life. Several datasets reported a suspiciously high number 
in this age group which may be related to errors in the recording of the date of birth/admission 
or errors in the diagnosis. For example, necrotising enterocolitis and other neonatal congenital 
problems may be misdiagnosed as intussusception (37).  
 
Conclusion 
The incidence, age distribution and case fatality of intussusception hospital admissions varies 
by region. Understanding and recognising these differences will be important when assessing 
the number of intussusception cases that could be associated with different rotavirus 
vaccination schedules in different settings. 
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Table 1. Incidence rates, age distributions and CFRs among intussusception hospital admissions 
aged <5 years in different WHO regions before the introduction of rotavirus vaccines 
 
  
Africa Americas Eastern 
Med. 
Europe South East 
Asia 
Western 
Pacific 
Median (IQR) incidence per 100,000 per year             
<1 year 34 (24-45) 36 (27-48) 78 (64-86) 41 (26-68) 77 (24-176) 90 (50-165) 
<5 years 8 (6-11) 11 (8-14) 19 (16-21) 14 (9-25) 19 (6-42) 52 (25-92) 
Median (IQR) age of admission             
Age in weeks (IQR) 29 (22-43) 41 (27-69) 30 (22-42) 47 (29-89) 33 (24-47) 70 (42-126) 
Median parameters of the Burr distribution             
Shape 1 (γ)  4.80 3.62 4.08 2.81 4.17 2.65 
Shape 2 (α) 0.44 0.39 0.65 0.44 0.55 0.51 
Scale (θ) 22.20 26.15 25.46 29.33 26.39 46.83 
Median cumulative % of admissions by age*             
6w 0.1% 0.2% 0.2% 0.5% 0.1% 0.2% 
10w 0.9% 1.2% 1.4% 2.0% 1.0% 0.8% 
14w 4.4% 3.8% 5.3% 5.0% 3.7% 2.0% 
15w 6.0% 4.8% 6.8% 6.0% 4.9% 2.4% 
1m 0.0% 0.1% 0.0% 0.2% 0.0% 0.1% 
2m 0.5% 0.7% 0.8% 1.4% 0.5% 0.6% 
3m 3.2% 3.0% 4.0% 4.1% 2.8% 1.7% 
4m 11.0% 7.7% 11.5% 8.6% 8.5% 3.5% 
5m 24.3% 14.8% 23.7% 14.4% 18.3% 6.1% 
6m 39.4% 23.5% 37.9% 21.0% 30.7% 9.3% 
7m 52.5% 32.3% 51.4% 27.7% 43.3% 13.1% 
8m 62.7% 40.5% 62.4% 34.2% 54.4% 17.4% 
9m 70.2% 47.7% 70.8% 40.1% 63.3% 21.8% 
10m 75.9% 53.9% 77.1% 45.5% 70.2% 26.3% 
11m 80.1% 59.0% 81.8% 50.2% 75.6% 30.8% 
12m 83.4% 63.4% 85.4% 54.4% 79.8% 35.1% 
18m 92.9% 78.9% 94.8% 70.8% 91.9% 55.6% 
24m 96.1% 85.9% 97.6% 79.2% 95.8% 68.1% 
36m 98.3% 92.0% 99.2% 87.3% 98.4% 80.9% 
48m 99.1% 94.7% 99.6% 91.0% 99.2% 87.0% 
60m 99.4% 96.1% 99.8% 93.2% 99.5% 90.3% 
Case fatality ratio             
Pooled number of deaths 407 117 3 18 8 6 
Pooled number of cases 3,739 47,616 368 10,365 2,467 11,606 
CFR (age unadjusted) 10.89% 0.25% 0.82% 0.17% 0.32% 0.05% 
CFR (adjusted to age <5 years) 10.08% 0.17% 0.81% 0.17% 0.32% 0.03% 
CFR (age unadjusted) meta-analysis 11.50% 0.41% 0.46% 0.20% 0.27% 0.05% 
CFR (age unadjusted) meta-analysis, 95% CI (7.24% - 17.78%) 
(0.11% - 
1.54%) 
(0.02% - 
8.74%) 
(0.05% - 
0.89%) 
(0.03% - 
2.48%) 
(0.02% - 
0.12%) 
 
*The best fitting parameters for each WHO region were calculated by re-fitting Burr distributions to the pooled proportion of intussusception 
admissions in each week of age <5yrs. Cumulative proportions below 100% by age 60 months indicate that some cases are estimated to occur 
after this age. The Burr distribution (Burr type XII) has shape 1 (γ), shape 2 (α) and scale (θ), all of which must be positive values (note: the 
Burr distribution becomes the Log Logistic distribution when the shape 2 parameter equals 1.0). The cumulative distribution function (cdf) of 
the Burr distribution is: 
𝑓𝑓(𝑥𝑥) = 1 − �1 + �𝑥𝑥
𝜃𝜃
�
𝛾𝛾
�
−𝛼𝛼
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Figure 1. Flow diagram to show search for country datasets 
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Figure 2. Alternative distributions fitted to age distributions for intussusception hospital 
admissions among children aged <5 years for selected country datasets  
 
England (2002-2012)        USA (1994-2004) 
 
Hong Kong (1997-2011)       Taiwan (1998-2013) 
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Figure 3. Intussusception hospital admissions among children aged <5 years by WHO region 
Africa         Americas  
 
 
 
 
 
 
Eastern Mediterranean      Europe 
 
 
 
 
 
 
South East Asia       Western Pacific 
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Figure 4. Incidence of intussusception hospital admissions among children aged <1 year and <5 
years, by country and WHO region 
Aged <1 year 
 
 
 
 
 
 
 
 
 
 
 
 
Aged <5 years 
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Appendix to: 
 
Global review of the incidence, age distribution and case fatality of intussusception hospital 
admissions among children aged < 5 years, before the introduction of rotavirus vaccination. 
Clark A, Hasso-Agopsowicz M, Kraus M, Stockdale L, Sanderson CFB, Parashar U, Tate J.  
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Appendix Table 1.  Characteristics of country datasets included in the analysis 
 
Region Country Location From To Prosp. 
study 
design? 
Specific 
ICD 
code or 
BCL? 
Included 
in Jiang 
et al 
2012? 
Author 
shared 
granular 
age data? 
Single 
year 
age 
counts 
<5yrs? 
Fitted 
age 
distro. 
<5yrs? 
Age-
specific 
incidence 
rate? 
CFR? Risk of 
bias* 
First Author Year Ref 
                                
TOTAL         42 100 63 33 31 61 71 95       
                                
AFR         11 8 10 9 5 14 2 27       
AMR         12 27 10 6 3 7 20 13       
EMR         1 3 4 2 3 4 3 4       
EUR         8 25 17 6 5 13 19 17       
SEA         6 14 8 1 6 7 7 16       
WPR         4 23 14 9 9 16 20 18       
                                
AFR Africa 10 countries 1993 2003     Yes     Yes   Yes Medium Steele 2012 (28) 
AFR Ethiopia Addis Ababa 2011 2014           Yes   Yes Low Gadisa 2016 (38) 
AFR Ethiopia 6 hospitals 2013 2016 Yes Yes   Yes   Yes   Yes Medium Tate 2018 (13) 
AFR Ghana Kumasi 2004 2007 Yes   Yes         Yes Low Abantanga 2008 (39) 
AFR Ghana Accra 2008 2009     Yes   Yes Yes     Low Enweronu-Laryea 2012 (40) 
AFR Ghana 2 hospitals 2012 2016 Yes Yes   Yes   Yes   Yes Medium Tate 2018 (13) 
AFR Kenya Eldoret  2000 2003     Yes         Yes Medium Kuremu 2004 (41) 
AFR Kenya National 2002 2013   Yes   Yes Yes Yes   Yes Low Omore 2016 (42) 
AFR Kenya Bomet 2009 2013               Yes Low Ooko 2016 (43) 
AFR Kenya 5 hospitals 2014 2016 Yes Yes   Yes Yes Yes   Yes Medium Tate 2018 (13) 
AFR Malawi 4 hospitals 2013 2016 Yes Yes   Yes        Yes Medium Tate 2018 (13) 
AFR Nigeria Lagos 1995 2001 Yes   Yes   Yes Yes   Yes Medium Bode 2008 (44) 
AFR Nigeria Enugu 2008 2009     Yes         Yes Low Ekenze 2010 (45) 
AFR Nigeria Enugu 1998 2007     Yes         Yes Low Ekenze 2011 (46) 
AFR Nigeria Enugu 2009 2013        Yes Low Ekenze 2015 (47) 
AFR Nigeria Ibadan 2002 2011           Yes   Yes Low Ogundoyin 2016 (48) 
AFR Nigeria Ile-Ife 1993 2011           Yes   Yes Low Talabi 2013 (49) 
AFR Rwanda Kigali 2009 2012               Yes Low Ngendahayo 2014 (50) 
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AFR South Africa Johannesburg 2007 2010 Yes     Yes        Yes Low Carapinha 2016 (32) 
AFR South Africa 9 hospitals 1998 2003     Yes       Yes Yes Low Moore 2010 (51) 
AFR South Africa Bloemfontein 2003 2011               Yes Low Venter 2013 (52) 
AFR South Africa Not reported 1996 2001     Yes         Yes Low Wiersma 2004 (53) 
AFR Tanzania Dar es Salaam 2000 2004     Yes         Yes Low Carneiro 2004 (54) 
AFR Tanzania Mwanza 2010 2012 Yes       Yes     Yes Low Chalya 2014 (55) 
AFR Tanzania 7 hospitals 2013 2016 Yes Yes   Yes   Yes   Yes Medium Tate 2018 (13) 
AFR Zambia 9 hospitals 2007 2011           Yes Yes Yes Low Mpabalwani 2014 (56) 
AFR Zambia 4 hospitals 2013 2016 Yes Yes   Yes   Yes   Yes Medium Tate 2018 (13) 
AFR Zimbabwe Harare 2014 2016 Yes Yes   Yes   Yes   Yes Medium Tate 2018 (13) 
AMR Argentina Mendoza 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Brazil Not reported 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Brazil National 2001 2006   Yes   Yes Yes Yes     Medium Teles 2015 (58) 
AMR Canada Toronto 2002 2006               Yes Low Bailey 2007 (59) 
AMR Canada Ontario 2010 2010             Yes   Low Ducharme 2013 (60) 
AMR Chile Santiago 2000 2001   Yes Yes     Yes Yes Yes V. Low O’Ryan 2003 (61) 
AMR Chile Not reported 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Colombia Cali 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Costa Rica San Jose 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Dominican Rep. Santo Domingo 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Honduras Tegucigalpa 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Latin America 11 countries 2003 2005 Yes Yes       Yes   Yes V. Low Sáez-Llorens 2013 (57) 
AMR Mexico Mexico City 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Nicaragua Managua 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Panama National 1998 2002   Yes Yes       Yes Yes Medium Sáez-Llorens 2004 (62) 
AMR Panama Panama City 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Peru Lima City 2003 2005 Yes Yes         Yes   V. Low Sáez-Llorens 2013 (57) 
AMR Trinidad & Tobago Champ Fleurs 2000 2007     Yes         Yes Medium Tota-Maharaj 2010 (63) 
AMR USA 41 states 1988 2005   Yes   Yes Yes Yes     Low Aboagye 2014 (64) 
AMR USA Kansas 2001 2004   Yes Yes         Yes Low Burjonrappa 2007 (65) 
AMR USA California 2000 2005   Yes   Yes    Yes Yes   Low Contopoulos-I. 2015 (21) 
AMR USA Cinc./Nash./Roch. 2001 2006   Yes Yes       Yes Yes Low Cortese 2009 (66) 
AMR USA National 1998 2006   Yes           Yes V. Low Desai 2012 (67) 
AMR USA National 2001 2005   Yes Yes       Yes   Low Eng 2012 (68) 
AMR USA Texas 1996 2005               Yes Low Munden 2007 (69) 
AMR USA California 1996 2007   Yes Yes         Yes V. Low Shekherdimian 2011 (70) 
AMR USA 16 States/National 1993 2004   Yes Yes Yes Yes  Yes    Yes Low Tate 2008 (26) 
AMR USA 26 States 2000 2005   Yes   Yes     Yes   Low Tate 2016 (71) 
AMR USA 26 States 2000 2005   Yes Yes Yes       Yes Medium Yen 2012 (72) 
AMR USA National 2006 2006   Yes         Yes   Medium Zickafoose 2012 (73) 
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AMR Venezuela Carabobo 1998 2001   Yes Yes     Yes Yes Yes Low Perez-Schael 2003 (74) 
EMR Egypt Zagazig 2014 2016       Yes Yes Yes     Medium Ahmed 2015 (75) 
EMR Israel (Arab) North 1992 2009   Yes         Yes   V. Low Muhsen 2014 (76) 
EMR Israel (Bedouin) South 1990 2004   Yes Yes Yes Yes Yes Yes Yes Low Greenberg 2008 (77) 
EMR Pakistan Karachi 2012 2015   Yes       Yes   Yes Low Yousafzai 2017 (78) 
EMR Saudi Arabia Abha 1993 2000     Yes         Yes Low Al-Malki 2005 (79) 
EMR Saudi Arabia Riyadh 1984 2000     Yes         Yes Low Crankson 2003 (80) 
EMR Tunisia Monastir 1995 2003 Yes   Yes   Yes Yes Yes   Medium Chouikha 2009 (81) 
EUR Austria Graz 1999 2006     Yes         Yes V. Low Saxena 2007 (82) 
EUR Denmark National 1980 2001   Yes Yes     Yes Yes   Medium Fischer 2004 (83) 
EUR England National 2002 2012   Yes   Yes Yes Yes     V. Low Stowe 2016 (35) 
EUR Finland National 2001 2006     Yes       Yes   Low Lappalainen 2012 (84) 
EUR Finland National 1999 2005   Yes         Yes   Low Leino 2016 (85) 
EUR Finland National 2000 2005       Yes   Yes     ** Vesikari (unpub) 2018  
EUR France Toulouse 2002 2011   Yes       Yes     V. Low Serayssol 2014 (24) 
EUR Germany National 2006 2007   Yes Yes       Yes   V. Low Jenke 2011 (86) 
EUR Germany Bavaria 2005 2006   Yes Yes Yes Yes Yes Yes   ** Kohl 2010 (87) 
EUR Germany NRW and Bavaria 2006 2007   Yes Yes       Yes   Low Weiss 2011 (88) 
EUR Iceland National 1986 2010   Yes   Yes Yes Yes Yes   ** Pétursdóttir 2013 (89) 
EUR Israel Holon 1990 2002     Yes         Yes ** Eshed 2003 (90) 
EUR Israel (Jewish) South 1990 2004   Yes Yes Yes Yes Yes Yes Yes Low Greenberg 2008 (77) 
EUR Israel (Jewish) North 1992 2009   Yes         Yes   V. Low Muhsen 2014 (76) 
EUR Italy Sicily 2003 2012   Yes       Yes     Low Costantino 2015 (30) 
EUR Italy National 2009 2014   Yes       Yes Yes Yes V. Low Restivo 2017 (91) 
EUR Italy National 2002 2012   Yes       Yes   Yes Low Trotta 2016 (92) 
EUR Netherlands National 2008 2012   Yes         Yes   V. Low Gadroen 2017 (93) 
EUR Rep. of Ireland Waterford 1990 2000     Yes         Yes Low Hillal 2002 (94) 
EUR Rep. of Ireland National 2008 2009 Yes Yes         Yes   V. Low Samad 2013 (20) 
EUR Rep. of Ireland Not reported 2007 2010     Yes         Yes Low Tareen 2011 (95) 
EUR Romania Iasi 2009 2013   Yes           Yes Low Tarca 2015 (96) 
EUR Russia Vladivostok 1994 2005     Yes         Yes Low Shapkina 2006 (97) 
EUR Serbia Belgrade 1995 2012 Yes             Yes Low Vujovic 2014 (98) 
EUR Spain Malaga NR NR     Yes         Yes Medium Rubi 2002 (99) 
EUR Switzerland National 2003 2006 Yes Yes Yes   Yes Yes Yes   V. Low Buettcher  2007 (100) 
EUR Turkey Ankara 2002 2014   Yes           Yes Low Guney 2016 (31) 
EUR Turkey Sanliurfa 2010 2012               Yes Low Ocal 2014 (101) 
EUR Turkey Ankara 1991 2007     Yes         Yes Low Sonmez 2012 (102) 
EUR Turkey Ankara 1993 2003     Yes         Yes Low Yalcin 2009 (103) 
EUR UK England 2002 2012   Yes         Yes   Medium Clark 2014 (10) 
EUR UK England 2008 2009 Yes Yes       Yes Yes   V. Low Samad 2013 (20) 
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EUR UK N. Ireland 2008 2009 Yes Yes         Yes   V. Low Samad 2013 (20) 
EUR UK Scotland 2008 2009 Yes Yes         Yes   V. Low Samad 2013 (20) 
EUR UK Wales 2008 2009 Yes Yes         Yes   V. Low Samad 2013 (20) 
EUR UK/Rep. of Ireland National 2008 2009 Yes Yes Yes         Yes Low Samad 2012 (104) 
EUR Uzbekistan Bukhara 2004 2008   Yes Yes Yes    Yes Yes Yes Low Latipov 2011 (22) 
SEA Bangladesh Matlab 2004 2006 Yes Yes Yes    Yes  Low Zaman 2009 (18) 
SEA Bangladesh National 2012 2016 Yes Yes       Yes     Low Satter 2017 (105) 
SEA India Delhi 2000 2003 Yes   Yes       Yes   V. Low Bahl 2009 (106) 
SEA India Vellore 2001 2004   Yes Yes         Yes Low Bhowmick 2009 (107) 
SEA India Chandigargh 2009 2015 Yes Yes     Yes   Yes Yes Low Gupta 2017 (108) 
SEA India Vellore 2010 2013               Yes Low Jehangir 2014 (109) 
SEA India Delhi, Pune, Vellore 2010 2013 Yes Yes         Yes Yes Low John 2014 (110) 
SEA India 28 hospitals 2013 2015   Yes         Yes   Medium Mathew 2016 (111) 
SEA India Chennai 2012 2013   Yes     Yes Yes Yes Yes Low Mehendale 2016 (112) 
SEA India Chennai NR NR     Yes         Yes Low Ramachandran 2008 (113) 
SEA India Vellore 1991 2000   Yes Yes     Yes   Yes Low Raman 2003 (114) 
SEA India Manipal, Lucknow 2007 2012   Yes     Yes     Yes Low Singh 2014 (115) 
SEA India Chennai 2013 2016   Yes     Yes Yes   Yes Low Srinivasan 2017 (116) 
SEA India Vellore 2010 2017   Yes   Yes Yes Yes   Yes Low Srinivasan 2017 (116) 
SEA Nepal Kathmandu 2011 2014   Yes       Yes   Yes V. Low Rayamajhi 2017 (117) 
SEA Nepal Dharan 2004 2009               Yes Low Shakya 2011 (118) 
SEA Nepal Katmandu 2008 2009 Yes             Yes Low Thapa 2012 (119) 
SEA Thailand Bangkok 1992 2009   Yes     Yes Medium Kruatrachue 2011 (120) 
SEA Thailand 5 hospitals 2001 2006   Yes Yes   Yes Yes Yes Yes Medium Khumjui 2009 (121) 
SEA Thailand Bangkok 2000 2005   Yes Yes         Yes Medium Pruksananonda 2007 (33) 
WPR Australia Brisbane 1994 2004     Yes         Yes ** Blanch 2007 (122) 
WPR Australia National 1994 2000   Yes           Yes Low Justice 2005 (123) 
WPR Australia Melbourne 1995 2001   Yes Yes Yes Yes Yes     ** Justice 2006 (124) 
WPR Australia Melbourne 2001 2006   Yes Yes Yes     Yes Yes V. Low Lloyd-Johnsen 2012 (125) 
WPR Australia National 2000 2006   Yes         Yes   Low Palupi-Baroto 2015 (126) 
WPR China Suzhou 2007 2013   Yes         Yes Yes ** Cui 2016 (127) 
WPR China Jinan 2011 2015   Yes         Yes   ** Cui 2018 (14) 
WPR China Chenzhou, Kaifeng 2009 2013   Yes   Yes   Yes Yes Yes Low Liu 2018 (15) 
WPR China Shenyang 2004 2009     Yes         Yes ** Zhang 2011 (128) 
WPR Hong Kong National 1997 2011   Yes Yes Yes Yes Yes Yes   Low Hong Kong ISG 2007 (34) 
WPR Hong Kong Pokfulam 1997 2014       Yes Yes Yes     Low Wong 2015 (129) 
WPR Japan Akita 1978 2002     Yes   Yes Yes Yes   Low Nakagomi 2006 (130) 
WPR Japan Akita 2001 2010   Yes   Yes   Yes Yes   Medium Noguchi 2012 (131) 
WPR Japan National 2007 2008   Yes Yes Yes Yes Yes Yes Yes V. Low Takeuchi 2012 (8) 
WPR Malaysia 3 hospitals 2000 2003   Yes Yes   Yes Yes Yes Yes Low Giak 2008 (132) 
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WPR New Zealand National 1998 2003   Yes Yes     Yes Yes Yes Low Chen 2005 (133) 
WPR New Zealand Auckland 1998 2007   Yes Yes         Yes V. Low Kodikara 2010 (134) 
WPR Singapore 7 Hospitals 2002 2010 Yes Yes       Yes Yes Yes Low Phua 2013 (23) 
WPR Singapore National 1997 2004 Yes Yes Yes       Yes Yes Medium Tan 2009 (135) 
WPR Singapore 1 hospital 2009 2013   Yes           Yes Low Yap Shiyi 2017 (136) 
WPR South Korea Joenbuk 2000 2002   Yes Yes   Yes Yes Yes Yes Low Jo 2009 (137) 
WPR Taiwan National 1998 2007   Yes Yes Yes Yes Yes Yes   Low Chen 2010 (6) 
WPR Taiwan National 2000 2007   Yes         Yes   Low Hsiao 2013 (138) 
WPR Taiwan Taipei 1995 2010               Yes Medium Hsu 2012 (139) 
WPR Taiwan National 2001 2005   Yes       Yes Yes Yes Low Yen 2017 (140) 
WPR Vietnam Hanoi 2002 2004 Yes   Yes     Yes Yes Yes V. Low Bines 2006 (141) 
WPR Vietnam Hai Phong, Hue 2013 2016 Yes Yes   Yes    Yes     Low Trang 2018 (16) 
WPR Vietnam Ho Chi Min City 2009 2011   Yes         Yes Yes V. Low Van Trang 2014 (142) 
WPR Vietnam Nha Trang 2009 2011   Yes     Yes Yes Yes   V. Low Tran 2013 (25) 
 
*Risk of bias (very low, low, medium) was assigned to each included study after assessing: a) selection bias - are participants representative of the general population?; b) 
baseline confounding - are characteristics of the participants reported?; c) outcome measurement - is the definition of  intussusception the same for all participants?; d) 
blinding at outcome assessment - are data abstractors blinded to the hypothesis?; and, e) description of missing information - are drop-outs, withdrawals, missing data, or 
controls described?). Studies with valuable data but no full text were assigned ** to indicate that they may have a high risk of bias.
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Appendix Table 2. Studies reporting the % of intussusception hospital admissions <5 years by 
single year of age, before rotavirus vaccine introduction 
 
WHO 
region 
Country Location U5MR 
quintile 
Period   n Cumulative % of admissions by age 
From To 1y 2y 3y 4y 5y 
AFR Ghana Accra Very high 2008 2009 77 86% 96% 99% 100% 100% 
AFR Kenya National High 2002 2013 280 69% 84% 92% 97% 100% 
AFR Kenya 5 hospitals High 2014 2016 175 78% 93% 96% 98% 100% 
AFR Nigeria Lagos Very high 1995 2001 169 90% 96% 98% 99% 100% 
AFR Tanzania Mwanza Very high 2010 2012 55 76% 87% 93% 99% 100% 
AFR Median           78% 93% 96% 99% 100% 
AMR Brazil National Medium 2001 2006 943 80% 90% 95% 98% 100% 
AMR USA 41 states Low 1988 2005 1171 62% 83% 95% 100% 100% 
AMR USA 16 states/National Low 1994 2004 24035 57% 77% 90% 96% 100% 
AMR Median           62% 83% 95% 98% 100% 
EMR Egypt Zagazig Medium 2014 2016 132 94% 97% 97% 98% 100% 
EUR Israel (Bedouin) South Medium 1990 2004 87 77% 95% 97% 98% 100% 
EMR Tunisia Monastir Medium 1995 2003 533 77% 90% 97% 98% 100% 
EMR Median           77% 95% 97% 98% 100% 
EUR England National Very low 2002 2012 3196 67% 84% 92% 97% 100% 
EUR Germany Bavaria Very low 2005 2011 752 27% 56% 75% 90% 100% 
EUR Iceland National Very low 1986 2010 64 70% 91% 95% 100% 100% 
EUR Israel (Jewish) South Very low 1990 2004 275 66% 87% 95% 98% 100% 
EUR Switzerland National Very low 2003 2006 246 34% 61% 84% 93% 100% 
EUR Median           66% 84% 92% 97% 100% 
SEA India Vellore High 2010 2017 219 75% 92% 95% 98% 100% 
SEA India Chennai High 2012 2013 201 66% 85% 93% 96% 100% 
SEA India Chennai High 2013 2016 284 67% 82% 93% 97% 100% 
SEA India Chandigarh High 2009 2015 277 72% 83% 92% 97% 100% 
SEA India Manipal + Luck. High 2007 2012 187 56% 79% 91% 97% 100% 
SEA Thailand 5 hospitals Low 2001 2006 77 84% 94% 96% 100% 100% 
SEA Median           70% 84% 93% 97% 100% 
WPR Australia Melbourne Very low 1995 2001 190 78% 93% 97% 99% 100% 
WPR Hong Kong Pokfulam Very low 1997 2014 163 53% 73% 86% 94% 100% 
WPR Hong Kong National Very low 1997 2011 520 62% 82% 92% 96% 100% 
WPR Japan National Very low 2006 2007 1065 25% 55% 78% 91% 100% 
WPR Japan Akita Very low 1978 2002 91 45% 70% 91% 98% 100% 
WPR Malaysia 3 hospitals Low 2000 2003 62 74% 90% 95% 98% 100% 
WPR South Korea Joenbuk Very low 2000 2002 408 53% 83% 93% 97% 100% 
WPR Taiwan National Very low 1998 2013 10331 24% 58% 83% 94% 100% 
WPR Vietnam Nha Trang Medium 2009 2011 192 31% 75% 90% 94% 100% 
WPR Median           53% 75% 91% 96% 100% 
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Appendix Table 3. Burr age distribution parameters fitted to each country and WHO region 
WHO 
region 
Country Location U5MR 
quintile 
n age 
grps 
n Parameters  
    Shape1 Shape2 Scale RMSE MAE 
AFR Africa 10 countries Very high 16 938 0.3 6.3 19.9 1% 1% 
AFR Ethiopia 6 hospitals Very high 56 207 0.9 3.3 32.3 1% 1% 
AFR Ethiopia Addis Ababa Very high 6 121 0.2 4.1 17.8 5% 4% 
AFR Ghana Accra Very high 10 77 0.4 7.8 24.7 1% 1% 
AFR Ghana 2 hospitals Very high 56 485 0.3 6.3 22.4 2% 1% 
AFR Kenya National High 60 279 0.3 4.0 16.3 5% 4% 
AFR Kenya 5 hospitals High 71 175 0.3 6.7 20.2 2% 2% 
AFR Nigeria Lagos Very high 27 169 3588.5 3.1 294.1 6% 4% 
AFR Nigeria Ibadan Very high 5 53 0.3 8.5 21.1 7% 4% 
AFR Nigeria Ile-Ife Very high 7 77 1.9 2.5 34.9 4% 3% 
AFR Tanzania 7 hospitals Very high 56 257 0.3 7.2 20.1 3% 2% 
AFR Zambia 4 hospitals Very high 56 78 0.5 5.9 23.4 4% 3% 
AFR Zambia 9 hospitals Very high 10 121 0.1 14.0 19.4 6% 4% 
AFR Zimbabwe Harare Very high 56 115 0.3 5.2 20.5 2% 1% 
AFR Pooled         0.4 4.8 22.2 1% 1% 
AMR Brazil National Medium 19 943 0.5 3.9 23.4 3% 3% 
AMR Chile Santiago Low 27 104 0.2 4.9 19.9 3% 2% 
AMR Latin America 11 countries Medium 27 576 0.2 7.3 19.6 4% 3% 
AMR USA 41 states Low 99 1171 2.0 3.5 43.0 2% 1% 
AMR USA 16 states /National Low 56 20027 0.3 3.6 25.2 3% 2% 
AMR USA California Low 56 1907 0.5 3.3 31.8 3% 2% 
AMR Venezuela Carabobo Medium 16 95 0.1 12.0 16.1 5% 4% 
AMR Pooled     27 23300 0.4 3.6 26.1 1% 0% 
EMR Israel (Bedouins) South Medium 16 83 0.4 6.1 26.0 2% 1% 
EMR Egypt Zagazig Medium 60 132 0.1 17.1 21.2 5% 3% 
EMR Pakistan Karachi Very high 27 156 0.4 5.3 23.2 2% 1% 
EMR Tunisia Monastir Medium 27 514 0.6 3.7 22.7 3% 2% 
EMR Pooled     27 880 0.6 4.1 25.5 1% 1% 
EUR Denmark National Very low 7 872 0.7 2.8 29.4 3% 2% 
EUR England National Very low 100 3196 0.4 3.5 22.9 2% 1% 
EUR England England Very low 16 287 0.5 2.8 25.2 2% 2% 
EUR Finland National Very low 27 280 0.4 4.9 24.4 4% 3% 
EUR France Toulouse Very low 14 276 8.4 1.7 295.8 2% 2% 
EUR Germany Bavaria Very low 16 750 0.6 2.0 61.5 4% 3% 
EUR Iceland National Very low 60 64 0.1 14.8 18.7 2% 2% 
EUR Italy National Very low 16 3088 0.5 2.2 47.2 3% 2% 
EUR Italy National Very low 9 5222 0.4 2.5 33.9 2% 2% 
EUR Italy Sicily Very low 16 340 0.2 3.9 24.0 3% 2% 
EUR Israel (Jewish) South Very low 16 273 0.4 4.6 29.3 1% 1% 
EUR Switzerland National Very low 16 246 0.1 5.7 18.4 7% 5% 
EUR Uzbekistan Bukhara High 13 80 0.2 3.3 16.9 10% 5% 
EUR Pooled     27 13539 0.4 2.8 29.3 1% 1% 
SEAR Bangladesh National High 19 182 0.3 7.5 24.4 4% 3% 
SEAR India Chennai High 7 207 1.6 3.2 43.4 5% 4% 
SEAR India Chennai High 7 201 0.8 3.5 27.4 6% 5% 
SEAR India Vellore High 8 137 0.5 3.6 25.2 4% 3% 
SEAR India Vellore High 16 217 0.3 6.2 22.6 2% 2% 
SEAR Nepal Kathmandu High 27 101 0.3 5.0 21.7 3% 2% 
SEAR Thailand 5 hospitals Low 60 77 0.5 4.2 21.2 2% 2% 
SEA Pooled     27 1112 0.6 4.2 26.4 0% 0% 
WPR Australia Melbourne Very low 16 190 0.5 4.9 26.7 1% 1% 
WPR China Chenz./, Kaif. Medium 104 2283 0.2 4.9 24.6 3% 2% 
WPR Hong Kong Pokfulam Very low 15 163 0.2 4.4 20.1 4% 3% 
WPR Hong Kong National Very low 60 520 0.2 5.8 21.6 2% 1% 
WPR Japan National Very low 100 1063 15.9 1.8 524.3 3% 2% 
WPR Japan Akita Very low 6 91 0.4 2.9 35.3 6% 5% 
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WPR Japan Akita Very low 16 232 0.3 4.5 28.1 3% 2% 
WPR South Korea Joenbuk Very low 6 408 1.0 2.2 51.4 6% 4% 
WPR Malaysia 3 hospitals Low 7 62 0.4 4.2 25.4 3% 2% 
WPR New Zealand National Very low 38 305 0.5 3.1 28.6 2% 2% 
WPR Singapore 7 Hospitals Very low 27 223 0.1 5.6 23.7 5% 3% 
WPR Taiwan National Very low 100 10331 5180.6 1.9 8709.8 3% 2% 
WPR Taiwan National Very low 9 360 0.4 3.3 33.9 4% 3% 
WPR Vietnam Nha Trang Medium 60 192 0.8 2.9 61.0 2% 2% 
WPR Vietnam Hai Phong, Hue Medium 108 2916 0.4 3.4 43.6 2% 2% 
WPR Vietnam Hanoi Medium 68 779 0.2 5.3 26.6 3% 2% 
WPR Pooled         0.5 2.7 46.8 3% 2% 
 
* The best fitting parameters for each WHO region were calculated by re-fitting Burr distributions to the pooled proportion of intussusception 
admissions in each week of age <5yrs. The Burr distribution (Burr type XII) has shape 1 (α), shape 2 (γ) and scale (θ), all of which must be 
positive values. The cumulative distribution function (cdf) is: 
𝑓𝑓(𝑥𝑥) = 1 − �1 + �𝑥𝑥
𝜃𝜃
�
𝛾𝛾
�
−𝛼𝛼
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Appendix Table 4.  Median (IQR) age and cumulative proportion of intussusception hospital admissions, by age and WHO region 
 
WHO 
region 
Country Location U5MR 
quintile 
n 
age 
grps 
n IQR (weeks) Cumulative % of intussusception hospital admissions by age 
    25th 50th 75th 6w 2m 10w 14w 15w 4m 6m 9m 12m 18m 24m 36m 48m 60m 
AFR Africa 10 countries Very high 16 938 22 30 46 0% 0% 0% 3% 4% 9% 38% 67% 79% 89% 93% 97% 98% 99% 
AFR Ethiopia 6 hospitals Very high 56 207 24 34 48 0% 1% 2% 6% 7% 11% 30% 61% 79% 93% 97% 99% 100% 100% 
AFR Ethiopia Addis Ababa Very high 6 121 22 36 73 0% 1% 2% 7% 9% 14% 34% 54% 65% 77% 82% 88% 91% 93% 
AFR Ghana Accra Very high 10 77 25 30 39 0% 0% 0% 0% 1% 2% 30% 75% 89% 97% 99% 100% 100% 100% 
AFR Ghana 2 hospitals Very high 56 485 24 31 45 0% 0% 0% 2% 2% 5% 33% 67% 81% 92% 95% 98% 99% 99% 
AFR Kenya National High 60 279 19 30 57 1% 2% 4% 11% 14% 21% 43% 62% 73% 82% 87% 92% 94% 95% 
AFR Kenya 5 hospitals High 71 175 23 30 45 0% 0% 0% 2% 3% 7% 38% 68% 80% 90% 94% 97% 98% 99% 
AFR Nigeria Lagos Very high 27 169 15 19 24 2% 5% 8% 22% 27% 39% 83% 100% 100% 100% 100% 100% 100% 100% 
AFR Nigeria Ibadan Very high 5 53 22 27 35 0% 0% 0% 1% 2% 5% 46% 81% 91% 97% 99% 100% 100% 100% 
AFR Nigeria Ile-Ife Very high 7 77 17 25 36 2% 5% 8% 16% 19% 26% 52% 80% 92% 98% 100% 100% 100% 100% 
AFR Tanzania 7 hospitals Very high 56 257 22 29 42 0% 0% 0% 2% 3% 8% 41% 72% 84% 92% 96% 98% 99% 99% 
AFR Zambia 4 hospitals Very high 56 78 23 29 38 0% 0% 0% 2% 3% 7% 39% 76% 89% 96% 98% 99% 100% 100% 
AFR Zambia 9 hospitals Very high 10 121 24 33 56 0% 0% 0% 0% 0% 2% 32% 60% 72% 84% 89% 93% 96% 97% 
AFR Zimbabwe Harare Very high 56 115 22 31 50 0% 0% 1% 4% 5% 10% 36% 63% 76% 87% 92% 96% 97% 98% 
AFR Pooled         22 29 43 0% 0% 1% 4% 6% 11% 39% 70% 83% 93% 96% 98% 99% 99% 
AMR Brazil National Medium 19 943 21 30 44 0% 1% 2% 7% 8% 14% 39% 68% 82% 92% 96% 98% 99% 99% 
AMR Chile Santiago Low 27 104 24 36 68 0% 0% 1% 4% 5% 9% 30% 54% 66% 79% 85% 90% 93% 95% 
AMR Latin America 11 countries Medium 27 576 23 32 52 0% 0% 0% 2% 3% 6% 34% 62% 75% 86% 91% 95% 96% 97% 
AMR USA 41 states Low 99 1171 25 33 43 0% 1% 1% 4% 5% 8% 28% 66% 89% 99% 100% 100% 100% 100% 
AMR USA 16 states/Nat. Low 56 20027 28 45 86 0% 1% 1% 3% 4% 7% 21% 42% 57% 72% 80% 87% 91% 93% 
AMR USA California Low 56 1907 29 43 68 0% 1% 1% 3% 4% 7% 20% 44% 62% 80% 88% 94% 96% 98% 
AMR Venezuela Carabobo Medium 16 95 22 33 67 0% 0% 0% 1% 3% 9% 37% 58% 68% 78% 84% 89% 92% 93% 
AMR Pooled     27 23300 27 41 69 0% 1% 1% 4% 5% 8% 23% 48% 63% 79% 86% 92% 95% 96% 
EMR Israel (Bedouins) South Medium 16 83 27 35 49 0% 0% 0% 1% 1% 3% 22% 60% 78% 91% 95% 98% 99% 99% 
EMR Egypt Zagazig Medium 60 132 25 31 44 0% 0% 0% 0% 0% 0% 32% 68% 81% 91% 95% 98% 99% 99% 
EMR Pakistan Karachi Very high 27 156 23 31 43 0% 0% 0% 3% 4% 8% 35% 69% 83% 93% 96% 99% 99% 100% 
EMR Tunisia Monastir Medium 27 514 20 28 41 0% 2% 3% 9% 11% 17% 44% 72% 84% 93% 97% 99% 99% 100% 
EMR Pooled     27 880 22 30 42 0% 1% 1% 5% 7% 12% 38% 71% 85% 95% 98% 99% 100% 100% 
EUR Denmark National Very low 7 872 23 35 57 1% 2% 3% 8% 10% 14% 31% 56% 71% 86% 92% 96% 98% 99% 
EUR England National Very low 100 3196 24 37 66 0% 1% 2% 6% 7% 11% 29% 52% 66% 80% 86% 92% 94% 96% 
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EUR England England Very low 16 287 23 37 65 1% 3% 4% 9% 10% 14% 32% 53% 67% 81% 87% 93% 95% 97% 
EUR Finland National Very low 27 280 26 35 54 0% 0% 0% 2% 3% 6% 26% 57% 73% 87% 92% 96% 98% 98% 
EUR France Toulouse Very low 14 276 43 72 110 1% 2% 2% 4% 5% 6% 11% 22% 33% 55% 72% 91% 97% 99% 
EUR Germany Bavaria Very low 16 750 49 94 196 1% 1% 2% 3% 3% 4% 9% 18% 27% 43% 54% 68% 76% 81% 
EUR Iceland National Very low 60 64 25 37 73 0% 0% 0% 0% 0% 2% 29% 53% 65% 77% 82% 88% 91% 93% 
EUR Italy National Very low 16 3088 40 74 150 1% 1% 2% 4% 4% 6% 12% 24% 35% 52% 64% 76% 83% 86% 
EUR Italy National Very low 9 5222 33 58 116 1% 1% 2% 4% 5% 7% 17% 32% 45% 62% 72% 82% 87% 90% 
EUR Italy Sicily Very low 16 340 32 57 140 0% 0% 1% 2% 3% 5% 16% 34% 46% 60% 68% 77% 82% 85% 
EUR Israel (Jewish) South Very low 16 273 30 42 64 0% 0% 0% 1% 2% 3% 16% 45% 65% 82% 89% 95% 97% 98% 
EUR Switzerland National Very low 16 246 38 109 651 0% 0% 0% 1% 2% 4% 13% 25% 33% 43% 49% 56% 61% 64% 
EUR Uzbekistan Bukhara High 13 80 27 60 214 1% 2% 3% 7% 8% 11% 24% 37% 46% 57% 63% 70% 75% 78% 
EUR Pooled     27 13539 29 47 89 0% 1% 2% 5% 6% 9% 21% 40% 54% 71% 79% 87% 91% 93% 
SEAR Bangladesh National High 19 182 26 33 46 0% 0% 0% 0% 1% 2% 24% 64% 80% 92% 96% 98% 99% 99% 
SEAR India Chennai High 7 207 26 36 48 0% 1% 1% 4% 5% 8% 25% 58% 80% 96% 99% 100% 100% 100% 
SEAR India Chennai High 7 201 21 30 42 0% 1% 2% 7% 9% 14% 40% 71% 86% 95% 98% 99% 100% 100% 
SEAR India Vellore High 8 137 24 34 54 0% 1% 2% 6% 7% 11% 31% 58% 73% 86% 92% 96% 98% 98% 
SEAR India Vellore High 16 217 24 32 47 0% 0% 0% 2% 2% 5% 31% 65% 79% 90% 94% 97% 99% 99% 
SEAR Nepal Kathmandu High 27 101 25 36 62 0% 0% 1% 3% 4% 7% 28% 55% 69% 82% 87% 93% 95% 96% 
SEAR Thailand 5 hospitals Low 60 77 20 28 41 0% 1% 2% 8% 10% 16% 45% 73% 85% 93% 96% 98% 99% 99% 
SEA Pooled     27 1112 24 33 47 0% 1% 1% 4% 5% 8% 31% 63% 80% 92% 96% 98% 99% 99% 
WPR Australia Melbourne Very low 16 190 26 35 49 0% 0% 0% 2% 3% 5% 25% 60% 78% 91% 95% 98% 99% 99% 
WPR China Chenz./Kaif. Medium 104 2283 30 47 91 0% 0% 0% 1% 2% 3% 17% 40% 55% 71% 78% 86% 90% 92% 
WPR Hong Kong Pokfulam Very low 15 163 27 47 109 0% 0% 1% 3% 4% 7% 23% 42% 54% 67% 74% 81% 85% 88% 
WPR Hong Kong National Very low 60 520 27 41 79 0% 0% 0% 1% 2% 5% 23% 47% 61% 75% 81% 88% 91% 93% 
WPR Japan National Very low 100 1063 53 89 134 1% 1% 2% 3% 3% 4% 8% 15% 24% 43% 60% 83% 94% 98% 
WPR Japan Akita Very low 6 91 36 59 111 0% 1% 1% 3% 3% 5% 13% 29% 44% 63% 73% 83% 88% 91% 
WPR Japan Akita Very low 16 232 32 49 88 0% 0% 0% 1% 2% 3% 14% 37% 54% 71% 80% 88% 91% 93% 
WPR South Korea Joenbuk Very low 6 408 32 52 86 1% 2% 3% 5% 6% 8% 18% 35% 50% 71% 82% 92% 95% 97% 
WPR Malaysia 3 hospitals Low 7 62 25 35 53 0% 0% 1% 3% 5% 8% 28% 58% 75% 88% 93% 97% 98% 99% 
WPR New Zealand National Very low 38 305 26 40 66 0% 1% 2% 6% 7% 10% 26% 49% 65% 81% 88% 94% 96% 97% 
WPR Singapore 7 Hospitals Very low 27 223 35 63 169 0% 0% 0% 1% 1% 2% 12% 30% 43% 57% 65% 74% 78% 82% 
WPR Taiwan National Very low 100 10331 55 86 123 0% 1% 1% 2% 2% 3% 7% 14% 23% 44% 63% 89% 98% 100% 
WPR Taiwan National Very low 9 360 33 51 87 0% 0% 1% 2% 3% 4% 14% 34% 51% 71% 80% 89% 93% 95% 
WPR Vietnam Nha Trang Medium 60 192 47 70 107 0% 0% 0% 1% 1% 2% 6% 17% 31% 57% 74% 88% 94% 96% 
WPR Vietnam Hai Phong, Hue Medium 108 2916 43 67 115 0% 0% 0% 1% 1% 2% 6% 20% 35% 58% 71% 84% 89% 92% 
WPR Vietnam Hanoi Medium 68 779 33 51 98 0% 0% 0% 1% 1% 2% 12% 35% 51% 68% 76% 85% 89% 91% 
WPR Pooled         42 70 126 0% 1% 1% 2% 2% 3% 9% 22% 35% 56% 68% 81% 87% 90% 
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Appendix Table 5. Studies reporting the incidence of intussusception hospital admissions among 
children aged <1 year and <5 years, before rotavirus vaccine introduction 
 
WHO 
region 
Country Location U5MR 
quintile 
Period n* Age 
group 
Rate per 
100,0000 
per year 
Rate 
adjusted 
(<1yr) 
Rate 
adjusted 
(<5yrs) 
From To 
AFR South Africa 9 hospitals High 1998 2003 384 <2yrs 32.0 55.6 13.5 
AFR Zambia 9 hospitals Very high 2009 2011 105 <2yrs 7.5 12.9 3.3 
AFR Median               34.2 8.4 
AMR Canada Ontario Very low 2010 2010 117 <2yrs 18.0 28.2 8.1 
AMR Chile Santiago Low 2000 2001 95 <2yrs 33.5 52.0 15.2 
AMR Panama National Medium 1998 2002 111 <3yrs 11.0 23.4 7.2 
AMR Argentina Mendoza Medium 2003 2005 43 <1yr 105.3 105.3 33.7 
AMR Brazil Not reported Medium 2003 2005 19 <1yr 3.8 3.8 1.2 
AMR Chile Not reported Low 2003 2005 57 <1yr 47.0 47.0 14.3 
AMR Colombia Cali Medium 2003 2005 37 <1yr 37.4 37.4 11.7 
AMR Costa Rica San Jose Low 2003 2005 27 <1yr 18.9 18.9 5.7 
AMR Dominican Rep. Santo Domingo Medium 2003 2005 36 <1yr 37.8 37.8 11.9 
AMR Honduras Tegucigalpa High 2003 2005 40 <1yr 30.4 30.4 9.5 
AMR Mexico Mexico City Medium 2003 2005 112 <1yr 87.8 87.8 28.3 
AMR Nicaragua Managua Medium 2003 2005 10 <1yr 19.6 19.6 6.0 
AMR Panama Panama City Medium 2003 2005 112 <1yr 69.4 69.4 22.3 
AMR Peru Lima City High 2003 2005 10 <1yr 25.1 25.1 8.1 
AMR USA National Low 2001 2005 22 <1yr 33.0 33.0 9.9 
AMR USA National Low 2006 2006 1548 <1yr 36.5 36.5 10.9 
AMR USA California Low 2000 2005 1187 <1yr 37.0 37.0 11.1 
AMR USA Cinc./Nash./Roch. Low 2001 2006 156 <1yr 49.3 49.3 14.7 
AMR USA 26 States Low 2000 2005 15231 <1yr 35.9 35.9 10.7 
AMR Venezuela Carabobo Medium 1998 2001 67 <1yr 35.0 35.0 11.0 
AMR Median               36.2 11.0 
EMR Tunisia Monastir Medium 1984 2003 533 <5yrs 13.0 51.1 13.0 
EMR Israel (Arab) North Medium 1992 2009 76 <5yrs 23.2 95.2 23.2 
EMR Israel (Bedouin) South Medium 1990 2004 75 <5yrs 18.9 77.5 18.9 
EMR Median               77.5 18.9 
EUR Denmark National Very low 1980 2001 1814 <5yrs 27.2 90.9 27.2 
EUR Finland National Very low 2001 2006 53 <1yr 20.0 20.0 7.0 
EUR Finland National Very low 1999 2005 52 <1yr 12.1 12.1 4.2 
EUR Germany National Very low 2006 2007 1200 <2yrs 51.5 75.6 26.2 
EUR Germany NRW and Bavaria Very low 2006 2007 169 <1yr 61.7 61.7 23.0 
EUR Germany Bavaria Very low 2005 2006 518 <1yr 72.0 72.0 26.8 
EUR Iceland National Very low 1986 2010 42 <1yr 40.0 40.0 13.6 
EUR Ireland National Very low 2008 2009 21 <1yr 24.8 24.8 8.6 
EUR Israel (Jewish) South Very low 1990 2004 241 <5yrs 49.3 137.9 49.3 
EUR Israel (Jewish) North Very low 1992 2009 114 <5yrs 36.1 101.0 36.1 
EUR Italy National Very low 2009 2014 3088 <5yrs 20.2 64.2 20.2 
EUR Netherlands National Very low 2008 2012 15 <3yrs 21.3 42.4 14.6 
EUR Switzerland National Very low 2003 2006 294 <3yrs 26.0 51.8 18.0 
EUR UK England Very low 2002 2012 2692 <2yrs 18.0 27.0 8.8 
EUR UK England Very low 2008 2009 190 <1yr 24.2 24.2 8.5 
EUR UK N. Ireland Very low 2008 2009 12 <1yr 40.6 40.6 14.3 
EUR UK Scotland Very low 2008 2009 20 <1yr 28.7 28.7 10.1 
EUR UK Wales Very low 2008 2009 7 <1yr 16.9 16.9 5.9 
EUR Uzbekistan Bukhara High 2004 2008 67 <2yrs 23.0 34.3 11.5 
EUR Median               40.6 14.3 
SEA Bangladesh Matlab High 2004 2006 3 <2yrs 9.4 15.6 3.9 
SEA India Delhi High 2000 2003 5 <1yr 17.7 17.7 4.3 
SEA India Chandigargh High 2009 2015 277 <5yrs 5.0 20.7 5.0 
SEA India Delhi/Pune/Vellore High 2010 2013 3 <2yrs 71.0 120.1 28.9 
SEA India 28 hospitals High 2013 2015 98 <5yrs 46.8 194.1 46.8 
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SEA India Chennai High 2012 2013 201 <5yrs 61.0 253.0 61.0 
SEA Thailand 5 hospitals Low 2001 2006 112 <5yrs 8.1 33.6 8.1 
SEA Median               33.6 8.1 
WPR Australia Melbourne Very low 2001 2006 135 <2yrs 19.9 23.0 11.4 
WPR Australia National Very low 2000 2006 1650 <2yrs 45.1 52.1 25.9 
WPR China Suzhou Medium 2007 2013 594 <2yrs 57.3 65.3 33.8 
WPR China Jinan Medium 2011 2015 93 <2yrs 86.3 98.3 50.9 
WPR China Suzhou Medium 2007 2013 1715 <2yrs 112.9 128.7 66.6 
WPR Hong Kong National Very low 1997 2003 531 <5yrs 38.4 82.4 38.4 
WPR Taiwan National Very low 1998 2007 8217 <5yrs 45.5 78.6 45.5 
WPR Taiwan National Very low 2000 2007 5721 <5yrs 56.6 97.7 56.6 
WPR Taiwan 26 States Very low 2001 2005 189 <1yr 82.2 82.2 52.7 
WPR Japan National Very low 2007 2008 2427 <1yr 185.0 185.0 103.2 
WPR Japan North Very low 1978 2002 91 <5yrs 77.8 154.5 77.8 
WPR Japan Akita Very low 2001 2010 122 <1yr 158.0 158.0 88.1 
WPR Malaysia 3 hospitals Low 2000 2003 62 <5yrs 4.8 9.0 4.8 
WPR New Zealand National Very low 1998 2003 277 <3yrs 30.0 45.0 21.7 
WPR South Korea Jeonbuk Very low 2000 2002 408 <5yrs 106.4 208.6 106.4 
WPR Singapore National Very low 1997 2004 217 <2yrs 32.4 36.9 18.8 
WPR Singapore 7 Hospitals Very low 2002 2010 167 <2yrs 26.1 29.8 15.2 
WPR Vietnam Hanoi Medium 2002 2004 533 <1yr 302.0 302.0 172.4 
WPR Vietnam Ho Chi Min City Medium 2009 2011 869 <1yr 287.0 287.0 163.9 
WPR Vietnam Nha Trang Medium 2009 2011 187 <5yrs 196.1 380.2 196.1 
WPR Median               90.1 51.8 
 
* some numerators were derived from incidence and denominator data 
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Appendix Table 6. Case fatality ratios for intussusception hospital admissions among children 
aged <5 years 
 
WHO 
region 
Country Location U5MR 
quintile 
Age 
group 
CFR (age unadjusted), meta-analysis % CFR 
adjusted 
to <5 years Deaths Cases % CFR L95 U95 
AFR Africa 10 countries Very high <1yr 108 863  12.51% 10.38% 14.91% 10.77% 
AFR Ethiopia Addis Ababa Very high <5yrs+ 6 130  4.62% 1.71% 9.78% 4.62% 
AFR Ethiopia 6 hospitals Very high <1yr 19 155  12.26% 7.54% 18.48% 10.53% 
AFR Ghana Kumasi Very high <5yrs+ 1 44  2.27% 0.06% 12.02% 2.27% 
AFR Ghana 2 hospitals Very high <1yr 9 360  2.50% 1.15% 4.69% 2.15% 
AFR Kenya Eldoret  High <5yrs+ 5 36  13.89% 4.67% 29.50% 13.89% 
AFR Kenya National High <5yrs 18 280  6.43% 3.85% 9.97% 6.43% 
AFR Kenya Bomet High <5yrs+ 3 30  10.00% 2.11% 26.53% 10.00% 
AFR Kenya 5 hospitals High <1yr 20 126  15.87% 9.97% 23.44% 13.58% 
AFR Malawi 4 hospitals Very high <1yr 4 26  15.38% 4.36% 34.87% 13.09% 
AFR Nigeria Lagos Very high <5yrs+ 21 174  12.07% 7.63% 17.86% 12.07% 
AFR Nigeria Enugu Very high <5yrs+ 7 87  8.05% 3.30% 15.88% 8.05% 
AFR Nigeria Enugu Very high <2yrs 0 20  0.00% 0.00% 16.84% 0.00% 
AFR Nigeria Ile-Ife Very high <5yrs+ 12 78  15.38% 8.21% 25.33% 15.38% 
AFR Nigeria Enugu Very high <5yrs+ 2 58 3.45% 0.42% 11.91% 3.45% 
AFR Nigeria Ibadan Very high <5yrs+ 3 55  5.45% 1.14% 15.12% 5.45% 
AFR Rwanda Kigali Very high <5yrs+ 17 60  28.33% 17.45% 41.44% 28.33% 
AFR South Africa Not reported High <5yrs+ 10 106  9.43% 4.62% 16.67% 9.43% 
AFR South Africa 9 hospitals High <5yrs+ 9 423  2.13% 0.98% 4.00% 2.13% 
AFR South Africa Bloemfontein High <5yrs+ 0 35  0.00% 0.00% 10.00% 0.00% 
AFR South Africa Johannesburg High <3yrs 9 99  9.09% 4.24% 16.56% 9.01% 
AFR Tanzania Dar es Salaam Very high <5yrs+ 7 28  25.00% 10.69% 44.87% 25.00% 
AFR Tanzania Mwanza Very high <5yrs+ 8 56  14.29% 6.38% 26.22% 14.29% 
AFR Tanzania 7 hospitals Very high <1yr 57 182  31.32% 24.66% 38.60% 26.85% 
AFR Zambia 9 hospitals Very high <2yrs 31 92  33.70% 24.17% 44.30% 32.83% 
AFR Zambia 4 hospitals Very high <1yr 13 54  24.07% 13.49% 37.64% 20.69% 
AFR Zimbabwe Harare Very high <1yr 8 82  9.76% 4.31% 18.32% 8.37% 
  Africa       407 3739 11.50% 7.24% 17.78% 10.08% 
AMR Canada Toronto Very low <5yrs+ 0 41  0.00% 0.00% 8.60% 0.00% 
AMR Chile Santiago Low <2yrs 0 86  0.00% 0.00% 4.20% 0.00% 
AMR Latin America 11 countries Medium <2yrs 13 476  2.73% 1.46% 4.62% 2.48% 
AMR Panama National Medium <3yrs 1 111  0.90% 0.02% 4.92% 0.87% 
AMR Trinidad & Tobago Champ Fleurs High <3yrs 0 65  0.00% 0.00% 5.52% 0.00% 
AMR USA Texas Low <5yrs+ 1 35  2.86% 0.07% 14.92% 2.86% 
AMR USA Kansas Low <5yrs+ 0 26  0.00% 0.00% 13.23% 0.00% 
AMR USA 16 States/National Low <1yr 14 3,463  0.40% 0.22% 0.68% 0.27% 
AMR USA Cinc./Nash./Roch. Low <1yr 2 156  1.28% 0.16% 4.55% 0.86% 
AMR USA California Low <5yrs+ 0 188  0.00% 0.00% 1.94% 0.00% 
AMR USA 26 States Low <1yr 6 6,502  0.09% 0.03% 0.20% 0.06% 
AMR USA National Low <1yr 80 36,400  0.22% 0.17% 0.27% 0.15% 
AMR Venezuela Carabobo Medium <1yr 0 67  0.00% 0.00% 5.36% 0.00% 
  Americas       117 47616 0.41% 0.11% 1.54% 0.17% 
EMR Israel Holon Very low <5yrs 0 148  0.00% 0.00% 2.46% 0.00% 
EMR Pakistan Karachi Very high <2yrs 3 149  2.01% 0.42% 5.77% 1.97% 
EMR Saudi Arabia Riyadh Medium <3yrs 0 37  0.00% 0.00% 9.49% 0.00% 
EMR Saudi Arabia Abha Medium <5yrs+ 0 34  0.00% 0.00% 10.28% 0.00% 
  Eastern Mediterranean     3 368 0.46% 0.02% 8.74% 0.81% 
EUR Austria Graz Very low <5yrs+ 0 111  0.00% 0.00% 3.27% 0.00% 
EUR Israel (Bedouin) South Very low <5yrs 0 75  0.00% 0.00% 4.80% 0.00% 
EUR Israel (Jewish) South Very low <5yrs 0 241  0.00% 0.00% 1.52% 0.00% 
EUR Italy National Very low <5yrs 6 5,222  0.11% 0.04% 0.25% 0.11% 
EUR Italy National Very low <5yrs 2 3,088  0.06% 0.01% 0.23% 0.06% 
EUR Rep. of Ireland Waterford Very low <2yrs 0 24  0.00% 0.00% 14.25% 0.00% 
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EUR Rep. of Ireland Not reported Very low <5yrs+ 0 256  0.00% 0.00% 1.43% 0.00% 
EUR Romania Iasi Low <5yrs+ 3 45  6.67% 1.40% 18.27% 6.67% 
EUR Russia Vladivostok Low <5yrs+ 0 280  0.00% 0.00% 1.31% 0.00% 
EUR Serbia Belgrade Low <5yrs+ 0 107  0.00% 0.00% 3.39% 0.00% 
EUR Spain Malaga Very low <5yrs+ 1 151  0.66% 0.02% 3.63% 0.66% 
EUR Turkey Ankara Medium <5yrs+ 0 179  0.00% 0.00% 2.04% 0.00% 
EUR Turkey Ankara Medium <5yrs+ 1 105  0.95% 0.02% 5.19% 0.95% 
EUR Turkey Sanliurfa Medium <5yrs+ 0 72  0.00% 0.00% 4.99% 0.00% 
EUR Turkey Ankara Medium <5yrs+ 0 81  0.00% 0.00% 4.45% 0.00% 
EUR UK/Rep. of Ireland National Very low <1yr 1 261  0.38% 0.01% 2.12% 0.23% 
EUR Uzbekistan Bukhara High <2yrs 4 67  5.97% 1.65% 14.59% 5.14% 
  Europe       18 10,365  0.20% 0.05% 0.89% 0.17% 
SEA India Vellore High <5yrs 1 137  0.73% 0.02% 4.00% 0.73% 
SEA India Chennai High <5yrs+ 0 179  0.00% 0.00% 2.04% 0.00% 
SEA India Vellore High <5yrs 0 31  0.00% 0.00% 11.22% 0.00% 
SEA India Delhi, Pune, Vellore High <2yrs 0 3  0.00% 0.00% 70.76% 0.00% 
SEA India Vellore High <2yrs 0 59  0.00% 0.00% 6.06% 0.00% 
SEA India Manipal, Lucknow High <5yrs 0 187  0.00% 0.00% 1.95% 0.00% 
SEA India Chennai High <5yrs 0 201  0.00% 0.00% 1.82% 0.00% 
SEA India Chennai High <5yrs 3 207  1.45% 0.30% 4.18% 1.45% 
SEA India Vellore High <5yrs 0 77  0.00% 0.00% 4.68% 0.00% 
SEA India Chandigargh High <5yrs 0 277  0.00% 0.00% 1.32% 0.00% 
SEA Nepal Dharan High <5yrs+ 3 47  6.38% 1.34% 17.54% 6.38% 
SEA Nepal Kathmandu High <5yrs+ 0 34  0.00% 0.00% 10.28% 0.00% 
SEA Nepal Kathmandu High <2yrs 1 85  1.18% 0.03% 6.38% 1.14% 
SEA Thailand Bangkok Low <5yrs+ 0 94  0.00% 0.00% 3.85% 0.00% 
SEA Thailand 5 hospitals Low <5yrs 0 112  0.00% 0.00% 3.24% 0.00% 
SEA Thailand Bangkok Low <5yrs+ 0 737  0.00% 0.00% 0.50% 0.00% 
  South East Asia       8 2467 0.27% 0.03% 2.48% 0.32% 
WPR Australia National Very low <1yr 1 1,794  0.06% 0.00% 0.31% 0.02% 
WPR Australia Brisbane Very low <5yrs+ 0 141  0.00% 0.00% 2.58% 0.00% 
WPR Australia Melbourne Very low <2yrs 0 135  0.00% 0.00% 2.70% 0.00% 
WPR China Shenyang Medium <5yrs+ 0 56  0.00% 0.00% 6.38% 0.00% 
WPR China Suzhou Medium <2yrs 0 594  0.00% 0.00% 0.62% 0.00% 
WPR China Chenzhou, Kaifeng Medium <2yrs 0 1,714  0.00% 0.00% 0.21% 0.00% 
WPR Japan National Very low <5yrs+ 2 2,427  0.08% 0.01% 0.30% 0.08% 
WPR Malaysia 3 hospitals Low <5yrs 0 62  0.00% 0.00% 5.78% 0.00% 
WPR New Zealand National Very low <3yrs 0 277  0.00% 0.00% 1.32% 0.00% 
WPR New Zealand Auckland Very low <5yrs+ 0 189  0.00% 0.00% 1.93% 0.00% 
WPR Singapore National Very low <2yrs 0 217  0.00% 0.00% 1.69% 0.00% 
WPR Singapore 7 hospitals Very low <2yrs 1 167  0.60% 0.02% 3.29% 0.47% 
WPR Singapore 1 hospital Very low <5yrs+ 0 391  0.00% 0.00% 0.94% 0.00% 
WPR South Korea Joenbuk Very low <5yrs 1 408  0.25% 0.01% 1.36% 0.25% 
WPR Taiwan Taipei Very low <5yrs+ 0 686  0.00% 0.00% 0.54% 0.00% 
WPR Taiwan National Very low <1yr 1 946  0.11% 0.00% 0.59% 0.05% 
WPR Vietnam Hanoi Medium <2yrs 0 533  0.00% 0.00% 0.69% 0.00% 
WPR Vietnam Ho Chi Min City Medium <1yr 0 869  0.00% 0.00% 0.42% 0.00% 
  Western Pacific       6 11606 0.05% 0.02% 0.12% 0.03% 
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9.0 Chapter 9 - Mortality benefits and intussusception risks of rotavirus vaccination 
 
9.1  Contribution of paper to the aim and objectives of the thesis 
 
This paper brings together the various methods and sources of evidence described in 
chapters 4-8. It outlines the modelling approach, algorithms and assumptions used to 
estimate benefits and risks. The aim of the paper is fully aligned with the aim of the 
thesis, to estimate the potential mortality benefits (averted RVGE deaths <5 years of 
age) and risks (excess intussusception deaths <5 years of age) of alternative rotavirus 
vaccination schedules in LMICs.  
 
9.2 Independent academic contribution 
 
I was the LSHTM principal investigator for this work. I developed the model, 
synthesised the evidence, ran the benefit-risk analysis, constructed the tables and 
figures and wrote the first draft of the paper. I also presented the work to the WHO 
IVIR-AC committee.  
 
New meta-analyses were done to estimate the risk of intussusception and the relative 
effectiveness of 1 dose compared to 2/3 doses. I gathered and synthesised the evidence 
for these, but the actual meta analyses were done by Colin Sanderson and Cochrane 
Response.  Figure 1 (the global map) was prepared by Matt Hasso-Agopsowicz. My 
contribution to the development of the other modelling inputs (RVGE deaths, RVGE 
age distributions, coverage and timeliness, rotavirus efficacy and waning, 
intussusception incidence, age distributions and CFRs) has been described in previous 
chapters. 
 
9.3  Ethical approval 
 
I did not seek ethical approval for this analysis because it uses data that is in the public 
domain and uses methods and data inputs that are covered by the LSHTM ethical 
approvals described in chapters 5, 7 and 8.  
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Abstract 
 
Background: Infant rotavirus vaccines have led to substantial reductions in gastroenteritis 
hospital admissions and costs, but some studies have reported an elevated risk of 
intussusception, a rare bowel disorder, in vaccinated infants. 
Methods: We estimated the mortality reduction benefits and intussusception risks of two 
schedules currently recommended by WHO, and explored the potential of 16 alternative 
schedules, assuming introduction of rotavirus vaccines in 135 low- and middle-income 
countries (LMICs). We calculated numbers of rotavirus gastroenteritis (RVGE) deaths and 
intussusception deaths in each week of age for all infants born in the year 2015 between birth 
and age 5.0 years, for each schedule with and without age restrictions. We calculated benefit-
risk ratios (number of RVGE deaths prevented per excess intussusception death) and other 
indicators. 
Findings: We estimate that an age-unrestricted schedule co-administered with Diphtheria-
Tetanus-Pertussis (DTP) vaccination could prevent ~65,000 RVGE deaths (38% reduction) 
and lead to 146 excess intussusception deaths (1.0% increase) compared to no vaccination; a 
benefit-risk ratio of 446:1 (2.5th and 97.5th percentiles, 194:1 - 1383:1). Infants that received 
their first dose before 15 weeks and their last dose before 32 weeks had a benefit-risk ratio of 
623:1 (2.5th and 97.5th percentiles, 275:1 - 2046:1) compared to 186:1 (84:1 – 522:1) among 
infants vaccinated after these ages. If each country were to implement the age-unrestricted 
schedule with the greatest predicted impact on RVGE deaths (including birth and/or booster 
doses) around 72,000 RVGE deaths could be prevented (42% reduction) and 107 excess 
intussusception deaths caused (0.7% increase) compared to no vaccination (benefit-risk ratio 
666:1).  
Interpretation: Rotavirus vaccines have a favourable benefit-risk profile in LMICs. 
Schedules involving birth and booster doses could further increase benefits and reduce risks, 
but more research is needed to assess their feasibility, safety and impact.  
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Introduction 
Infant rotavirus vaccines have led to substantial reductions in gastroenteritis hospital 
admissions compared to pre-introduction baselines (1), but some studies have reported an 
elevated risk of intussusception, a rare bowel disorder, in vaccinated infants (2, 3). In 2012 we 
estimated the potential mortality benefits and intussusception risks of introducing rotavirus 
vaccines into the national immunization programmes of 158 countries (4). That analysis 
provided reassurance about the highly positive benefit-risk profile of rotavirus vaccines. It 
also informed a World Health Organization (WHO) recommendation to remove age 
restrictions for vaccination given that the benefits of preventing additional rotavirus mortality 
from later vaccination greatly exceeded the intussusception risks (5). Since our 2012 analysis, 
estimates of the number of rotavirus gastroenteritis (RVGE) deaths in children <5 years of age 
(without vaccination) have decreased from ~450,000 in 2008 to ~200,000 in 2015 (6). The 
evidence for several other modelling parameters has also been significantly strengthened, 
including: a) a meta-regression to estimate  the instantaneous efficacy of live oral rotavirus 
vaccines by duration of follow-up (7); b) a systematic review of the age distribution of RVGE 
hospital admissions in children <5 years of age (8); c) a systematic review of intussusception 
incidence rates, age distributions and case fatality ratios (CFRs) in children <5 years of age 
(9); and, d) a systematic review and meta-analysis of the relative risk of intussusception shortly 
after administration of rotavirus vaccination (10), including the first published risk estimates 
from a high mortality setting (11). Hence, we are in a position to generate updated and much 
more robust benefit-risk estimates.  
The scale of potential mortality benefits and intussusception risks is linked to the choice of 
vaccination schedule. For programmatic and economic reasons rotavirus vaccines are 
currently co-administered with Diphtheria-Tetanus-Pertussis (DTP)-containing vaccines in 
the first six months of life. All countries currently give two doses with DTP1 and DTP2, or 
three doses with DTP1, DTP2, and DTP3 as per current WHO recommendations. Rotavirus 
programmes using these schedules have demonstrated high and durable efficacy in high-
income countries but more modest efficacy in low- and middle-income countries (LMICs) (4). 
This has stimulated interest in the potential value of alternative schedules to help improve 
impact. This could include a birth dose given at the same time as Bacillus Calmette-Guérin 
(BCG)(12) and/or a booster dose given with the first dose of measles-containing vaccine 
(MCV1, referred to hereafter as Meas1) (13). A birth dose has the potential to prevent disease 
that occurs very early in life, and has been shown to be efficacious (12). A booster dose has 
the potential to mitigate the effects of waning rotavirus vaccine protection and has been shown 
to be non-interfering and immune-boosting in trials (7). The optimal number and timing of 
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doses (concurrent with different combinations of BCG, DTP1, DTP2, DTP3 and Meas1) will 
depend on several criteria, including the balance of benefits to risks. 
The aim of this analysis is to provide national decision makers in LMICs with evidence on the 
potential mortality benefits and risks of the two current rotavirus vaccination schedules, and 
to explore whether alternative schedules could have some advantages. 
 
Methods 
We  included all LMICs, defined as countries with a GNI per capita below $12,236 in the 
2018 fiscal year (14). To calculate potential benefits and risks we used UNIVAC (universal 
vaccine decision support model), an Excel-based static cohort model with a finely 
disaggregated age structure (weeks of age <5 years) (15). In each of the 135 countries, we 
predicted the experience of all infants born in the year 2015 from birth to age 5.0 years. For 
each vaccination schedule, we calculated numbers of doses administered, fully vaccinated 
infants (FVI), RVGE deaths, intussusception cases and intussusception deaths in children <5 
years of age. Estimated benefits (RVGE deaths averted) and risks (excess intussusception 
cases and deaths) were calculated by comparing each schedule scenario to a scenario with no 
rotavirus vaccination. We further estimated the incremental benefits and risks of moving from 
age-restricted schedules to age-unrestricted schedules. The primary outcome was the benefit-
risk ratio (number of RVGE deaths prevented per excess intussusception death). We also 
estimated the percent reduction in RVGE deaths, percent increase in intussusception deaths, 
number of FVI per excess intussusception case, and number of RVGE deaths prevented per 
dose administered.  
Vaccination schedule scenarios 
There are several licensed rotavirus vaccines available today, but insufficient comparative 
evidence from the same populations to demonstrate conclusive superiority of one brand over 
another in terms of vaccine efficacy/effectiveness/impact (4, 16, 17) or intussusception risks 
(3, 18). We therefore ran a product-neutral analysis assuming that the vaccine products were 
equivalent. To limit the number of vaccine schedule scenarios to a practical list, we assumed 
that no schedules would require more than three doses, and that the first dose would always 
be co-administered with either BCG or DTP1. We ran scenarios for 18 schedules in 135 
countries (Table 1). For the first 11 schedule options (all primary dose schedules) we ran 
scenarios with and without strict adherence to age restrictions (first dose <15 weeks; last dose 
< 32 weeks).  
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Potential benefits of rotavirus vaccination 
For each country we predicted the number of person-years lived between birth and age 5.0 
years in the 2015 birth cohort (19) and multiplied this by the RVGE mortality rate among 
children <5 years of age to estimate the number of RVGE deaths expected to occur between 
birth and age 5.0 years. Three sources of country-specific rotavirus mortality rates for children 
<5 years of age were recently updated (WHO/CDC (20), IHME/GBD (21) and MCEE (21)) 
so we used them to calculate means and 95% confidence intervals for each country in the year 
2015, treating the three separate estimates as distinct samples from a population. For countries 
that had introduced rotavirus vaccines prior to 2016, we used WHO/UNICEF coverage 
estimates to identify the year of introduction, and used the RVGE mortality rate for the year 
before vaccine introduction (22). RVGE deaths <5 years were assigned to each week of age 
by applying Log Logistic age distributions estimated in a recent global systematic review of 
92 hospital datasets (8). If no dataset was available for a given country, then we used the Log 
Logistic age distribution for the relevant under-five mortality stratum, defined by the median 
scale and shape parameters in each stratum. The median age were 38 weeks (inter-quartile 
range IQR: 25-58), 43 weeks (IQR: 28-68), 46 weeks (IQR: 29-72) and 65 weeks (IQR: 40-
107) in countries with very high, high, medium and low/very low child mortality, respectively. 
For a given week of age, the number of RVGE deaths was estimated by the following equation: 
Rw * (1 – (C3w * E3w + (C2w – C3w) * E2w + (C1w - C2w) * E1w)) 
 
Where: 
Rw = Number of RVGE deaths in week of age (without vaccination) 
E1w = 1-dose vaccine efficacy in week of age, adjusted for vaccine waning 
E2w = 2-dose vaccine efficacy in week of age, adjusted for vaccine waning 
E3w = 3-dose vaccine efficacy in week of age, adjusted for vaccine waning 
C1w = Coverage of dose one in week of age, adjusted for age restriction scenario 
C2w = Coverage of dose two in week of age, adjusted for age restriction scenario 
C3w = Coverage of dose three in week of age, adjusted for age restriction scenario 
 
For BCG, DTP1, DTP2, DTP3 and Meas1 we estimated the proportion of final (age 3.0 years) 
coverage achieved in each week of age using Log Logistic curves fitted to age- and country-
specific coverage rates derived from survival analysis of 73 nationally representative 
household surveys (R v 3.4.0, packages MASS and fitdistrplus) (23). Methods used for the 
survival analyses have been described elsewhere (23). Compared to lognormal, gamma and 
weibull distributions, the Log Logistic distribution had the most favourable goodness of fit 
(based on the Akaike Information Criterion - AIC). For countries without a recent household 
survey we identified the target ages for BCG, DTP1, DTP2, DTP3 and Meas1 in each country 
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(24) and used timeliness curves defined by the median of the Log Logistic scale and shape 
parameters for all other countries with the same schedule. For countries with unique schedules 
and no timeliness data, we used the average parametric curve for the closest matching schedule 
and added a shift parameter to capture the difference in the target ages. All age-specific 
coverage estimates were scaled to national WHO/UNICEF coverage estimates for the year 
2015 (22). 
We assumed that vaccine protection would start two weeks after administration of each dose. 
We assumed the same vaccine efficacy for two and three doses, but applied waning in the 
interval between doses. We estimated the efficacy of rotavirus vaccination in each week of 
follow-up based on a Bayesian meta-regression analysis, and gamma function fitted to 50 
observation points from 31 randomised controlled trials (RCTs)(7). We assumed that efficacy 
against severe RVGE was a reasonable proxy for efficacy against RVGE deaths. Different 
efficacy/waning assumptions were used for countries in different child mortality strata. We 
further assumed the same rate of waning protection following one, two or three doses. The 
relative efficacy of 1 dose compared to 2 or 3 doses was estimated to be 0.63 (95% CI 0.51 – 
0.79) based on a random effects meta-analysis of published estimates of vaccine effectiveness 
against RVGE hospital admissions from 10 case control studies in LMICs (Appendix Table 
1) (17). 
Potential risks of rotavirus vaccination 
Previously described methods (25) were used to estimate excess intussusception cases in the 
two periods of risk (1-7 days and 8-21 days) following both the first and second dose. In each 
country, the number of excess (vaccine-related) intussusception cases was calculated as 
follows: 
PY × (Cw – Cw-1)  number of new doses given in week of age 
×  
[Iw × (RR1-7 – 1)  incidence of vaccine-related intussusception cases, 1-7 day period 
+ 
Iw+1  × (RR8-21 – 1) incidence of vaccine-related intussusception cases, 8-14 day period 
+ 
Iw+2  × (RR8-21 – 1)] incidence of vaccine-related intussusception cases, 15-21 day period 
 
Where: 
PY = Mid-year population for single year of age 
Cw = Cumulative coverage estimate for the week of age 
Cw-1  = Cumulative coverage estimate for the week preceding the current week of age 
Iw  = Age-specific incidence of intussusception week 1 after dose (1-7 days) 
Iw+1 = Age-specific incidence of intussusception week 2 after dose (8-14 days) 
Iw+2 = Age-specific incidence of intussusception in week 3 after dose (15-21 days) 
RR1-7   =  Relative risk of intussusception versus background rate 1-7 days after dose 
RR8-21 =  Relative risk of intussusception versus background rate 8-21 days after dose. 
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Estimates of the background incidence of intussusception were based on the incidence of 
intussusception hospital admissions from 71 pre-vaccination country datasets identified in a 
recent systematic literature review (9). The median incidence of hospital admissions within its 
WHO region was used for each country without data. Intussusception incidence rates among 
children <5 years of age were based on children who were admitted to hospital (IH).  
We assumed that all countries with very low and low mortality would have 100% access to 
treatment. For all other countries we divided IH by the average 2010-2015 DTP1 coverage 
estimates (range from 53% in Somalia to 99% in China)(22), assumed to be a proxy for access 
to intussusception treatment, in order to calculate overall/community incidence rates. The 
adjusted national annual incidence rates were 9 (range 4-17) per 100,000 children <5 year of 
age in Africa, 11 (1-35) in the Americas, 19 (13-36) in the Eastern Mediterranean region, 14 
(4-36) in Europe, 19 (4-33) in South East Asia and 54 (5-185) in the Western Pacific region. 
We estimated the number of intussusception cases in each week of age <5 years based on 
parametric (Burr) age distributions fitted to 61 country datasets identified in the recent 
systematic review (9). The median ages ranged from 29 weeks in Africa (83% of cases in the 
first year of life) to 70 weeks in the Western Pacific region (35% of cases in the first year of 
life). For countries without a fitted age distribution, we used the distribution fitted to the 
pooled age distributions of counts for each WHO region.  
Intussusception mortality rates per 100,000 children <5 years of age per year were calculated 
as: 
IM = (IH* CFRH) + (((IH / DTP1) - IH) * 90%) 
Where: 
IM   = Mortality rate for intussusception hospital admissions <5 years of age 
IH   = Incidence rate for intussusception hospital admissions <5 years of age 
CFRH  = In-hospital intussusception case fatality ratio (CFR) <5 years of age 
DTP1  = DTP1 coverage (proxy for access to intussusception treatment) 
 
In-hospital CFRs (CFRH) were based on the pooled estimate for each WHO region, based on 
a meta-analysis of 95 data points identified in a global systematic review.(9) Pooled estimates 
ranged from 0.05% 95% CI 0.02 - 0.12%) in the Western Pacific region to 11.5% (7.2 - 17.8%) 
in Africa. We assumed a 90% CFR for children without access to hospital based on the 
proportion (10%) of children in a Bangkok case series who improved spontaneously without 
treatment (26). 
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We estimated the relative risk of intussusception (compared to the background incidence rate) 
in the 1-7 day period and 8-21 day period after the first and second dose. We only evaluated 
risk estimates based on the self-controlled case series (SCCS) method because this is based 
on large numbers of post-licensure vaccine recipients, and is less prone to the biases associated 
with other approaches (such as lack of statistical power to detect rare events, known and 
unknown differences between case and control groups). Post-licensure SCCS data points were 
taken from a recently updated global systematic literature review of the relative risk of 
intussusception (10). We derived risk estimates for the 1-7 and 8-21 day post-vaccination 
periods if they were not explicitly reported, using the same approach used in a previous global 
meta-analysis (2). We excluded a Finnish study because it was not possible to derive estimates 
for the periods of interest (27). All available global risk estimates were pooled using a random 
effects meta-analysis (Table 2). In the 1-7 day period the pooled relative risk was 4.2 (95% CI 
2.3 - 7.9) after dose 1 and 1.5 (1.0 - 2.1) after dose 2. The corresponding values for the 8-21 
day period were 1.8 (1.4 – 2.3) and 1.3 (1.0 – 1.6). There is a tendency towards little or no 
excess risk as the under-five mortality rate increases (Appendix Figure 1) but this is based on 
very few studies from LMICs so we conservatively used the global pooled estimate. We 
assumed the relative risks were only dose-dependent and did not change with age of vaccine 
administration. For age-restricted neonatal schedules, we assumed the first dose had to be 
administered before 15 weeks but allowed all subsequent doses, including doses given with 
DTP1, to be given up to 32 weeks of age.  
Uncertainty and scenario analysis 
We ran probabilistic simulations to calculate 95% uncertainty intervals around the benefit-risk 
ratios and the number of FVI per excess intussusception case, for age-restricted and age-
unrestricted schedules co-administered with DTP. Parameters and their distributions are 
described in Appendix Table 2. In addition, we ran three alternative ‘what-if’ scenarios: 
i) a scenario with less rapid waning efficacy, based on a power function that has 
been described in detail elsewhere (7); 
ii) a scenario with double the mean duration of protection for all primary doses 
administered as part of a neonatal dose schedule, consistent with the results of the 
RV3-BB trial in Indonesia (Appendix Figure 2)(7, 12); and, 
iii) a scenario with pessimistic assumptions about access to intussusception 
treatment, based on the proportion of children who are within two hours of a 
public hospital (28). We used country-specific values for 46 African countries, 
and assumed the population-weighted proportion (71%) for all other high/very 
high mortality countries.   
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Results 
We evaluated benefits and risks for 31 low income, 51 lower-middle income and 53 upper-
middle income countries. We estimated ~170,000 RVGE deaths <5 years of age in the year 
2015, of which 17-41% could be prevented by vaccination, depending on the schedule used. 
We estimated ~14,500 background intussusception deaths <5 years of age in the year 2015 for 
all 135 LMICs combined, of which no more than ~150 deaths (~1%) were attributed to 
rotavirus vaccination for any schedule evaluated (Table 3). 
Benefits and risks of currently recommended WHO schedules 
For age-unrestricted schedules co-administered with DTP, the predicted reduction in RVGE 
deaths was 17%, 29% and 32% for one, two and three dose schedules, respectively.  The 
number of doses required to prevent each death was ~3400, ~4000 and ~5200, respectively 
(Table 3). A three-dose age-unrestricted schedule co-administered with DTP could prevent 
~65,000 RVGE deaths (38% reduction) and lead to 146 excess intussusception deaths (1.0% 
increase), compared to no vaccination; a benefit-risk ratio of 446:1 (2.5th and 97.5th percentiles, 
194:1 - 1383:1). Infants that received their first dose before 15 weeks and their last dose before 
32 weeks had a benefit-risk ratio of 623:1 (2.5th and 97.5th percentiles, 275:1 - 2046:1) 
compared to 186:1 (84:1 – 522:1) among infants vaccinated after these ages. Compared to an 
age-restricted schedule, the age-unrestricted schedule is estimated to prevent an additional 
~11,000 RVGE deaths and cause an additional 59 intussusception deaths (Table 3). Among 
children vaccinated outside of the age windows, the benefit-risk ratio was greater than 100:1 
in 87% (117/135) of LMICs, but in eight countries (Argentina, Equatorial Guinea, Mauritius, 
Moldova, Samoa, Syria, Tonga, Vietnam) the ratio was below 50:1 (Appendix Table 3). For 
infants vaccinated inside the age windows, we estimate one excess intussusception case per 
95,000 FVI (2.5th and 97.5th percentiles 39,000 – 304,000) compared to 31,000 (2.5th and 97.5th 
percentiles 13,000 – 87,000) among children vaccinated outside the age windows (Appendix 
Table 3).  
Benefits and risks of schedules not currently recommended by WHO 
For all age-unrestricted schedules we found that giving the first dose with BCG rather than 
DTP1 reduced the estimated number of excess intussusception deaths by more than 50% 
(Table 3). If each country were to implement the age-unrestricted schedule with the greatest 
predicted impact on RVGE deaths (including birth and/or booster doses) around 72,000 
RVGE deaths could be prevented (42% reduction) and 107 excess intussusception deaths 
caused (0.7% increase) compared to no vaccination (benefit-risk ratio 666:1). Thus, compared 
to current age-unrestricted schedules co-administered with DTP, more deaths could be 
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prevented (72,000 vs 65,000) and fewer intussusception deaths caused (107 vs 146). 
Compared to age-restricted schedules co-administered with DTP, far more deaths could be 
prevented (72,000 vs 54,000 deaths prevented) and intussusception deaths would be slightly 
higher (107 vs 87). Excess intussusception deaths are only slightly higher (0.74% vs 0.60% 
increase) because the schedules with the highest impact typically involve co-administering the 
first dose with BCG when the background risk of intussusception is lower.  
However, the schedule with the highest predicted reduction in RVGE deaths varied 
considerably by country (Figure 1, Appendix Table 4, Appendix Figure 3). In 28 countries a 
neonatal schedule (with BCG+DTP1+DTP3) predicted the highest impact, but in most other 
countries combinations involving a booster dose (either with or without a birth dose) were 
likely to be best.  
Using a power waning function (less rapid waning) improved the estimated impact and 
benefit-risk ratios (Appendix Tables 5 and 6). If doses given as part of a neonatal schedule 
were assumed to have double the mean duration of protection, then schedules with a birth dose 
had the highest predicted impact in most countries (Appendix Tables 7 and 8). A scenario with 
pessimistic access to care assumptions had less favourable benefit-risk ratios (202:1 versus 
446:1 for a three-dose age-unrestricted schedule co-administered with DTP) but there were no 
more than ~350 excess intussusception deaths each year across all countries modelled for any 
schedule evaluated (Appendix Tables 9 and 10).  
 
Discussion 
Our previous analysis was based on the 2010 birth cohort in 158 countries defined by WHO 
as in strata B, C, D or E. This classification, based on rates of all-cause child mortality in the 
year 1999, is now almost twenty years old (29). This time we used the 2018 World Bank 
classification of LMICs. We excluded high income countries (HICs) because the 
overwhelming majority of RVGE and intussusception deaths are in LMICs. Other factors such 
as healthcare treatment costs and cost-effectiveness become more influential in HICs, and 
these were beyond the scope of our analysis. Compared to the previous analysis(4) we 
estimated far fewer RVGE deaths averted in the 2015 birth cohort for an equivalent age-
unrestricted 3-dose schedule (DTP1+DTP2+DTP3). This is because of lower official 
estimates of the number of RVGE deaths without vaccination, mainly due to improved access 
to supportive care following acute gastroenteritis in LMICs, but also due to improved methods 
of RVGE mortality estimation (6). Our estimates of excess intussusception deaths were also 
much lower because the median age of intussusception from recent estimates was higher (9), 
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resulting in fewer background intussusception cases around the time of DTP1 vaccination. 
Our new benefit-risk ratio for an age-unrestricted schedule co-administered with DTP (446:1), 
is more favourable than our previous estimate (371:1), with the benefits of rotavirus vaccine 
introduction still greatly exceeding the risk.  
In our previous analysis we found that removing age restrictions from a standard infant 
schedule co-administered with DTP could prevent an additional ~47,000 RVGE deaths and 
cause an additional ~300 intussusception deaths each year (4). In our new analysis the 
equivalent estimates for a standard 3-dose DTP schedule are much lower (~11,000 RVGE 
deaths prevented and 59 excess intussusception deaths) but the incremental benefit-risk ratio 
is more favourable (186:1 versus 154:1). Our new analysis therefore still supports the WHO 
recommendation to remove age restrictions in countries where the benefit would greatly 
exceed the risk (5). 
We conservatively used a global pooled estimate of the relative risk of intussusception, but 
this may greatly over-estimate the risk in many LMICs. Only one study (a multi-country study 
in Africa (11)) has evaluated post-licensure risk of intussusception in a high mortality setting, 
and this found no elevated risk of intussusception. Had we applied a gradient of risk consistent 
with under-five mortality, we would have predicted zero excess risk in many LMICs, 
including large countries such as India, Nigeria and Pakistan. More post-licensure estimates 
are needed to confirm the finding of no risk in high mortality settings. However, even with 
pessimistic risk assumptions, there was less than one excess intussusception case per 60,000 
FVI for a standard schedule co-administered with DTP. This is far more favourable than the 
rate associated with RotaShield® (more than one case per 10,000 FVI), an early rotavirus 
vaccine that was withdrawn from the market following evidence of its link with 
intussusception (30). 
To our knowledge this is the first estimate of the number of background intussusception deaths 
in LMICs (~14,500). The Global Burden of Disease Project (GBD 2017) estimated 22,395 
deaths globally due to paralytic ileus and intestinal obstruction, and 31,460 deaths for all 
digestive disorders combined, for children <5 years of age in the year 2015 (31). We used 
DTP1 coverage as a proxy for access to intussusception treatment because it may better 
represent care-seeking for very severe conditions than household survey indicators based on 
milder symptoms. A more pessimistic scenario, based on the proportion of children with 
timely (two-hour) access to public hospitals was influential (led to less favourable benefit-risk 
ratios), but this is probably too pessimistic as many intussusception cases in Africa are known 
to present to hospital more than two days after the onset of symptoms (32). In medium 
mortality countries, access to care adjustments led to large increases in the background 
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intussusception mortality rate relative to the (often very low) pre-vaccination RVGE mortality 
rate. Had we assumed 100% access to treatment in medium mortality countries (as per the low 
and very low mortality stratum), then the benefit-risk ratios would have been far more 
favourable. Better estimates of intussusception treatment utilisation are needed. 
Our analysis highlights the potential value of a birth dose in future rotavirus vaccination 
programmes. A birth dose has the potential to avoid the peak background age of 
intussusception as well as preventing rotavirus deaths that occur very early in life. We assumed 
that the risks of intussusception were relative to the baseline incidence, rather than assuming 
an absolute risk difference. This assumption favoured neonatal schedules. However, our base 
case analysis also assumed that doses administered as part of a neonatal schedule would have 
equivalent efficacy/waning assumptions to those administered as part of an infant schedule, 
but evidence suggests they may have more durable protection. Indeed, with this assumption, 
schedules with a birth doses had the highest predicted impact in most countries. In some 
countries neonatal schedules did not predict the highest impact because infant schedules 
achieved higher impact during the peak age of RVGE disease (e.g. Bangladesh) or because no 
BCG visit currently exists (e.g. Lebanon, Suriname). However, an important feature of many 
of the countries where neonatal schedules were not preferred (including large countries such 
as India and DR Congo) is that BCG coverage was lower than DTP1 coverage in the year 
2015. In these countries our calculations of vaccine impact did not allow for opportunities to 
catch-up on missed doses at later visits. This is probably not realistic. More evidence is needed 
on the post-licensure safety of birth doses, and on the efficacy and feasibility of administering 
the globally licensed rotavirus vaccines at birth. The RV3-BB vaccine demonstrated high 
initial efficacy following a neonatal schedule, but it is unclear if the currently licensed vaccines 
would have similar efficacy if administered as a neonatal schedule.  
Our analysis also highlights the potential benefit of booster doses to mitigate the waning 
protection of rotavirus vaccines (33). We assumed that a 3rd dose co-administered with Meas1 
would have the same efficacy (and waning) as the 2nd dose co-administered with DTP. This 
assumption is consistent with a Rotarix® immunogenicity study in Bangladesh, where 
seropositivity (IgA titres ≥ 20 U/mL) increased from 53% to 70% after a 3rd dose was 
administered concurrently with the first dose of measles vaccine (13). A study in Mali also 
found an increase in IgA titres and no negative impact on the immune response of other 
vaccines administered at the same visit e.g. measles, yellow fever (34). However, more 
evidence is needed on the clinical efficacy and safety of booster doses, particularly since most 
cases of vaccine-related intussusception with RotaShield® were associated with doses 
administered as part of a catch-up campaign among older infants (35). However, these were 
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associated with the first and second dose, and post-licensure studies have reported no 
significant relative risk with the third dose of RotaTeq administered at ~6 months (13). 
We used a transparent static cohort model to estimate the potential direct effects of vaccination 
by week of age. Inclusion of herd effects could make the benefit-risk ratios more favourable 
in some settings, but it would be challenging to obtain robust estimates of the scale and 
duration of these effects in each of the 135 LMICs. Transmission dynamic models calibrated 
to data from Niger (36) and India (37) have predicted a minimal contribution of indirect 
effects, and while short-term herd effects have been observed in El Salvador (38), Ghana (1), 
Moldova (1) and Rwanda (39), no substantial herd effects were observed in Malawi,(40), 
South Africa (41), Tanzania (1) or Zambia (42). Transmission dynamic models could be used 
to help anticipate the longer-term effects of different schedules on the age-specific incidence 
and severity of natural infections. This would ideally require data on social mixing and 
transmission patterns in very granular age groups <5 years of age. In the interim, our analysis 
provides a useful starting point for thinking about the schedules that might have advantages 
in different countries. Beyond this, with the aggregated impact on RVGE deaths <5 years of 
age not exceeding 50% for any schedule or scenario evaluated, more efficacious rotavirus 
vaccines would be needed to achieve more substantial improvements in impact in LMICs.  
 
Conclusion 
Rotavirus vaccination has a favourable benefit-risk profile in LMICs despite pessimistic 
assumptions about the potential scale of intussusception risks. Schedules involving birth and 
booster doses could further increase benefits and reduce risks, but more research is needed to 
assess their feasibility, safety and impact.  
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Table 1. List of rotavirus schedules evaluated 
# 
Rotavirus doses co-
administered with: 
Birth dose 
schedule? 
Booster dose 
schedule? 
Age-restricted 
scenario? 
Age-unrestricted 
scenario? 
1 BCG Yes   Yes Yes 
2 DTP1   Yes Yes 
3 BCG + DTP1  Yes  Yes Yes 
4 BCG + DTP2 Yes  Yes Yes 
5 BCG + DTP3 Yes  Yes Yes 
6 DTP1 + DTP2^     Yes Yes 
7 DTP1 + DTP3    Yes Yes 
8 BCG + DTP1 + DTP2$ Yes  Yes Yes 
9 BCG + DTP1 + DTP3 Yes  Yes Yes 
10 BCG + DTP2 + DTP3 Yes  Yes Yes 
11 DTP1 + DTP2 + DTP3^       Yes Yes 
12 BCG + Meas1 Yes Yes  Yes 
13 DTP1 + Meas1  Yes  Yes 
14 BCG + DTP1 + Meas1 Yes Yes  Yes 
15 BCG + DTP2 + Meas1 Yes Yes  Yes 
16 BCG + DTP3 + Meas1 Yes Yes  Yes 
17 DTP1 + DTP2 + Meas1*  Yes  Yes 
18 DTP1 + DTP3 + Meas1   Yes   Yes 
 
^ schedules recommended by WHO. The three-dose schedule has been evaluated in efficacy trials for Rotarix, 
RotaTeq, ROTAVAC, ROTASIIL and RV3-BB. The two-dose schedule has been evaluated in Rotarix efficacy 
studies (7). 
$ schedule evaluated in RV3-BB efficacy study in Indonesia (12). 
*schedule evaluated in Rotarix immunogenicity studies in Bangladesh (13) and Mali (34). 
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Table 2. Pooled random effects meta-analysis of the relative risk of intussusception in the 1-7 
day period and 8-21 day period after administration of rotavirus vaccine doses 1 and 2 
 
Country 2010-2015 
under five 
mortality rate 
per 1000 live 
births 
Vaccine Period post dose 1       Period post dose 2       
  
 
1-7 days 
 
8-21 days   1-7 days 
 
8-21 days   
    Mid L95 U95 Mid L95 U95 Mid L95 U95 Mid L95 U95 
Singapore(43) 3 Rotarix 8·4 2·4 29·0 1·5 0·9 2·5 3·1 0·4 12·4 1·5 0·2 11·7 
Australia(18) 5 Rotarix 6·8 2·4 19·0 3·5 1·3 8·9 2·8 1·1 7·3 2·1 1·0 4·6 
Australia(18) 5 RotaTeq 9·9 3·7 26·4 6·3 2·8 14·4 2·8 1·2 6·8 1·8 0·8 3·9 
England(2) 5 Rotarix 13·8 6·4 28·3 1·6 0·3 3·8 2·2 0·5 5·0 2·8 1·4 5·3 
USA1(44) 7 Rotarix 1·6 0·3 5·8 - - - 0·7 -0·1 3·0 - - - 
USA2(3) 7 Rotarix - - - - - - 3·5 0·5 25·1 1·2 0·4 3·4 
Multinational(45) 7 RotaTeq 3·5 1·8 6·6 0·9 0·5 1·6 1·6 0·9 3·1 1·1 0·6 1·8 
USA2(3) 7 RotaTeq 9·1 2·2 38·6 1·8 0·8 4·1 1·8 0·4 7·2 0·9 0·5 1·8 
Brazil(46) 18 Rotarix 1·1 0·3 3·3 0·5 0·2 1·3 2·6 1·3 5·2 1·1 0·7 1·9 
Mexico1(46) 23 Rotarix 5·3 3·0 9·3 1·0 0·5 1·9 1·8 0·9 3·8 2·2 1·4 3·5 
Mexico2(47) 23 Rotarix 6·5 4·2 10·1 1·1 0·9 1·4 1·3 0·8 2·1 1·0 0·8 1·2 
South Africa(48) 47 Rotarix 1·0 0·7 1·6 2·8 0·7 10·6 2·1 1·2 3·6 0·9 0·6 1·6 
7 African 
countries(40) 67 Rotarix 0·3 0·0 1·0 1·0 0·3 2·3 0·8 0·2 1·7 0·7 0·4 1·2 
                     
Pooled (random effects) with I-squared = 83% 4·2 2·3 7·9 1·8 1·4 2·3 1·5 1·0 2·1 1·3 1·0 1·6 
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Table 3. Potential benefits and risks of alternative rotavirus vaccination schedule options if used in all 135 low- and middle-income countries 
Schedule Doses   RVGE deaths <5 years   Intussusception deaths <5 years Summary indicators   
Vaccines in the existing 
schedule that rotavirus 
would be co-administered 
with 
Total 
doses 
(millions) 
Fully 
vaccinated 
children 
(FVC) 
(millions) Number Averted 
Incremental 
number 
averted vs 
age-restricted Number 
Excess 
vs no 
vaccine 
Incremental 
excess 
number vs 
age-restricted 
% 
reduction 
in RVGE 
deaths 
Doses 
per RVGE 
death 
averted 
Number 
of FVC 
per 
excess IS 
case 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Incremental 
RVGE deaths 
averted per 
excess IS 
death vs age-
restricted 
NO VACCINE 0 0 169,450 - - 14,478 - - - - - - - 
Age-restricted (primary)                  
BCG 109 104 140,066 29,384 - 14,498 21 - 17.3% 3,712 838,053 1,420 - 
DTP1 87 82 141,323 28,126 - 14,531 54 - 16.6% 3,085 177,189 524 - 
BCG+DTP1 217 102 118,208 51,241 - 14,515 38 - 30.2% 4,236 299,990 1,357 - 
BCG+DTP2 213 99 115,630 53,820 - 14,536 58 - 31.8% 3,969 172,357 924 - 
BCG+DTP3 192 79 118,111 51,338 - 14,540 62 - 30.3% 3,740 136,944 829 - 
DTP1+DTP2^ 173 82 120,829 48,621 - 14,564 87 - 28.7% 3,567 106,531 561 - 
DTP1+DTP3 164 73 121,110 48,340 - 14,572 94 - 28.5% 3,397 85,499 512 - 
BCG+DTP1+DTP2 321 99 111,746 57,704 - 14,515 38 - 34.1% 5,571 290,268 1,529 - 
BCG+DTP1+DTP3 300 79 109,115 60,335 - 14,515 38 - 35.6% 4,970 230,160 1,598 - 
BCG+DTP2+DTP3 296 79 110,324 59,125 - 14,536 58 - 34.9% 5,014 136,687 1,015 - 
DTP1+DTP2+DTP3^ 250 73 115,469 53,981 - 14,564 87 - 31.9% 4,646 95,149 623 - 
Age-unrestricted (primary)                   
BCG 114 108 138,147 31,303 1,919 14,512 34 14 18.5% 3,652 501,786 910 140 
DTP1 117 111 134,966 34,484 6,357 14,584 106 53 20.4% 3,397 89,616 324 121 
BCG+DTP1 227 107 115,233 54,217 2,975 14,527 49 11 32.0% 4,190 255,004 1,109 267 
BCG+DTP2 225 105 112,435 57,015 3,195 14,551 73 15 33.6% 3,952 152,843 780 216 
BCG+DTP3 223 101 112,616 56,833 5,495 14,559 81 19 33.5% 3,924 130,653 699 284 
DTP1+DTP2^ 230 107 111,331 58,119 9,498 14,624 146 59 34.3% 3,966 63,209 398 160 
DTP1+DTP3 226 102 111,080 58,370 10,030 14,632 154 59 34.4% 3,887 56,731 380 169 
BCG+DTP1+DTP2 338 105 108,232 61,218 3,514 14,526 48 10 36.1% 5,523 255,667 1,269 335 
BCG+DTP1+DTP3 335 101 104,188 65,262 4,927 14,526 49 11 38.5% 5,145 241,584 1,338 447 
BCG+DTP2+DTP3 334 101 105,787 63,662 4,537 14,551 73 15 37.6% 5,246 146,921 872 308 
DTP1+DTP2+DTP3^ 339 102 104,501 64,949 10,968 14,623 146 59 38.3% 5,238 60,045 446 186 
Age-unrestricted (booster)                  
BCG+Meas1 222 73 119,210 50,240 - 14,537 60 - 29.6% 4,426 128,271 842 - 
DTP1+Meas1 225 73 116,653 52,797 - 14,609 131 - 31.2% 4,276 45,914 403 - 
BCG+DTP1+Meas1 335 73 102,302 67,148 - 14,527 49 - 39.6% 4,987 173,813 1,376 - 
BCG+DTP2+Meas1 332 73 100,947 68,503 - 14,551 73 - 40.4% 4,857 105,773 938 - 
BCG+DTP3+Meas1 329 72 103,072 66,378 - 14,559 81 - 39.2% 4,964 93,984 818 - 
DTP1+DTP2+Meas1 338 72 99,777 69,673 - 14,623 146 - 41.1% 4,861 42,810 478 - 
DTP1+DTP3+Meas1 333 72 101,489 67,961 - 14,631 154 - 40.1% 4,916 40,444 442 - 
 
^ shaded rows reflect the current WHO recommended schedule options 
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Figure 1. Schedules with the highest predicted impact on RVGE deaths <5 years of age 
 
Age-restricted schedules 
 
 
Age-unrestricted schedules 
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Appendix to: 
 
Potential mortality benefits and intussusception risks of alternative rotavirus vaccination 
schedule options in 135 low- and middle-income countries.  
 
Andy Clark, Jacqueline E. Tate, Umesh Parashar, Mark Jit, Mateusz Hasso-Agopsowicz, Benjamin 
Lopman, Clint Pecenka, Ximena Riveros, Ana Maria Henao-Restrepo, Colin Sanderson 
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Appendix Table 1. Relative effectiveness of 1 dose of rotavirus vaccination (compared to 2/3 
doses) against rotavirus-positive hospital admissions in LMICs 
 
Country Vaccine RR of 1 dose (1 - VE) RR of 2/3 doses (1 - VE) 
Relative VE of 1 dose 
compared to 2/3 doses 
    Mid L95 U95 Mid L95 U95 Mid L95 U95 
Bolivia(49) Rotarix 0.64 0.41 1.00 0.31 0.21 0.46 0.48 0.27 0.88 
Bolivia(50) Rotarix 0.74 0.42 0.75 0.41 0.27 0.63 0.55 0.33 0.93 
Botswana(51) Rotarix 0.46 0.19 1.07 0.47 0.24 0.92 1.02 0.34 3.05 
Brazil(52) Rotarix 0.40 0.25 0.63 0.28 0.15 0.56 0.70 0.31 1.57 
El Salvador(53) Rotarix 0.49 0.33 0.74 0.24 0.16 0.36 0.49 0.28 0.87 
Mexico(46) Rotarix 0.16 0.01 1.55 0.06 0.00 0.84 0.38 0.01 14.18 
Moldova(54) Rotarix 0.40 0.15 0.96 0.21 0.12 0.38 0.53 0.18 1.55 
Nicaragua(55) RotaTeq 0.45 0.25 0.83 0.51 0.32 0.81 1.13 0.53 2.42 
South Africa(56) Rotarix 0.60 0.43 0.84 0.43 0.32 0.60 0.72 0.45 1.13 
Zambia(57) Rotarix 0.38 0.04 3.61 0.44 0.14 0.66 1.16 0.11 12.52 
                 
Pooled (random effects) 0.57 0.49 0.66 0.35 0.28 0.43 0.63 0.51 0.79 
 
10 case control studies with partial VE estimates from LMICs were identified from a recent review by Jonesteller et al(17). We used (1 – 
VE) to calculate the risk ratios (with 95% confidence intervals) in each study for 1 dose and for 2/3 doses. We carried out a meta-analysis of 
the difference in each study between ln(RR[1 dose]) and ln(RR[2/3 doses]) to provide a paired analysis estimate of the mean ratio of RR[2/3 
doses] to RR[1 dose]. This ratio was used to estimate the relative effectiveness of 1 dose compared to 2/3 doses. We used the Stata 
command metan (58). 
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Appendix Table 2. Parameters and distributions used for probabilistic simulations* 
 
Parameter Base case (95% CI) Probability distribution Source 
Population projections for the 2015 birth cohort       
Population by single age/year between birth and 5.0 years Country-specific Beta-PERT (mid = UNPOP medium variant, range = UNPOP low/high variant) (19) 
Disease burden estimates       
RVGE mortality rate <5 years Country-specific Beta-PERT (mid = Log transformed mean of 3 sources of country estimates, range = 95% CI) (6) 
Intussusception incidence rate <5 years Country-specific Beta-PERT (mid = median for country/WHO region, range = 95% CI for country or IQR for region) (9) 
Intussusception mortality rate <5 years Country-specific Beta-PERT (mid = median for country/WHO region, range = 95% CI for country or IQR for region) (9) 
Age distribution of RVGE deaths       
Log Logistic scale parameter$ Country-specific Beta-PERT (mid = best fit for country/U5MR stratum, range = 95% CI for country/U5MR stratum) (8) 
Age distribution of background intussusception cases       
Burr distribution scale parameter$ Country-specific Beta-PERT (mid = best fit for country/WHO region, range = 95% CI for country/WHO region) (9) 
Vaccine coverage       
Doses with BCG, DTP1, DTP2, DTP3 or Meas1 Country-specific Beta-PERT (mid = WUENIC 2015, range = WUENIC 2015 +/-10%) (22) 
Vaccine timeliness       
Log Logistic scale parameter$ Country-specific Beta-PERT (mid = best fit for country or schedule stratum, range = median age +/-10%) (23) 
Initial efficacy against RVGE mortality (2wks after dose administered)$     
Low mortality 99.6% (99.4-99.7) Beta (alpha = 4918.07, beta = 19.83, [A] = 0%, [B] = 100%) (7) 
Medium mortality 91.4% (89.8-92.7) Beta (alpha = 1394.26, beta = 131.74, [A] = 0%, [B] = 100%) (7) 
High mortality (excluding India) 88.0% (85.8-90.2) Beta (alpha = 723.19, beta = 98.31, [A] = 0%, [B] = 100%) (7) 
India 70.0% (63.8-75.5) Beta (alpha = 163.63, beta = 69.98, [A] = 0%, [B] = 100%) (7) 
Mean duration of vaccine efficacy in months $       
Low mortality 176.8 (114.7-268.0) Gamma (alpha = 21.82, beta = 8.41) (7) 
Medium mortality 121.9 (81.3-182.4) Gamma (alpha = 24.01, beta = 5.28) (7) 
High mortality (excluding India) 8.3 (6.4-11.2) Gamma (alpha = 50.75, beta = 0.17) (7) 
India 17.9 (8.8-38.2) Gamma (alpha = 7.56, beta = 2.76) (7) 
Relative efficacy of 1 dose versus 2/3 doses       
Low- and middle-income countries (LMICs) 0.63 (0.51-0.79) Beta (alpha = 27.05, beta = 15.68, [A] = 0, [B] = 1) Ap. Table 1 
Relative risk of vaccine-related intussusception vs background rate       
Dose 1, 1-7 days 4.2 (2.3-7.9) Lognormal (m = ln(4.2), sd = 0.32) Table 2 
Dose 1, 8-21 days 1.8 (1.4-2.3) Lognormal (m = ln(1.8), sd = 0.13) Table 2 
Dose 2, 1-7 days 1.5 (1.0-2.1) Lognormal (m = ln(1.0), sd = 0.18) Table 2 
Dose 2, 8-21 days 1.3 (1.0-1.6) Lognormal (m = ln(1.0), sd = 0.11) Table 2 
 
*We calculated 95% uncertainty intervals for age-restricted and age-unrestricted schedules co-administered with DTP1+DTP2+DTP3. Intervals represent the 2.5th and 97.5th percentiles of 1000 Monte-Carlo simulations. We compared estimates of 
the benefit-risk ratio after 100, 200, 300 runs etc., and found stability (no change in the whole number of the ratio) after ~200 runs for central estimates (mean, median) and after ~500 runs for 2.5th and 97.5th percentiles. The deterministic estimate of 
the benefit-risk ratio was consistent with the median, and generally lower than the mean, of the 1000 benefit-risk ratios, so this value was reported as the central estimate for consistency with the estimates for other schedules. 
$ Other associated parameters of the distribution were fixed during PSA simulations. For example, a three-parameter gamma distribution was used to estimate VE over time. Two parameters (VE after 2 weeks, mean duration) were varied in PSA. 
The third parameter (alpha) was fixed for low (0.93), medium (0.4), high (excluding India) (0.69) mortality strata, and for India alone (0.27). 
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Appendix Table 3. Potential benefit-risk ratios and FVI per excess intussusception case, with 95% uncertainty intervals, for infants inside and outside 
the age restriction windows (first dose before 15 weeks, last dose before 32 weeks) for a 3-dose schedule co-administered with DTP: base case scenario 
 
Country Infants within age window Infants outside age window 
  
RVGE deaths 
averted per 
excess IS 
death 95% uncertainty range 
Number of 
FVI per 
excess IS 
case 95% uncertainty range 
RVGE deaths 
averted per 
excess IS 
death 95% uncertainty range 
Number of 
FVI per 
excess IS 
case 95% uncertainty range 
ALL 135 LMICs 623 (275 - 2046) 95149 (37524 - 303736) 186 (84 - 522) 30668 (12731 - 86510) 
                
Afghanistan 411 (179 - 1455) 69278 (31336 - 214952) 121 (54 - 385) 19045 (8449 - 56147) 
Albania 270 (120 - 913) 94108 (36315 - 266821) 170 (76 - 552) 158425 (64011 - 434406) 
Algeria 90 (41 - 343) 111033 (49412 - 340660) 56 (26 - 201) 60937 (26920 - 172093) 
Angola 1685 (788 - 6092) 76429 (33560 - 243185) 868 (414 - 2538) 106060 (46206 - 276441) 
Argentina 37 (18 - 126) 38535 (19154 - 138610) 19 (9 - 62) 53846 (26676 - 174077) 
Armenia 200 (82 - 540) 113381 (45956 - 321407) 128 (52 - 332) 70414 (28667 - 192802) 
Azerbaijan 301 (138 - 999) 120225 (49048 - 342466) 236 (109 - 738) 73868 (29731 - 202290) 
Bangladesh 22196 (1631 - 36233) 1843580 (182359 - 4271518) 3182 (242 - 4112) 142179 (15429 - 270882) 
Belarus 380 (73 - 1105) 109371 (44634 - 304926) 274 (53 - 790) 77125 (31231 - 212185) 
Belize 583 (251 - 1797) 112631 (49678 - 340786) 313 (132 - 865) 186648 (80759 - 515292) 
Benin 2147 (939 - 6818) 200038 (89005 - 667134) 671 (286 - 1805) 54586 (23764 - 148053) 
Bhutan 790 (255 - 2106) 122081 (43714 - 383907) 264 (91 - 626) 37557 (13396 - 110382) 
Bolivia 3701 (1691 - 12110) 121881 (53245 - 367069) 2204 (984 - 6480) 170308 (74008 - 474883) 
Bosnia & Herzegovina 557 (119 - 1517) 98292 (39507 - 277219) 345 (73 - 903) 85736 (34761 - 233105) 
Botswana 430 (201 - 1452) 143042 (63327 - 455741) 211 (102 - 624) 65479 (29384 - 179586) 
Brazil 13263 (817 - 24065) 648210 (57564 - 1344826) 7550 (505 - 12614) 994756 (97286 - 1824685) 
Bulgaria 2048 (333 - 6821) 125607 (51326 - 357540) 1226 (200 - 4054) 77626 (31271 - 212426) 
Burkina Faso 1653 (718 - 4960) 158401 (70584 - 504850) 644 (275 - 1770) 41226 (19223 - 127426) 
Burundi 3898 (1575 - 12211) 243976 (110041 - 829851) 901 (359 - 2310) 32646 (13896 - 87269) 
Cabo Verde 262 (116 - 842) 101362 (44635 - 325512) 124 (54 - 343) 132690 (57727 - 359363) 
Cambodia 411 (197 - 1343) 101456 (39817 - 312274) 209 (101 - 628) 73191 (28494 - 194326) 
Cameroon 2633 (1105 - 8345) 213480 (95403 - 711472) 589 (244 - 1548) 34994 (15008 - 97250) 
Central African Republic 1058 (489 - 3687) 81975 (36598 - 272585) 268 (122 - 707) 36475 (15911 - 93831) 
Chad 1065 (478 - 3533) 103662 (45963 - 347917) 321 (138 - 849) 36070 (15619 - 96947) 
China 304 (141 - 968) 49000 (19557 - 152605) 136 (63 - 403) 21266 (8569 - 62499) 
Colombia 410 (182 - 1290) 106895 (48379 - 337088) 213 (93 - 596) 234396 (105355 - 665122) 
Comoros 821 (374 - 2828) 179653 (80423 - 611314) 278 (125 - 772) 95218 (42386 - 257175) 
Congo 600 (266 - 1855) 150101 (66532 - 474222) 236 (104 - 651) 42078 (17795 - 119851) 
Costa Rica 2471 (339 - 7137) 281490 (88553 - 710704) 1334 (190 - 3665) 1102220 (371777 - 2538855) 
Côte d'Ivoire 1521 (683 - 5142) 167106 (75316 - 556894) 446 (196 - 1175) 45432 (19621 - 123787) 
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Croatia 421 (60 - 1560) 91120 (35316 - 258732) 262 (38 - 958) 156645 (63114 - 429596) 
Cuba 742 (165 - 2353) 124623 (54443 - 375326) 388 (87 - 1190) 174139 (75673 - 485566) 
DR Congo 1480 (646 - 4634) 180188 (80062 - 592845) 424 (183 - 1163) 49447 (21549 - 136295) 
Djibouti 476 (204 - 1539) 75976 (34714 - 239843) 167 (74 - 451) 28577 (12620 - 81975) 
Dominican Republic 790 (349 - 2583) 198656 (90852 - 623943) 308 (148 - 959) 106250 (50429 - 330820) 
Ecuador 283 (130 - 946) 106609 (46573 - 321150) 147 (69 - 445) 151055 (65762 - 417980) 
Egypt 1066 (299 - 4632) 128465 (56375 - 750167) 476 (141 - 1191) 314393 (127753 - 995792) 
El Salvador 809 (354 - 2508) 138467 (60115 - 427179) 710 (301 - 1812) 1914512 (782943 - 4678763) 
Equatorial Guinea 146 (61 - 645) 72509 (32287 - 233995) 40 (16 - 153) 26228 (11364 - 67915) 
Eritrea 916 (375 - 2823) 203432 (91154 - 676166) 379 (155 - 986) 67323 (29423 - 183797) 
Ethiopia 481 (147 - 1840) 188970 (56238 - 771983) 190 (87 - 569) 56028 (24490 - 169180) 
Fiji 3228 (1323 - 9376) 102958 (40420 - 314011) 1191 (496 - 3416) 41252 (16803 - 119244) 
Gabon 316 (134 - 946) 168847 (74897 - 557631) 106 (44 - 276) 47827 (20994 - 131097) 
Gambia 868 (414 - 3210) 146602 (65221 - 463356) 464 (225 - 1451) 60092 (26478 - 167681) 
Georgia 2157 (380 - 6795) 124361 (50855 - 353957) 1297 (230 - 3968) 77244 (31132 - 211172) 
Ghana 2492 (938 - 9798) 439313 (177255 - 1824114) 317 (129 - 881) 39932 (17060 - 109465) 
Grenada 2906 (777 - 8533) 119629 (52983 - 397597) 1236 (323 - 3319) 304846 (135937 - 842511) 
Guatemala 1013 (457 - 3159) 70052 (31095 - 215146) 653 (289 - 1688) 175381 (77086 - 463741) 
Guinea 682 (305 - 2225) 150971 (66715 - 499238) 199 (88 - 526) 30799 (13302 - 85286) 
Guinea-Bissau 1849 (754 - 5834) 161113 (72279 - 534972) 670 (269 - 1757) 70833 (31081 - 194224) 
Guyana 3084 (1119 - 8196) 121486 (52834 - 370504) 2459 (926 - 6141) 328001 (141509 - 907193) 
Haiti 934 (423 - 3329) 125304 (55873 - 394856) 327 (148 - 1037) 54175 (23489 - 146989) 
Honduras 4085 (1301 - 10455) 146272 (58257 - 431939) 11550 (3463 - 25360) 2816042 (1095229 - 6971471) 
India 450 (183 - 1750) 100993 (35540 - 418222) 99 (42 - 290) 20293 (7486 - 65840) 
Indonesia 554 (166 - 1577) 70022 (25076 - 215774) 288 (85 - 745) 33942 (11973 - 96496) 
Iran 486 (96 - 1027) 46995 (21170 - 149263) 248 (49 - 493) 64280 (28556 - 184291) 
Iraq 106 (48 - 337) 32172 (14481 - 101982) 51 (23 - 141) 48673 (21560 - 133002) 
Jamaica 380 (157 - 1130) 134556 (59096 - 424987) 150 (61 - 399) 259660 (111268 - 713162) 
Jordan 178 (57 - 375) 50447 (22696 - 151098) 97 (31 - 198) 29948 (13451 - 87663) 
Kazakhstan 718 (323 - 2449) 88478 (36022 - 249131) 412 (184 - 1360) 86640 (34385 - 236525) 
Kenya 2295 (878 - 8887) 478074 (200141 - 1920814) 230 (86 - 628) 18576 (7876 - 51226) 
Kiribati 1068 (516 - 3541) 93376 (36667 - 285289) 466 (220 - 1430) 38709 (15758 - 111132) 
Kyrgyzstan 1049 (436 - 2923) 114236 (45692 - 326019) 596 (245 - 1570) 137417 (55560 - 377402) 
Lao PDR 783 (354 - 2493) 72207 (28583 - 224813) 376 (169 - 1090) 29061 (11821 - 82175) 
Lebanon 592 (42 - 2808) 46316 (20827 - 146748) 298 (22 - 1359) 64199 (28404 - 182125) 
Lesotho 3237 (1282 - 10690) 266629 (119270 - 928600) 982 (378 - 2431) 172521 (76515 - 450386) 
Liberia 1216 (571 - 4277) 120845 (54011 - 398085) 361 (169 - 979) 62273 (27329 - 162042) 
Libya 89 (29 - 206) 46610 (21000 - 148078) 51 (16 - 105) 63756 (28320 - 182793) 
Madagascar 662 (302 - 2273) 158162 (69792 - 522113) 221 (99 - 600) 39855 (17333 - 109573) 
Malawi 2561 (1016 - 8260) 223241 (100307 - 755193) 591 (238 - 1528) 76934 (33210 - 195039) 
Malaysia 22079 (867 - 34825) 299706 (17434 - 516761) 9536 (391 - 14246) 277942 (16594 - 429684) 
Maldives 1041 (76 - 4918) 63296 (21645 - 201690) 484 (36 - 2223) 78635 (28037 - 230275) 
Mali 1322 (606 - 4629) 160116 (70563 - 530571) 381 (175 - 1052) 36272 (15742 - 99144) 
Marshall Islands 9620 (2817 - 20050) 53589 (21135 - 166846) 6284 (2031 - 13346) 82740 (33416 - 237787) 
Mauritania 1558 (701 - 5014) 202232 (89080 - 655078) 419 (184 - 1122) 28247 (12086 - 80490) 
Mauritius 123 (50 - 382) 211235 (94227 - 698206) 41 (17 - 109) 68585 (29971 - 187892) 
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Mexico 332 (165 - 1161) 42802 (21771 - 155442) 143 (70 - 443) 54904 (27829 - 168628) 
Micronesia (FSO) 373 (137 - 2159) 43050 (16961 - 134275) 232 (82 - 1317) 73400 (29563 - 204942) 
Mongolia 649 (179 - 7434) 92249 (36095 - 276319) 360 (99 - 4122) 53179 (21220 - 155824) 
Montenegro 468 (67 - 1721) 84394 (34078 - 240985) 296 (44 - 1066) 139155 (55624 - 371715) 
Morocco 1971 (347 - 4325) 66031 (29767 - 202655) 905 (160 - 1860) 31681 (14415 - 91085) 
Mozambique 891 (404 - 2869) 134706 (59800 - 432457) 357 (159 - 931) 53240 (23361 - 147143) 
Myanmar 350 (156 - 1139) 54067 (18527 - 173053) 225 (98 - 634) 69331 (24781 - 203256) 
Namibia 979 (392 - 2989) 274918 (122988 - 943295) 175 (68 - 430) 29433 (12589 - 78633) 
Nepal 384 (143 - 1286) 135395 (44315 - 490216) 91 (36 - 245) 20007 (7203 - 66350) 
Nicaragua 7651 (2828 - 22384) 222947 (74128 - 561500) 3988 (1462 - 10576) 313280 (108196 - 718355) 
Niger 2125 (948 - 6733) 142212 (63388 - 468087) 600 (256 - 1536) 53437 (23158 - 138465) 
Nigeria 353 (158 - 1098) 50262 (21331 - 150790) 229 (110 - 642) 26726 (11900 - 72103) 
North Korea 785 (253 - 2205) 117880 (42288 - 371171) 222 (75 - 592) 36648 (13075 - 107786) 
Pakistan 402 (152 - 1653) 93659 (38171 - 343516) 95 (39 - 309) 16544 (7557 - 47027) 
Panama 1543 (393 - 3478) 137592 (39179 - 333371) 742 (197 - 1473) 220955 (65776 - 471632) 
Papua New Guinea 309 (145 - 1058) 86938 (34075 - 272505) 113 (54 - 343) 46492 (18851 - 128044) 
Paraguay 570 (248 - 1943) 111965 (49548 - 341924) 362 (162 - 1094) 161866 (70528 - 445532) 
Peru 817 (313 - 2541) 135162 (51510 - 375925) 859 (332 - 2307) 778563 (291983 - 1848699) 
Philippines 286 (134 - 914) 77495 (30457 - 237973) 120 (54 - 348) 35407 (14378 - 99595) 
Republic of Moldova 66 (26 - 178) 108933 (41590 - 309108) 38 (15 - 100) 103094 (40327 - 286185) 
Romania 2638 (584 - 7128) 261092 (51420 - 360021) 1817 (399 - 4713) 195109 (67003 - 604695) 
Russian Federation 1275 (191 - 4531) 106907 (43613 - 299562) 925 (138 - 3311) 80053 (32414 - 220265) 
Rwanda 2060 (861 - 6523) 313717 (138421 - 1076955) 346 (134 - 890) 8675 (3661 - 24914) 
Saint Lucia 373 (129 - 1038) 123127 (53789 - 370823) 195 (69 - 507) 172050 (74765 - 479740) 
Saint Vincent & the Gr. 682 (243 - 1926) 121603 (53296 - 366970) 356 (130 - 930) 170873 (74309 - 475293) 
Samoa 63 (27 - 270) 68017 (26713 - 208255) 21 (9 - 84) 33347 (13568 - 91267) 
Sao Tome and Principe 1207 (466 - 3723) 294973 (131072 - 1040610) 397 (155 - 957) 212403 (93874 - 545434) 
Senegal 968 (400 - 3045) 192965 (86464 - 641994) 294 (123 - 780) 48560 (20947 - 136029) 
Serbia 816 (116 - 3024) 111477 (45193 - 315418) 537 (78 - 1966) 99420 (40408 - 272879) 
Sierra Leone 3814 (1624 - 12178) 190494 (85289 - 649500) 1135 (470 - 2933) 88118 (38614 - 235963) 
Solomon Islands 1300 (588 - 3947) 100579 (39551 - 307241) 568 (250 - 1636) 40670 (16570 - 117358) 
Somalia 247 (111 - 861) 38547 (17684 - 122104) 78 (35 - 227) 16224 (7110 - 43872) 
South Africa 332 (174 - 1264) 95671 (47882 - 348315) 79 (43 - 255) 33608 (16712 - 100917) 
South Sudan 407 (189 - 1391) 114429 (50893 - 378537) 120 (55 - 317) 42436 (18625 - 110658) 
Sri Lanka 992 (111 - 3250) 63296 (21645 - 201690) 476 (53 - 1569) 78635 (28037 - 230275) 
Sudan 4074 (1376 - 9851) 89762 (41361 - 287683) 1383 (452 - 2863) 34278 (15208 - 99642) 
Suriname 239 (109 - 819) 166186 (72637 - 527044) 122 (57 - 370) 121352 (52548 - 354948) 
Swaziland 2902 (1153 - 9610) 352377 (157052 - 1237222) 1832 (713 - 4701) 898648 (396133 - 2350494) 
Syrian Arab Republic 28 (7 - 277) 21738 (9944 - 68900) 12 (3 - 98) 38733 (17389 - 103221) 
Tajikistan 2170 (909 - 6006) 134110 (54621 - 379584) 1392 (575 - 3652) 71588 (29224 - 197100) 
Tanzania 2108 (885 - 8215) 364837 (157561 - 1463874) 371 (158 - 1020) 58450 (25469 - 165802) 
TFYR Macedonia 1443 (217 - 5072) 109639 (44765 - 310778) 1021 (154 - 3567) 69753 (28806 - 193383) 
Thailand 3362 (128 - 9271) 86525 (15162 - 220580) 1980 (82 - 5509) 136178 (28077 - 299240) 
Timor-Leste 564 (200 - 1623) 103394 (36699 - 321230) 167 (63 - 428) 19694 (7106 - 58109) 
Togo 1801 (735 - 5830) 221421 (99300 - 750442) 489 (197 - 1249) 92119 (40821 - 242671) 
Tonga 64 (31 - 207) 79352 (31174 - 243151) 23 (11 - 70) 34799 (14148 - 98761) 
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Tunisia 209 (46 - 391) 58969 (22527 - 171260) 131 (30 - 223) 178871 (72374 - 446615) 
Turkey 165 (62 - 448) 92004 (35548 - 260879) 104 (39 - 271) 155690 (62839 - 426872) 
Turkmenistan 2356 (1025 - 7492) 126654 (51617 - 360500) 1571 (703 - 4821) 77401 (31138 - 212159) 
Tuvalu 746 (335 - 2443) 99528 (39296 - 304214) 332 (158 - 1064) 40999 (16715 - 117936) 
Uganda 655 (275 - 2090) 144169 (64222 - 473373) 275 (114 - 710) 78925 (35129 - 209039) 
Ukraine 1643 (434 - 4149) 53044 (21776 - 150003) 981 (252 - 2289) 20713 (8368 - 54174) 
Uzbekistan 1130 (329 - 6888) 100492 (27402 - 367343) 1029 (361 - 4663) 79425 (29759 - 227981) 
Vanuatu 129 (60 - 444) 65762 (25851 - 202144) 54 (25 - 173) 30616 (12425 - 85763) 
Venezuela 398 (175 - 1317) 75899 (32783 - 271323) 132 (59 - 353) 76110 (33051 - 203200) 
Viet Nam 164 (44 - 1189) 55998 (24864 - 170950) 39 (12 - 319) 17784 (8072 - 54157) 
Yemen 360 (155 - 1096) 70644 (32031 - 223960) 117 (50 - 304) 18676 (8402 - 52246) 
Zambia 4094 (843 - 13271) 644523 (142978 - 2193397) 712 (184 - 1614) 141845 (38334 - 319803) 
Zimbabwe 2903 (910 - 11748) 301904 (102474 - 1226337) 717 (284 - 2063) 142848 (62348 - 405825) 
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Appendix Table 4. Potential benefits and risks of a standard age-restricted three-dose infant schedule (co-administered with DTP1+DTP2+DTP3) 
compared to age-restricted and age-unrestricted schedules with the highest predicted impact in each country: base case scenario 
 
Country NO VACCINE   
Age-restricted standard 
schedule (DTP1+DTP2+DTP3) 
Age-restricted schedule with the highest predicted 
impact on RVGE deaths<5 years 
Age-unrestricted schedule with the highest predicted 
impact on RVGE deaths<5 years 
  
RVGE 
deaths 
<5 years 
IS 
deaths 
<5 
years 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Schedule with 
highest predicted 
impact 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Schedule with 
highest predicted 
impact 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
ALL 135 LMICs 169,450 14,478 32% 0.6% 623   36% 0.4% 1,107   42% 0.7% 666 
                      
Afghanistan 2,420 296 21% 0.4% 411 BCG-DTP1-DTP3 32% 0.3% 777 BCG-DTP1-DTP3 37% 0.5% 562 
Albania 1 0 59% 1.0% 270 BCG-DTP1-DTP2 74% 0.4% 811 BCG-DTP1-DTP3 77% 0.4% 785 
Algeria 206 48 16% 0.7% 90 BCG-DTP1-DTP3 47% 0.5% 367 BCG-DTP1-Meas1 52% 0.5% 409 
Angola 6,921 125 31% 1.0% 1,685 BCG-DTP1-DTP2 39% 0.3% 7,254 BCG-DTP1-DTP3 42% 0.3% 6,770 
Argentina 36 65 56% 0.8% 37 BCG-DTP1-DTP2 72% 0.3% 141 BCG-DTP1-DTP3 74% 0.3% 130 
Armenia 2 1 38% 0.6% 200 BCG-DTP1-DTP3 68% 0.3% 733 BCG-DTP1-Meas1 74% 0.3% 774 
Azerbaijan 74 7 24% 0.9% 301 BCG-DTP1-DTP3 30% 0.4% 768 BCG-DTP3-Meas1 42% 0.6% 799 
Bangladesh 1,623 11 40% 0.3% 22,196 DTP1-DTP2-DTP3 40% 0.3% 22,196 DTP1-DTP3-Meas1 56% 0.6% 12,174 
Belarus 1 0 32% 0.5% 380 BCG-DTP1-DTP3 86% 0.5% 1,053 BCG-DTP1-Meas1 90% 0.5% 1,038 
Belize 1 0 59% 0.9% 583 BCG-DTP1-DTP2 71% 0.3% 1,906 BCG-DTP1-DTP3 76% 0.4% 1,628 
Benin 1,582 39 41% 0.8% 2,147 BCG-DTP1-DTP3 47% 0.2% 9,367 BCG-DTP3-Meas1 51% 0.5% 4,006 
Bhutan 6 0 40% 0.7% 790 BCG-DTP1-DTP3 45% 0.2% 2,848 BCG-DTP2-Meas1 52% 0.4% 1,650 
Bolivia 253 3 41% 0.9% 3,701 BCG-DTP1-DTP2 50% 0.3% 13,876 BCG-DTP1-DTP3 54% 0.3% 13,551 
Bosnia & Herzegovina 0 0 52% 0.6% 557 BCG-DTP1-DTP3 84% 0.3% 2,044 BCG-DTP1-Meas1 86% 0.3% 2,071 
Botswana 43 3 37% 1.3% 430 BCG-DTP1-DTP3 45% 0.4% 1,764 BCG-DTP2-Meas1 52% 0.7% 1,142 
Brazil 1,032 3 58% 1.5% 13,263 BCG-DTP1-DTP2 74% 0.5% 51,357 BCG-DTP1-DTP3 77% 0.5% 48,288 
Bulgaria 2 0 67% 0.8% 2,048 BCG-DTP1-DTP3 85% 0.3% 5,876 BCG-DTP1-Meas1 88% 0.4% 5,654 
Burkina Faso 2,279 48 42% 1.2% 1,653 BCG-DTP1-DTP3 49% 0.3% 7,339 BCG-DTP2-Meas1 53% 0.6% 4,224 
Burundi 1,606 21 47% 0.9% 3,898 DTP1-DTP2-DTP3 47% 0.9% 3,898 DTP1-DTP3-Meas1 53% 1.2% 3,436 
Cabo Verde 4 1 58% 1.3% 262 BCG-DTP1-DTP2 71% 0.3% 1,214 BCG-DTP1-Meas1 74% 0.4% 1,151 
Cambodia 212 64 38% 0.3% 411 BCG-DTP1-DTP3 39% 0.1% 1,354 BCG-DTP3-Meas1 47% 0.2% 897 
Cameroon 2,967 60 44% 0.8% 2,633 DTP1-DTP2-DTP3 44% 0.8% 2,633 DTP1-DTP2-Meas1 50% 1.1% 2,172 
Central African Republic 928 42 30% 0.6% 1,058 BCG-DTP1-DTP2 38% 0.2% 3,445 BCG-DTP1-DTP3 40% 0.3% 2,840 
Chad 4,309 182 16% 0.4% 1,065 BCG-DTP1-DTP3 25% 0.3% 1,807 BCG-DTP1-Meas1 31% 0.7% 1,107 
China 1,384 414 26% 0.3% 304 BCG-DTP1-DTP3 73% 0.2% 978 BCG-DTP1-Meas1 77% 0.3% 908 
Colombia 152 26 61% 0.9% 410 BCG-DTP1-DTP2 69% 0.2% 2,279 BCG-DTP1-DTP3 71% 0.2% 2,328 
Comoros 39 2 43% 0.9% 821 BCG-DTP1-DTP3 46% 0.2% 4,132 DTP1-DTP2-Meas1 51% 1.2% 736 
Congo 252 14 35% 1.0% 600 BCG-DTP1-DTP3 43% 0.3% 2,510 BCG-DTP2-Meas1 46% 0.5% 1,535 
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Costa Rica 2 0 81% 0.9% 2,471 DTP1-DTP2-DTP3 81% 0.9% 2,471 DTP1-DTP2-Meas1 85% 1.0% 2,453 
Côte d'Ivoire 2,477 75 42% 0.9% 1,521 DTP1-DTP2-DTP3 42% 0.9% 1,521 DTP1-DTP2-Meas1 51% 1.4% 1,167 
Croatia 0 0 70% 0.8% 421 BCG-DTP1-DTP3 88% 0.3% 1,257 BCG-DTP1-Meas1 91% 0.4% 1,215 
Cuba 3 0 71% 0.9% 742 BCG-DTP1-DTP3 89% 0.3% 2,843 BCG-DTP1-Meas1 92% 0.3% 2,644 
DR Congo 12,377 435 38% 0.7% 1,480 BCG-DTP1-DTP3 40% 0.2% 5,820 DTP1-DTP3-Meas1 46% 1.2% 1,077 
Djibouti 26 2 39% 0.9% 476 BCG-DTP1-DTP3 45% 0.3% 1,667 BCG-DTP2-Meas1 48% 0.5% 1,020 
Dominican Republic 74 9 17% 0.2% 790 BCG-DTP1-DTP3 60% 0.2% 2,784 BCG-DTP1-DTP2 70% 0.2% 2,756 
Ecuador 95 23 48% 0.7% 283 BCG-DTP1-DTP2 64% 0.2% 1,103 BCG-DTP1-Meas1 66% 0.3% 1,017 
Egypt 1,095 98 70% 0.7% 1,066 BCG-DTP1-DTP3 77% 0.0% 123,972 BCG-DTP1-DTP3 77% 0.0% 51,557 
El Salvador 50 5 69% 0.9% 809 BCG-DTP1-DTP3 75% 0.2% 5,273 BCG-DTP1-Meas1 76% 0.2% 5,327 
Equatorial Guinea 42 13 11% 0.3% 146 BCG-DTP1-DTP3 18% 0.1% 602 BCG-DTP1-Meas1 19% 0.1% 530 
Eritrea 269 9 28% 0.9% 916 BCG-DTP1-DTP3 31% 0.3% 3,559 DTP1-DTP3-Meas1 40% 1.4% 873 
Ethiopia 5,130 407 22% 0.6% 481 DTP1-DTP2-DTP3 22% 0.6% 481 DTP1-DTP2-Meas1 38% 1.3% 367 
Fiji 7 0 65% 0.3% 3,228 BCG-DTP1-DTP3 74% 0.1% 8,234 BCG-DTP1-Meas1 77% 0.2% 7,607 
Gabon 57 7 33% 0.8% 316 BCG-DTP1-DTP3 41% 0.3% 1,153 BCG-DTP2-Meas1 45% 0.5% 691 
Gambia 130 4 33% 1.3% 868 BCG-DTP1-DTP3 41% 0.4% 3,213 BCG-DTP2-Meas1 50% 0.7% 2,338 
Georgia 2 0 70% 0.8% 2,157 BCG-DTP1-DTP3 86% 0.4% 6,049 BCG-DTP1-Meas1 90% 0.4% 5,954 
Ghana 1,436 56 44% 0.5% 2,492 BCG-DTP1-DTP3 47% 0.1% 16,353 BCG-DTP2-Meas1 51% 0.3% 4,352 
Grenada 0 0 73% 0.7% 2,906 DTP1-DTP2-DTP3 73% 0.7% 2,906 DTP1-DTP2-Meas1 85% 1.0% 2,536 
Guatemala 349 13 33% 0.9% 1,013 BCG-DTP1-DTP2 38% 0.3% 3,959 DTP1-DTP2-Meas1 44% 1.3% 946 
Guinea 1,097 71 24% 0.5% 682 BCG-DTP1-DTP3 33% 0.2% 2,330 BCG-DTP2-Meas1 35% 0.4% 1,433 
Guinea-Bissau 197 4 37% 1.0% 1,849 BCG-DTP1-DTP3 42% 0.3% 5,777 BCG-DTP2-Meas1 48% 0.8% 2,989 
Guyana 11 0 42% 1.0% 3,084 BCG-DTP2-DTP3 46% 0.4% 7,557 BCG-DTP2-Meas1 51% 0.5% 7,994 
Haiti 375 24 25% 0.4% 934 BCG-DTP1-DTP2 33% 0.3% 1,875 BCG-DTP1-DTP3 39% 0.5% 1,173 
Honduras 103 1 48% 1.0% 4,085 BCG-DTP2-DTP3 48% 0.4% 9,799 BCG-DTP1-DTP3 51% 0.2% 22,485 
India 25,839 4,025 31% 0.4% 450 BCG-DTP2-DTP3 34% 0.3% 716 DTP1-DTP3-Meas1 40% 0.9% 292 
Indonesia 3,000 157 27% 0.9% 554 BCG-DTP2-DTP3 28% 0.6% 920 DTP1-DTP2-Meas1 40% 1.4% 532 
Iran 213 20 59% 1.3% 486 BCG-DTP1-DTP2 74% 0.4% 2,021 BCG-DTP1-Meas1 77% 0.5% 1,861 
Iraq 669 189 29% 1.0% 106 BCG-DTP1-DTP2 42% 0.3% 474 BCG-DTP1-DTP3 43% 0.4% 431 
Jamaica 3 1 64% 0.7% 380 BCG-DTP1-DTP3 74% 0.2% 1,336 BCG-DTP1-DTP3 77% 0.3% 1,212 
Jordan 25 5 26% 0.7% 178 BCG-DTP1-DTP3 75% 0.6% 649 BCG-DTP1-DTP3 77% 0.6% 614 
Kazakhstan 46 5 55% 0.8% 718 BCG-DTP2-DTP3 73% 0.3% 2,167 DTP1-DTP2-DTP3 76% 1.3% 599 
Kenya 1,986 90 43% 0.4% 2,295 DTP1-DTP2-DTP3 43% 0.4% 2,295 DTP1-DTP3-Meas1 50% 0.7% 1,519 
Kiribati 4 0 32% 0.2% 1,068 BCG-DTP1-DTP3 36% 0.1% 2,745 DTP1-DTP3-Meas1 41% 0.4% 922 
Kyrgyzstan 45 3 64% 0.9% 1,049 BCG-DTP1-DTP3 75% 0.3% 4,372 BCG-DTP1-Meas1 76% 0.3% 4,454 
Lao PDR 431 54 23% 0.2% 783 BCG-DTP2-DTP3 27% 0.2% 1,169 DTP1-DTP2-Meas1 43% 0.5% 625 
Lebanon 5 0 60% 1.2% 592 DTP1-DTP2-DTP3 60% 1.2% 592 DTP1-DTP2-Meas1 75% 1.8% 504 
Lesotho 187 3 48% 0.8% 3,237 BCG-DTP1-DTP3 48% 0.2% 17,371 DTP1-DTP3-Meas1 54% 1.1% 2,874 
Liberia 443 16 32% 0.7% 1,216 BCG-DTP1-DTP3 34% 0.2% 4,749 DTP1-DTP2-Meas1 38% 1.0% 1,062 
Libya 8 3 40% 1.3% 89 BCG-DTP1-DTP2 50% 0.4% 358 BCG-DTP1-DTP3 54% 0.5% 344 
Madagascar 1,696 109 26% 0.6% 662 BCG-DTP1-DTP3 31% 0.3% 1,735 DTP1-DTP2-Meas1 40% 1.4% 429 
Malawi 1,556 35 49% 0.9% 2,561 BCG-DTP1-DTP3 50% 0.2% 13,172 DTP1-DTP2-Meas1 52% 0.9% 2,520 
Malaysia 17 0 71% 0.9% 22,079 BCG-DTP1-DTP3 89% 0.3% 87,740 BCG-DTP1-Meas1 92% 0.3% 78,643 
Maldives 0 0 71% 1.0% 1,041 BCG-DTP1-DTP3 89% 0.3% 4,486 BCG-DTP1-Meas1 92% 0.4% 4,034 
Mali 2,438 83 28% 0.6% 1,322 BCG-DTP1-DTP3 38% 0.4% 2,758 BCG-DTP1-Meas1 44% 0.7% 1,871 
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Marshall Islands 1 0 36% 0.4% 9,620 BCG-DTP1-DTP2 45% 0.2% 27,569 BCG-DTP1-DTP3 49% 0.2% 27,358 
Mauritania 400 12 31% 0.7% 1,558 BCG-DTP1-DTP3 40% 0.3% 4,229 BCG-DTP2-Meas1 43% 0.5% 2,649 
Mauritius 1 1 59% 0.9% 123 BCG-DTP1-DTP3 65% 0.5% 258 BCG-DTP2-Meas1 72% 0.8% 167 
Mexico 626 142 58% 0.8% 332 BCG-DTP1-DTP2 75% 0.2% 1,465 BCG-DTP1-Meas1 76% 0.2% 1,481 
Micronesia (FSO) 1 0 36% 0.4% 373 DTP1-DTP2-DTP3 36% 0.4% 373 DTP1-DTP2-Meas1 45% 0.5% 340 
Mongolia 9 3 77% 0.4% 649 BCG-DTP1-DTP3 79% 0.1% 2,723 BCG-DTP1-Meas1 81% 0.1% 2,768 
Montenegro 0 0 67% 0.8% 468 BCG-DTP1-DTP2 79% 0.3% 1,455 DTP1-DTP2-Meas1 84% 1.2% 423 
Morocco 604 9 38% 1.3% 1,971 BCG-DTP1-DTP3 48% 0.7% 4,514 BCG-DTP2-Meas1 52% 1.0% 3,324 
Mozambique 2,160 84 32% 0.9% 891 BCG-DTP1-DTP3 45% 0.4% 3,140 BCG-DTP1-Meas1 49% 0.4% 2,877 
Myanmar 818 82 34% 1.0% 350 BCG-DTP2-DTP3 41% 0.5% 765 DTP1-DTP2-Meas1 48% 1.5% 329 
Namibia 108 6 42% 0.7% 979 DTP1-DTP2-DTP3 42% 0.7% 979 DTP1-DTP3-Meas1 49% 1.0% 858 
Nepal 258 42 39% 0.6% 384 BCG-DTP1-DTP3 42% 0.2% 1,472 BCG-DTP2-Meas1 46% 0.5% 584 
Nicaragua 53 0 59% 0.9% 7,651 BCG-DTP1-DTP2 74% 0.3% 29,781 BCG-DTP1-DTP3 77% 0.3% 28,282 
Niger 4,557 94 36% 0.8% 2,125 BCG-DTP1-DTP3 37% 0.2% 9,672 DTP1-DTP2-Meas1 43% 1.1% 1,832 
Nigeria 35,129 2,103 23% 1.1% 353 BCG-DTP1-DTP3 27% 0.8% 556 BCG-DTP2-Meas1 32% 1.0% 512 
North Korea 151 17 64% 0.7% 785 BCG-DTP1-DTP3 73% 0.2% 2,864 BCG-DTP1-Meas1 76% 0.3% 2,468 
Pakistan 7,694 971 29% 0.6% 402 BCG-DTP1-DTP3 38% 0.3% 1,100 BCG-DTP1-DTP3 41% 0.5% 678 
Panama 25 1 57% 0.9% 1,543 BCG-DTP1-DTP2 74% 0.3% 5,961 BCG-DTP1-Meas1 76% 0.3% 5,514 
Papua New Guinea 191 89 34% 0.2% 309 BCG-DTP1-DTP3 36% 0.1% 733 DTP1-DTP2-Meas1 41% 0.3% 298 
Paraguay 41 3 38% 0.9% 570 BCG-DTP1-DTP2 46% 0.3% 2,093 BCG-DTP1-DTP3 51% 0.3% 2,072 
Peru 144 8 43% 1.0% 817 DTP1-DTP2-DTP3 43% 1.0% 817 DTP1-DTP2-Meas1 49% 1.1% 837 
Philippines 1,893 811 28% 0.2% 286 BCG-DTP1-DTP3 33% 0.1% 707 BCG-DTP1-Meas1 38% 0.1% 719 
Republic of Moldova 1 1 50% 0.7% 66 BCG-DTP1-DTP3 72% 0.3% 267 BCG-DTP1-DTP3 73% 0.3% 270 
Romania 8 0 68% 0.8% 2,638 BCG-DTP1-DTP2 88% 0.4% 7,883 BCG-DTP1-DTP3 90% 0.4% 7,576 
Russian Federation 54 3 31% 0.5% 1,275 BCG-DTP1-DTP3 86% 0.5% 3,699 BCG-DTP1-Meas1 89% 0.5% 3,619 
Rwanda 700 19 40% 0.7% 2,060 BCG-DTP1-DTP3 41% 0.1% 12,405 DTP1-DTP3-Meas1 49% 1.0% 1,828 
Saint Lucia 0 0 59% 0.9% 373 BCG-DTP1-DTP3 67% 0.6% 678 BCG-DTP1-DTP3 76% 0.7% 584 
Saint Vincent & the Gr. 0 0 59% 0.9% 682 BCG-DTP1-DTP2 74% 0.3% 2,633 BCG-DTP1-DTP3 77% 0.3% 2,448 
Samoa 0 1 57% 0.3% 63 BCG-DTP1-DTP3 62% 0.1% 173 DTP1-DTP2-Meas1 64% 0.4% 55 
Sao Tome and Principe 7 0 44% 0.8% 1,207 BCG-DTP1-DTP3 44% 0.1% 9,033 DTP1-DTP3-Meas1 52% 1.0% 1,105 
Senegal 876 34 36% 1.0% 968 BCG-DTP1-DTP3 42% 0.3% 3,380 BCG-DTP2-Meas1 45% 0.7% 1,761 
Serbia 1 0 72% 0.9% 816 BCG-DTP1-DTP3 90% 0.3% 3,379 BCG-DTP1-Meas1 91% 0.3% 3,434 
Sierra Leone 1,263 15 39% 0.8% 3,814 BCG-DTP1-DTP3 42% 0.2% 16,719 DTP1-DTP2-Meas1 47% 1.2% 3,195 
Solomon Islands 9 1 40% 0.3% 1,300 BCG-DTP1-DTP3 44% 0.1% 3,333 DTP1-DTP3-Meas1 50% 0.5% 1,110 
Somalia 2,432 415 22% 0.5% 247 DTP1-DTP2-DTP3 22% 0.5% 247 DTP1-DTP2-Meas1 27% 0.7% 220 
South Africa 1,734 267 41% 0.8% 332 DTP1-DTP2-DTP3 41% 0.8% 332 DTP1-DTP2-Meas1 46% 1.1% 261 
South Sudan 937 102 16% 0.4% 407 BCG-DTP1-DTP3 19% 0.1% 1,586 BCG-DTP1-DTP3 20% 0.1% 1,371 
Sri Lanka 11 1 73% 1.0% 992 BCG-DTP1-DTP3 90% 0.3% 4,194 BCG-DTP1-Meas1 93% 0.3% 3,784 
Sudan 2,726 30 40% 0.9% 4,074 DTP1-DTP2-DTP3 40% 0.9% 4,074 DTP1-DTP2-Meas1 50% 1.3% 3,381 
Suriname 1 0 35% 0.4% 239 DTP1-DTP2-DTP3 35% 0.4% 239 DTP1-DTP2-Meas1 63% 1.1% 173 
Swaziland 77 2 47% 0.6% 2,902 BCG-DTP1-DTP3 49% 0.1% 21,638 BCG-DTP2-Meas1 52% 0.3% 7,077 
Syrian Arab Republic 80 136 36% 0.8% 28 BCG-DTP1-DTP2 48% 0.3% 114 BCG-DTP1-Meas1 50% 0.3% 103 
Tajikistan 236 5 34% 0.7% 2,170 BCG-DTP1-DTP3 47% 0.4% 5,872 DTP1-DTP3-Meas1 53% 1.2% 2,014 
Tanzania 2,880 109 49% 0.6% 2,108 DTP1-DTP2-DTP3 49% 0.6% 2,108 DTP1-DTP3-Meas1 57% 1.0% 1,494 
TFYR Macedonia 1 0 37% 0.6% 1,443 BCG-DTP1-DTP2 83% 0.4% 4,348 BCG-DTP1-Meas1 87% 0.4% 4,273 
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Thailand 65 1 71% 1.7% 3,362 BCG-DTP1-DTP3 89% 0.5% 13,381 BCG-DTP1-Meas1 92% 0.6% 12,559 
Timor-Leste 90 9 30% 0.5% 564 BCG-DTP1-DTP3 35% 0.3% 1,408 BCG-DTP2-Meas1 42% 0.6% 783 
Togo 609 17 43% 0.9% 1,801 DTP1-DTP2-DTP3 43% 0.9% 1,801 DTP1-DTP2-Meas1 48% 0.9% 1,803 
Tonga 0 1 56% 0.3% 64 BCG-DTP1-DTP3 60% 0.1% 172 DTP1-DTP2-Meas1 65% 0.4% 55 
Tunisia 15 3 70% 2.0% 209 BCG-DTP1-DTP3 77% 0.4% 1,111 BCG-DTP1-DTP3 78% 0.4% 1,127 
Turkey 53 21 58% 0.9% 165 BCG-DTP1-DTP3 65% 0.5% 300 DTP1-DTP2-Meas1 73% 1.2% 150 
Turkmenistan 89 2 37% 0.9% 2,356 BCG-DTP1-DTP3 46% 0.4% 6,472 BCG-DTP2-Meas1 51% 0.5% 5,541 
Tuvalu 0 0 37% 0.3% 746 BCG-DTP1-DTP3 42% 0.1% 1,887 DTP1-DTP3-Meas1 49% 0.5% 656 
Uganda 2,478 150 35% 0.9% 655 BCG-DTP1-DTP3 39% 0.3% 2,005 BCG-DTP2-Meas1 47% 0.7% 1,194 
Ukraine 13 1 20% 0.2% 1,643 BCG-DTP1-DTP2 35% 0.1% 5,762 DTP1-DTP2-Meas1 46% 0.8% 1,245 
Uzbekistan 181 4 33% 1.3% 1,130 BCG-DTP1-DTP3 41% 0.6% 3,204 DTP1-DTP3-Meas1 49% 1.7% 1,296 
Vanuatu 5 5 30% 0.2% 129 BCG-DTP1-DTP3 32% 0.1% 332 DTP1-DTP3-Meas1 35% 0.3% 108 
Venezuela 273 36 58% 1.1% 398 BCG-DTP1-DTP2 75% 0.3% 1,811 BCG-DTP1-DTP3 77% 0.4% 1,585 
Viet Nam 365 854 29% 0.1% 164 BCG-DTP1-DTP3 64% 0.1% 276 BCG-DTP1-DTP2 73% 0.1% 221 
Yemen 1,434 170 29% 0.7% 360 DTP1-DTP2-DTP3 29% 0.7% 360 DTP1-DTP2-Meas1 39% 1.2% 267 
Zambia 1,235 21 45% 0.6% 4,094 BCG-DTP1-DTP3 49% 0.2% 15,196 BCG-DTP1-DTP3 53% 0.3% 10,472 
Zimbabwe 1,295 29 44% 0.7% 2,903 DTP1-DTP2-DTP3 44% 0.7% 2,903 DTP1-DTP3-Meas1 50% 0.9% 2,554 
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Appendix Table 5. Potential benefits and risks of alternative rotavirus vaccination schedule options if used in all 135 low- and middle-income countries: 
scenario with the waning function changed from a gamma function (more rapid waning) to a power function (more conservative waning) 
Schedule Doses   RVGE deaths <5 years   Intussusception deaths <5 years Summary indicators   
Vaccines in the existing 
schedule that rotavirus 
would be co-administered 
with 
Total 
doses 
(millions) 
Fully 
vaccinated 
children 
(FVC) 
(millions) Number Averted 
Incremental 
number 
averted vs 
age-restricted Number 
Excess 
vs no 
vaccine 
Incremental 
excess 
number vs 
age-restricted 
% 
reduction 
in RVGE 
deaths 
Doses 
per RVGE 
death 
averted 
Number 
of FVC 
per 
excess IS 
case 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Incremental 
RVGE deaths 
averted per 
excess IS 
death vs age-
restricted 
NO VACCINE 0 0 169,450 - - 14,478 - - - - - - - 
Age-restricted (primary)                  
BCG 109 104 135,263 34,187 - 14,498 21 - 20.2% 3,191 838,053 1,652 - 
DTP1 87 82 137,736 31,713 - 14,531 54 - 18.7% 2,736 177,189 590 - 
BCG+DTP1 217 102 112,240 57,210 - 14,515 38 - 33.8% 3,793 299,990 1,515 - 
BCG+DTP2 213 99 111,119 58,331 - 14,536 58 - 34.4% 3,662 172,357 1,001 - 
BCG+DTP3 192 79 114,338 55,112 - 14,540 62 - 32.5% 3,484 136,944 889 - 
DTP1+DTP2^ 173 82 116,659 52,791 - 14,564 87 - 31.2% 3,285 106,531 609 - 
DTP1+DTP3 164 73 118,007 51,443 - 14,572 94 - 30.4% 3,191 85,499 545 - 
BCG+DTP1+DTP2 321 99 107,522 61,928 - 14,515 38 - 36.5% 5,191 290,268 1,641 - 
BCG+DTP1+DTP3 300 79 105,686 63,764 - 14,515 38 - 37.6% 4,702 230,160 1,689 - 
BCG+DTP2+DTP3 296 79 107,248 62,202 - 14,536 58 - 36.7% 4,765 136,687 1,068 - 
DTP1+DTP2+DTP3^ 250 73 112,738 56,712 - 14,564 87 - 33.5% 4,422 95,149 654 - 
Age-unrestricted (primary)                   
BCG 114 108 133,212 36,238 2,051 14,512 34 14 21.4% 3,154 501,786 1,054 150 
DTP1 117 111 130,918 38,532 6,819 14,584 106 53 22.7% 3,039 89,616 362 129 
BCG+DTP1 227 107 109,103 60,347 3,137 14,527 49 11 35.6% 3,764 255,004 1,234 281 
BCG+DTP2 225 105 107,846 61,604 3,273 14,551 73 15 36.4% 3,657 152,843 843 221 
BCG+DTP3 223 101 109,052 60,397 5,285 14,559 81 19 35.6% 3,692 130,653 743 273 
DTP1+DTP2^ 230 107 106,827 62,623 9,832 14,624 146 59 37.0% 3,680 63,209 429 166 
DTP1+DTP3 226 102 107,822 61,628 10,184 14,632 154 59 36.4% 3,681 56,731 401 171 
BCG+DTP1+DTP2 338 105 103,968 65,482 3,554 14,526 48 10 38.6% 5,163 255,667 1,358 339 
BCG+DTP1+DTP3 335 101 101,179 68,271 4,507 14,526 49 11 40.3% 4,918 241,584 1,400 409 
BCG+DTP2+DTP3 334 101 103,026 66,424 4,222 14,551 73 15 39.2% 5,027 146,921 910 286 
DTP1+DTP2+DTP3^ 339 102 101,863 67,587 10,875 14,623 146 59 39.9% 5,033 60,045 464 184 
Age-unrestricted (booster)                  
BCG+Meas1 222 73 116,456 52,994 - 14,537 60 - 31.3% 4,196 128,271 888 - 
DTP1+Meas1 225 73 114,590 54,860 - 14,609 131 - 32.4% 4,115 45,914 418 - 
BCG+DTP1+Meas1 335 73 100,043 69,407 - 14,527 49 - 41.0% 4,824 173,813 1,422 - 
BCG+DTP2+Meas1 332 73 99,833 69,617 - 14,551 73 - 41.1% 4,779 105,773 953 - 
BCG+DTP3+Meas1 329 72 102,406 67,044 - 14,559 81 - 39.6% 4,915 93,984 826 - 
DTP1+DTP2+Meas1 338 72 98,761 70,689 - 14,623 146 - 41.7% 4,791 42,810 485 - 
DTP1+DTP3+Meas1 333 72 101,139 68,310 - 14,631 154 - 40.3% 4,891 40,444 445 - 
 
^ shaded rows reflect the current WHO recommended schedule options 
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Appendix Table 6. Potential benefits and risks of a standard age-restricted three-dose infant schedule (co-administered with DTP1+DTP2+DTP3) 
compared to age-restricted and age-unrestricted schedules with the highest predicted impact in each country: scenario with the waning function changed 
from a gamma function (more rapid waning) to a power function (more conservative waning) 
 
Country NO VACCINE   
Age-restricted standard 
schedule (DTP1+DTP2+DTP3) 
Age-restricted schedule with the highest predicted 
impact on RVGE deaths<5 years 
Age-unrestricted schedule with the highest predicted 
impact on RVGE deaths<5 years 
  
RVGE 
deaths 
<5 years 
IS 
deaths 
<5 
years 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Schedule with 
highest predicted 
impact 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Schedule with 
highest predicted 
impact 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
ALL 135 LMICs 169,450 14,478 33% 0.6% 654   38% 0.3% 1,374   43% 0.7% 726 
                      
Afghanistan 2,420 296 21% 0.4% 425 BCG-DTP1-DTP3 33% 0.3% 807 BCG-DTP1-DTP3 38% 0.5% 573 
Albania 1 0 59% 1.0% 269 BCG-DTP1-DTP2 75% 0.4% 818 BCG-DTP1-DTP3 77% 0.4% 776 
Algeria 206 48 16% 0.7% 95 BCG-DTP1-DTP3 49% 0.5% 386 BCG-DTP1-Meas1 54% 0.5% 419 
Angola 6,921 125 32% 1.0% 1,723 BCG-DTP1-DTP2 41% 0.3% 7,517 BCG-DTP1-DTP3 43% 0.3% 6,932 
Argentina 36 65 56% 0.8% 37 BCG-DTP1-DTP2 73% 0.3% 142 BCG-DTP1-DTP3 74% 0.3% 129 
Armenia 2 1 41% 0.6% 217 BCG-DTP1-DTP3 75% 0.3% 804 BCG-DTP1-Meas1 76% 0.3% 796 
Azerbaijan 74 7 29% 0.9% 352 BCG-DTP1-DTP3 35% 0.4% 902 BCG-DTP3-Meas1 45% 0.6% 858 
Bangladesh 1,623 11 44% 0.3% 24,273 DTP1-DTP2-DTP3 44% 0.3% 24,273 DTP1-DTP3-Meas1 56% 0.6% 12,338 
Belarus 1 0 33% 0.5% 391 BCG-DTP1-DTP2 89% 0.5% 1,081 BCG-DTP1-Meas1 91% 0.5% 1,047 
Belize 1 0 59% 0.9% 581 BCG-DTP1-DTP2 72% 0.3% 1,921 BCG-DTP1-DTP3 75% 0.4% 1,612 
Benin 1,582 39 42% 0.8% 2,220 BCG-DTP1-DTP3 49% 0.2% 9,766 BCG-DTP2-Meas1 52% 0.4% 5,004 
Bhutan 6 0 42% 0.7% 839 BCG-DTP1-DTP3 48% 0.2% 3,029 BCG-DTP2-Meas1 53% 0.4% 1,692 
Bolivia 253 3 42% 0.9% 3,777 BCG-DTP1-DTP2 52% 0.3% 14,355 BCG-DTP1-DTP3 55% 0.3% 13,769 
Bosnia & Herzegovina 0 0 53% 0.6% 571 BCG-DTP1-DTP3 87% 0.3% 2,101 BCG-DTP1-Meas1 87% 0.3% 2,095 
Botswana 43 3 39% 1.3% 452 BCG-DTP1-DTP3 48% 0.4% 1,866 BCG-DTP2-Meas1 53% 0.7% 1,165 
Brazil 1,032 3 58% 1.5% 13,217 BCG-DTP1-DTP2 75% 0.5% 51,774 BCG-DTP1-DTP3 76% 0.5% 47,776 
Bulgaria 2 0 69% 0.8% 2,103 BCG-DTP1-DTP3 88% 0.3% 6,034 BCG-DTP1-Meas1 89% 0.4% 5,712 
Burkina Faso 2,279 48 43% 1.2% 1,714 BCG-DTP1-DTP3 51% 0.3% 7,602 BCG-DTP2-Meas1 54% 0.6% 4,280 
Burundi 1,606 21 49% 0.9% 4,064 DTP1-DTP2-DTP3 49% 0.9% 4,064 DTP1-DTP3-Meas1 54% 1.2% 3,452 
Cabo Verde 4 1 58% 1.3% 262 BCG-DTP1-DTP2 71% 0.3% 1,224 BCG-DTP1-Meas1 73% 0.4% 1,134 
Cambodia 212 64 41% 0.3% 451 BCG-DTP1-DTP3 43% 0.1% 1,490 BCG-DTP3-Meas1 49% 0.2% 929 
Cameroon 2,967 60 45% 0.8% 2,672 DTP1-DTP2-DTP3 45% 0.8% 2,672 DTP1-DTP2-Meas1 50% 1.1% 2,180 
Central African Republic 928 42 30% 0.6% 1,061 BCG-DTP1-DTP2 39% 0.2% 3,508 BCG-DTP1-DTP3 41% 0.3% 2,874 
Chad 4,309 182 17% 0.4% 1,104 BCG-DTP1-DTP3 26% 0.3% 1,891 BCG-DTP1-Meas1 32% 0.7% 1,134 
China 1,384 414 27% 0.3% 311 BCG-DTP1-DTP2 74% 0.2% 998 BCG-DTP1-Meas1 76% 0.3% 901 
Colombia 152 26 60% 0.9% 409 BCG-DTP1-DTP2 70% 0.2% 2,301 BCG-DTP1-DTP3 70% 0.2% 2,308 
Comoros 39 2 44% 0.9% 853 BCG-DTP1-DTP3 49% 0.2% 4,321 BCG-DTP2-Meas1 52% 0.5% 1,983 
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Congo 252 14 36% 1.0% 622 BCG-DTP1-DTP3 44% 0.3% 2,596 BCG-DTP2-Meas1 47% 0.5% 1,553 
Costa Rica 2 0 83% 0.9% 2,530 DTP1-DTP2-DTP3 83% 0.9% 2,530 DTP1-DTP2-Meas1 86% 1.0% 2,471 
Côte d'Ivoire 2,477 75 43% 0.9% 1,567 DTP1-DTP2-DTP3 43% 0.9% 1,567 DTP1-DTP2-Meas1 52% 1.4% 1,184 
Croatia 0 0 72% 0.8% 432 BCG-DTP1-DTP3 90% 0.3% 1,290 BCG-DTP1-Meas1 92% 0.4% 1,228 
Cuba 3 0 72% 0.9% 760 BCG-DTP1-DTP3 91% 0.3% 2,918 BCG-DTP1-Meas1 93% 0.3% 2,671 
DR Congo 12,377 435 39% 0.7% 1,504 BCG-DTP1-DTP3 40% 0.2% 5,931 DTP1-DTP2-Meas1 46% 1.1% 1,153 
Djibouti 26 2 40% 0.9% 495 BCG-DTP1-DTP3 47% 0.3% 1,739 BCG-DTP2-Meas1 49% 0.5% 1,041 
Dominican Republic 74 9 17% 0.2% 795 BCG-DTP1-DTP3 62% 0.2% 2,872 BCG-DTP1-DTP2 72% 0.2% 2,828 
Ecuador 95 23 47% 0.7% 282 BCG-DTP1-DTP2 65% 0.2% 1,114 BCG-DTP1-DTP3 66% 0.3% 1,009 
Egypt 1,095 98 67% 0.7% 1,016 BCG-DTP1-DTP3 74% 0.0% 119,259 BCG-DTP1-DTP3 74% 0.0% 49,430 
El Salvador 50 5 69% 0.9% 803 BCG-DTP1-DTP3 75% 0.2% 5,294 BCG-DTP1-DTP3 76% 0.2% 5,303 
Equatorial Guinea 42 13 12% 0.3% 152 BCG-DTP1-DTP3 19% 0.1% 648 BCG-DTP1-Meas1 21% 0.1% 558 
Eritrea 269 9 32% 0.9% 1,064 BCG-DTP1-DTP3 36% 0.3% 4,146 DTP1-DTP3-Meas1 43% 1.4% 941 
Ethiopia 5,130 407 24% 0.6% 525 DTP1-DTP2-DTP3 24% 0.6% 525 DTP1-DTP2-Meas1 39% 1.3% 382 
Fiji 7 0 66% 0.3% 3,263 BCG-DTP1-DTP3 75% 0.1% 8,335 BCG-DTP1-Meas1 77% 0.2% 7,573 
Gabon 57 7 36% 0.8% 337 BCG-DTP1-DTP3 44% 0.3% 1,239 BCG-DTP2-Meas1 47% 0.5% 722 
Gambia 130 4 35% 1.3% 941 BCG-DTP1-DTP3 44% 0.4% 3,498 BCG-DTP2-Meas1 52% 0.7% 2,413 
Georgia 2 0 72% 0.8% 2,217 BCG-DTP1-DTP3 88% 0.4% 6,221 BCG-DTP1-Meas1 91% 0.4% 6,019 
Ghana 1,436 56 47% 0.5% 2,614 BCG-DTP1-DTP3 49% 0.1% 17,171 BCG-DTP2-Meas1 52% 0.3% 4,446 
Grenada 0 0 75% 0.7% 2,977 DTP1-DTP2-DTP3 75% 0.7% 2,977 DTP1-DTP2-Meas1 85% 1.0% 2,557 
Guatemala 349 13 36% 0.9% 1,076 BCG-DTP1-DTP2 40% 0.3% 4,231 DTP1-DTP2-Meas1 45% 1.3% 983 
Guinea 1,097 71 25% 0.5% 709 BCG-DTP1-DTP3 34% 0.2% 2,441 BCG-DTP1-Meas1 36% 0.3% 2,090 
Guinea-Bissau 197 4 39% 1.0% 1,930 BCG-DTP1-DTP3 44% 0.3% 6,070 BCG-DTP2-Meas1 49% 0.8% 3,047 
Guyana 11 0 44% 1.0% 3,203 BCG-DTP1-DTP3 49% 0.2% 14,830 BCG-DTP2-Meas1 52% 0.5% 8,195 
Haiti 375 24 26% 0.4% 969 BCG-DTP1-DTP2 34% 0.3% 1,965 BCG-DTP1-DTP3 40% 0.5% 1,212 
Honduras 103 1 50% 1.0% 4,239 BCG-DTP2-DTP3 50% 0.4% 10,202 BCG-DTP1-DTP3 53% 0.2% 23,301 
India 25,839 4,025 35% 0.4% 507 BCG-DTP1-DTP3 38% 0.1% 2,511 DTP1-DTP2-Meas1 41% 0.8% 345 
Indonesia 3,000 157 31% 0.9% 624 BCG-DTP2-DTP3 32% 0.6% 1,036 DTP1-DTP2-Meas1 42% 1.4% 572 
Iran 213 20 59% 1.3% 486 BCG-DTP1-DTP2 75% 0.4% 2,046 BCG-DTP1-DTP3 76% 0.5% 1,845 
Iraq 669 189 30% 1.0% 107 BCG-DTP1-DTP2 43% 0.3% 483 BCG-DTP1-DTP3 44% 0.4% 437 
Jamaica 3 1 64% 0.7% 379 BCG-DTP1-DTP3 75% 0.2% 1,354 BCG-DTP1-DTP3 76% 0.3% 1,203 
Jordan 25 5 25% 0.7% 171 BCG-DTP1-DTP2 72% 0.6% 624 BCG-DTP1-DTP3 73% 0.6% 583 
Kazakhstan 46 5 56% 0.8% 728 BCG-DTP2-DTP3 75% 0.3% 2,200 DTP1-DTP2-DTP3 75% 1.3% 594 
Kenya 1,986 90 46% 0.4% 2,442 DTP1-DTP2-DTP3 46% 0.4% 2,442 DTP1-DTP3-Meas1 51% 0.7% 1,551 
Kiribati 4 0 34% 0.2% 1,134 BCG-DTP1-DTP3 38% 0.1% 2,924 DTP1-DTP3-Meas1 42% 0.4% 940 
Kyrgyzstan 45 3 64% 0.9% 1,050 BCG-DTP1-DTP3 75% 0.3% 4,406 BCG-DTP1-DTP3 76% 0.3% 4,417 
Lao PDR 431 54 25% 0.2% 880 BCG-DTP2-DTP3 30% 0.2% 1,312 DTP1-DTP2-Meas1 45% 0.5% 652 
Lebanon 5 0 61% 1.2% 607 DTP1-DTP2-DTP3 61% 1.2% 607 DTP1-DTP2-Meas1 76% 1.8% 511 
Lesotho 187 3 50% 0.8% 3,383 BCG-DTP1-DTP3 50% 0.2% 18,196 DTP1-DTP3-Meas1 54% 1.1% 2,893 
Liberia 443 16 33% 0.7% 1,264 BCG-DTP1-DTP3 36% 0.2% 5,009 BCG-DTP1-Meas1 39% 0.2% 4,780 
Libya 8 3 41% 1.3% 91 BCG-DTP1-DTP2 51% 0.4% 371 BCG-DTP1-DTP3 55% 0.5% 350 
Madagascar 1,696 109 27% 0.6% 684 BCG-DTP1-DTP3 32% 0.3% 1,795 DTP1-DTP2-Meas1 40% 1.4% 433 
Malawi 1,556 35 50% 0.9% 2,596 BCG-DTP1-DTP3 50% 0.2% 13,367 DTP1-DTP2-Meas1 52% 0.9% 2,526 
Malaysia 17 0 73% 0.9% 22,634 BCG-DTP1-DTP3 91% 0.3% 90,077 BCG-DTP1-Meas1 93% 0.3% 79,951 
Maldives 0 0 72% 1.0% 1,067 BCG-DTP1-DTP3 91% 0.3% 4,604 BCG-DTP1-Meas1 93% 0.4% 4,088 
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Mali 2,438 83 29% 0.6% 1,375 BCG-DTP1-DTP3 40% 0.4% 2,885 BCG-DTP1-Meas1 46% 0.7% 1,926 
Marshall Islands 1 0 38% 0.4% 10,014 BCG-DTP1-DTP2 48% 0.2% 29,186 BCG-DTP1-DTP3 51% 0.2% 28,403 
Mauritania 400 12 33% 0.7% 1,618 BCG-DTP1-DTP3 42% 0.3% 4,404 BCG-DTP1-Meas1 45% 0.4% 3,483 
Mauritius 1 1 65% 0.9% 137 BCG-DTP1-DTP3 73% 0.5% 287 BCG-DTP1-Meas1 76% 0.6% 243 
Mexico 626 142 59% 0.8% 334 BCG-DTP1-DTP2 76% 0.2% 1,485 BCG-DTP1-DTP3 76% 0.2% 1,471 
Micronesia (FSO) 1 0 38% 0.4% 389 DTP1-DTP2-DTP3 38% 0.4% 389 DTP1-DTP2-Meas1 47% 0.5% 350 
Mongolia 9 3 75% 0.4% 635 BCG-DTP1-DTP3 78% 0.1% 2,668 BCG-DTP1-Meas1 78% 0.1% 2,673 
Montenegro 0 0 68% 0.8% 480 BCG-DTP1-DTP2 81% 0.3% 1,494 DTP1-DTP2-Meas1 85% 1.2% 428 
Morocco 604 9 39% 1.3% 2,030 BCG-DTP1-DTP3 49% 0.7% 4,657 BCG-DTP1-Meas1 53% 0.8% 4,337 
Mozambique 2,160 84 33% 0.9% 920 BCG-DTP1-DTP3 47% 0.4% 3,270 BCG-DTP1-Meas1 51% 0.4% 2,951 
Myanmar 818 82 37% 1.0% 374 BCG-DTP2-DTP3 43% 0.5% 819 DTP1-DTP2-Meas1 50% 1.5% 338 
Namibia 108 6 46% 0.7% 1,054 DTP1-DTP2-DTP3 46% 0.7% 1,054 DTP1-DTP3-Meas1 51% 1.0% 883 
Nepal 258 42 41% 0.6% 402 BCG-DTP1-DTP3 44% 0.2% 1,532 BCG-DTP2-Meas1 48% 0.5% 599 
Nicaragua 53 0 59% 0.9% 7,624 BCG-DTP1-DTP2 74% 0.3% 30,022 BCG-DTP1-DTP3 76% 0.3% 27,973 
Niger 4,557 94 38% 0.8% 2,206 BCG-DTP1-DTP3 39% 0.2% 10,147 DTP1-DTP2-Meas1 44% 1.1% 1,861 
Nigeria 35,129 2,103 24% 1.1% 369 BCG-DTP1-DTP3 28% 0.8% 587 BCG-DTP1-Meas1 33% 1.0% 547 
North Korea 151 17 64% 0.7% 794 BCG-DTP1-DTP3 74% 0.2% 2,900 BCG-DTP1-Meas1 75% 0.3% 2,437 
Pakistan 7,694 971 30% 0.6% 417 BCG-DTP1-DTP3 39% 0.3% 1,140 BCG-DTP1-DTP3 42% 0.5% 699 
Panama 25 1 57% 0.9% 1,541 BCG-DTP1-DTP2 75% 0.3% 6,021 BCG-DTP1-Meas1 76% 0.3% 5,471 
Papua New Guinea 191 89 37% 0.2% 329 BCG-DTP1-DTP3 39% 0.1% 787 BCG-DTP1-Meas1 42% 0.1% 800 
Paraguay 41 3 40% 0.9% 593 BCG-DTP1-DTP2 48% 0.3% 2,213 BCG-DTP1-DTP3 52% 0.3% 2,144 
Peru 144 8 45% 1.0% 852 BCG-DTP1-DTP2 45% 0.2% 4,373 DTP1-DTP2-Meas1 50% 1.1% 858 
Philippines 1,893 811 29% 0.2% 303 BCG-DTP1-DTP3 36% 0.1% 759 BCG-DTP1-Meas1 40% 0.1% 750 
Republic of Moldova 1 1 50% 0.7% 65 BCG-DTP1-DTP3 72% 0.3% 269 BCG-DTP1-DTP3 73% 0.3% 268 
Romania 8 0 70% 0.8% 2,716 BCG-DTP1-DTP2 90% 0.4% 8,099 BCG-DTP1-DTP3 92% 0.4% 7,669 
Russian Federation 54 3 32% 0.5% 1,301 BCG-DTP1-DTP3 88% 0.5% 3,772 BCG-DTP1-Meas1 89% 0.5% 3,640 
Rwanda 700 19 44% 0.7% 2,261 BCG-DTP1-DTP3 45% 0.1% 13,597 BCG-DTP3-Meas1 51% 0.6% 3,193 
Saint Lucia 0 0 59% 0.9% 371 BCG-DTP1-DTP3 67% 0.6% 684 BCG-DTP1-DTP3 75% 0.7% 579 
Saint Vincent & the Gr. 0 0 59% 0.9% 680 BCG-DTP1-DTP2 75% 0.3% 2,654 BCG-DTP1-DTP3 77% 0.3% 2,421 
Samoa 0 1 58% 0.3% 64 BCG-DTP1-DTP3 63% 0.1% 177 BCG-DTP1-Meas1 64% 0.1% 174 
Sao Tome and Principe 7 0 47% 0.8% 1,291 BCG-DTP1-DTP3 47% 0.1% 9,669 DTP1-DTP3-Meas1 53% 1.0% 1,126 
Senegal 876 34 38% 1.0% 1,022 BCG-DTP1-DTP3 44% 0.3% 3,558 BCG-DTP1-Meas1 47% 0.5% 2,728 
Serbia 1 0 74% 0.9% 837 BCG-DTP1-DTP3 92% 0.3% 3,467 BCG-DTP1-Meas1 92% 0.3% 3,478 
Sierra Leone 1,263 15 41% 0.8% 3,984 BCG-DTP1-DTP3 44% 0.2% 17,580 DTP1-DTP2-Meas1 48% 1.2% 3,273 
Solomon Islands 9 1 42% 0.3% 1,380 BCG-DTP1-DTP3 47% 0.1% 3,547 DTP1-DTP3-Meas1 51% 0.5% 1,134 
Somalia 2,432 415 23% 0.5% 257 DTP1-DTP2-DTP3 23% 0.5% 257 DTP1-DTP2-Meas1 27% 0.7% 223 
South Africa 1,734 267 41% 0.8% 331 DTP1-DTP2-DTP3 41% 0.8% 331 DTP1-DTP2-Meas1 45% 1.1% 258 
South Sudan 937 102 17% 0.4% 422 BCG-DTP1-DTP3 20% 0.1% 1,667 BCG-DTP1-DTP3 21% 0.1% 1,432 
Sri Lanka 11 1 74% 1.0% 1,012 BCG-DTP1-DTP3 92% 0.3% 4,292 BCG-DTP1-Meas1 94% 0.3% 3,819 
Sudan 2,726 30 42% 0.9% 4,253 DTP1-DTP2-DTP3 42% 0.9% 4,253 DTP1-DTP2-Meas1 51% 1.3% 3,448 
Suriname 1 0 35% 0.4% 238 DTP1-DTP2-DTP3 35% 0.4% 238 DTP1-DTP2-Meas1 61% 1.1% 168 
Swaziland 77 2 49% 0.6% 3,022 BCG-DTP1-DTP3 51% 0.1% 22,551 BCG-DTP2-Meas1 53% 0.3% 7,219 
Syrian Arab Republic 80 136 36% 0.8% 28 BCG-DTP1-DTP2 49% 0.3% 115 BCG-DTP1-Meas1 50% 0.3% 103 
Tajikistan 236 5 36% 0.7% 2,289 BCG-DTP1-DTP3 49% 0.4% 6,182 BCG-DTP2-Meas1 53% 0.5% 5,249 
Tanzania 2,880 109 51% 0.6% 2,183 DTP1-DTP2-DTP3 51% 0.6% 2,183 DTP1-DTP3-Meas1 57% 1.0% 1,491 
234 
 
TFYR Macedonia 1 0 38% 0.6% 1,478 BCG-DTP1-DTP2 86% 0.4% 4,462 BCG-DTP1-Meas1 88% 0.4% 4,318 
Thailand 65 1 72% 1.7% 3,444 BCG-DTP1-DTP3 91% 0.5% 13,734 BCG-DTP1-Meas1 93% 0.6% 12,726 
Timor-Leste 90 9 32% 0.5% 599 BCG-DTP1-DTP3 37% 0.3% 1,498 BCG-DTP2-Meas1 43% 0.6% 805 
Togo 609 17 45% 0.9% 1,869 DTP1-DTP2-DTP3 45% 0.9% 1,869 DTP1-DTP2-Meas1 49% 0.9% 1,834 
Tonga 0 1 57% 0.3% 64 BCG-DTP1-DTP3 61% 0.1% 174 DTP1-DTP2-Meas1 63% 0.4% 54 
Tunisia 15 3 69% 2.0% 204 BCG-DTP1-DTP3 76% 0.4% 1,095 BCG-DTP1-DTP3 76% 0.4% 1,097 
Turkey 53 21 58% 0.9% 165 BCG-DTP1-DTP3 65% 0.5% 302 BCG-DTP1-DTP3 73% 0.6% 281 
Turkmenistan 89 2 39% 0.9% 2,478 BCG-DTP1-DTP3 48% 0.4% 6,837 BCG-DTP2-Meas1 52% 0.5% 5,699 
Tuvalu 0 0 40% 0.3% 801 BCG-DTP1-DTP3 46% 0.1% 2,033 BCG-DTP2-Meas1 50% 0.2% 1,532 
Uganda 2,478 150 37% 0.9% 697 BCG-DTP1-DTP3 42% 0.3% 2,158 BCG-DTP2-Meas1 48% 0.7% 1,226 
Ukraine 13 1 21% 0.2% 1,735 BCG-DTP1-DTP2 37% 0.1% 6,105 DTP1-DTP2-Meas1 48% 0.8% 1,251 
Uzbekistan 181 4 36% 1.3% 1,221 BCG-DTP1-DTP3 45% 0.6% 3,477 BCG-DTP2-Meas1 51% 0.6% 3,481 
Vanuatu 5 5 32% 0.2% 137 BCG-DTP1-DTP3 35% 0.1% 355 DTP1-DTP2-Meas1 36% 0.3% 120 
Venezuela 273 36 57% 1.1% 393 BCG-DTP1-DTP2 75% 0.3% 1,804 BCG-DTP1-DTP3 76% 0.4% 1,557 
Viet Nam 365 854 30% 0.1% 167 BCG-DTP1-DTP3 65% 0.1% 280 BCG-DTP1-DTP2 75% 0.1% 226 
Yemen 1,434 170 30% 0.7% 373 DTP1-DTP2-DTP3 30% 0.7% 373 DTP1-DTP2-Meas1 40% 1.2% 271 
Zambia 1,235 21 45% 0.6% 4,118 BCG-DTP1-DTP3 50% 0.2% 15,338 BCG-DTP1-DTP3 54% 0.3% 10,532 
Zimbabwe 1,295 29 46% 0.7% 3,049 DTP1-DTP2-DTP3 46% 0.7% 3,049 DTP1-DTP2-Meas1 50% 0.7% 3,190 
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Appendix Table 7. Potential benefits and risks of alternative rotavirus vaccination schedule options if used in all 135 low- and middle-income countries: 
scenario assuming all doses given as part of a neonatal schedule have double the mean duration of protection as doses given as part of a non-neonatal schedule 
Schedule Doses   RVGE deaths <5 years   Intussusception deaths <5 years Summary indicators   
Vaccines in the existing 
schedule that rotavirus 
would be co-administered 
with 
Total 
doses 
(millions) 
Fully 
vaccinated 
children 
(FVC) 
(millions) Number Averted 
Incremental 
number 
averted vs 
age-restricted Number 
Excess 
vs no 
vaccine 
Incremental 
excess 
number vs 
age-restricted 
% 
reduction 
in RVGE 
deaths 
Doses 
per RVGE 
death 
averted 
Number 
of FVC 
per 
excess IS 
case 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Incremental 
RVGE deaths 
averted per 
excess IS 
death vs age-
restricted 
NO VACCINE 0 0 169,450 - - 14,478 - - - - - - - 
Age-restricted (primary)                  
BCG 109 104 129,991 39,459 - 14,498 21 - 23.3% 2,764 838,053 1,907 - 
DTP1 87 82 141,323 28,126 - 14,531 54 - 16.6% 3,085 177,189 524 - 
BCG+DTP1 217 102 103,769 65,680 - 14,515 38 - 38.8% 3,304 299,990 1,740 - 
BCG+DTP2 213 99 102,779 66,671 - 14,536 58 - 39.3% 3,203 172,357 1,144 - 
BCG+DTP3 192 79 106,485 62,965 - 14,540 62 - 37.2% 3,049 136,944 1,016 - 
DTP1+DTP2^ 173 82 120,829 48,621 - 14,564 87 - 28.7% 3,567 106,531 561 - 
DTP1+DTP3 164 73 121,110 48,340 - 14,572 94 - 28.5% 3,397 85,499 512 - 
BCG+DTP1+DTP2 321 99 98,947 70,502 - 14,515 38 - 41.6% 4,559 290,268 1,868 - 
BCG+DTP1+DTP3 300 79 96,912 72,538 - 14,515 38 - 42.8% 4,133 230,160 1,922 - 
BCG+DTP2+DTP3 296 79 98,884 70,566 - 14,536 58 - 41.6% 4,200 136,687 1,211 - 
DTP1+DTP2+DTP3^ 250 73 115,469 53,981 - 14,564 87 - 31.9% 4,646 95,149 623 - 
Age-unrestricted (primary)                   
BCG 114 108 127,594 41,855 2,396 14,512 34 14 24.7% 2,730 501,786 1,217 175 
DTP1 117 111 134,966 34,484 6,357 14,584 106 53 20.4% 3,397 89,616 324 121 
BCG+DTP1 227 107 100,130 69,320 3,639 14,527 49 11 40.9% 3,277 255,004 1,417 326 
BCG+DTP2 225 105 99,012 70,438 3,767 14,551 73 15 41.6% 3,198 152,843 964 254 
BCG+DTP3 223 101 100,427 69,023 6,058 14,559 81 19 40.7% 3,230 130,653 849 313 
DTP1+DTP2^ 230 107 111,331 58,119 9,498 14,624 146 59 34.3% 3,966 63,209 398 160 
DTP1+DTP3 226 102 111,080 58,370 10,030 14,632 154 59 34.4% 3,887 56,731 380 169 
BCG+DTP1+DTP2 338 105 94,895 74,555 4,053 14,526 48 10 44.0% 4,534 255,667 1,546 387 
BCG+DTP1+DTP3 335 101 91,758 77,692 5,154 14,526 49 11 45.8% 4,321 241,584 1,593 468 
BCG+DTP2+DTP3 334 101 94,111 75,339 4,773 14,551 73 15 44.5% 4,432 146,921 1,032 324 
DTP1+DTP2+DTP3^ 339 102 104,501 64,949 10,968 14,623 146 59 38.3% 5,238 60,045 446 186 
Age-unrestricted (booster)                  
BCG+Meas1 222 73 108,445 61,005 - 14,537 60 - 36.0% 3,644 128,271 1,023 - 
DTP1+Meas1 225 73 116,653 52,797 - 14,609 131 - 31.2% 4,276 45,914 403 - 
BCG+DTP1+Meas1 335 73 89,759 79,691 - 14,527 49 - 47.0% 4,201 173,813 1,633 - 
BCG+DTP2+Meas1 332 73 89,975 79,475 - 14,551 73 - 46.9% 4,186 105,773 1,088 - 
BCG+DTP3+Meas1 329 72 93,080 76,369 - 14,559 81 - 45.1% 4,314 93,984 941 - 
DTP1+DTP2+Meas1 338 72 99,777 69,673 - 14,623 146 - 41.1% 4,861 42,810 478 - 
DTP1+DTP3+Meas1 333 72 101,489 67,961 - 14,631 154 - 40.1% 4,916 40,444 442 - 
 
^ shaded rows reflect the current WHO recommended schedule options 
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Appendix Table 8. Potential benefits and risks of a standard age-restricted three-dose infant schedule (co-administered with DTP1+DTP2+DTP3) 
compared to age-restricted and age-unrestricted schedules with the highest predicted impact in each country: scenario assuming all doses given as part 
of a neonatal schedule have double the mean duration of protection as doses given as part of a non-neonatal schedule 
 
Country NO VACCINE   
Age-restricted standard 
schedule (DTP1+DTP2+DTP3) 
Age-restricted schedule with the highest predicted 
impact on RVGE deaths<5 years 
Age-unrestricted schedule with the highest predicted 
impact on RVGE deaths<5 years 
  
RVGE 
deaths 
<5 years 
IS 
deaths 
<5 
years 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Schedule with 
highest predicted 
impact 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Schedule with 
highest predicted 
impact 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
ALL 135 LMICs 169,450 14,478 32% 0.6% 623   43% 0.3% 1,526   48% 0.5% 1,147 
                      
Afghanistan 2,420 296 21% 0.4% 411 BCG-DTP1-DTP3 39% 0.3% 942 BCG-DTP1-DTP3 44% 0.5% 662 
Albania 1 0 59% 1.0% 270 BCG-DTP1-DTP2 78% 0.4% 852 BCG-DTP1-DTP3 81% 0.4% 819 
Algeria 206 48 16% 0.7% 90 BCG-DTP1-DTP3 58% 0.5% 453 BCG-DTP1-Meas1 62% 0.5% 488 
Angola 6,921 125 31% 1.0% 1,685 BCG-DTP1-DTP2 47% 0.3% 8,739 BCG-DTP1-DTP3 50% 0.3% 8,036 
Argentina 36 65 56% 0.8% 37 BCG-DTP1-DTP2 76% 0.3% 148 BCG-DTP1-DTP3 78% 0.3% 136 
Armenia 2 1 38% 0.6% 200 BCG-DTP1-DTP3 74% 0.3% 792 BCG-DTP1-Meas1 79% 0.3% 819 
Azerbaijan 74 7 24% 0.9% 301 BCG-DTP1-DTP3 43% 0.4% 1,099 BCG-DTP2-Meas1 53% 0.6% 1,060 
Bangladesh 1,623 11 40% 0.3% 22,196 BCG-DTP1-DTP3 51% 0.0% 209,062 BCG-DTP3-Meas1 65% 0.7% 13,028 
Belarus 1 0 32% 0.5% 380 BCG-DTP1-DTP3 89% 0.5% 1,091 BCG-DTP1-Meas1 92% 0.5% 1,063 
Belize 1 0 59% 0.9% 583 BCG-DTP1-DTP2 75% 0.3% 2,001 BCG-DTP1-DTP3 79% 0.4% 1,699 
Benin 1,582 39 41% 0.8% 2,147 BCG-DTP1-DTP3 58% 0.2% 11,494 BCG-DTP2-Meas1 60% 0.4% 5,828 
Bhutan 6 0 40% 0.7% 790 BCG-DTP1-DTP3 56% 0.2% 3,573 BCG-DTP2-Meas1 62% 0.4% 1,968 
Bolivia 253 3 41% 0.9% 3,701 BCG-DTP1-DTP2 60% 0.3% 16,662 BCG-DTP1-DTP3 64% 0.3% 15,884 
Bosnia & Herzegovina 0 0 52% 0.6% 557 BCG-DTP1-DTP3 87% 0.3% 2,121 BCG-DTP1-Meas1 89% 0.3% 2,126 
Botswana 43 3 37% 1.3% 430 BCG-DTP1-DTP3 56% 0.4% 2,194 BCG-DTP1-Meas1 61% 0.4% 2,080 
Brazil 1,032 3 58% 1.5% 13,263 BCG-DTP1-DTP2 78% 0.5% 53,930 BCG-DTP1-DTP3 80% 0.5% 50,391 
Bulgaria 2 0 67% 0.8% 2,048 BCG-DTP1-DTP3 89% 0.3% 6,090 BCG-DTP1-Meas1 91% 0.4% 5,801 
Burkina Faso 2,279 48 42% 1.2% 1,653 BCG-DTP1-DTP3 59% 0.3% 8,840 BCG-DTP1-Meas1 62% 0.4% 8,155 
Burundi 1,606 21 47% 0.9% 3,898 BCG-DTP1-DTP3 56% 0.2% 23,832 BCG-DTP2-Meas1 60% 0.5% 9,875 
Cabo Verde 4 1 58% 1.3% 262 BCG-DTP1-DTP2 74% 0.3% 1,275 BCG-DTP1-Meas1 77% 0.4% 1,200 
Cambodia 212 64 38% 0.3% 411 BCG-DTP1-DTP3 51% 0.1% 1,788 BCG-DTP3-Meas1 57% 0.2% 1,086 
Cameroon 2,967 60 44% 0.8% 2,633 BCG-DTP1-DTP3 45% 0.1% 16,442 DTP1-DTP2-Meas1 50% 1.1% 2,172 
Central African Republic 928 42 30% 0.6% 1,058 BCG-DTP1-DTP2 45% 0.2% 4,057 BCG-DTP1-DTP3 47% 0.3% 3,320 
Chad 4,309 182 16% 0.4% 1,065 BCG-DTP1-DTP3 31% 0.3% 2,216 BCG-DTP1-Meas1 37% 0.7% 1,318 
China 1,384 414 26% 0.3% 304 BCG-DTP1-DTP3 77% 0.2% 1,031 BCG-DTP1-Meas1 80% 0.3% 948 
Colombia 152 26 61% 0.9% 410 BCG-DTP1-DTP2 73% 0.2% 2,395 BCG-DTP1-DTP3 74% 0.2% 2,431 
Comoros 39 2 43% 0.9% 821 BCG-DTP1-DTP3 57% 0.2% 5,060 BCG-DTP2-Meas1 60% 0.5% 2,296 
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Congo 252 14 35% 1.0% 600 BCG-DTP1-DTP3 52% 0.3% 3,017 BCG-DTP1-Meas1 54% 0.3% 2,768 
Costa Rica 2 0 81% 0.9% 2,471 DTP1-DTP2-DTP3 81% 0.9% 2,471 DTP1-DTP2-Meas1 85% 1.0% 2,453 
Côte d'Ivoire 2,477 75 42% 0.9% 1,521 BCG-DTP1-DTP3 47% 0.2% 8,941 DTP1-DTP2-Meas1 51% 1.4% 1,167 
Croatia 0 0 70% 0.8% 421 BCG-DTP1-DTP3 91% 0.3% 1,303 BCG-DTP1-Meas1 94% 0.4% 1,247 
Cuba 3 0 71% 0.9% 742 BCG-DTP1-DTP3 92% 0.3% 2,946 BCG-DTP1-Meas1 95% 0.3% 2,712 
DR Congo 12,377 435 38% 0.7% 1,480 BCG-DTP1-DTP3 47% 0.2% 6,865 BCG-DTP2-Meas1 49% 0.5% 3,119 
Djibouti 26 2 39% 0.9% 476 BCG-DTP1-DTP3 55% 0.3% 2,032 BCG-DTP1-Meas1 57% 0.4% 1,822 
Dominican Republic 74 9 17% 0.2% 790 BCG-DTP1-DTP3 64% 0.2% 2,947 BCG-DTP1-DTP2 74% 0.2% 2,912 
Ecuador 95 23 48% 0.7% 283 BCG-DTP1-DTP2 67% 0.2% 1,159 BCG-DTP1-Meas1 69% 0.3% 1,063 
Egypt 1,095 98 70% 0.7% 1,066 BCG-DTP1-DTP3 80% 0.0% 128,169 BCG-DTP1-DTP3 80% 0.0% 53,241 
El Salvador 50 5 69% 0.9% 809 BCG-DTP1-DTP3 79% 0.2% 5,530 BCG-DTP1-Meas1 79% 0.2% 5,572 
Equatorial Guinea 42 13 11% 0.3% 146 BCG-DTP1-DTP3 23% 0.1% 772 BCG-DTP1-Meas1 24% 0.1% 660 
Eritrea 269 9 28% 0.9% 916 BCG-DTP1-DTP3 44% 0.3% 5,039 BCG-DTP2-Meas1 51% 0.5% 2,873 
Ethiopia 5,130 407 22% 0.6% 481 BCG-DTP1-DTP3 27% 0.2% 1,572 BCG-DTP2-Meas1 41% 0.9% 582 
Fiji 7 0 65% 0.3% 3,228 BCG-DTP1-DTP3 78% 0.1% 8,659 BCG-DTP1-Meas1 81% 0.2% 7,959 
Gabon 57 7 33% 0.8% 316 BCG-DTP1-DTP3 52% 0.3% 1,469 BCG-DTP2-Meas1 56% 0.5% 847 
Gambia 130 4 33% 1.3% 868 BCG-DTP1-DTP3 53% 0.4% 4,169 BCG-DTP2-Meas1 60% 0.7% 2,814 
Georgia 2 0 70% 0.8% 2,157 BCG-DTP1-DTP3 89% 0.4% 6,277 BCG-DTP1-Meas1 92% 0.4% 6,111 
Ghana 1,436 56 44% 0.5% 2,492 BCG-DTP1-DTP3 57% 0.1% 20,099 BCG-DTP2-Meas1 61% 0.3% 5,161 
Grenada 0 0 73% 0.7% 2,906 DTP1-DTP2-DTP3 73% 0.7% 2,906 DTP1-DTP2-Meas1 85% 1.0% 2,536 
Guatemala 349 13 33% 0.9% 1,013 BCG-DTP1-DTP2 47% 0.3% 4,970 BCG-DTP2-Meas1 51% 0.5% 2,738 
Guinea 1,097 71 24% 0.5% 682 BCG-DTP1-DTP3 40% 0.2% 2,861 BCG-DTP1-Meas1 42% 0.3% 2,452 
Guinea-Bissau 197 4 37% 1.0% 1,849 BCG-DTP1-DTP3 51% 0.3% 7,108 BCG-DTP1-Meas1 57% 0.5% 5,733 
Guyana 11 0 42% 1.0% 3,084 BCG-DTP1-DTP3 57% 0.2% 17,459 BCG-DTP2-Meas1 61% 0.5% 9,545 
Haiti 375 24 25% 0.4% 934 BCG-DTP1-DTP2 40% 0.3% 2,299 BCG-DTP1-DTP3 47% 0.5% 1,410 
Honduras 103 1 48% 1.0% 4,085 BCG-DTP1-DTP3 59% 0.2% 26,225 BCG-DTP1-DTP3 61% 0.2% 27,180 
India 25,839 4,025 31% 0.4% 450 BCG-DTP2-DTP3 39% 0.3% 821 BCG-DTP2-Meas1 44% 0.3% 807 
Indonesia 3,000 157 27% 0.9% 554 BCG-DTP2-DTP3 38% 0.6% 1,245 BCG-DTP2-Meas1 45% 0.7% 1,305 
Iran 213 20 59% 1.3% 486 BCG-DTP1-DTP2 78% 0.4% 2,125 BCG-DTP1-Meas1 81% 0.5% 1,944 
Iraq 669 189 29% 1.0% 106 BCG-DTP1-DTP2 49% 0.3% 555 BCG-DTP1-DTP3 51% 0.4% 503 
Jamaica 3 1 64% 0.7% 380 BCG-DTP1-DTP3 78% 0.2% 1,406 BCG-DTP1-DTP3 80% 0.3% 1,266 
Jordan 25 5 26% 0.7% 178 BCG-DTP1-DTP3 77% 0.6% 671 BCG-DTP1-DTP3 79% 0.6% 632 
Kazakhstan 46 5 55% 0.8% 718 BCG-DTP2-DTP3 77% 0.3% 2,281 BCG-DTP2-DTP3 79% 0.3% 2,319 
Kenya 1,986 90 43% 0.4% 2,295 BCG-DTP1-DTP3 50% 0.0% 28,825 BCG-DTP3-Meas1 56% 0.5% 2,251 
Kiribati 4 0 32% 0.2% 1,068 BCG-DTP1-DTP3 45% 0.1% 3,451 BCG-DTP2-Meas1 49% 0.2% 2,533 
Kyrgyzstan 45 3 64% 0.9% 1,049 BCG-DTP1-DTP3 79% 0.3% 4,591 BCG-DTP1-Meas1 80% 0.3% 4,653 
Lao PDR 431 54 23% 0.2% 783 BCG-DTP2-DTP3 36% 0.2% 1,581 BCG-DTP2-Meas1 48% 0.3% 1,367 
Lebanon 5 0 60% 1.2% 592 DTP1-DTP2-DTP3 60% 1.2% 592 DTP1-DTP2-Meas1 75% 1.8% 504 
Lesotho 187 3 48% 0.8% 3,237 BCG-DTP1-DTP3 59% 0.2% 21,349 BCG-DTP2-Meas1 63% 0.5% 7,448 
Liberia 443 16 32% 0.7% 1,216 BCG-DTP1-DTP3 42% 0.2% 5,895 BCG-DTP1-Meas1 46% 0.2% 5,607 
Libya 8 3 40% 1.3% 89 BCG-DTP1-DTP2 60% 0.4% 430 BCG-DTP1-DTP3 63% 0.5% 404 
Madagascar 1,696 109 26% 0.6% 662 BCG-DTP1-DTP3 38% 0.3% 2,092 BCG-DTP2-Meas1 43% 0.7% 985 
Malawi 1,556 35 49% 0.9% 2,561 BCG-DTP1-DTP3 58% 0.2% 15,381 BCG-DTP2-Meas1 60% 0.5% 5,704 
Malaysia 17 0 71% 0.9% 22,079 BCG-DTP1-DTP3 92% 0.3% 90,927 BCG-DTP1-Meas1 94% 0.3% 80,968 
Maldives 0 0 71% 1.0% 1,041 BCG-DTP1-DTP3 92% 0.3% 4,648 BCG-DTP1-Meas1 94% 0.4% 4,145 
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Mali 2,438 83 28% 0.6% 1,322 BCG-DTP1-DTP3 47% 0.4% 3,377 BCG-DTP1-Meas1 53% 0.7% 2,246 
Marshall Islands 1 0 36% 0.4% 9,620 BCG-DTP1-DTP2 56% 0.2% 34,296 BCG-DTP1-DTP3 60% 0.2% 33,154 
Mauritania 400 12 31% 0.7% 1,558 BCG-DTP1-DTP3 49% 0.3% 5,140 BCG-DTP1-Meas1 52% 0.4% 4,074 
Mauritius 1 1 59% 0.9% 123 BCG-DTP1-DTP3 71% 0.5% 280 BCG-DTP1-Meas1 77% 0.6% 247 
Mexico 626 142 58% 0.8% 332 BCG-DTP1-DTP2 79% 0.2% 1,541 BCG-DTP1-Meas1 80% 0.2% 1,548 
Micronesia (FSO) 1 0 36% 0.4% 373 BCG-DTP1-DTP2 44% 0.1% 1,487 BCG-DTP2-Meas1 47% 0.2% 974 
Mongolia 9 3 77% 0.4% 649 BCG-DTP1-DTP3 82% 0.1% 2,833 BCG-DTP1-Meas1 83% 0.1% 2,867 
Montenegro 0 0 67% 0.8% 468 BCG-DTP1-DTP2 82% 0.3% 1,508 DTP1-DTP2-Meas1 84% 1.2% 423 
Morocco 604 9 38% 1.3% 1,971 BCG-DTP1-DTP3 57% 0.7% 5,379 BCG-DTP1-Meas1 61% 0.8% 5,018 
Mozambique 2,160 84 32% 0.9% 891 BCG-DTP1-DTP3 55% 0.4% 3,819 BCG-DTP1-Meas1 59% 0.4% 3,436 
Myanmar 818 82 34% 1.0% 350 BCG-DTP2-DTP3 51% 0.5% 971 BCG-DTP2-Meas1 58% 0.6% 990 
Namibia 108 6 42% 0.7% 979 BCG-DTP1-DTP3 53% 0.1% 9,628 BCG-DTP2-Meas1 58% 0.3% 3,219 
Nepal 258 42 39% 0.6% 384 BCG-DTP1-DTP3 51% 0.2% 1,772 BCG-DTP1-Meas1 55% 0.2% 1,670 
Nicaragua 53 0 59% 0.9% 7,651 BCG-DTP1-DTP2 77% 0.3% 31,272 BCG-DTP1-DTP3 80% 0.3% 29,510 
Niger 4,557 94 36% 0.8% 2,125 BCG-DTP1-DTP3 45% 0.2% 11,902 BCG-DTP2-Meas1 49% 0.4% 5,390 
Nigeria 35,129 2,103 23% 1.1% 353 BCG-DTP1-DTP3 33% 0.8% 692 BCG-DTP1-Meas1 38% 1.0% 643 
North Korea 151 17 64% 0.7% 785 BCG-DTP1-DTP3 77% 0.2% 3,013 BCG-DTP1-Meas1 79% 0.3% 2,575 
Pakistan 7,694 971 29% 0.6% 402 BCG-DTP1-DTP3 45% 0.3% 1,321 BCG-DTP1-Meas1 49% 0.5% 813 
Panama 25 1 57% 0.9% 1,543 BCG-DTP1-DTP2 78% 0.3% 6,264 BCG-DTP1-Meas1 80% 0.3% 5,763 
Papua New Guinea 191 89 34% 0.2% 309 BCG-DTP1-DTP3 46% 0.1% 933 BCG-DTP1-Meas1 50% 0.1% 939 
Paraguay 41 3 38% 0.9% 570 BCG-DTP1-DTP2 57% 0.3% 2,599 BCG-DTP1-DTP3 61% 0.3% 2,498 
Peru 144 8 43% 1.0% 817 BCG-DTP1-DTP2 53% 0.2% 5,140 BCG-DTP2-Meas1 57% 0.4% 2,543 
Philippines 1,893 811 28% 0.2% 286 BCG-DTP1-DTP3 42% 0.1% 900 BCG-DTP1-Meas1 47% 0.1% 880 
Republic of Moldova 1 1 50% 0.7% 66 BCG-DTP1-DTP3 75% 0.3% 281 BCG-DTP1-DTP3 76% 0.3% 282 
Romania 8 0 68% 0.8% 2,638 BCG-DTP1-DTP2 91% 0.4% 8,173 BCG-DTP1-DTP3 93% 0.4% 7,781 
Russian Federation 54 3 31% 0.5% 1,275 BCG-DTP1-DTP3 89% 0.5% 3,815 BCG-DTP1-Meas1 91% 0.5% 3,701 
Rwanda 700 19 40% 0.7% 2,060 BCG-DTP1-DTP3 54% 0.1% 16,237 BCG-DTP3-Meas1 60% 0.6% 3,753 
Saint Lucia 0 0 59% 0.9% 373 BCG-DTP1-DTP3 70% 0.6% 712 BCG-DTP1-DTP3 79% 0.7% 610 
Saint Vincent & the Gr. 0 0 59% 0.9% 682 BCG-DTP1-DTP2 78% 0.3% 2,765 BCG-DTP1-DTP3 81% 0.3% 2,554 
Samoa 0 1 57% 0.3% 63 BCG-DTP1-DTP3 65% 0.1% 183 BCG-DTP1-Meas1 67% 0.1% 182 
Sao Tome and Principe 7 0 44% 0.8% 1,207 BCG-DTP1-DTP3 56% 0.1% 11,437 BCG-DTP2-Meas1 61% 0.4% 3,543 
Senegal 876 34 36% 1.0% 968 BCG-DTP1-DTP3 51% 0.3% 4,143 BCG-DTP1-Meas1 55% 0.5% 3,189 
Serbia 1 0 72% 0.9% 816 BCG-DTP1-DTP3 93% 0.3% 3,500 BCG-DTP1-Meas1 94% 0.3% 3,529 
Sierra Leone 1,263 15 39% 0.8% 3,814 BCG-DTP1-DTP3 52% 0.2% 20,584 BCG-DTP2-Meas1 55% 0.5% 9,068 
Solomon Islands 9 1 40% 0.3% 1,300 BCG-DTP1-DTP3 55% 0.1% 4,184 BCG-DTP2-Meas1 59% 0.2% 3,080 
Somalia 2,432 415 22% 0.5% 247 BCG-DTP1-DTP3 22% 0.1% 1,679 DTP1-DTP2-Meas1 27% 0.7% 220 
South Africa 1,734 267 41% 0.8% 332 BCG-DTP1-DTP3 45% 0.1% 2,324 BCG-DTP1-DTP3 46% 0.1% 2,237 
South Sudan 937 102 16% 0.4% 407 BCG-DTP1-DTP3 24% 0.1% 1,957 BCG-DTP1-DTP3 25% 0.1% 1,676 
Sri Lanka 11 1 73% 1.0% 992 BCG-DTP1-DTP3 93% 0.3% 4,342 BCG-DTP1-Meas1 95% 0.3% 3,880 
Sudan 2,726 30 40% 0.9% 4,074 BCG-DTP1-DTP3 42% 0.2% 19,098 BCG-DTP2-Meas1 53% 0.8% 5,675 
Suriname 1 0 35% 0.4% 239 DTP1-DTP2-DTP3 35% 0.4% 239 DTP1-DTP2-Meas1 63% 1.1% 173 
Swaziland 77 2 47% 0.6% 2,902 BCG-DTP1-DTP3 60% 0.1% 26,297 BCG-DTP2-Meas1 62% 0.3% 8,374 
Syrian Arab Republic 80 136 36% 0.8% 28 BCG-DTP1-DTP2 51% 0.3% 120 BCG-DTP1-Meas1 52% 0.3% 108 
Tajikistan 236 5 34% 0.7% 2,170 BCG-DTP1-DTP3 58% 0.4% 7,282 BCG-DTP2-Meas1 62% 0.5% 6,127 
Tanzania 2,880 109 49% 0.6% 2,108 BCG-DTP1-DTP3 58% 0.1% 19,058 BCG-DTP2-Meas1 65% 0.6% 3,091 
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TFYR Macedonia 1 0 37% 0.6% 1,443 BCG-DTP1-DTP2 86% 0.4% 4,504 BCG-DTP1-Meas1 89% 0.4% 4,383 
Thailand 65 1 71% 1.7% 3,362 BCG-DTP1-DTP3 92% 0.5% 13,865 BCG-DTP1-Meas1 94% 0.6% 12,903 
Timor-Leste 90 9 30% 0.5% 564 BCG-DTP1-DTP3 44% 0.3% 1,766 BCG-DTP2-Meas1 50% 0.6% 936 
Togo 609 17 43% 0.9% 1,801 BCG-DTP1-DTP3 52% 0.2% 11,313 BCG-DTP2-Meas1 55% 0.5% 4,292 
Tonga 0 1 56% 0.3% 64 BCG-DTP1-DTP3 63% 0.1% 181 BCG-DTP1-Meas1 65% 0.1% 181 
Tunisia 15 3 70% 2.0% 209 BCG-DTP1-DTP3 80% 0.4% 1,158 BCG-DTP1-DTP3 81% 0.4% 1,170 
Turkey 53 21 58% 0.9% 165 BCG-DTP1-DTP3 68% 0.5% 315 BCG-DTP1-Meas1 77% 0.6% 296 
Turkmenistan 89 2 37% 0.9% 2,356 BCG-DTP1-DTP3 57% 0.4% 8,033 BCG-DTP2-Meas1 61% 0.5% 6,649 
Tuvalu 0 0 37% 0.3% 746 BCG-DTP1-DTP3 54% 0.1% 2,407 BCG-DTP2-Meas1 59% 0.2% 1,800 
Uganda 2,478 150 35% 0.9% 655 BCG-DTP1-DTP3 50% 0.3% 2,569 BCG-DTP2-Meas1 56% 0.7% 1,429 
Ukraine 13 1 20% 0.2% 1,643 BCG-DTP1-DTP2 37% 0.1% 6,094 DTP1-DTP2-Meas1 46% 0.8% 1,245 
Uzbekistan 181 4 33% 1.3% 1,130 BCG-DTP1-DTP3 53% 0.6% 4,129 BCG-DTP2-Meas1 59% 0.6% 4,085 
Vanuatu 5 5 30% 0.2% 129 BCG-DTP1-DTP3 41% 0.1% 420 BCG-DTP2-Meas1 43% 0.1% 299 
Venezuela 273 36 58% 1.1% 398 BCG-DTP1-DTP2 79% 0.3% 1,894 BCG-DTP1-DTP3 80% 0.4% 1,650 
Viet Nam 365 854 29% 0.1% 164 BCG-DTP1-DTP3 67% 0.1% 291 BCG-DTP1-DTP2 77% 0.1% 233 
Yemen 1,434 170 29% 0.7% 360 DTP1-DTP2-DTP3 29% 0.7% 360 DTP1-DTP2-Meas1 39% 1.2% 267 
Zambia 1,235 21 45% 0.6% 4,094 BCG-DTP1-DTP3 57% 0.2% 17,572 BCG-DTP1-DTP3 61% 0.3% 12,039 
Zimbabwe 1,295 29 44% 0.7% 2,903 BCG-DTP1-DTP3 54% 0.1% 26,723 BCG-DTP2-Meas1 58% 0.3% 7,732 
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Appendix Table 9. Potential benefits and risks of alternative rotavirus vaccination schedule options if used in all 135 low- and middle-income countries: 
scenario assuming access to healthcare in high/very high mortality settings is equivalent to the proportion of children with 2-hour access to public hospitals 
Schedule Doses   RVGE deaths <5 years   Intussusception deaths <5 years Summary indicators   
Vaccines in the existing 
schedule that rotavirus 
would be co-administered 
with 
Total 
doses 
(millions) 
Fully 
vaccinated 
children 
(FVC) 
(millions) Number Averted 
Incremental 
number 
averted vs 
age-restricted Number 
Excess 
vs no 
vaccine 
Incremental 
excess 
number vs 
age-restricted 
% 
reduction 
in RVGE 
deaths 
Doses 
per RVGE 
death 
averted 
Number 
of FVC 
per 
excess IS 
case 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Incremental 
RVGE deaths 
averted per 
excess IS 
death vs age-
restricted 
NO VACCINE 0 0 169,450 - - 33,513 - - - - - - - 
Age-restricted (primary)                  
BCG 109 104 140,066 29,384 - 33,544 31 - 17.3% 3,714 766,452 945 - 
DTP1 87 82 141,323 28,126 - 33,623 111 - 16.6% 3,091 155,907 254 - 
BCG+DTP1 217 102 118,208 51,241 - 33,575 63 - 30.2% 4,238 277,449 817 - 
BCG+DTP2 213 99 115,630 53,820 - 33,634 121 - 31.8% 3,974 153,682 444 - 
BCG+DTP3 192 79 118,111 51,338 - 33,650 137 - 30.3% 3,745 119,493 374 - 
DTP1+DTP2^ 173 82 120,829 48,621 - 33,704 191 - 28.7% 3,575 92,582 254 - 
DTP1+DTP3 164 73 121,110 48,340 - 33,730 217 - 28.5% 3,405 73,785 223 - 
BCG+DTP1+DTP2 321 99 111,746 57,704 - 33,575 63 - 34.1% 5,573 268,455 920 - 
BCG+DTP1+DTP3 300 79 109,115 60,335 - 33,575 63 - 35.6% 4,972 212,866 962 - 
BCG+DTP2+DTP3 296 79 110,324 59,125 - 33,634 121 - 34.9% 5,019 121,877 488 - 
DTP1+DTP2+DTP3^ 250 73 115,469 53,981 - 33,704 191 - 31.9% 4,655 82,690 282 - 
Age-unrestricted (primary)                   
BCG 114 108 138,147 31,303 1,919 33,574 62 31 18.5% 3,655 440,158 508 63 
DTP1 117 111 134,966 34,484 6,357 33,737 224 113 20.4% 3,408 81,055 154 56 
BCG+DTP1 227 107 115,233 54,217 2,975 33,592 80 17 32.0% 4,193 235,715 680 174 
BCG+DTP2 225 105 112,435 57,015 3,195 33,665 153 31 33.6% 3,958 135,448 374 102 
BCG+DTP3 223 101 112,616 56,833 5,495 33,694 181 44 33.5% 3,931 114,206 313 125 
DTP1+DTP2^ 230 107 111,331 58,119 9,498 33,834 322 131 34.3% 3,978 56,669 181 73 
DTP1+DTP3 226 102 111,080 58,370 10,030 33,858 346 128 34.4% 3,900 50,705 169 78 
BCG+DTP1+DTP2 338 105 108,232 61,218 3,514 33,591 78 16 36.1% 5,526 236,453 782 226 
BCG+DTP1+DTP3 335 101 104,188 65,262 4,927 33,592 79 17 38.5% 5,147 223,327 821 294 
BCG+DTP2+DTP3 334 101 105,787 63,662 4,537 33,665 152 31 37.6% 5,252 130,219 418 146 
DTP1+DTP2+DTP3^ 339 102 104,501 64,949 10,968 33,834 322 131 38.3% 5,252 53,828 202 84 
Age-unrestricted (booster)                  
BCG+Meas1 222 73 119,210 50,240 - 33,639 126 - 29.6% 4,432 113,455 398 - 
DTP1+Meas1 225 73 116,653 52,797 - 33,800 288 - 31.2% 4,289 41,353 183 - 
BCG+DTP1+Meas1 335 73 102,302 67,148 - 33,592 80 - 39.6% 4,989 160,619 843 - 
BCG+DTP2+Meas1 332 73 100,947 68,503 - 33,665 152 - 40.4% 4,863 93,720 449 - 
BCG+DTP3+Meas1 329 72 103,072 66,378 - 33,694 181 - 39.2% 4,972 82,126 366 - 
DTP1+DTP2+Meas1 338 72 99,777 69,673 - 33,834 322 - 41.1% 4,873 38,377 217 - 
DTP1+DTP3+Meas1 333 72 101,489 67,961 - 33,858 345 - 40.1% 4,930 36,145 197 - 
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^ shaded rows reflect the current WHO recommended schedule options 
 
 
Appendix Table 10. Potential benefits and risks of a standard age-restricted three-dose infant schedule (co-administered with DTP1+DTP2+DTP3) 
compared to age-restricted and age-unrestricted schedules with the highest predicted impact in each country: scenario assuming access to healthcare in 
high/very high mortality settings is equivalent to the proportion of children with 2-hour access to public hospitals 
 
Country NO VACCINE   
Age-restricted standard 
schedule (DTP1+DTP2+DTP3) 
Age-restricted schedule with the highest predicted 
impact on RVGE deaths<5 years 
Age-unrestricted schedule with the highest predicted 
impact on RVGE deaths<5 years 
  
RVGE 
deaths 
<5 years 
IS 
deaths 
<5 
years 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Schedule with 
highest predicted 
impact 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
Schedule with 
highest predicted 
impact 
% 
impact 
on 
RVGE 
deaths 
% 
increase 
in IS 
deaths 
RVGE 
deaths 
averted 
per 
excess IS 
death 
ALL 135 LMICs 169,450 33,513 32% 0.6% 282   36% 0.3% 524   42% 0.8% 263 
                      
Afghanistan 2,420 369 21% 0.4% 329 BCG-DTP1-DTP3 32% 0.3% 623 BCG-DTP1-DTP3 37% 0.5% 450 
Albania 1 0 59% 1.0% 270 BCG-DTP1-DTP2 74% 0.4% 811 BCG-DTP1-DTP3 77% 0.4% 785 
Algeria 206 188 16% 0.7% 23 BCG-DTP1-DTP3 47% 0.5% 94 BCG-DTP1-Meas1 52% 0.5% 105 
Angola 6,921 291 31% 1.0% 726 BCG-DTP1-DTP2 39% 0.3% 3,125 BCG-DTP1-DTP3 42% 0.3% 2,917 
Argentina 36 65 56% 0.8% 37 BCG-DTP1-DTP2 72% 0.3% 141 BCG-DTP1-DTP3 74% 0.3% 130 
Armenia 2 1 38% 0.6% 200 BCG-DTP1-DTP3 68% 0.3% 733 BCG-DTP1-Meas1 74% 0.3% 774 
Azerbaijan 74 47 24% 0.9% 43 BCG-DTP1-DTP3 30% 0.4% 111 BCG-DTP3-Meas1 42% 0.6% 115 
Bangladesh 1,623 221 40% 0.3% 1,151 DTP1-DTP2-DTP3 40% 0.3% 1,151 DTP1-DTP3-Meas1 56% 0.6% 631 
Belarus 1 0 32% 0.5% 380 BCG-DTP1-DTP3 86% 0.5% 1,053 BCG-DTP1-Meas1 90% 0.5% 1,038 
Belize 1 0 59% 0.9% 583 BCG-DTP1-DTP2 71% 0.3% 1,906 BCG-DTP1-DTP3 76% 0.4% 1,628 
Benin 1,582 59 41% 0.8% 1,406 BCG-DTP1-DTP3 47% 0.2% 6,132 BCG-DTP3-Meas1 51% 0.5% 2,622 
Bhutan 6 5 40% 0.7% 65 BCG-DTP1-DTP3 45% 0.2% 235 BCG-DTP2-Meas1 52% 0.4% 136 
Bolivia 253 49 41% 0.9% 242 BCG-DTP1-DTP2 50% 0.3% 909 BCG-DTP1-DTP3 54% 0.3% 888 
Bosnia & Herzegovina 0 0 52% 0.6% 557 BCG-DTP1-DTP3 84% 0.3% 2,044 BCG-DTP1-Meas1 86% 0.3% 2,071 
Botswana 43 8 37% 1.3% 148 BCG-DTP1-DTP3 45% 0.4% 606 BCG-DTP2-Meas1 52% 0.7% 392 
Brazil 1,032 3 58% 1.5% 13,263 BCG-DTP1-DTP2 74% 0.5% 51,357 BCG-DTP1-DTP3 77% 0.5% 48,288 
Bulgaria 2 0 67% 0.8% 2,048 BCG-DTP1-DTP3 85% 0.3% 5,876 BCG-DTP1-Meas1 88% 0.4% 5,654 
Burkina Faso 2,279 251 42% 1.2% 317 BCG-DTP1-DTP3 49% 0.3% 1,407 BCG-DTP2-Meas1 53% 0.6% 810 
Burundi 1,606 25 47% 0.9% 3,251 DTP1-DTP2-DTP3 47% 0.9% 3,251 DTP1-DTP3-Meas1 53% 1.2% 2,865 
Cabo Verde 4 1 58% 1.3% 262 BCG-DTP1-DTP2 71% 0.3% 1,214 BCG-DTP1-Meas1 74% 0.4% 1,151 
Cambodia 212 336 38% 0.3% 79 BCG-DTP1-DTP3 39% 0.1% 259 BCG-DTP3-Meas1 47% 0.2% 171 
Cameroon 2,967 99 44% 0.8% 1,598 DTP1-DTP2-DTP3 44% 0.8% 1,598 DTP1-DTP2-Meas1 50% 1.1% 1,318 
Central African Republic 928 67 30% 0.6% 663 BCG-DTP1-DTP2 38% 0.2% 2,160 BCG-DTP1-DTP3 40% 0.3% 1,780 
Chad 4,309 260 16% 0.4% 746 BCG-DTP1-DTP3 25% 0.3% 1,266 BCG-DTP1-Meas1 31% 0.7% 775 
China 1,384 414 26% 0.3% 304 BCG-DTP1-DTP3 73% 0.2% 978 BCG-DTP1-Meas1 77% 0.3% 908 
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Colombia 152 26 61% 0.9% 410 BCG-DTP1-DTP2 69% 0.2% 2,279 BCG-DTP1-DTP3 71% 0.2% 2,328 
Comoros 39 1 43% 0.9% 1,241 BCG-DTP1-DTP3 46% 0.2% 6,246 DTP1-DTP2-Meas1 51% 1.2% 1,113 
Congo 252 32 35% 1.0% 266 BCG-DTP1-DTP3 43% 0.3% 1,113 BCG-DTP2-Meas1 46% 0.5% 681 
Costa Rica 2 0 81% 0.9% 2,471 DTP1-DTP2-DTP3 81% 0.9% 2,471 DTP1-DTP2-Meas1 85% 1.0% 2,453 
Côte d'Ivoire 2,477 195 42% 0.9% 586 DTP1-DTP2-DTP3 42% 0.9% 586 DTP1-DTP2-Meas1 51% 1.4% 450 
Croatia 0 0 70% 0.8% 421 BCG-DTP1-DTP3 88% 0.3% 1,257 BCG-DTP1-Meas1 91% 0.4% 1,215 
Cuba 3 0 71% 0.9% 742 BCG-DTP1-DTP3 89% 0.3% 2,843 BCG-DTP1-Meas1 92% 0.3% 2,644 
DR Congo 12,377 1,112 38% 0.7% 579 BCG-DTP1-DTP3 40% 0.2% 2,277 DTP1-DTP3-Meas1 46% 1.2% 421 
Djibouti 26 4 39% 0.9% 304 BCG-DTP1-DTP3 45% 0.3% 1,064 BCG-DTP2-Meas1 48% 0.5% 651 
Dominican Republic 74 9 17% 0.2% 790 BCG-DTP1-DTP3 60% 0.2% 2,784 BCG-DTP1-DTP2 70% 0.2% 2,756 
Ecuador 95 23 48% 0.7% 283 BCG-DTP1-DTP2 64% 0.2% 1,103 BCG-DTP1-Meas1 66% 0.3% 1,017 
Egypt 1,095 98 70% 0.7% 1,066 BCG-DTP1-DTP3 77% 0.0% 123,972 BCG-DTP1-DTP3 77% 0.0% 51,557 
El Salvador 50 5 69% 0.9% 809 BCG-DTP1-DTP3 75% 0.2% 5,273 BCG-DTP1-Meas1 76% 0.2% 5,327 
Equatorial Guinea 42 6 11% 0.3% 294 BCG-DTP1-DTP3 18% 0.1% 1,213 BCG-DTP1-Meas1 19% 0.1% 1,067 
Eritrea 269 83 28% 0.9% 97 BCG-DTP1-DTP3 31% 0.3% 378 DTP1-DTP3-Meas1 40% 1.4% 93 
Ethiopia 5,130 1,280 22% 0.6% 153 DTP1-DTP2-DTP3 22% 0.6% 153 DTP1-DTP2-Meas1 38% 1.3% 117 
Fiji 7 0 65% 0.3% 3,228 BCG-DTP1-DTP3 74% 0.1% 8,234 BCG-DTP1-Meas1 77% 0.2% 7,607 
Gabon 57 7 33% 0.8% 348 BCG-DTP1-DTP3 41% 0.3% 1,268 BCG-DTP2-Meas1 45% 0.5% 760 
Gambia 130 15 33% 1.3% 231 BCG-DTP1-DTP3 41% 0.4% 854 BCG-DTP2-Meas1 50% 0.7% 622 
Georgia 2 0 70% 0.8% 2,157 BCG-DTP1-DTP3 86% 0.4% 6,049 BCG-DTP1-Meas1 90% 0.4% 5,954 
Ghana 1,436 90 44% 0.5% 1,562 BCG-DTP1-DTP3 47% 0.1% 10,248 BCG-DTP2-Meas1 51% 0.3% 2,727 
Grenada 0 0 73% 0.7% 2,906 DTP1-DTP2-DTP3 73% 0.7% 2,906 DTP1-DTP2-Meas1 85% 1.0% 2,536 
Guatemala 349 83 33% 0.9% 157 BCG-DTP1-DTP2 38% 0.3% 612 DTP1-DTP2-Meas1 44% 1.3% 146 
Guinea 1,097 111 24% 0.5% 438 BCG-DTP1-DTP3 33% 0.2% 1,498 BCG-DTP2-Meas1 35% 0.4% 921 
Guinea-Bissau 197 17 37% 1.0% 448 BCG-DTP1-DTP3 42% 0.3% 1,400 BCG-DTP2-Meas1 48% 0.8% 724 
Guyana 11 3 42% 1.0% 155 BCG-DTP2-DTP3 46% 0.4% 381 BCG-DTP2-Meas1 51% 0.5% 403 
Haiti 375 50 25% 0.4% 441 BCG-DTP1-DTP2 33% 0.3% 885 BCG-DTP1-DTP3 39% 0.5% 554 
Honduras 103 34 48% 1.0% 145 BCG-DTP2-DTP3 48% 0.4% 348 BCG-DTP1-DTP3 51% 0.2% 798 
India 25,839 12,827 31% 0.4% 141 BCG-DTP2-DTP3 34% 0.3% 225 DTP1-DTP3-Meas1 40% 0.9% 92 
Indonesia 3,000 1,696 27% 0.9% 51 BCG-DTP2-DTP3 28% 0.6% 85 DTP1-DTP2-Meas1 40% 1.4% 49 
Iran 213 20 59% 1.3% 486 BCG-DTP1-DTP2 74% 0.4% 2,021 BCG-DTP1-Meas1 77% 0.5% 1,861 
Iraq 669 411 29% 1.0% 49 BCG-DTP1-DTP2 42% 0.3% 218 BCG-DTP1-DTP3 43% 0.4% 198 
Jamaica 3 1 64% 0.7% 380 BCG-DTP1-DTP3 74% 0.2% 1,336 BCG-DTP1-DTP3 77% 0.3% 1,212 
Jordan 25 5 26% 0.7% 178 BCG-DTP1-DTP3 75% 0.6% 649 BCG-DTP1-DTP3 77% 0.6% 614 
Kazakhstan 46 5 55% 0.8% 718 BCG-DTP2-DTP3 73% 0.3% 2,167 DTP1-DTP2-DTP3 76% 1.3% 599 
Kenya 1,986 110 43% 0.4% 1,880 DTP1-DTP2-DTP3 43% 0.4% 1,880 DTP1-DTP3-Meas1 50% 0.7% 1,245 
Kiribati 4 3 32% 0.2% 180 BCG-DTP1-DTP3 36% 0.1% 463 DTP1-DTP3-Meas1 41% 0.4% 155 
Kyrgyzstan 45 3 64% 0.9% 1,049 BCG-DTP1-DTP3 75% 0.3% 4,372 BCG-DTP1-Meas1 76% 0.3% 4,454 
Lao PDR 431 146 23% 0.2% 292 BCG-DTP2-DTP3 27% 0.2% 436 DTP1-DTP2-Meas1 43% 0.5% 233 
Lebanon 5 0 60% 1.2% 592 DTP1-DTP2-DTP3 60% 1.2% 592 DTP1-DTP2-Meas1 75% 1.8% 504 
Lesotho 187 19 48% 0.8% 553 BCG-DTP1-DTP3 48% 0.2% 2,969 DTP1-DTP3-Meas1 54% 1.1% 491 
Liberia 443 42 32% 0.7% 473 BCG-DTP1-DTP3 34% 0.2% 1,848 DTP1-DTP2-Meas1 38% 1.0% 413 
Libya 8 44 40% 1.3% 5 BCG-DTP1-DTP2 50% 0.4% 22 BCG-DTP1-DTP3 54% 0.5% 21 
Madagascar 1,696 371 26% 0.6% 195 BCG-DTP1-DTP3 31% 0.3% 510 DTP1-DTP2-Meas1 40% 1.4% 126 
Malawi 1,556 46 49% 0.9% 1,927 BCG-DTP1-DTP3 50% 0.2% 9,908 DTP1-DTP2-Meas1 52% 0.9% 1,895 
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Malaysia 17 0 71% 0.9% 22,079 BCG-DTP1-DTP3 89% 0.3% 87,740 BCG-DTP1-Meas1 92% 0.3% 78,643 
Maldives 0 0 71% 1.0% 1,041 BCG-DTP1-DTP3 89% 0.3% 4,486 BCG-DTP1-Meas1 92% 0.4% 4,034 
Mali 2,438 179 28% 0.6% 611 BCG-DTP1-DTP3 38% 0.4% 1,274 BCG-DTP1-Meas1 44% 0.7% 864 
Marshall Islands 1 0 36% 0.4% 9,620 BCG-DTP1-DTP2 45% 0.2% 27,569 BCG-DTP1-DTP3 49% 0.2% 27,358 
Mauritania 400 87 31% 0.7% 214 BCG-DTP1-DTP3 40% 0.3% 582 BCG-DTP2-Meas1 43% 0.5% 364 
Mauritius 1 1 59% 0.9% 123 BCG-DTP1-DTP3 65% 0.5% 258 BCG-DTP2-Meas1 72% 0.8% 167 
Mexico 626 142 58% 0.8% 332 BCG-DTP1-DTP2 75% 0.2% 1,465 BCG-DTP1-Meas1 76% 0.2% 1,481 
Micronesia (FSO) 1 2 36% 0.4% 42 DTP1-DTP2-DTP3 36% 0.4% 42 DTP1-DTP2-Meas1 45% 0.5% 39 
Mongolia 9 3 77% 0.4% 649 BCG-DTP1-DTP3 79% 0.1% 2,723 BCG-DTP1-Meas1 81% 0.1% 2,768 
Montenegro 0 0 67% 0.8% 468 BCG-DTP1-DTP2 79% 0.3% 1,455 DTP1-DTP2-Meas1 84% 1.2% 423 
Morocco 604 246 38% 1.3% 72 BCG-DTP1-DTP3 48% 0.7% 166 BCG-DTP2-Meas1 52% 1.0% 122 
Mozambique 2,160 430 32% 0.9% 174 BCG-DTP1-DTP3 45% 0.4% 613 BCG-DTP1-Meas1 49% 0.4% 562 
Myanmar 818 311 34% 1.0% 93 BCG-DTP2-DTP3 41% 0.5% 203 DTP1-DTP2-Meas1 48% 1.5% 87 
Namibia 108 11 42% 0.7% 544 DTP1-DTP2-DTP3 42% 0.7% 544 DTP1-DTP3-Meas1 49% 1.0% 477 
Nepal 258 188 39% 0.6% 86 BCG-DTP1-DTP3 42% 0.2% 330 BCG-DTP2-Meas1 46% 0.5% 131 
Nicaragua 53 0 59% 0.9% 7,651 BCG-DTP1-DTP2 74% 0.3% 29,781 BCG-DTP1-DTP3 77% 0.3% 28,282 
Niger 4,557 485 36% 0.8% 414 BCG-DTP1-DTP3 37% 0.2% 1,884 DTP1-DTP2-Meas1 43% 1.1% 357 
Nigeria 35,129 518 23% 1.1% 1,434 BCG-DTP1-DTP3 27% 0.8% 2,259 BCG-DTP2-Meas1 32% 1.0% 2,081 
North Korea 151 17 64% 0.7% 785 BCG-DTP1-DTP3 73% 0.2% 2,864 BCG-DTP1-Meas1 76% 0.3% 2,468 
Pakistan 7,694 1,765 29% 0.6% 221 BCG-DTP1-DTP3 38% 0.3% 605 BCG-DTP1-DTP3 41% 0.5% 373 
Panama 25 1 57% 0.9% 1,543 BCG-DTP1-DTP2 74% 0.3% 5,961 BCG-DTP1-Meas1 76% 0.3% 5,514 
Papua New Guinea 191 199 34% 0.2% 138 BCG-DTP1-DTP3 36% 0.1% 327 DTP1-DTP2-Meas1 41% 0.3% 133 
Paraguay 41 27 38% 0.9% 67 BCG-DTP1-DTP2 46% 0.3% 245 BCG-DTP1-DTP3 51% 0.3% 243 
Peru 144 91 43% 1.0% 70 DTP1-DTP2-DTP3 43% 1.0% 70 DTP1-DTP2-Meas1 49% 1.1% 72 
Philippines 1,893 2,213 28% 0.2% 105 BCG-DTP1-DTP3 33% 0.1% 259 BCG-DTP1-Meas1 38% 0.1% 264 
Republic of Moldova 1 1 50% 0.7% 66 BCG-DTP1-DTP3 72% 0.3% 267 BCG-DTP1-DTP3 73% 0.3% 270 
Romania 8 0 68% 0.8% 2,638 BCG-DTP1-DTP2 88% 0.4% 7,883 BCG-DTP1-DTP3 90% 0.4% 7,576 
Russian Federation 54 3 31% 0.5% 1,275 BCG-DTP1-DTP3 86% 0.5% 3,699 BCG-DTP1-Meas1 89% 0.5% 3,619 
Rwanda 700 34 40% 0.7% 1,152 BCG-DTP1-DTP3 41% 0.1% 6,936 DTP1-DTP3-Meas1 49% 1.0% 1,022 
Saint Lucia 0 0 59% 0.9% 373 BCG-DTP1-DTP3 67% 0.6% 678 BCG-DTP1-DTP3 76% 0.7% 584 
Saint Vincent & the Gr. 0 0 59% 0.9% 682 BCG-DTP1-DTP2 74% 0.3% 2,633 BCG-DTP1-DTP3 77% 0.3% 2,448 
Samoa 0 1 57% 0.3% 63 BCG-DTP1-DTP3 62% 0.1% 173 DTP1-DTP2-Meas1 64% 0.4% 55 
Sao Tome and Principe 7 0 44% 0.8% 1,134 BCG-DTP1-DTP3 44% 0.1% 8,486 DTP1-DTP3-Meas1 52% 1.0% 1,038 
Senegal 876 154 36% 1.0% 211 BCG-DTP1-DTP3 42% 0.3% 738 BCG-DTP2-Meas1 45% 0.7% 384 
Serbia 1 0 72% 0.9% 816 BCG-DTP1-DTP3 90% 0.3% 3,379 BCG-DTP1-Meas1 91% 0.3% 3,434 
Sierra Leone 1,263 68 39% 0.8% 868 BCG-DTP1-DTP3 42% 0.2% 3,803 DTP1-DTP2-Meas1 47% 1.2% 727 
Solomon Islands 9 16 40% 0.3% 73 BCG-DTP1-DTP3 44% 0.1% 188 DTP1-DTP3-Meas1 50% 0.5% 63 
Somalia 2,432 362 22% 0.5% 283 DTP1-DTP2-DTP3 22% 0.5% 283 DTP1-DTP2-Meas1 27% 0.7% 252 
South Africa 1,734 127 41% 0.8% 698 DTP1-DTP2-DTP3 41% 0.8% 698 DTP1-DTP2-Meas1 46% 1.1% 549 
South Sudan 937 522 16% 0.4% 80 BCG-DTP1-DTP3 19% 0.1% 312 BCG-DTP1-DTP3 20% 0.1% 269 
Sri Lanka 11 1 73% 1.0% 992 BCG-DTP1-DTP3 90% 0.3% 4,194 BCG-DTP1-Meas1 93% 0.3% 3,784 
Sudan 2,726 1,200 40% 0.9% 103 DTP1-DTP2-DTP3 40% 0.9% 103 DTP1-DTP2-Meas1 50% 1.3% 86 
Suriname 1 0 35% 0.4% 239 DTP1-DTP2-DTP3 35% 0.4% 239 DTP1-DTP2-Meas1 63% 1.1% 173 
Swaziland 77 7 47% 0.6% 824 BCG-DTP1-DTP3 49% 0.1% 6,148 BCG-DTP2-Meas1 52% 0.3% 2,011 
Syrian Arab Republic 80 136 36% 0.8% 28 BCG-DTP1-DTP2 48% 0.3% 114 BCG-DTP1-Meas1 50% 0.3% 103 
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Tajikistan 236 63 34% 0.7% 175 BCG-DTP1-DTP3 47% 0.4% 474 DTP1-DTP3-Meas1 53% 1.2% 163 
Tanzania 2,880 343 49% 0.6% 670 DTP1-DTP2-DTP3 49% 0.6% 670 DTP1-DTP3-Meas1 57% 1.0% 475 
TFYR Macedonia 1 0 37% 0.6% 1,443 BCG-DTP1-DTP2 83% 0.4% 4,348 BCG-DTP1-Meas1 87% 0.4% 4,273 
Thailand 65 1 71% 1.7% 3,362 BCG-DTP1-DTP3 89% 0.5% 13,381 BCG-DTP1-Meas1 92% 0.6% 12,559 
Timor-Leste 90 14 30% 0.5% 342 BCG-DTP1-DTP3 35% 0.3% 855 BCG-DTP2-Meas1 42% 0.6% 475 
Togo 609 27 43% 0.9% 1,150 DTP1-DTP2-DTP3 43% 0.9% 1,150 DTP1-DTP2-Meas1 48% 0.9% 1,151 
Tonga 0 1 56% 0.3% 64 BCG-DTP1-DTP3 60% 0.1% 172 DTP1-DTP2-Meas1 65% 0.4% 55 
Tunisia 15 3 70% 2.0% 209 BCG-DTP1-DTP3 77% 0.4% 1,111 BCG-DTP1-DTP3 78% 0.4% 1,127 
Turkey 53 21 58% 0.9% 165 BCG-DTP1-DTP3 65% 0.5% 300 DTP1-DTP2-Meas1 73% 1.2% 150 
Turkmenistan 89 38 37% 0.9% 94 BCG-DTP1-DTP3 46% 0.4% 259 BCG-DTP2-Meas1 51% 0.5% 222 
Tuvalu 0 0 37% 0.3% 746 BCG-DTP1-DTP3 42% 0.1% 1,887 DTP1-DTP3-Meas1 49% 0.5% 656 
Uganda 2,478 203 35% 0.9% 484 BCG-DTP1-DTP3 39% 0.3% 1,483 BCG-DTP2-Meas1 47% 0.7% 883 
Ukraine 13 1 20% 0.2% 1,643 BCG-DTP1-DTP2 35% 0.1% 5,762 DTP1-DTP2-Meas1 46% 0.8% 1,245 
Uzbekistan 181 135 33% 1.3% 34 BCG-DTP1-DTP3 41% 0.6% 96 DTP1-DTP3-Meas1 49% 1.7% 39 
Vanuatu 5 7 30% 0.2% 103 BCG-DTP1-DTP3 32% 0.1% 265 DTP1-DTP3-Meas1 35% 0.3% 86 
Venezuela 273 36 58% 1.1% 398 BCG-DTP1-DTP2 75% 0.3% 1,811 BCG-DTP1-DTP3 77% 0.4% 1,585 
Viet Nam 365 854 29% 0.1% 164 BCG-DTP1-DTP3 64% 0.1% 276 BCG-DTP1-DTP2 73% 0.1% 221 
Yemen 1,434 289 29% 0.7% 212 DTP1-DTP2-DTP3 29% 0.7% 212 DTP1-DTP2-Meas1 39% 1.2% 157 
Zambia 1,235 68 45% 0.6% 1,265 BCG-DTP1-DTP3 49% 0.2% 4,695 BCG-DTP1-DTP3 53% 0.3% 3,236 
Zimbabwe 1,295 75 44% 0.7% 1,122 DTP1-DTP2-DTP3 44% 0.7% 1,122 DTP1-DTP3-Meas1 50% 0.9% 987 
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Appendix Figure 1. Relative risk of intussusception reported in studies using the SCCS 
methodology, 1-7 days after administration of the first dose of Rotarix or RotaTeq 
 
Black point represent each study observation and their respective 95% confidence intervals. Blue lines represent 
the pooled estimate (and 95% confidence intervals) calculated in a global random effects meta-analysis. The red 
line represents the maximum likelihood fit for the relationship between under-five mortality and relative risk, and 
suggests no risk in countries with an under-five mortality rate of 40 or more per 1000 live births. This would 
exclude any risk in ~65 high mortality countries. 
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Appendix Figure 2. Estimated instantaneous vaccine efficacy (iVE) of live oral 
rotavirus vaccines in high mortality settings by duration of follow-up: alternative 
scenarios of waning after 2/3 doses for neonatal and infant schedules 
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Appendix Figure 3. Graphical examples of age-unrestricted rotavirus vaccination 
schedules predicted to have the highest impact on RVGE deaths aged <5 years, 
compared to no vaccination 
 
Afghanistan, RV with BCG+DTP1+DTP3         Algeria, RV with BCG+DTP1+Meas1 
 
India, RV with DTP1+DTP3+Meas1             Kazakhstan, RV with DTP1+DTP2+DTP3 
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10.0 Chapter 10: Reflections on thesis research 
 
In this chapter the overall results of the thesis and its implications for informing 
national and global decision-making are considered. This is more comprehensive than 
the discussion section of the benefit-risk paper (Chapter 9) but there is considerable 
overlap, and some of the content appears in both. 
 
10.1 Estimation of rotavirus vaccine mortality benefits 
 
This research has involved the review and development of new methods for estimating 
RVGE deaths and granular RVGE age distributions in children <5 years of age, in the 
absence of vaccination. It has also involved new methods for estimating the potential 
timeliness, efficacy and waning of rotavirus vaccination in different settings. Taken 
as a whole, this substantially updates and strengthens the evidence necessary for 
estimating the mortality reduction benefits of rotavirus vaccination in different 
LMICs. 
 
For this analysis a transparent static cohort model was used to estimate the potential 
direct effects of rotavirus vaccination by week of age. Herd effects were excluded, 
and this could have led to under-estimates of vaccine impact in some settings. 
Including herd effects would make benefit-risk ratios more favourable, but it would 
have been very challenging to obtain robust estimates of the scale and duration of 
these effects in each of the 135 LMICs. Two important birth cohort studies from India 
(1) and Mexico (2) have provided estimates of the level of protection acquired from 
successive natural rotavirus infections, and these data could have been extrapolated 
to a wider number of countries. However, this may not have been appropriate, and 
there are other important uncertainties e.g. about the level and duration of vaccine 
protection against asymptomatic natural infections. Transmission dynamic models 
calibrated to data from Niger (3) and India (4) have suggested a very small 
contribution from indirect effects, and while short-term herd effects have been 
observed in post-introduction studies in El Salvador (5), Ghana (6), Moldova (6) and 
Rwanda (7), no substantial herd effects were observed in Malawi,(8), South Africa 
(9), Tanzania (6) or Zambia (10). The incremental value of including herd immunity 
effects in benefit-risk analysis is also limited given the highly positive benefit-risk 
ratios without including them. In the context of schedules, transmission dynamic 
models could have been used to explore the potential effects of different schedules on 
the age-specific incidence and severity of natural infections. This could provide some 
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validation (or raise important questions) about the schedules predicted to have the 
highest impact in different countries. However, this would ideally require data on 
social mixing and transmission patterns in very granular age groups <5 years of age. 
In the interim, our analysis provides a useful starting point for thinking about the 
schedules that might have advantages in different countries. 
 
Not all children have the same risk of dying before their fifth birthday. For several 
reasons (nationality, wealth, education, nutrition etc.) some children are more 
vulnerable than others. The gross disparity in child mortality between rich and poor 
nations is well documented but there are very large differences within countries, 
which are masked by aggregated national mortality rates (11). In principle, if all 
children have equal access to timely and effective health care, then it follows that the 
most vulnerable groups will see the biggest improvements in health, and disparities 
in child mortality will reduce. In reality not all children have the same access to 
effective health care. Indeed, children at greatest risk of disease mortality are in many 
contexts the least likely to have access to preventative or curative health care. If the 
two are highly correlated (high risk and low access), the most vulnerable children will 
not be reached, and disparities will increase – the so called inverse equity hypothesis 
(12) or inverse care law (13): the most vulnerable in society benefit the least. 
Improvements in coverage may ultimately start to reach the most vulnerable groups 
leading to overall improvements in equity, but the evidence suggests this is not yet 
happening in many of the world’s poorest countries (14). Most modelled estimates of 
health benefit, including the results of this analysis, assume that all children benefit 
equally from an intervention. Failure to account for differences in individual risk and 
individual protection could lead to inflated estimates of effective coverage, and thus 
health benefit, in the most vulnerable groups. Rheingans et al were the first to evaluate 
formally the inverse equity effect for a vaccine, using the example of rotavirus 
vaccination in 25 high mortality countries. For eight of the countries, the bias can be 
quantified by comparing estimates of deaths prevented based on disparities in 
risk/coverage with estimates based on nationally reported risk/coverage alone. In 
Bangladesh, DR Congo, Ethiopia, Kenya, Niger and Uganda the bias was less than 
5%, but in India it was 8% and in Nigeria it was 20% (15). The major weakness of 
this analysis was that it was restricted to a single indicator of heterogeneity (wealth 
quintile), so the study is unlikely to represent the true extent of the bias. In reality, 
there is likely to be a wide range of correlated predictors of mortality and a similar set 
of predictors for coverage and timeliness of vaccination. Wealth may be just one part 
of the story; other factors, including nutrition, maternal education, access, rurality etc., 
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are also likely to be important (16). An adjustment for inverse equity would have led 
to lower estimates of RVGE deaths prevented in this study, but equally could have 
led to lower estimates of intussusception deaths caused. This could be the case if the 
background incidence and case fatality risk of intussusception were much higher in 
children excluded from the vaccination programme, which seems likely. Vaccinated 
infants would then have a lower background incidence rate and case fatality risk than 
the average estimated for the entire cohort, leading to fewer vaccine-related 
intussusception deaths. Conversely, vaccine-related risks may be lower in infants with 
lower socioeconomic status. There is some support for this hypothesis given the 
relatively lower relative risks shown in high mortality settings compared to low 
mortality settings (Chapter 9, Appendix Figure 1). 
 
A more general concern about estimates of rotavirus vaccine impact on mortality, is 
whether the rotavirus attributable fraction among GE hospital admissions is a 
reasonable proxy for rotavirus-attributable fraction among GE deaths. Our analysis of 
the various RVGE estimates methods suggests that acute water diarrhoea (with which 
rotavirus is primarily associated) may represent a lower proportion of GE deaths than 
GE admissions. Evidence is emerging on the impact of rotavirus vaccines on hospital 
admissions (17), but more research is needed to assess the impact of rotavirus vaccines 
on GE deaths in high mortality settings. 
 
10.2 Estimation of rotavirus vaccine-related intussusception risks 
 
This research has collected new data and developed new methods for estimating the 
incidence, age distribution, case fatality and vaccine-related relative risks of 
intussusception among children <5 years of age, in LMICs. This substantially updates 
the evidence necessary for estimating vaccine-related intussusception risks in 
different LMICs. In particular, our analysis highlights the inequity of outcomes for 
children in Africa, compared to children in the rest of the world. In Africa, more 
investment is needed to increase access to hospitals and equip those hospitals with the 
appropriate imaging technology and trained staff. This should be coupled with 
strategies to raise community awareness about the need for urgent treatment when 
children experience symptoms of intussusception. This would help to shift the primary 
form of diagnoses away from high-risk surgery towards lower-risk enema treatment. 
  
This analysis may provide the first estimate of the background number of 
intussusception deaths in LMICs (~14,500). This estimate is highly uncertain because 
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it relies on fairly crude assumptions about access to healthcare and CFRs among 
children without access to hospitals. The Global Burden of Disease Project (GBD 
2017) estimated 22,395 deaths globally due to paralytic ileus and intestinal 
obstruction, and 31,460 deaths for all digestive disorders combined, for children <5 
years of age in the year 2015 (18). DTP1 coverage was used as a proxy for access to 
intussusception treatment because it may better represent care-seeking for very severe 
conditions than household survey indicators based on milder symptoms. A more 
pessimistic scenario, based on the proportion of children with timely (two-hour) 
access to public hospitals was influential (led to less favourable benefit-risk ratios), 
but this is probably too pessimistic as many intussusception cases in Africa are known 
to present to hospital more than two days after the onset of symptoms (19). In medium 
mortality countries, changes to access to care parameters led to large increases in the 
background intussusception mortality rate relative to the (often very low) pre-
vaccination RVGE mortality rate. Had 100% access to treatment been assumed in 
medium mortality countries (as per the low and very low mortality stratum), then the 
benefit-risk ratios would have been far more favourable. Better estimates of 
intussusception treatment utilisation rates are needed.  
 
A global pooled estimate of the relative risk of intussusception was used, but this may 
greatly over-estimate the risk in many LMICs. Only one study (a multi-country study 
in Africa (20)) has evaluated post-licensure risk of intussusception in a high mortality 
setting, and this found no elevated risk of intussusception. Had a gradient of risk been 
applied, consistent with under-five mortality, zero excess cases would have been 
predicted in many LMICs, including large countries such as India, Nigeria and 
Pakistan. More post-licensure estimates are needed to confirm the finding of no risk 
in high mortality settings. However, even with pessimistic risk assumptions, there was 
less than one excess intussusception case per 60,000 FVI for a standard schedule co-
administered with DTP. This is far more favourable than the rate associated with 
RotaShield® (more than one case per 10,000 FVI), an early rotavirus vaccine that was 
withdrawn from the market following evidence of its link with intussusception (21). 
 
Another important consideration in settings where an elevated risk has been 
documented, is whether rotavirus vaccination may simply be triggering 
intussusception events that would otherwise occur in the same children anyway at a 
later date (22).    
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10.3 Estimation of the benefit-risk ratio for rotavirus vaccines 
 
My colleagues and I previously evaluated the 2010 birth cohort in 158 countries 
defined by WHO as in strata B, C, D or E. This classification, based on rates of all-
cause child mortality in the year 1999, is now almost twenty years old.(23) This time 
we used the 2018 World Bank classification of LMICs. Compared to the previous 
analysis (24) far fewer RVGE deaths were averted for an equivalent age-unrestricted 
3-dose schedule (DTP1+DTP2+DTP3). This is because of lower official estimates of 
the number of RVGE deaths without vaccination, mainly due to improved access to 
supportive care such as oral rehydration following acute gastroenteritis in LMICs, but 
also due to improved methods of RVGE mortality estimation (25). Estimates of excess 
intussusception deaths were also much lower because the median age of 
intussusception from recent estimates was higher (26), resulting in fewer background 
intussusception cases around the time of DTP1 vaccination. The new benefit-risk ratio 
for an age-unrestricted schedule co-administered with DTP (446:1), is more 
favourable than the previous estimate (371:1), with the benefits of rotavirus vaccine 
introduction still greatly exceeding the risk.  
 
Other benefit-risk analyses in LMICs have reported ratios of 395:1 in Latin America 
(27) and 260:1 in Brazil and Mexico (28). Several benefit-risk analyses have also been 
published for high income countries. In England, my colleagues and I previously 
estimated that Rotarix® would cause 88 fewer RVGE deaths for every additional 
intussusception death (benefit-risk ratio 88:1)(29). The benefit-risk ratio for deaths 
was estimated to be 273:1 in France (30), 77:1 in the USA (31) and  366:1 in Japan 
(32). HICs were excluded from the analysis reported here because deaths from 
rotavirus and intussusception are extremely rare in these settings, so other factors 
become more influential. These include the costs to Governments of providing 
treatment in clinics and hospitals, and the costs to families of seeking healthcare and 
taking time off work (29). These factors, as well as other economic considerations 
(e.g. cost-effectiveness, budget impact), were beyond the scope of this thesis. In 
addition, some of the essential data required to evaluate HICs, such as vaccine 
timeliness, are not routinely available in the public domain.  
 
In our previous analysis we found that removing age restrictions from a standard 
infant schedule co-administered with DTP could prevent an additional ~47,000 
RVGE deaths and cause an additional ~300 intussusception deaths each year (24). In 
the new analysis the equivalent estimates for a standard 3-dose DTP schedule are 
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much lower (~11,000 RVGE deaths prevented and 59 excess intussusception deaths) 
but the incremental benefit-risk ratio is more favourable (186:1 versus 154:1). This 
analysis therefore still supports the WHO recommendation to remove age restrictions 
in countries where the benefit would greatly exceed the risk (33). 
 
10.4 Alternative schedules for rotavirus vaccination 
 
This analysis highlights the potential value of a birth dose in future rotavirus 
vaccination programmes. A birth dose has the potential to avoid the peak background 
age of intussusception as well as preventing rotavirus deaths that occur very early in 
life. The risks of intussusception were assumed to be relative to the baseline incidence, 
rather than assuming an absolute risk difference. This assumption favoured neonatal 
schedules. However, the base case analysis also assumed that doses administered as 
part of a neonatal schedule would have equivalent efficacy/waning assumptions to 
those administered as part of an infant schedule, but evidence suggests they may have 
more durable protection. Indeed, with this assumption, schedules with a birth doses 
had the highest predicted impact in most countries. In some countries neonatal 
schedules did not predict the highest impact because infant schedules achieved higher 
impact during the peak age of RVGE disease (e.g. Bangladesh) or because no BCG 
visit currently exists (e.g. Lebanon, Suriname). However, an important feature of 
many of the countries where neonatal schedules were not preferred (including large 
countries such as India and DR Congo) is that BCG coverage was lower than DTP1 
coverage in the year 2015. In these countries calculations of vaccine impact did not 
allow for opportunities to catch-up on missed doses at later visits. This is probably not 
realistic. More evidence is needed on the post-licensure safety of birth doses, and on 
the efficacy and feasibility of administering the globally licensed rotavirus vaccines 
at birth. The RV3-BB vaccine demonstrated high initial efficacy following a neonatal 
schedule, but it is unclear if the currently licensed vaccines would have similar 
efficacy if administered as a neonatal schedule.  
 
This analysis also highlights the potential benefit of booster doses to mitigate the 
waning protection of rotavirus vaccines (34). A 3rd dose co-administered with Meas1 
was assumed to have the same efficacy (and waning) as a 2nd dose co-administered 
with DTP. This assumption is consistent with a Rotarix® immunogenicity study in 
Bangladesh, where seropositivity (IgA titres ≥ 20 U/mL) increased from 53% to 70% 
after a 3rd dose was administered concurrently with the first dose of measles vaccine 
(35). A study in Mali also found an increase in IgA titres and no negative impact on 
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the immune response of other vaccines administered at the same visit e.g. measles and 
yellow fever (36). However, more evidence is needed on the clinical efficacy and 
safety of booster doses, particularly since most cases of vaccine-related 
intussusception with RotaShield® were associated with doses administered as part of 
a catch-up campaign among older infants (37). However, these were associated with 
the first and second dose, and post-licensure studies have reported no significant 
relative risk with the third dose of RotaTeq administered at ~6 months (35). 
 
Equivalent efficacy and waning was assumed following two or three doses co-
administered with DTP because post-licensure studies have found no material 
difference in schedules that use two or three doses (17, 38). Schedules that 
incorporated a third dose co-administered with DTP had a small incremental 
advantage over schedules with only two primary doses because the third dose 
provided some mitigation for short-term waning. In South Africa and Malawi a 2-
dose Rotarix schedule co-administered with DTP2 and DTP3 was directly compared 
to a 3-dose Rotarix schedule co-administered with DTP1, DTP2 and DTP3. In both 
settings the delayed 2-dose schedule had similar initial efficacy but less durable 
protection than the 3-dose schedule (39). Schedule options without a first dose 
administered with BCG or DTP1 were excluded as they do not provide direct vaccine 
protection to infants in the first 2 months of life.  
 
Schedule options that would involve introducing a new immunisation visit were not 
evaluated as this would be costly and may negatively impact overall coverage of the 
immunisation programme. In addition, options that would involve changes to the 
recommended target ages for BCG, DTP and MCV were excluded, as this would have 
implications for other diseases not considered in this analysis. 
 
10.5 Potential areas of further research 
 
One potentially convenient way to explore the influence of indirect and/or inverse 
equity effects on predictions of rotavirus vaccine mortality benefit would be to use an 
individual-based simulation model. Models of this kind, also known as agent-based 
models or micro-simulation models, track the life histories of individuals in the 
population, and then aggregate the results. Simulating individuals is advantageous if 
the risk of an event, such as rotavirus mortality or vaccination, is likely to depend on 
multiple variables or risk factors, such as age, wealth, nutrition, education etc. These 
attributes can be assigned to individuals relatively easily and new attributes can be 
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added as required without the need to restructure the entire model. In principle this 
type of model is also well-suited to incorporating transmission and the influence of 
immunity acquired from repeated natural wild type infections, and waning can 
conveniently be captured for each individual irrespective of when they receive the 
vaccine. It would be difficult to calibrate such a model to data from 135 countries, so 
one or two countries with good data could be selected and evaluated in greater depth. 
An individual-based model was developed by Rose et al to evaluate the impact of 
ROTAVAC® in India (4), and Clark and Sanderson have previously developed an 
individual based model to assess the impact of rotavirus and other vaccines in 
Bangladesh and Peru (40). 
 
Another important avenue for further research would be to assess the potential 
economic implications of alternative schedule options in LMICs. In this analysis the 
dose efficiency of each option was calculated (number of doses administered per 
RVGE death prevented). For age-unrestricted schedules co-administered with DTP, 
the predicted reduction in RVGE deaths was 17%, 29% and 32% for one, two and 
three dose schedules, respectively, but the number of doses required to prevent each 
death was ~3400, ~4000 and ~5200, respectively (Chapter 9, Table 3). An incremental 
cost-effectiveness analysis could more clearly elucidate the incremental value-for-
money of the 18 different schedule options compared to one another and compared to 
standard willingness to pay benchmarks. This analysis should also try to estimate the 
potential costs involved in changing a schedule such as training staff, changes to staff 
time, cold chain cost implications, community awareness campaigns, printing new 
vaccination cards etc. This may be revealing because a small incremental increase in 
predicted benefit may not be a wise use of Government funds. This analysis could be 
extended to consider the cost implications (price per dose, wastage, cold chain costs 
etc.) of the vaccine brands that are available globally (i.e. currently Rotarix, RotaTeq 
and ROTAVAC) and potentially other brands in the pipeline. 
 
10.6 Implications of research for individual, national and global decision-making 
 
One important dimension of this analysis is how individual families and caregivers 
perceive potential benefits and risks of vaccination, and how their priorities may differ 
from those who are responsible for the public health of the population (41). The 
potential negative consequences of adverse events on the coverage of other vaccines 
adds another layer of complexity. In England, concerns about the safety of whole-cell 
pertussis and MMR (measles mumps and rubella) vaccines have led to substantial 
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short-term declines in coverage (65). However, countries with a clearly documented 
small level of intussusception risks continue to have high coverage of rotavirus 
vaccination, suggesting that the current low levels of risk are currently acceptable to 
both individuals and health policy makers. 
 
At national level, our analysis provides information that can be used to make more 
informed assessments. The next step should be to update country-specific policy 
briefs (example shown in Appendix 10) that were previously commissioned by WHO 
and published online (www.vaccine-schedules.com). The target audience for these 
policy briefs is National Immunization Advisory Groups of Experts (NITAGs) or their 
equivalents in LMICs. In addition, the UNIVAC decision support model used in this 
analysis is a user-friendly decision support model designed to be used at country-level 
(www.provac-toolkit.com). This could be used to build within-country consensus 
about data values and explore scenarios appropriate for the national context (42). We 
find that our results depend quite strongly on the country and the type of schedule 
used, so a national focus will be important. The optimal schedule for each country 
will also depend on several other locally relevant criteria including costs, cost-
effectiveness and other programmatic considerations. In the absence of better 
evidence from clinical trials or conflicting predictions from transmission models, one 
approach would be to implement favourable schedules in specific geographical 
locations with good surveillance and assess whether they offer material advantages in 
impact and/or safety compared to existing schedules. 
 
At the global level, the results of this thesis support the current WHO 
recommendations favouring the use of rotavirus vaccines globally, and the removal 
of age restrictions in countries where the benefits greatly exceed the risk. The policy 
briefs and decision-support tools described above should help countries to make more 
informed decisions based on their local data and context. The Global Advisory 
Committee on Vaccines Safety (GACVS) and Strategic Advisory Group of Experts 
(SAGE) are the principal advisory groups to WHO on issues around the safety and 
acceptability of rotavirus vaccines. Currently the committee members have to make 
value judgements informed by the best available evidence on benefits and risks, as 
well as other criteria. However, one way to improve the consistency of 
recommendations around the benefits and risks of different vaccines, would be to 
develop a rule/threshold for the minimum number of deaths that would need to be 
prevented per death caused, in order for the vaccine in question to be recommended. 
This would then serve as a transparent threshold for future recommendation made by 
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GACVS and SAGE about any vaccine. For example, similar benefit-risk deliberations 
may be needed for Dengue vaccines, and a threshold would ensure consistency 
between vaccines. In 2012, the WHO recommended the removal of the 
manufacturer’s age restriction on the basis of a benefit-risk ratio of 150:1, suggesting 
a ratio of this order is considered to be acceptable (24). The lowest published estimate 
of the benefit-risk ratio for deaths is 77:1, as reported in the USA (31). In our analysis, 
some countries had a benefit-risk ratio below 50:1 but many were medium mortality 
countries where assumptions about access to treatment (and intussusception CFRs) 
were very influential. A threshold could stimulate more engagement from policy 
makers about the need to re-assess benefit-risk using their own locally-relevant data 
and decision criteria. This would ideally include an assessment of the potential merits 
of alternative schedules that could further increase impact and reduce risks.   
 
10.7 Final reflections and conclusion 
  
In this analysis, rotavirus vaccination has a favourable benefit-risk profile in most 
LMICs despite pessimistic assumptions about the potential scale of intussusception 
risks. This analysis also supports the current WHO recommendation to remove age 
restrictions in countries where the benefits of late vaccination greatly exceed the risks. 
Further, it provides a useful starting point for thinking about the schedules that might 
have advantages in different countries. Schedules involving birth and booster doses 
could further increase benefits and reduce risks, but more research is needed to assess 
their feasibility, safety and impact. Beyond this, with the aggregated impact on RVGE 
deaths <5 years of age not exceeding 50% for any schedule or scenario evaluated, 
more efficacious rotavirus vaccines would be needed to achieve more substantial 
improvements in impact in LMICs. 
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Background: To minimize potential risk of intussusception, the World Health Organization (WHO) recommended in 2009
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Introduction
Rotavirus infection is the leading cause of fatal diarrhea among
children younger than 5 y, accounting for 453,000 deaths in the
year 2008 based on recently published World Health Organiza-
tion (WHO) estimates [1]. To curb this large toll of severe
rotavirus disease, in 2006, the WHO recommended two rotavirus
vaccines—Rotarix (GSK Biologicals) and RotaTeq (Merck &
Co.)—for use in Europe and the Americas, and in 2009, they
expanded this recommendation to all children worldwide [2].
These recommendations reflected the growing availability of
evidence of the good efficacy profile of rotavirus vaccines—first
from clinical trials in high- and middle-income countries in the
Americas and Europe in 2006 and then also from low-income
settings in Africa and Asia in 2009 [3–6].
Because a previous rotavirus vaccine (RotaShield) was found to
be associated with intussusception, a rare form of bowel
obstruction [7], the pivotal pre-licensure trials in the Americas
and Europe for both currently available rotavirus vaccines were
conducted in over 60,000 infants each to exclude this risk; these
trials did not show an increase in risk of vaccine-associated
intussusception similar to that found with Rotashield [3,4].
However, recent data on the postlicensure safety of rotavirus
vaccines generated from these countries has suggested a possible
low level risk of intussusception (,one to two excess cases per
100,000 vaccinated infants) in some countries but not in others
[8,9]. On the basis of considerations that this low level risk is
greatly exceeded by the observed health benefits of vaccination,
national and international policy and regulatory bodies have
continued to support recommendations for use of rotavirus vaccine
[8,9].
In 2009, WHO recommended that rotavirus vaccines should
not be initiated for infants aged 15 wk or older, with all doses
being completed by 32 wk [2]. These age restrictions were driven
by concerns about intussusception risk. Natural intussusception
rarely occurs before 3 mo of age and the incidence increases 10-
fold between 3 and 6 mo of age [10]. Therefore, a constant
vaccine-associated relative risk (RR) of intussusception, particu-
larly with the first vaccine dose that has been primarily associated
with risk, would translate to more excess cases if infants were
vaccinated late, beyond 3 mo of age. Similar findings were
observed in the United States after use of RotaShield, prompting a
debate about whether restriction of RotaShield to infants younger
than 3 mo of age would have averted withdrawal of the vaccine
[10–12]. A consequence of these strict age restrictions in countries
with vaccination delays is that those arriving late for immunization
would potentially not have access to the benefits of rotavirus
vaccination [13,14].
To facilitate decision making, we previously undertook a
scenario analysis assessing the benefits and risks of a rotavirus
vaccination strategy with and without an age restriction [15].
Since this analysis, new evidence has been published on several key
parameters for the scenario analysis, including data on efficacy of
rotavirus vaccines in Africa and Asia [5,6], the effect of rotavirus
vaccines on diarrhea deaths [16,17], postlicensure data on risk of
intussusception with current rotavirus vaccines [8,9,18], the
release of updated estimates of rotavirus mortality by WHO [1]
and age distribution of rotavirus disease by week of age [19], and
updated data on timeliness of vaccination coverage in low- and
middle-income countries [20]. The availability of these new data
and the imminent introduction of rotavirus vaccines in many
developing countries in Africa during the next 2 y prompted us to
revise our previous analysis to provide policy makers with the most
up-to-date evidence to inform decisions of best approaches to
global implementation of rotavirus vaccines.
Methods
We focused this analysis exclusively on the benefits of rotavirus
mortality reduction and potential risk of fatal intussusception in
children ,5 y of age in 158 low- and middle-income countries
with a birth cohort of 123.6 million where 99.9% of the global
rotavirus mortality occurs. To explore the effect of age restriction
in different parts of the world, we grouped these countries on the
basis of child mortality rates, according to WHO mortality strata
[21], and assigned to one of four groups: group B and C (countries
with low child mortality), group D-Americas (countries in the
Americas with high child mortality), group D-Asia (countries in
Asia with high child mortality), and group D & E-Africa (countries
in Africa with high child mortality). Because group A countries
with very low child mortality (i.e., high-income) represent ,0.1%
of the global rotavirus deaths, they were excluded from this
analysis.
Vaccination Strategies and Coverage Estimates
For both immunization strategies, restricted and unrestricted,
we assumed that rotavirus vaccine would be given at the same time
as the diphtheria-tetanus-pertussis (DTP) vaccine and that vaccine
coverage in the individual countries would be equal to the
proportion of infants receiving each of the three DTP doses by
week of age (i.e., proportion vaccinated, rv) during the first 3 y of
life. Under the restricted schedule, if infants received their first
DTP dose by #14 wk of age, we assumed they would receive all
doses up to 32 wk of age, but if they first appeared after 14 wk,
they would remain unvaccinated. On the unrestricted schedule,
vaccine would be administered according to the age-specific
coverage rates for each of the DTP dose up to 3 y of age.
Our DTP coverage estimates are based on vaccination data
from household USAID Demographic and Health Surveys (DHSs)
[22] and the United Nations Children’s Fund (UNICEF) Multiple
Indicator Cluster Surveys (MICS) [23] that were administered in
48 countries between 1996 and 2009. To estimate coverage for
countries without DHS or MICS data, overall WHO-UNICEF
2010 country-specific coverage estimates were converted into age-
specific coverage rates using regression coefficients to predict
lognormal curves of timeliness. These were derived from the
available DHS/MICS survey data and extrapolated to countries
without a survey within a WHO region and mortality stratum.
Timeliness was determined by WHO sub-region and adjusted for
trends between the DHS/MICS survey year and 2010 using the
WHO-UNICEF 2010 best estimates for DTP coverage data,
drop-out rate between DTP1 and DTP3, the target age
recommended in the country schedule, and the gross domestic
product per capita [24]. This process was done separately for
DTP1 and DTP3. DTP2 timeliness assumed the average of the
regression coefficients used for DTP1 and DTP3.
Our analysis does not allow catch-up immunization and
assumes no improvement in timeliness with the introduction of
rotavirus vaccine.
Assessment of Benefits—Base Scenario
Estimated numbers of country-specific rotavirus deaths (lrv)
were obtained from WHO, using the 95% CIs to define the
triangular distributions around the point estimate (Table 1) [1].
On the basis of a WHO-sponsored review of published and
unpublished studies on age distribution of diarrhea mortality and
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rotavirus-associated hospitalizations by week of age, we predicted
1-wk gamma age distributions for the first year of life and 4-wk age
categories thereafter for countries in different WHO regions [19].
Rotavirus vaccine efficacy (erv) against fatal rotavirus disease was
estimated from clinical trials or vaccine effectiveness studies in
each WHO region (Tables 1–2) [3,5,6,25–29]. Because efficacy
against rotavirus mortality could not be directly measured in the
trials, we applied efficacy estimates against the most severe
rotavirus disease outcome reported in the study [3,5,6,25–29].
This approach was reasonable given that three nationwide studies
from Latin America have documented reductions in diarrhea
deaths after vaccine introduction that has approximated reduc-
tions based on the efficacy of these vaccines against severe
rotavirus disease [16,17,30]. Because both rotavirus vaccines have
performed similarly in clinical trials, we assumed the same overall
efficacy for the two-dose Rotarix and the three-dose RotaTeq
vaccine. The efficacy parameters were age-stratified (,1 y and
.1 y of age) because studies have documented lower efficacy
among children older than 1 y of age [5,25,27]. Efficacy of partial
vaccination (first dose) was also available from one country in the
B & C region [27], and one country in the D-Americas region
[25], but not for D-Asia and D & E-Africa. We therefore reduced
the point estimates for full vaccine efficacy for Asia and Africa by
the same proportion as the relative difference in efficacy between
the full and partial series in D: Americas region. We used 95% CIs
from the respective studies to define the beta distribution around
the vaccine efficacy point estimates.
The number of rotavirus deaths prevented was obtained from
lrvervrv, where lrv is the number of rotavirus deaths by week of age, erv is
the vaccine efficacy, and rv is the proportion vaccinated by week of age.
Assessment of Risk—Base Scenario
Risk of intussusception has been documented after postlicensure
use of Rotarix and RotaTeq in four different studies [8,9,31,32].
Each of these studies identified an approximate 4- to 6-fold
increase in risk relative to background during the first week after
dose 1 (Table 3), a magnitude of risk that would not have been
detected in the clinical trials. No effect modification of risk with
age at vaccination was reported in these studies, but the first dose
of vaccine was largely administered before 15 wk. In two
Table 1. Estimates of rotavirus mortality and intussusception incidence by WHO mortality group.
Mortality, Incidence, and Fatality WHO Mortality Group Estimate (Lower Bound, Upper Bound)
B & C D: Americas D: Asia D & E: Africa
Rotavirus mortality 26,700 (24,000–29,000) 5,300 (4,600–5,900) 188,300 (160,000–217,000) 232,500 (198,000–268,000)
Intussusception incidence (range) 53.3 (17.7–88.2) 53.3 (17.7–88.2) 53.3 (17.7–88.2) 53.3 (17.7–88.2)
Intussusception case fatality 5% (4–6) 10% (8–12) 25% (20–30) 25% (20–30)
doi:10.1371/journal.pmed.1001330.t001
Table 2. Estimates of efficacy for partial and full series of rotavirus vaccine against the most severe reported outcome of rotavirus
gastroenteritis, by WHO mortality group.
WHO Mortality Group Reference Location Outcome Vaccine Efficacy
a
,1 y of Age 1 y of Age
Percent (95% CI) Percent (95% CI)
Full series efficacy during
first year of life
B & Cb [26] Latin America $19 97 84–100 97 84–100
D: Americasb [25] Nicaragua $15 77 39–92 77 39–92
D: Asia/D & E Africa [5,6,29] Bangladesh, Vietnam,
Ghana, Kenya, Mali
$15 67 37–84 34 216 to 63
D & E Africac [28]b South Africa & Malawi $11 61 44–73 — —
Partial series efficacy
B & C [27] El Salvador Hospitalizations 51 26–67 51 26–67
D: Americas [25] Nicaragua Hospitalizations 55 22–74 55 22–74
D: Asia/D & E Africad — — — 48 30–68 24 0–51
aBecause vaccine efficacy against rotavirus deaths was not available, the model input was efficacy against the most severe reported form of rotavirus gastroenteritis in
the clinical trial ($11 denotes ‘‘severe’’ diarrhea and $15 denotes ‘‘very severe’’ diarrhea on 20 point Vesikari clinical scoring system).
bNo decline in efficacy by age was reported by age for the very severe outcome, thus the efficacy estimate for children ,2 were applied to both age groups,1 and 1 y
of age.
cThis trial measured efficacy during the first year of life. No estimates of efficacy were available against very severe disease that would serve as a better proxy for death
(i.e., Vesikari $15) at these sites in Malawi and South Africa. Consistent with all other rotavirus efficacy trials where positive correlation exists between efficacy and
severity score, it was assumed that efficacy in South Africa and Malawi would be higher against Vesikari score $15 than Vesikari $11. For the model, estimates of
efficacy against ‘‘very severe’’ rotavirus diarrhea were from sites in Africa and Asia where these data were available [5,6,29].
dBecause no partial vaccine efficacy estimates were available for Africa and Asia, we assumed that a proportional difference in efficacy between full and partial
vaccination that was observed in high mortality country of Nicaragua [25].
doi:10.1371/journal.pmed.1001330.t002
Rotavirus Vaccine Benefit Risk
PLOS Medicine | www.plosmedicine.org 3 October 2012 | Volume 9 | Issue 10 | e1001330
additional countries, no risk of intussusception was identified after
the first vaccine dose [9,18]. Risk of intussusception was not
identified after the first dose in Brazil (RR=1.1; 95% CI= 0.3–
3.3) or the United States (RR=1.2; 95% CI=0.03–6.8). However
in view of the wide CIs, particularly in the United States, a risk of
small magnitude similar to that detected in the other four studies
cannot be excluded [9,18]. In Brazil, a statistically significant 2-
fold risk was also identified in the first week after dose 2.
We obtained dose-specific pooled estimates of RR from each of
the regions where some increase in RR of intussusception was
identified (Table 3). To err on the side of risk, we excluded the US
safety data from the pooled analysis because no risk was identified.
For pooled estimates of vaccine-associated intussusception risk, we
used the weighted average of the logarithm of the RR,
glog(RRi)vi/gvi, where weight (vi) for each study [8,9,31,32] is
the inverse of the variance computed from the reported 95% CIs
[33]. The variance of the weighted average log RR is the inverse of
the sum of the each weight (1/gvi) and was used to compute the
95% CIs for the pooled risk estimate. For the uncertainty analyses,
we used the 95% CIs to define the gamma distribution around the
RR estimates.
The average annual incidence of natural intussusception by week
of age ((lis) was estimated from published studies. Because natural
intussusception is a very rare disease, we restricted our review to
studies reporting either national incidence of intussusception or
incidence of intussusception from a minimum of five hospitals with
known catchment population, stratified by age [34–51]. While
intussusception incidence in this review ranged from 18–88 per
100,000 infants, the age distribution of intussusception was similar
between the different studies. Thus, to obtain intussusception
incidence by week of age (lis), we applied the global intussusception
incidence among infants and fit a gamma curve to intussusception
surveillance data from the United States [45], the only country
where intussusception incidence was available by week of age. For
uncertainty analysis, parameters of the gamma curve for lis were
sampled from a normal distribution, assuming standard deviation is
equal to 5% of the mid-parameter values.
Death caused by intussusception is uncommon in industrialized
countries, occurring in ,1% of the cases [52]. In a recently
conducted national study from 16 hospitals in Mexico and 43
hospitals in Brazil (WHO group B & C), case fatality for
intussusception was 1% and 5%, respectively [9]. One large study
from nine countries across Africa indicated an average case fatality
of about 12% [53]. No reliable estimates of case fatality were
available for countries in D-Americas and D-Asia. Thus, we
conservatively estimated the case fatality (dis) to be 5% for B & C
countries, 10% for D-Americas, 25% for D-Asia, and 25% for D &
E-Africa. We sampled from a beta distribution, assuming standard
deviation is equal to 5% of the mid parameter values to specify the
upper and lower limits of dis in uncertainty analyses.
The number of intussusception deaths associated with vaccination,
during the first week after dose 1 and 2, was obtained fromBrv[(lisRRi)
2 lis]dis, where B is the number of births, rv is the proportion
vaccinated by week of age, lis is the intussusception incidence by week
of age, RRi is the RR during the week after each dose, and dis the
proportion of intussusception events that lead to death.
Sensitivity Analysis
We conducted a one-way sensitivity analysis to determine the
impact on the benefit-risk ratios when assuming four conservative
scenarios that would favor risk and one that would favor vaccine:
(1) We assumed a relative increase of 20% in incidence and case
fatality of intussusception. (2) We explored the impact of effect
modification of risk by age at vaccination, by doubling estimates of
RR of intussusception when dose 1 of rotavirus vaccine was
administered to infants older than 14 wk of age. (3) We assumed a
scenario of low vaccine efficacy by inputting the lower confidence
limit for each of the efficacy estimates. (4) We explored the effect of
a ‘‘pessimistic’’ situation combining all of the preceding three
scenarios. (5) We also assessed the effect of an ‘‘optimistic’’
scenario of high vaccine efficacy related to factors such as possible
indirect benefits or higher efficacy among children vaccinated at
older ages with lesser interference of vaccine take from circulating
transplacental antibodies.
Uncertainty Analysis
The above analyses yielded estimates of rotavirus deaths averted and
intussusception deaths caused under age-restricted and -unrestricted
Table 3. Pooled estimates of risk after doses 1 and 2 of rotavirus vaccine.
Country Reference Rotavirus Vaccine RR Lower 95% Limit
Upper 95%
Limit
Dose 1
Australia [8] Pentavalent 3.9 1.5 9.9
Australia [8] Monovalent 4.1 1.3 13.5
Mexico [9] Monovalent 5.3 3 9.3
Mexico [31] Monovalent 6.5 4.2 10.1
Global reporting [32] Monovalent 5.0 1.7 14.3
Pooled estimatea 5.5 4.1 7.5
Dose 2
Mexico [9] Monovalent 1.8 0.9 3.8
Mexico [31] Monovalent 1.3 0.8 2.1
Brazil [9] Monovalent 2.6 1.3 5.2
Pooled estimatea 1.7 1.2 2.4
aWe used the weighted average of the logarithm of the RR, glog(RRi)vi/gvi, where weight (vi) for each study is the inverse of the variance computed from the
reported 95% CIs [33]. The variance of the weighted average log RR is the inverse of the sum of each weight (1/gvi) and was used to compute the 95% CIs for the
pooled risk estimate.
doi:10.1371/journal.pmed.1001330.t003
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vaccination strategies. We conducted a probabilistic uncertainty
analysis to assess the potential impact of simultaneous variation
of each of the model inputs (lrv, erv, rv, lis, RR) on the
precision of the benefit-risk estimates. We shifted the lognormal
timeliness curves and gamma rotavirus and intussusception age
curves by simultaneously sampling new shape, shift, and scale
parameters for each run, with each parameter being sampled
from a normal distribution with standard deviation equal to 5%
of the original parameter value. On the basis of the error
estimates and error distributions described for each of the model
inputs, we conducted 2,000 simulations to obtain the median
estimates of deaths averted and caused as well as the
uncertainty ranges, defined as the 5th–95th percentile, to
provide an indication of the uncertainty in the estimates. All
analyses were done with Microsoft EXCEL (Microsoft Corp,
2007).
Results
Approximately 453,000 rotavirus-associated deaths are estimat-
ed among children younger than 5 y annually without a rotavirus
vaccination program (Figure 1). We project that a rotavirus
vaccination program under the current age-restricted schedule
would prevent almost 33% or 155,800 of these deaths (5th–95th
centiles, 83,300–217,700) if delivered at the same ages at which the
DTP vaccine is currently being delivered in these countries
(Table 4). Without the age restrictions, a program would prevent
45% or 203,000 deaths of all rotavirus deaths (102,000–281,500),
which would represent 47,200 more deaths prevented (18,700–
63,700) than with an age-restricted schedule. These additional
deaths prevented under an unrestricted vaccination schedule
reflect an additional 18%, 21%, 25%, and 22% of the children
receiving DTP1 in the WHO B & C, D-Americas, D-Asia, and D-
Africa countries, respectively, compared to the age-restricted
schedule in these countries (Figure 2).
From the perspective of risk, a rotavirus vaccination program
limiting vaccination to children ,15 wk of age would cause about
253 intussusception deaths (76–689) (Table 4). In contrast, a
program without age restrictions would cause nearly 547
intussusception deaths (237–1,160). Thus, a vaccination policy
without any age restrictions for use of rotavirus vaccines in low-
and middle-income WHO countries would avert an additional
47,200 rotavirus-associated deaths and cause an additional 294
intussusception-associated deaths, compared to the current age-
restricted strategy (Table 5). The median incremental benefit-risk
ratio in all mortality strata was nearly 154 deaths averted for every
death caused, ranging from 55–318 deaths averted for every death
caused across the different mortality strata (Figures 3 and 4).
Under the scenarios of effect modification of risk with age at
vaccination and increased incidence and case fatality of intussus-
ception, an unrestricted schedule would cause 603 (174–946) and
423 (232–678) excess deaths, respectively, while averting about
47,200 rotavirus deaths (18,700–63,700) (Table 5). A scenario
where efficacy approximated the lower confidence limit in the
clinical trials would avert an additional 20,400 rotavirus deaths
(8,500–34,300) under an unrestricted schedule. With pessimistic
assumptions of high intussusception incidence and case fatality,
high risk, and low efficacy, a vaccination program without age
restrictions would cause 868 intussusception deaths (506–1,362)
while preventing 20,400 rotavirus deaths (8,500–34,300), for a
Figure 1. Age distribution of rotavirus deaths among children under 5 y, by WHO mortality group.
doi:10.1371/journal.pmed.1001330.g001
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benefit-risk ratio of 24. In contrast, the benefit-risk ratio would
approximate 220 (116–407) under an optimistic scenario of high
vaccine efficacy.
Discussion
Our analysis demonstrates that if first dose of rotavirus vaccine
is restricted to children 14 wk of age or younger, rotavirus vaccines
would prevent about 155,800 of the 453,000 rotavirus deaths
occurring in children ,5 y of age annually worldwide while
resulting in 253 intussusception deaths. While most of the gap in
preventable rotavirus deaths is due to the moderate efficacy of the
vaccines in high mortality settings, the current age restrictions on
rotavirus vaccination also contribute by potentially excluding
nearly 21%–25% of the world’s children, those with the highest
risk of rotavirus mortality, from receiving these vaccines. Lifting
the age restriction for the first dose of rotavirus vaccination would
save an additional 47,200 lives yearly and would result in an
additional 294 intussusception deaths, for an incremental benefit
of saving 154 lives for each excess intussusception death caused.
In the past 5 y, with the introduction of rotavirus vaccines in
nearly 30 countries worldwide, substantial experience has been
gained with regard to the safety and effectiveness of these vaccines
in the real-world setting, including against deaths [8,9,16–
18,25,27,54,55]. Moreover, clinical trials for these vaccines have
documented their efficacy in target populations of Asia and Africa,
where majority of the rotavirus deaths occur. Given these
encouraging data, the ability of the vaccines to reach children
with the highest mortality will be a major determinant of their life-
saving impact.
Our base estimates are conservative, erring on the side of
overestimating vaccine risk for four reasons. First, over 45
publications have documented remarkable declines in severe
diarrhea and rotavirus disease, including deaths, since their
introduction in national immunization programs worldwide
[55]. Many of these studies from different locations have
demonstrated significant declines in unvaccinated members of
the community, indicating indirect benefits of vaccination that
we did not account for in our analysis [56–59]. Second, because
of interference from circulating transplacental antibodies during
the first several months of life, immune response to vaccine and
thus efficacy is likely to be higher when children are vaccinated
at older ages. For example, anti-rotavirus IgA geometric mean
titers for Vietnamese infants vaccinated against rotavirus at 9
and 13 wk were lower (77 U/ml) compared to infants vacci-
nated at 9 and 17 wk of life (176 U/ml) [60]. Third, we
assumed that some risk of intussusception exists following each
of the first two doses of rotavirus vaccine in all countries
worldwide; however, risk of intussusception has varied by
setting, and robust studies in two large countries have not
identified risk after dose 1 [9,18]. Fourth, even in our base
scenario, we assumed high rates of intussusception case fatality
in all WHO regions, about 2-fold higher than those reported in
the literature.
Table 4. Rotavirus deaths averted versus excess intussusception deaths caused under age-restricted and age-unrestricted
rotavirus vaccination strategies, by WHO mortality group and age.
Vaccination Strategy Rotavirus Deaths Averted (95% CI)
a Intussusception Deaths Causeda (95% CI)
Benefit to
Risk Ratio
Age Restrictionb
No Age
Restriction Excess Age Restrictionb
No Age
Restriction Excess
B & C countries
Median 18,200 22,700 4,500 35 53 18 247
5th percentile 15,500 19,700 4,200 10 19 9 138
95th percentile 20,500 25,200 4,700 94 127 33 519
D: Americas
Median 2,600 3,300 700 3 5 2 343
5th percentile 1,400 1,800 400 1 2 1 152
95th percentile 3,200 4,000 800 9 12 3 674
D: Asia
Median 55,400 76,800 21,400 118 275 157 133
5th percentile 25,200 32,200 7,000 36 120 84 43
95th percentile 83,400 115,300 31,900 317 576 259 286
D: Africa
Median 79,600 100,200 20,600 96 212 116 167
5th percentile 40,300 46,900 6,600 28 96 68 50
95th percentile 111,100 138,300 27,200 265 441 176 328
All strata
Median 155,800 203,000 47,200 253 547 294 154
5th percentile 83,300 102,000 18,700 76 237 161 55
95th percentile 217,700 281,500 63,700 689 1,160 471 318
aEstimates of rotavirus deaths averted and intussusception deaths caused are based on efficacy, risk, and case-fatality parameters in Tables 1–3. Vaccination coverage is
based on DTP vaccination rates from household DHSs and UNICEF MICSs.
bAge restriction denotes dose 1 administration by 15 wk and the full series by 32 wk of age.
doi:10.1371/journal.pmed.1001330.t004
Rotavirus Vaccine Benefit Risk
PLOS Medicine | www.plosmedicine.org 6 October 2012 | Volume 9 | Issue 10 | e1001330
On the other hand, the benefit-risk ratios might be inflated due
to several factors. First, our base scenario assumes that the risk of
intussusception relative to background does not increase with age.
After the withdrawal of RotaShield, a debate persisted with regard
to whether the RR of intussusception might have been higher for
infants vaccinated beyond 14 wk of age [11,12]. While limited
data from an evaluation in Mexico does not suggest effect
modification of risk by age for current vaccines [9], we
incorporated a scenario of increased risk with age at vaccination
that indicated that vaccination would avert 75 rotavirus deaths for
each excess intussusception death. Second, our model might have
overestimated vaccine coverage among children at the highest risk
of dying from rotavirus as these might be the hardest to reach, thus
inflating the mortality benefits of vaccination relative to the risks in
our model. However, data from Mexico and Brazil, where
substantial reductions in diarrhea deaths have occurred in all
regions of both countries after the introduction of vaccine [16,17],
provides some reassurance that vaccine is reaching those at the
highest risk of dying.
While the numerical benefits of relaxing the age restriction on
rotavirus vaccination exceed the risks, other factors are relevant for
policy considerations. First, the age restrictions for rotavirus
vaccines potentially offer an incentive to improve timeliness of
vaccination, which would potentially have far reaching benefits
beyond just prevention of rotavirus disease. However, reasons for
delays in vaccination in developing countries are complex and it is
not known if a policy of restricting the first dose of rotavirus
vaccines alone would be a sufficient motivational factor for parents
and countries to improve timeliness of vaccination. Indeed, some
delays may be due to unavoidable factors, such as contraindica-
tions. Second, while the unrestricted vaccination scenario allows
for vaccination at any age during the first 3 y of life, few children
arrive for vaccination beyond 1 y of life. It is important to note
that delays in vaccination particularly beyond 1 y of life will
reduce benefits substantially because of increasing probability of
acquiring natural immunity from wild-type rotavirus infection.
Third, a death caused by an intervention may be perceived worse
than a death caused by a failure to intervene [61–63]. However,
some evidence suggests that individuals may regret disease
resulting from withholding vaccine as much as side effects from
vaccination [63]. Furthermore, after the RotaShield experience,
ethicists argued equal culpability for deaths caused by withholding
the vaccine as for deaths resulting from the vaccine [64]. Finally,
our analysis did not address high income countries where mortality
from both rotavirus disease and from intussusception is uncom-
mon, and thus the benefit-risk considerations will differ. Further-
more, vaccination is more timely in these settings (e.g., in the
United States, 93% of the DTP1 is given by 15 wk of age [65]),
and thus decisions will likely have to be made at a country level
based on evaluation of local data.
In summary, using emerging, real-world data on rotavirus and
intussusception mortality and rotavirus vaccine efficacy, safety,
Figure 2. Vaccine coverage for dose 1 of DTP by week of age and WHO mortality group based on the DHSs and UNICEF MICs.
doi:10.1371/journal.pmed.1001330.g002
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Table 5. Additional lives saved versus deaths caused by loosening the age restrictions for rotavirus vaccines in WHO high and very
high mortality group.
Scenario Median (5th Percentile, 95th Percentile)
Lives Saved Deaths Caused Benefit/Risk Ratio
Basea 47,200 (18,700–63,700) 294 (161–471) 154 (55–318)
Base+higher intussusception rate and case fatalityb 47,200 (18,700–63,700) 423 (232–678) 107 (38–221)
Base+increase RR with age at dose 1c 47,200 (18,700–63,700) 603 (174–946) 75 (27–143)
Base with low vaccine efficacy 20,400 (8,500–4,300) 294 (161–471) 71 (24–159)
Pessimisticd 14,400 (7,400–28,300) 703 (459–1,042) 24 (9–51)
Optimistic (Base+high vaccine efficacy)e 65,800 (39,900–77,000) 294 (161–471) 220 (116–407)
aAssumes point estimates for vaccine efficacy and intussusception risk and case-fatality estimates presented in Tables 1–3.
bAssumes 20% relative increase in incidence and case fatality of intussusception compared to base scenario.
cAssumes a doubling of RR of vaccine associated risk of intussusception among children receiving dose 1 beyond 15 wk of age.
dPessimistic scenario assumes base scenario with: (1) 20% increase in background incidence and case fatality of intussusception compared to base scenario; (2) doubling
of relative among children vaccinated with dose 1 beyond 15 wk of age; and (3) lower 95% confidence limit for vaccine efficacy.
eOptimistic scenario assumes the upper confidence limit for vaccine efficacy in each setting.
doi:10.1371/journal.pmed.1001330.t005
Figure 3. Global analysis of the relationship between esimated number of rotavirus gastroenteritis deaths avoided versus
intussusception deaths caused by removal of the age restrictions for rotavirus vaccination. These estimates are from 2,000 simulations
with each blue dot representing a potential estimate of rotavirus deaths prevented (y-axis) versus intussusception deaths caused (x-axis) from
removal of the age restrictions given the uncertainty on the parameters in the model: rotavirus mortality, vaccine efficacy, vaccine coverage,
intussusception incidence, intussusception risk from vaccine, and intussusception fatality. The black square represents the median estimate.
doi:10.1371/journal.pmed.1001330.g003
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and coverage, we estimate that removing the age restrictions on
rotavirus vaccination would avert 47,200 additional rotavirus
deaths in low- and middle-income countries. In April 2012,
WHO’s Strategic Advisory Group of Experts reviewed the
evidence presented in this paper and recognized that the 15-wk
and 32-wk age restrictions for rotavirus vaccines are preventing
vaccination of many vulnerable children [66]. SAGE encourages
timely vaccination, but no longer universally recommends the age
restrictions, supporting their removal in seetings where mortality
benefits outweigh the risk so that many thousands more deaths
would be averted and immunization programs are able to
immunize children who are currently excluded from the benefits
of rotavirus vaccines. Age restriction policies will ultimately be
decided at country level, but this analysis has shown a clear case
for a change in policy that will be particularly instrumental for
saving lives in settings where mortality from rotavirus is high and
delays in timing of vaccination are common.
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Editors’ Summary
Background. Rotavirus causes severe diarrhea and vomit-
ing. It is responsible for a large number of hospitalizations
among young children in developed countries (an estimated
60,000 hospitalizations per year in the US in 2005, for
example). In poor countries, rotavirus is a major cause of
death in children under five. In 1998, the first rotavirus
vaccine, called RotaShield, was approved in the US by the
Food and Drug Administration. Shortly after the vaccine
became widely used, doctors noticed a small increase in a
problem called intussusception among the vaccinated
infants. Intussusception is a rare type of bowel obstruction
that occurs when the bowel telescopes in on itself. Prompt
treatment of intussusception normally leads to full recovery,
but some children with the condition need surgery, and
when the disease is left untreated it can be fatal. Because
intussusception is a serious condition and because very few
children die from rotavirus infection in the United States, the
US authorities stopped recommending vaccination with
RotaShield in 1999. The manufacturer withdrew the vaccine
from the market shortly thereafter.
Since then, two new vaccines (named Rotarix and RotaTeq)
have been developed. Before they were approved in the US
and elsewhere, they were extensively tested for any adverse
side effects, especially intussusception. No increase in the
risk for intussusception was found in these studies, and both
are now approved and recommended for vaccination of
infants around the world.
Why Was This Study Done? Since 2006, hundreds of
thousands of infants have been vaccinated with Rotarix or
RotaTeq, with safety being closely monitored. Some coun-
tries have reported a small increase in intussusception (one
to four additional cases per 100,000 vaccinated infants,
compared with one per 2,000 of cases that occur in
unvaccinated children). This increase is much lower than
the one seen previously with RotaShield. In response to
these findings, authorities in the US and other developed
countries as well as the World Health Organization declared
that the benefits of the vaccine outweigh the risks of the
small number of additional intussusception cases in both
developed and poor countries. However, because older
infants have a higher risk of naturally occurring intussuscep-
tion, they decided that the course of vaccination (three oral
doses for Rotarix and two for RotaTeq) should be initiated
before 15 weeks of age and completed before the age of 32
weeks. This is usually not a problem in countries with easy
access to health facilities. However, in many poor countries
where delays in infant vaccination are common, giving the
vaccine only to very young children means that many others
who could benefit from its protection will be excluded. In
this study, the researchers examined the risks and benefits of
rotavirus vaccination in poor countries where most of the
rotavirus deaths occur. Specifically, they looked at the
benefits and risks if the age restrictions were removed, with
a particular emphasis on allowing infants to initiate rotavirus
immunization even if they arrive after 15 weeks of age.
What Did the Researchers Do and Find? The researchers
used the most recent estimates for how well the vaccines
protect children in Africa and Asia from becoming infected
with rotavirus, how many deaths from rotavirus infection can
be avoided by vaccination, how many additional cases of
intussusception will likely occur in vaccinated children, and
what proportion of children would be excluded from
rotavirus vaccination because they are too old when they
come to a health facility for their infant vaccination. They
then estimated the number of rotavirus deaths prevented
and the number of intussusception deaths caused by
vaccination in two scenarios. The first one (the restricted
scenario) corresponds to previous guidelines from WHO and
others, in which rotavirus vaccination needs to be initiated
before 15 weeks and the full series completed before 32
weeks. The second one (called the unrestricted scenario)
allows rotavirus vaccination of children alongside current
routinely administered vaccines up to three years of age,
recognizing that most children receive their vaccination by 1
year of life.
The researchers estimated that removing the age restriction
would prevent an additional 154 rotavirus deaths for each
intussusception death caused by the vaccine. Under the
unrestricted scenario, roughly a third more children would
get vaccinated, which would prevent an additional approx-
imately 47,000 death from rotavirus while causing approx-
imately 300 additional intussusception deaths.
They also calculated some best- and worst-case scenarios.
The worst-case scenario assumed a much higher risk of
intussusception for children receiving their first dose after 15
weeks of life than what has been seen anywhere, and also
that an additional 20% of children with intussusception
would die from it than what was already assumed in their
routine scenario (again, a higher number than seen in
reality). In addition, it assumes a lower protection from
rotavirus death for the vaccine than has been observed in
children vaccinated so far. In this pessimistic case, the
number of rotavirus deaths prevented was 24 for each
intussusception death caused by the vaccine.
What Do These Findings Mean? If one accepts that
deaths caused by a vaccine are not fundamentally different
from deaths caused by a failure to vaccinate, then these
results show that the benefits of lifting the age restriction for
rotavirus vaccine clearly outweigh the risks, at least when
only examining mortality outcomes. The calculations are
valid only for low-income countries in Africa and Asia where
both vaccination delays and deaths from rotavirus are
common. The risk-benefit ratio will be different elsewhere.
There are also additional risks and benefits that are not
included in the study’s estimates. For example, early
vaccination might be seen as less of an urgent priority
when this vaccine can be had at a later date, leaving very
young children more vulnerable. On the other hand, when
many children in the community are vaccinated, even the
unvaccinated children are less likely to get infected (what is
known as ‘‘herd immunity’’), something that has not been
taken into account in the benefits here. The results of this
study (and its limitations) were reviewed in April 2012 by
WHO’s Strategic Advisory Group of Experts. The group then
recommended that, while early vaccination is still strongly
encouraged, the age restriction on rotavirus vaccination
should be removed in countries where delays in vaccination
and rotavirus mortality are common so that more vulnerable
children can be vaccinated and deaths from rotavirus
averted.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001330.
N The World Health Organization provides information on
rotavirus
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N Wikipedia has information on rotavirus vaccine and
intussusception (note that Wikipedia is a free online
encyclopedia that anyone can edit; available in several
languages)
N The US Centers for Disease Control and Prevention
rotavirus vaccination page includes a link to frequently
asked questions
N PATH Rotavirus Vaccine Access and Delivery has timely,
useful updates on status of rotavirus vaccines globally
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rotavirus vaccines
WHo position paper – 
January 2013
In accordance with its mandate to provide 
guidance to Member States on health pol-
icy matters, WHO issues a series of regu-
larly updated position papers on vaccines 
and combinations of vaccines against 
diseases that have an international public 
health impact. These papers are concerned 
primarily with the use of vaccines in 
large-scale immunization programmes; 
they summarize essential background 
information on diseases and vaccines, and 
conclude with the current WHO position 
on the use of vaccines worldwide.
The papers have been reviewed by exter-
nal experts and WHO staff, and are 
reviewed and endorsed by the WHO 
Strategic Advisory Group of Experts on 
Immunization (SAGE).1 The position 
papers are intended for use mainly by na-
tional public health officials and managers 
of immunization programmes. They may 
also be of interest to international funding 
agencies, vaccine manufacturers, the med-
ical community, the scientific media, and 
the public. A description of the processes 
followed for the development of vaccine 
position papers is available at http://www.
who.int/immunization/position_papers/
position_paper_process.pdf
This position paper replaces the corre-
sponding WHO position paper of 2007 and 
its update of 2009; it summarizes recent 
developments in the field, in particular the 
potential of rotavirus vaccines to further 
reduce mortality by employing more flex-
ible immunization schedules. All WHO 
recommendations appear at the end of 
this paper and reflect those offered by 
SAGE. Rotavirus vaccines were last dis-
cussed by SAGE at its meeting in April 
2012; evidence presented at the meeting 
Vaccins antirotavirus
Note de synthèse de l’omS
Conformément à son mandat qui consiste à 
orienter les États Membres sur les questions 
de santé publique, l’OMS diffuse une série de 
notes de synthèse régulièrement mises à jour 
sur les vaccins et associations de vaccins qui 
intéressent la santé publique internationale. 
Ces notes, qui concernent avant tout l’utilisa-
tion des vaccins dans les programmes de 
vaccination à grande échelle, résument les 
informations de base essentielles sur les mala-
dies et les vaccins dont il est question et 
indiquent la position actuelle de l’OMS sur 
l’utilisation des vaccins dans le contexte 
mondial.
Elles ont été soumises à l’examen d’un certain 
nombre d’experts externes et de membres du 
personnel de l’OMS et font l’objet d’un examen 
et d’une approbation par le groupe consultatif 
stratégique d’experts de l’OMS (SAGE) sur la 
vaccination.1 Les notes de synthèse sont prin-
cipalement destinées aux responsables natio-
naux de la santé publique et des programmes 
de vaccination. Elles peuvent toutefois aussi 
intéresser les organismes internationaux de 
financement, les fabricants de vaccins, le corps 
médical dans son ensemble, les médias scien-
tifiques et le grand public. Le processus suivi 
pour l’élaboration des notes de synthèse sur 
les vaccins est décrit sur: http://www.who.int/
immunization/position_papers/position_
paper_process.pdf
La présente note actualisée, qui remplace le 
document correspondant publié en 2007 et la 
mise à jour de 2009, récapitule l’évolution 
récente sur le terrain, en particulier le poten-
tiel qu’on les vaccins antirotavirus pour 
réduire davantage la mortalité en permettant 
des calendriers de vaccination plus flexibles. 
Toutes les recommandations de l’OMS sont 
données à la fin du document et reprennent 
celles proposées par le SAGE. Le sujet des 
vaccins antirotavirus a été discuté pour la 
dernière fois par le SAGE lors de sa réunion 
1 See http://www.who.int/immunization/sage/en 1 Voir http://www.who.int/immunization/sage/fr
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can be accessed at http://www.who.int/immunization/
sage/previous/en/index.html.
Background
Epidemiology 
Rotaviruses infect nearly every child by the age of 
3–5 years and are globally the leading cause of severe, 
dehydrating diarrhoea in children aged <5 years. In low 
income countries the median age at the primary rota-
virus infection ranges from 6 to 9 months (80% occur 
among infants <1 year old) whereas in high income 
countries, the first episode may occasionally be delayed 
until the age of 2–5 years, though the majority still 
occur in infancy (65% occur among infants <1 year 
old).2
In most low income countries in Asia and Africa, rota-
virus epidemiology is characterized by one or more 
periods of relatively intense rotavirus circulation 
against a background of year-round transmission, 
whereas in high income countries with temperate cli-
mates a distinct winter seasonality is typically observed. 
This difference, as well as differences in health care 
availability and childhood co-morbidity, drive the 
marked inequality in rotavirus disease burden between 
low and high income countries.3
WHO estimates that in 2008, approximately 453 000 
(420 000–494 000) rotavirus gastroenteritis (RVGE)-associ-
ated child deaths occurred worldwide (updated WHO 
estimates on global mortality due to RVGE are soon to 
be published). These fatalities accounted for about 5% of 
all child deaths and a cause-specific mortality rate 
of 86 deaths per 100 000 population aged <5 years. About 
90% of all rotavirus-associated fatalities occur in low in-
come countries in Africa and Asia and are related to poor 
health care. National cause-specific mortality rates ranged 
from 474/100 000 (Afghanistan) to < 1/100 000 (63 coun-
tries); in 4 countries (Afghanistan, Burundi, Chad and 
Somalia) mortality rates of >300/100 000 were recorded.4
Each year during the pre-vaccination era 1986–2000, 
>2 million children worldwide were hospitalized for 
rotavirus infections.5 In a recent report of sentinel hos-
pital-based rotavirus surveillance from 35 nations 
representing each of the 6 WHO Regions and different 
economic levels, an average of 40% (range 34%–45%) 
of hospitalizations for diarrhoea among children aged 
<5 years were attributable to rotavirus infection.6
en avril 2012. Le site http://www.who.int/immunization/sage/
previous/en/index.html permet d’accéder aux données factuelles 
présentées lors de cette réunion.
informations générales
Épidémiologie 
À l’âge de 3 à 5 ans, pratiquement tous les enfants ont été 
infectés par les rotavirus qui, partout dans le monde, sont la 
première cause de diarrhée sévère avec déshydratation chez les 
enfants de <5 ans. Dans les pays à faible revenu, l’âge médian 
de l’infection primaire à rotavirus s’établit entre 6 et 9 mois 
(80% des cas surviennent chez les nourrissons de moins d’un 
an) alors que, dans les pays à revenu élevé, le premier épisode 
n’arrive parfois pas avant l’âge de 2 à 5 ans, bien qu’en majorité, 
les nourrissons restent les plus atteints (65% des cas se 
produisent chez les nourrissons de <1 an).2
Dans la plupart des pays à faible revenu d’Asie et d’Afrique, 
l’épidémiologie du rotavirus se caractérise par une ou plusieurs 
périodes de circulation relativement intense, par rapport à une 
transmission de fond toute l’année alors que, dans les pays à 
revenu élevé des régions à climat tempéré, on observe classi-
quement une saisonnalité hivernale marquée. Cette différence 
et celles existant au niveau de la disponibilité des soins et des 
morbidités concomitantes dans l’enfance, induisent une forte 
inégalité de la charge de morbidité imputable aux rotavirus 
entre les pays à revenu faible et élevé.3
L’OMS estime qu’en 2008, il y a eu environ 453 000 (420 000- 
494 000) décès d’enfants liés à des gastroentérites à rotavirus 
(GERV) dans le monde (des estimations actualisées de l’OMS 
sur la mortalité mondiale due aux GERV vont être publiées 
prochainement). Ces morts ont représenté environ 5% des décès 
d’enfants, avec un taux de mortalité spécifique de 86 décès pour 
100 000 enfants de <5 ans. Près de 90% des décès dus aux rota-
virus surviennent dans les pays à faible revenu en Afrique et 
en Asie et ils sont liés à la mauvaise qualité des soins de santé. 
Les taux de mortalité spécifiques nationaux sont allés de 
474/100 000 (Afghanistan) à <1/100 000 (63 pays); dans 4 pays 
(Afghanistan, Burundi, Somalie et Tchad) on a enregistré des 
taux de mortalité >300/100 000.4
Chaque année, de 1986 à 2000, avant l’existence de la vaccina-
tion, >2 millions d’enfants dans le monde ont été hospitalisés 
pour des rotaviroses.5 Dans un rapport récent de la surveillance 
des rotavirus par des hôpitaux sentinelles de 35 pays représen-
tant chacune des 6 régions de l’OMS et des niveaux écono-
miques différents, en moyenne 40% (entre 34% et 45%) des 
hospitalisations pour diarrhée chez des enfants de <5 ans 
étaient dues à des rotaviroses.6
2 Sanderson C et al. Global review of rotavirus morbidity and mortality data by age 
and WHO region. Report to WHO/IVB, 2011 (www.who.int/entity/immunization/
sage/meetings/2012/april/presentations_background_docs/en/ - 45k).
3 Detailed review paper on rotavirus vaccines (presented to the WHO Strategic Advi-
sory Group of Experts (SAGE) on Immunization in April 2009). Geneva, World Health 
Organization, 2009. Available from (http://www.who.int/immunization/sage/3_De-
tailed_Review_Paper_on_Rota_Vaccines_17_3_2009.pdf).
4 WHO estimate for January 2012: http://www.who.int/immunization_monitoring/
burden/rotavirus_estimates/en/index.html
5 Parashar DU et al. Global illness and deaths caused by rotavirus disease in children. 
Emerging Infectious Diseases, 2003, 9:565–572.
6 See No. 47, 2008, pp. 421–425.
2 Sanderson C et al. Global review of rotavirus morbidity and mortality data by age and WHO 
region. Report to WHO/IVB, 2011 (www.who.int/entity/immunization/sage/meetings/2012/
april/presentations_background_docs/en/ - 45k).
3 Detailed review paper on rotavirus vaccines (présenté à la Réunion OMS du Groupe stratégique 
consultatif d’experts sur la vaccination en avril 2012). Genève, Organisation mondiale de la 
Santé, 2009. Disponible sur (http://www.who.int/immunization/sage/3_Detailed_Review_Pa-
per_on_Rota_Vaccines_17_3_2009.pdf). [Document disponible en anglais uniquement.]
4 WHO estimate for January 2012: http://www.who.int/immunization_monitoring/burden/rotavi-
rus_estimates/en/index.html
5 Parashar DU et al. Global illness and deaths caused by rotavirus disease in children. Emerging 
Infectious Diseases, 2003, 9:565–572.
6 Voir No 47, 2008, pp. 421-425.
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The universal occurrence of rotavirus infections even 
in settings with high standards of hygiene testifies to 
the high transmissibility of this virus.
Pathogen, disease and laboratory diagnosis
The pathogen
Rotaviruses are classified as a genus in the family of 
Reoviridae. The triple-layered viral particle encom-
passes a viral genome consisting of 11 segments 
of double-stranded RNA that encode 6 structural viral 
proteins (VPs) and 5 or 6 non-structural proteins 
(NSPs). Reassortment of the 11 gene segments may take 
place in coinfected host cells during the viral replication 
cycle. Formation of reassortants is in part responsible 
for the wide variety of rotavirus strains found in nature; 
even reassortants of animal-human strains have been 
identified. The outermost viral layer contains the viral 
proteins VP7 and VP4, which elicit the production of 
neutralizing antibodies in the host and hence are con-
sidered important for protective immunity. In human 
rotaviruses, at least 12 different VP7 antigens (G-types) 
and 15 different VP4 antigen (P-types) have been iden-
tified. As the combination of G- and P-types can vary 
independently, a binomial typing system is used to 
identify strains. Currently, 5 G-P combinations (G1P[8], 
G2P[4], G3P[8], G4P[8]) and G9P[8]) account for ap-
proximately 90% of all human rotavirus infections in 
many parts of the world; type G1P[8] is the most prev-
alent combination. However, data from countries in Asia 
and Africa show greater strain diversity with several 
rotavirus types circulating simultaneously. The preva-
lent types may vary from one season to the next, even 
within the same geographical area. The type of rotavi-
rus does not usually correlate with the severity of the 
disease. There are currently no known laboratory mark-
ers for rotavirus virulence.7, 8
During the first episode of rotavirus infection, rotavi-
ruses are shed for several days in very high concentra-
tions (>10¹² particles/gram) in the stools and vomitus 
of infected individuals. Transmission occurs primarily 
by the faecal-oral route directly from person to person, 
or indirectly via contaminated fomites. 
Disease
Rotavirus infections affect primarily the mature entero-
cytes on the tips of the small intestinal villi. Destruction 
of these cells reduces the absorptive capacity of the villi, 
resulting in diarrhoea.
The clinical spectrum of rotavirus disease is wide, rang-
ing from transient loose stools to severe diarrhoea and 
vomiting causing dehydration, electrolyte disturbances, 
shock and death. In typical cases, following an incuba-
tion period of 1–3 days, the onset of disease is abrupt, 
with fever and vomiting followed by explosive watery 
Le fait que les infections à rotavirus sévissent dans le monde 
entier, même dans les milieux aux normes d’hygiène élevées, 
atteste de la forte transmissibilité de ce virus. 
Agent pathogène, maladie et diagnostic en laboratoire
Agent pathogène
Les rotavirus sont classés en tant que genre dans la famille des 
réoviridés. La particule virale est dotée d’une capside protéique 
à triple couche et a un génome qui est constitué d’un ARN 
double-brin composé de 11 segments et qui code pour 
6 protéines structurales (VP) et 5 ou 6 protéines non structu-
rales (NSP). Un réassortiment des 11 segments génétiques peut 
s’opérer dans des cellules hôtes subissant une co-infection 
pendant le cycle de réplication du virus. L’apparition de virus 
réassortis est en partie responsable de la grande variété des 
souches rencontrées dans la nature et on en a même observées 
qui résultaient du réassortiment entre des souches humaines et 
animales. La couche virale la plus externe contient les protéines 
virales VP7 et VP4, qui déclenchent la production d’anticorps 
neutralisants chez l’hôte et qui sont donc considérés comme 
jouant un rôle important dans l’ immunité protectrice. Chez les 
rotavirus de l’homme, on a identifié au moins 12 antigènes VP7 
(sérotypes G) et 15 antigènes VP4 (sérotypes P) différents. Les 
sérotypes G et P pouvant se combiner indépendamment, on a 
eu recours à un système de typage binomial pour identifier les 
souches. Actuellement, dans de vastes régions du monde, 
5 combinaisons (G1P[8], G2P[4], G3P[8], G4P[8] et G9P[8]) sont 
à l’origine d’environ 90% de la totalité des rotaviroses humaines, 
le type G1P[8] ayant la plus forte prévalence. En revanche, des 
données provenant d’Asie et d’Afrique révèlent une plus grande 
diversité des types de rotavirus en circulation simultanée. Les 
sérotypes prévalents peuvent varier d’une saison à l’autre, y 
compris au sein d’une même zone géographique. Il n’y a pas 
habituellement de corrélation entre le sérotype et la gravité de 
la maladie. Il n’y a pas actuellement de marqueurs connus 
permettant de déterminer en laboratoire la virulence d’un rota-
virus.7, 8
Au cours du premier épisode de rotavirose, les virus sont excré-
tés pendant plusieurs jours à de très fortes concentrations 
(>10¹² particules/gramme) dans les selles et les vomissures des 
sujets infectés. La transmission se fait principalement par voie 
féco-orale directe entre 2 personnes, ou indirectement par des 
matières contaminées. 
Maladie
Les rotaviroses touchent principalement les entérocytes matures 
au sommet des villosités intestinales. La destruction de ces 
cellules réduit la capacité d’absorption des villosités, ce qui 
provoque la diarrhée. 
Le spectre clinique des rotaviroses est très large, allant d’un 
ramollissement transitoire des selles à une diarrhée sévère et 
des vomissements, entraînant une déshydratation, des troubles 
électrolytiques, un état de choc et la mort. Dans les cas typiques, 
après une incubation de 1 à 3 jours, la maladie se manifeste 
brutalement, avec de la fièvre, des vomissements, suivis d’une 
7 Hu L et al. Rotavirus non-structural proteins: structure and function. Current Opi-
nion in Virology, 2012, 2:380–388. 
8 Manual of rotavirus detection and characterization methods (WHO/IVB/08.17). 
Geneva, World Health Organization, 2009. Available from http://www.who.int/nuvi/
rotavirus/WHO_IVB_08.17_eng.pdf, accessed January 2013.
7 Hu L et al. Rotavirus non-structural proteins: structure and function. Current Opinion in Virology, 
2012, 2:380–388. 
8 Manual of rotavirus detection and characterization methods (WHO/IVB/08.17). Genève, Organisa-
tion mondiale de la Santé, 2009. Disponible sur http://www.who.int/vaccines-documents/Docs-
PDF02/www635.pdf, consulté en juin 2011. [Document disponible en anglais uniquement.]
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diarrhoea. Without adequate fluid replacement, dehy-
dration may ensue. Detailed clinical scoring systems 
have been developed to facilitate comparison of disease 
severity, particularly in vaccine trials. Gastrointestinal 
symptoms normally disappear within 3–7 days, but may 
last for up to 2–3 weeks. Although in most cases, recov-
ery is complete, fatalities due to RVGE may occur, 
mainly in children ≤1 year of age.2, 9, 10
No specific therapy is currently available against rota-
viruses. As with other childhood diarrhoeas, the corner-
stones of treatment are fluid replacement to prevent 
dehydration, and zinc treatment which decreases the 
severity and duration of diarrhoea. Solutions of low-
osmolarity oral rehydration salts (ORS) are more effec-
tive in replacing fluids than previous ORS formulations. 
Additional treatment measures during the diarrhoeal 
episode include continued feeding, including breast-
feeding, and if ORS are not available, use of appropriate 
fluids available in the home.11
Laboratory diagnosis
An etiological diagnosis of rotavirus gastroenteritis 
requires laboratory confirmation. A range of diagnostic 
tests are commercially available: enzyme immunoassays 
for detection of rotavirus antigen directly in stool spec-
imens are widely used, as are also the less sensitive, but 
rapid and simple-to-use test strips and latex agglutina-
tion assays. Reverse transcription polymerase chain 
reaction (RT-PCR), which is highly sensitive in detecting 
small concentrations of rotavirus in stool specimens, is 
also used for strain identification and further differen-
tiation.8 
Protective immunity
Protection against rotavirus infection is mediated by 
both humoral and cellular components of the immune 
system. Following the first infection, the serological 
response is directed mainly against the specific viral 
serotype (i.e. a homotypic response), whereas a broader, 
heterotypic antibody response is elicited following 
≥1 subsequent rotavirus infections.12
A study that monitored 200 Mexican infants from birth 
to 2 years of age by weekly home visits and stool col-
lections, detected on the basis of the fecal excretion of 
virus or a serologic response a total of 316 rotavirus 
infections, of which 52% were first and 48% repeated 
infections. Children with 1, 2, or 3 previous infections 
had progressively lower risk of subsequent rotavirus 
infection (adjusted relative risk, 0.62, 0.40, and 0.34, 
respectively) or of diarrhoea (adjusted relative risk, 0.23, 
diarrhée explosive et aqueuse. Si l’on ne remplace pas suffisam-
ment les liquides perdus, il peut s’ensuivre une déshydratation. 
Des systèmes d’évaluation clinique précis ont été mis au point 
pour permettre une comparaison plus facile de la gravité, 
notamment dans le cadre des essais de vaccins. Les symptômes 
gastro-intestinaux disparaissent normalement au bout de 3 à 
7 jours, mais peuvent perdurer pendant 2 à 3 semaines. Bien 
que, dans la plupart des cas, la récupération soit totale, les GERV 
peuvent entraîner la mort, principalement pour les nourrissons 
jusqu’à l’âge d’un an.2, 9, 10 
Il n’existe actuellement aucun traitement spécifique. Comme 
pour d’autres diarrhées de l’enfance, la thérapie se fonde sur 
le remplacement des liquides pour éviter la déshydratation et 
l’administration de zinc, qui diminue la gravité et la durée de 
la diarrhée. Les solutions de sels de réhydratation orale (SRO) 
à osmolarité réduite sont plus efficaces pour remplacer les 
liquides perdus que les anciennes présentations. Les mesures 
thérapeutiques complémentaires au cours de l’épisode diar-
rhéique comprennent la poursuite de l’alimentation, y compris 
l’allaitement au sein et, s’il n’y a pas de SRO, l’utilisation des 
liquides adaptés disponibles à domicile.11
Examens diagnostiques au laboratoire 
Le diagnostic étiologique d’une gastroentérite à rotavirus 
nécessite la confirmation d’un laboratoire. Il existe sur le 
marché toute une gamme d’essais: les tests immunoenzyma-
tiques pour la détection directe des antigènes de rotavirus dans 
les échantillons de selles sont largement utilisés, de même que 
des bandelettes réactives et des test d’agglutination sur latex, 
rapides mais moins sensibles. On a aussi recours à la RT-PCR 
(transcription inverse couplée à l’amplification génique), très 
sensible pour détecter de faibles concentrations de rotavirus 
dans les échantillons de selles, identifier et différentier les 
souches.8 
Immunité protectrice
La protection contre les rotaviroses fait appel à la fois à 
la médiation humorale et cellulaire du système immunitaire. La 
primo-infection entraîne une réponse sérologique dirigée prin-
cipalement contre le sérotype viral présent (c’est-à-dire une 
réponse homotypique), tandis qu’une ou plusieurs infections à 
rotavirus ultérieures induisent une réponse en anticorps plus 
large et hétérotypique.12
Une étude surveillant 200 nourrissons mexicains de la nais-
sance à l’âge de 2 ans au moyen de visites hebdomadaires au 
domicile et de prélèvements de selles a détecté, sur la base de 
l’excrétion fécale du virus ou d’une réponse sérologique, un 
total de 316 rotaviroses, dont 52% étaient des primo-infections 
et 48% des réinfections. Les enfants ayant déjà eu 1, 2 ou 3 infec-
tions avaient progressivement un risque plus faible de contrac-
ter de nouveau une rotavirose (risque relatif ajusté, 0,62, 0,40 
et 0,34 respectivement) ou une diarrhée (risque relatif ajusté, 
9 Gladstone BP et al. Protective effect of natural rotavirus infection in an Indian birth 
cohort. New England Journal of Medicine, 2011, 365:337–346.
10 Velazquez FR, Matson DO, Calva JJ et al. Rotavirus infection in infants as protection 
against subsequent infections. New England Journal of Medicine, 1996, 335:1022–
1028.
11 Oral rehydration salts. Production of the new ORS (WHO/FCH/CAH/06.1). Geneva, 
WHO/UNICEF, 2006. Available from http://whqlibdoc.who.int/hq/2006/WHO_FCH_
CAH_06.1.pdf, accessed January 2013.
12 Angel J et al. Rotavirus immune responses and correlates of protection. Current 
Opinion in Virology, 2012, 419-425.
9 Gladstone BP et al. Protective effect of natural rotavirus infection in an Indian birth cohort. New 
England Journal of Medicine, 2011, 365:337–346.
10 Velazquez FR, Matson DO, Calva JJ et al. Rotavirus infection in infants as protection against 
subsequent infections. New England Journal of Medicine, 1996, 335:1022–1028.
11 Oral rehydration salts. Production of the new ORS (WHO/FCH/CAH/06.1). Genève, OMS/UNICEF, 
2006. Disponible sur http://whqlibdoc.who.int/hq/2006/WHO_FCH_CAH_06.1.pdf, consulté en 
janvier 2013.
12 Angel J et al. Rotavirus immune responses and correlates of protection. Current Opinion in Viro-
logy, 2012, 419-425.
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0.17, and 0.08) than children who had no previous infec-
tions. Subsequent infections were significantly less se-
vere than first infections (p=0.02) and second infections 
were more likely to be caused by another G type 
(p=0.05).10 However, one study from India reported that 
the risk of severe disease continued after several re-
infections.9 
In immunocompromised patients, natural rotavirus in-
fection is not regularly associated with severe diarrhoea 
or systemic disease, although shedding of the virus may 
be prolonged. However, individuals with congenital im-
munodeficiency, bone marrow transplantation or solid 
organ transplantation sometimes experience severe, 
prolonged and even fatal RVGE.13 In South Africa, the 
estimated incidence of acute RVGE was 2.3 fold (95% 
confidence interval: 1.8–2.9) higher in HIV-infected 
than in non-infected individuals.14 A study in Malawi 
found no differences in rotavirus disease severity for 
hospitalized children with and without HIV infection, 
but of 29 HIV-infected and 45 HIV-uninfected children 
who completed at least 3 weeks of follow-up, 6 (21%) 
HIV-infected children shed rotavirus, compared with 
2 (4%) HIV-uninfected children (relative risk 4.7 [95% 
CI: 1.0–21.5], p=0.05). Shedding was not associated with 
diarrhoea.15
The immune correlates of protection against rotavirus 
infection are incompletely defined, but the immune 
responses to the VP4 and VP7 proteins are generally 
believed to be important. Serum anti-rotavirus IgA 
antibody responses have been used as a measure of 
immunogenicity of all the live attenuated rotavirus 
vaccines evaluated.16
rotavirus vaccines 
Currently available vaccines are live, oral, attenuated 
rotavirus strains of human and/or animal origin that 
replicate in the human intestine. Two oral rotavirus vac-
cines are marketed internationally: the monovalent 
(RV1) Rotarix® (GlaxoSmithKline Biologicals, Rixensart, 
Belgium) and the pentavalent (RV5) RotaTeq® (Merck 
& Co. Inc., West Point, PA, USA). In this document the 
2 vaccines are referred to as RV1 and RV5, respectively. 
Lanzhou lamb rotavirus vaccine,manufactured by the 
Lanzhou Institute of Biomedical Products in China, and 
Rotavin-M1, manufactured by Polyvac in Viet Nam, are 
not available internationally and hence not further 
discussed here.
WHO guidelines to assure the quality, safety and effi-
cacy of live attenuated rotavirus vaccines are available.15
 
0,23, 0,17 et 0,08) par rapport aux enfants sans antécédents 
d’infection. Les rotaviroses ultérieures ont été nettement moins 
graves que les primo-infections (p=0,02) et les deuxièmes infec-
tions ont eu une plus grande probabilité d’être causée par un 
autre sérotype G (p=0,05).10 Néanmoins, une étude en Inde a 
signalé que le risque de maladie grave persistait après plusieurs 
réinfections.9 
Chez les sujets immunodéprimés, les rotaviroses naturelles ne 
s’associent pas systématiquement à des diarrhées sévères ou à 
une maladie systémique, bien que l’excrétion du virus puisse 
se prolonger. En revanche, chez les sujets atteints d’immunodé-
ficience congénitale ou ayant eu une transplantation de moelle 
osseuse ou d’un organe solide, il arrive d’observer des gastroen-
térites à rotavirus sévères, prolongées et parfois mortelles.13 En 
Afrique du Sud, l’estimation de l’incidence de la gastroentérite 
aiguë à rotavirus a été 2,3 fois supérieure (intervalle de 
confiance (IC) à 95%: 1,8-2,9) chez les sujets infectés par le VIH 
par rapport aux personnes séronégatives.14 Une étude au Malawi 
n’a pas révélé de différence dans la gravité de la rotavirose chez 
les enfants hospitalisés avec ou sans VIH mais, sur les 29 enfants 
séropositifs et les 45 séronégatifs ayant achevé au moins 
3 semaines de suivi, 6 enfants infectés par le VIH (21%) excré-
taient des rotavirus, contre 2 (4%) enfants séronégatifs (risque 
relatif 4,7 [IC à 95%: 1,0-21,5], p=0,05). L’excrétion n’a pas été 
associée à une diarrhée.15
Les indicateurs de la protection immunitaire contre les rotavi-
roses ne sont pas complètement définis, mais on pense en géné-
ral que les réponses immunitaires aux protéines VP4 et VP7 
jouent un rôle important. Les réponses des anticorps sériques 
IgA spécifiques ont été utilisées pour mesurer l’immunogénicité 
de tous les vaccins antirotavirus vivants atténués qui ont été 
évalués.16
Vaccins antirotavirus
Les vaccins actuellement disponibles contiennent des souches 
vivantes, atténuées, d’origine humaine et/ou animale, adminis-
trées par voie orale et se répliquant dans l’intestin grêle. Deux 
vaccins oraux sont commercialisés au niveau international: le 
Rotarix®, monovalent (RV1) (GlaxoSmithKline Biologicals, Rixen-
sart, Belgique) et le RotaTeq®, pentavalent (RV5) (Merck & Co. 
Inc., West Point, PA, États-Unis d’Amérique). Dans le présent 
article, nous nous réfèrerons à ces 2 vaccins en les appelant 
respectivement RV1 et RV5. Le vaccin de Lanzhou, préparé à 
partir d’une souche de rotavirus d’agneau par le Lanzhou Insti-
tute of Biomedical Products en Chine et le Rotavin-M1, fabriqué 
par Polyvac au Viet Nam, ne sont pas disponibles sur le marché 
international et ne seront donc pas discutés davantage ici.
Il existe des lignes directrices de l’OMS pour garantir la qualité, 
l’innocuité et l’efficacité des vaccins antirotavirus vivants atté-
nués.15 
13	 Clark	HF	et	al.	Rotavirus	vaccines.	In:	Plotkin	S,	Orenstein	W,	Offit	P,	eds.	Vaccines, 
6th ed. Elsevier Saunders, 2013:669-687. 
14 Groome MJ et al. Five-year cohort study on the burden of hospitalisation for acute 
diarrhoeal disease in African HIV-infected and HIV-uninfected children: potential 
benefits	of	rotavirus	vaccine.	Vaccine, 2012, 30 Suppl 1:A173-178.
15 Cunliffe NA et al. Effect of concomitant HIV infection on presentation and outcome of 
rotavirus gastroenteritis in Malawian children. Lancet, 2001, 358(9281):550–555.
16 Guidelines	 to	assure	 the	quality,	 safety	and	efficacy	of	 live	attenuated	 rotavirus	
vaccine Annex 3). Geneva, World Health Organization, 2007, WHO Technical report 
series 941. Available from http://www.who.int/entity/biologicals/publications/trs/
areas/vaccines/rotavirus/Annex%203%20rotavirus%20vaccines.pdf, accessed 
January 2013. 
13	 Clark	HF	et	al.	Rotavirus	vaccines.	In:	Plotkin	S,	Orenstein	W,	Offit	P,	eds.	Vaccines, 6th ed. Else-
vier Saunders, 2013:669-687. 
14 Groome MJ et al. Five-year cohort study on the burden of hospitalisation for acute diarrhoeal 
disease	in	African	HIV-infected	and	HIV-uninfected	children:	potential	benefits	of	rotavirus	vac-
cine. Vaccine, 2012, 30 Suppl 1:A173-178.
15 Cunliffe NA et al. Effect of concomitant HIV infection on presentation and outcome of rotavirus 
gastroenteritis in Malawian children. Lancet, 2001, 358(9281):550-555.
16 Guidelines	 to	assure	 the	quality,	safety	and	efficacy	of	 live	attenuated	rotavirus	vaccine An-
nex 3). Genève, Organisation mondiale de la Santé, 2007. Série de rapports techniques de 
l’OMS No 941. Disponible sur http://www.who.int/entity/biologicals/publications/trs/areas/vac-
cines/rotavirus/Annex%203%20rotavirus%20vaccines.pdf, consulté en janvier 2013. [Docu-
ment disponible en anglais uniquement.] 
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The monovalent human rotavirus vaccine  
(lyophilized and liquid)
RV1 is a live, oral vaccine originating from a G1P[8] 
strain that was isolated from a case of infantile gastro-
enteritis. This strain has undergone multiple passages 
in tissue culture and the resulting attenuated vaccine 
strain, RIX4414, is propagated in Vero cells. First pre-
pared as a lyophilized vaccine, a ready-to-use liquid 
formulation containing the same RIX4414 strain has 
subsequently been developed for 2 presentations: oral 
applicator and squeezable tube. The vaccine should be 
kept at 2–8 °C, protected from light, and should not 
be frozen. The vaccine shelf-life is 3 years. Each dose 
contains a suspension of at least 106.0 – the median cell 
culture infective dose (CCID50) – of live, attenuated hu-
man G1P[8] rotavirus particles . The volume is 1ml for 
the lyophilized formulation and 1.5ml for the liquid 
formulation. The vaccine should be used immediately 
after reconstitution (for the lyophilized formulation) or 
after opening (for the liquid presentation). If not used 
immediately, reconstituted RV1 can be stored either re-
frigerated (2–8 °C) or at ambient temperature <25 °C 
but should be given within 24 hours. All presentations 
have a vaccine vial monitor (VVM 14).
The 2 vaccine doses are administered at an interval of 
at least 4 weeks. According to the manufacturer, the first 
dose should be administered to infants ≥6 weeks of age 
and the second dose prior to 24 weeks of age.17, 18 For 
WHO recommended schedules see WHO recommenda-
tions below.
The pentavalent human-bovine reassortant rotavirus 
vaccine 
RV5 is an oral vaccine that contains 5 reassortant rota-
viruses developed from human and bovine (WC3) 
parent rotavirus strains. Four WC3-based reassortants 
express one of the VP7 proteins G1, G2, G3 or G4 from 
the human strains and the VP4 protein P7[5] from the 
bovine strain, whereas the fifth reassortant virus ex-
presses the VP4 protein P1A[8] from a human strain 
and the G6 protein from the bovine parent strain. The 
reassortants are subsequently propagated in Vero cells 
using standard cell-culture techniques.
Each dose (2 ml) of the vaccine contains a minimum titre 
of approximately 2.0 – 2.8 x 106 infectious units per reas-
sortant, and not greater than 116 x 106 infectious units per 
aggregate dose. The 5 reassortant strains are suspended in 
a solution of buffer and stabilizer that should be stored at 
2–8 °C. RV5 should not be frozen. Following removal from 
refrigeration, the vaccine should be used as soon as pos-
sible. The vaccine tubes do not have VVMs.
The manufacturer’s recommended schedule prescribes 
3 oral doses at ages 2, 4 and 6 months. The first dose 
should be administered between ages 6–12 weeks and 
subsequent doses at intervals of 4–10 weeks. The man-
Le vaccin antirotavirus humain monovalent (lyophilisé  
et liquide)
Le RV1 est un vaccin oral vivant préparé avec une souche 
G1P[8] isolée à partir d’un cas de gastro-entérite infantile. Cette 
souche a subi de nombreux passages en culture tissulaire et la 
souche vaccinale atténuée qui en a résulté, RIX4414, est propa-
gée sur cellules Vero. Tout d’abord préparé sous forme lyophi-
lisée, une présentation liquide, prête à l’emploi, de la même 
souche RIX4414 a été ensuite élaborée sous 2 conditionnements: 
applicateur pour administration orale et tube souple. Il doit être 
conservé à 2-8 °C, protégé de la lumière et ne pas être congelé. 
Il a une durée de conservation de 3 ans. Chaque dose contient 
une dose médiane d’au moins 106.0 unités infectieuses en culture 
cellulaire (DI50 en CC) de rotavirus vivant, atténué, humain 
G1P[8]. Le volume est de 1 ml sous forme lyophilisée et de 
1,5 ml sous forme liquide. Le vaccin doit être utilisé immédia-
tement après reconstitution (pour la forme lyophilisée) ou 
après ouverture (pour la forme liquide). En cas d’utilisation 
différée, le RV1 reconstitué peut être conservé réfrigéré (2-8°C) 
ou à température ambiante jusqu’à 25°C mais pas >24 heures. 
Toutes les ampoules ont une pastille de contrôle (PVC 14).
Les 2 doses vaccinales sont administrées à un intervalle d’au 
moins 4 semaines. Selon le fabricant, la première doit être admi-
nistrée à des nourrissons âgés d’au moins 6 semaines et la 
seconde avant l’âge de 24 semaines.17, 18 Pour connaître le calen-
drier préconisé par l’OMS, voir ci-après les «Recommandations 
de l’OMS». 
Le vaccin antirotavirus pentavalent réassorti bovin-humain
Le RV5 est un vaccin oral contenant 5 souches de rotavirus 
(WC3) réassorties obtenues à partir de souches mères d’origine 
humaine et bovine. Quatre souches réassorties expriment une 
des protéines VP7 G1, G2, G3 ou G4 provenant des souches 
humaines et la protéine VP4 P7[5] issue de la souche bovine, 
tandis que le cinquième virus réassorti exprime la protéine VP4 
P1A[8] venant d’une souche humaine et la protéine G6 de la 
souche mère bovine. Les souches réassorties sont ensuite 
propagées sur cellules Vero par des techniques de cultures cellu-
laires classiques.
Chaque dose vaccinale (2 ml) contient un titre minimal d’envi-
ron 2,0 - 2,8 x 106 unités infectieuses par souches réassorties et 
pas plus de 116 x 106 unités infectieuses par dose combinée. 
Les 5 souches réassorties sont mises en suspension dans une 
solution tampon stabilisée qui doit être conservée à 2-8°C. Le 
RV5 ne doit pas être congelé. Après avoir été retiré du froid, 
le vaccin doit être utilisé aussi vite que possible. Les tubes n’ont 
pas de PCV.
Le calendrier recommandé par le fabricant consiste à adminis-
trer 3 doses orales aux âges de 2, 4 et 6 mois. La première dose 
sera administrée entre 6 et 12 semaines et les suivantes à des 
intervalles de 4 à 10 semaines. Le fabricant recommande d’ache-
17 See http://www.who.int/entity/immunization_standards/vaccine_quality/Rotarix_
liquid_tube_product_insert_text_2009.pdf 
18 See http://www.who.int/entity/immunization_standards/vaccine_quality/Rotarix_
liquid_oral_applicator_product_insert_text_2009.pdf
17 Voir http://www.who.int/entity/immunization_standards/vaccine_quality/Rotarix_liquid_tube_
product_insert_text_2009.pdf 
18 Voir http://www.who.int/entity/immunization_standards/vaccine_quality/Rotarix_liquid_oral_
applicator_product_insert_text_2009.pdf
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ufacturer recommends that all 3 doses should be ad-
ministered by age 32 weeks.19 For WHO recommended 
schedules see WHO recommendations below.
Efficacy and effectiveness of the rotavirus vaccine
A recent Cochrane review20 shows that RV1 and RV5 are 
most efficacious against severe RVGE in subregions with 
very low or low child and adult mortality (WHO mortal-
ity strata A and B as defined below),21 although the vac-
cines are also efficacious in subregions with high child 
mortality and high or very high adult mortality (WHO 
strata D and E).20 Based on 11 RCTs of RV1 and 6 RCTs 
of RV5, this Cochrane review showed protection against 
severe RVGE after 1 and/or 2 years of follow up, ranging 
from approximately 80%–90% with modest waning over 
the period of observation in stratum A as compared to 
approximately 40%–60% efficacy over 2 years of follow 
up in stratum E. 
However, since the incidence of severe rotavirus disease 
is significantly higher in high child mortality settings, 
the numbers of severe disease cases and deaths averted 
by vaccines in these settings are likely to be higher than 
in low mortality settings, despite the lower vaccine 
efficacy.3, 22 
A descriptive review of observational studies mostly 
from high income and middle income countries, and a 
systematic review of observational and impact studies 
from industrialized countries have reported a substan-
tial reduction in disease burden within a few years of 
vaccine implementation and also some evidence of herd 
protection in unvaccinated older children and adults. 
Data also suggest that rotavirus vaccination has delayed 
the onset and decreased the magnitude of the yearly 
seasons in several high income countries.23, 24
Observational studies in Mexico and Brazil after the 
introduction of RV1 reported a reduction in diarrhoea-
related deaths in infants and young children.25, 26 In 
ver la série de prises vaccinales au plus tard à l’âge de 
32 semaines.19 Pour connaître le calendrier préconisé par l’OMS, 
voir ci-après «Recommandations de l’OMS».
Efficacité et performance du vaccin antirotavirus
Selon une étude récente de Cochrane,20 le RV1 et le RV5 sont les 
plus efficaces contre les gastroentérites sévères à rotavirus dans 
les sous-régions ayant une mortalité faible ou très faible des 
enfants et des adultes (voir ci-dessous la définition par l’OMS 
des strates de mortalité A et B),21 bien que les vaccins soient 
efficaces également dans les sous régions ayant une forte morta-
lité des enfants et une mortalité forte ou très forte des adultes 
(strates D et E de l’OMS).20 Sur la base de 11 essais contrôlés rando-
misés (ECR) pour le RV1 et 6 pour le RV5, cette étude a mis à jour 
une protection contre les gastroentérites sévères à rotavirus après 
1 et/ou 2 ans de suivi, allant d’environ 80%-90%, avec une faible 
diminution sur la période d’observation dans la strate A, à une 
efficacité d’environ 40%-60% sur 2 ans de suivi dans la strate E. 
Toutefois, comme l’incidence des rotaviroses sévères est nette-
ment plus élevée dans les milieux où il y a une forte mortalité 
des enfants, le nombre des cas graves et des décès évités par la 
vaccination dans ce cadre est probablement plus élevé qu’en 
situation de faible mortalité, malgré une efficacité plus faible 
du vaccin.3, 22 
Un examen descriptif des études d’observation, provenant pour 
la plupart de pays à revenu élevé ou intermédiaire, et un examen 
systématique des études d’observation et d’impact dans les pays 
industrialisés ont indiqué une baisse substantielle de la charge 
de morbidité dans les quelques années suivant la mise en œuvre 
du vaccin et aussi quelques signes d’une immunité de groupe 
bénéficiant aux enfants plus âgés et aux adultes non vaccinés. 
Les données laissent à penser par ailleurs que la vaccination 
antirotavirus a retardé le démarrage et réduit l’ampleur des 
épidémies saisonnières dans plusieurs pays à haut revenu.23, 24
Des études d’observation au Mexique et au Brésil après l’intro-
duction du RV1 ont indiqué une baisse du nombre des décès dus 
aux diarrhées chez les nourrissons et les jeunes enfants.25, 26 Au 
19 See http://www.who.int/entity/immunization_standards/vaccine_quality/RotaTeq_
Product_Insert.pdf and http://www.merck.com/product/usa/pi_circulars/r/rotateq/
rotateq_pi.pdf
20 Soares-Weiser K et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. 
Cochrane Database Systematic Review, 2012, 11:CD008521.
21 To aid in cause of death and burden of disease analyses, WHO subregions are stra-
tified	(A	through	E)	based	on	levels	of	child	and	adult	mortality:	Stratum	A,	very	low	
child and very low adult mortality; Stratum B, low child and low adult mortality; 
Stratum C, low child and high adult mortality; Stratum D, high child and high adult 
mortality; Stratum E, high child and very high adult mortality. The 9 low- and 
middle-income subregions included in the model are: African Region: D and E; Re-
gion of the Americas: B and D; South-East Asia Region: B and D, Eastern Mediterra-
nean	Region:	B	and	D,	and	Western	Pacific	Region:	B.	Please	consult	 the	List of 
Member States by WHO region and mortality stratum available at www.who.int/
entity/whr/2003/en/member_states_182-184_en.pdf, accessed January 2013.
22	 Grading	of	scientific	evidence	–	Tables	1–4:	Does	RV1and	RV5	induce	protection	
against rotavirus morbidity and mortality in young children both in low and high 
mortality settings? Available from http://www.who.int/immunization/position_pa-
pers/rotavirus_grad_rv1_rv5_protection
23	 Patel	MM	et	al.	Removing	the	Age	Restrictions	for	Rotavirus	Vaccination:	A	Benefit-
Risk Modeling Analysis. PLoS Medicine, 2012, 9: e1001330. 
24 Giaquinto C et al. Summary of effectiveness and impact of rotavirus vaccination 
with the oral pentavalent rotavirus vaccine: a systematic review of the experience 
in industrialized countries. Human Vaccines, 2011, 7:734–748.
25 Richardson V et al. Effect of rotavirus vaccination on death from childhood diar-
rhoea in Mexico. New England Journal of Medicine, 2010, 362:299–305.
26 do Carmo GM et al. Decline in diarrhoea mortality and admissions after routine 
childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Medicine, 
2011,8:e1001024
19 Voir http://www.who.int/entity/immunization_standards/vaccine_quality/RotaTeq_Product_In-
sert.pdf et http://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf
20 Soares-Weiser K et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane 
Database Systemic Review, 2012, 11:CD008521.
21 Pour aider à analyser les causes de mortalité et la charge de morbidité, les sous-régions de 
l’OMS ont été réparties en strates (A à E) selon les niveaux de mortalité des enfants et des 
adultes: strate A, très faible mortalité des enfants et des adultes; strate B, faible mortalité des 
enfants et des adultes; strate C, faible mortalité des enfants et forte mortalité des adultes; strate 
D, forte mortalité des enfants et des adultes; strate E, très forte mortalité des enfants et des 
adultes. Les 9 sous-régions à revenu faible ou intermédiaire intégrées dans le modèle sont les 
suivantes: Région africaine: D et E; Région des Amériques: B et D; Région de l’Asie du Sud-Est: 
B	et	D,	Région	de	la	Méditerranée	orientale:	B	et	D,	et	Région	du	Pacifique	occidental:	B.	Veuil-
lez-vous référer à la Liste des États Membres par Région OMS et strate de mortalité sur: www.
who.int/entity/whr/2003/en/member_states_182-184_en.pdf, consulté en janvier 2013.
22	 Cotation	des	preuves	scientifiques	–	Tableaux	1-4:	Le	RV1	et	le	RV5	induisent-ils	une	protection	
contre la morbidité et la mortalité imputables aux rotavirus chez le jeune enfant dans les situa-
tions de faible et de forte mortalité? Disponible sur http://www.who.int/immunization/posi-
tion_papers/rotavirus_grad_rv1_rv5_protection
23	 Patel	MM	et	al.	Removing	the	Age	Restrictions	for	Rotavirus	Vaccination:	A	Benefit-Risk	Mode-
ling Analysis. PLoS Medicine, 2012, 9: e1001330. 
24 Giaquinto C et al. Summary of effectiveness and impact of rotavirus vaccination with the oral 
pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. 
Human Vaccines, 2011, 7:734–748.
25 Richardson V et al. Effect of rotavirus vaccination on death from childhood diarrhoea in Mexico. 
New England Journal of Medicine, 2010, 362:299–305.
26 do Carmo GM et al. Decline in diarrhoea mortality and admissions after routine childhood rota-
virus immunization in Brazil: a time-series analysis. PLoS Medicine, 2011,8:e1001024
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Mexico, the estimated decline in the rate of diarrhoea-
related deaths was greatest among infants <11 months 
of age (a relative reduction of 41% (95% CI: 36%–47%). 
There was also a relative reduction among children 
aged 12 23 months (29%, 95% CI: 17%–39%) but no sig-
nificant reduction was observed in children 24–
59 months of age (7%, 95% CI: 14%–26%).25 In Brazil, a 
study reported that compared to expected rates based 
on pre-vaccine era trends, rates for diarrhoea-related 
mortality were 22% (95% CI: 6%–44%) lower than ex-
pected. The largest reductions in deaths (22%–28%) 
were among children younger than 2 years, who had the 
highest rates of vaccination. In contrast, lower reduc-
tions in deaths (4%, 95% CI: 30%–29%) were noted 
among children 2–4 years of age, who were not age-
eligible for vaccination during the study period.26 
No randomized control trials (RCTs) have been 
conducted to specifically assess differences in all-cause 
mortality between different vaccine schedules or among 
studies in different WHO mortality strata.20 Data from 
case-control studies show that RV1 and RV5 are more 
efficacious when the full course is given, but some 
protection may also be achieved following an incom-
plete vaccination series. For example, RV5 exhibits 
substantial effectiveness against RVGE before comple-
tion of the full 3 dose regimen.20, 27 
The interchangeability of RV1 and RV5 has not been 
studied.
RV1 and RV5 have similar efficacy against severe RVGE 
in countries where a high diversity of strains co-circu-
late, suggesting an important role for heterotypic pro-
tective immunity. However, indirect evidence suggests 
that homotypic immunity also plays a role in protection 
against subsequent RV infection. Characterization of RV 
strains present in the environment post-vaccination is 
needed to exclude population-based selection of ‘escape’ 
strains due to long-term pressure exerted by homotypic 
immunity.11
Duration of protection
Published RCTs are not adequately powered to conclude 
definitively whether or not efficacy wanes for either RV1 
or RV5. With RV5, one RCT that enrolled subjects from 
11 countries, reported an efficacy against severe disease 
estimated at 98% (95% CI: 88%–100%) during the first 
rotavirus season and 88% (95% CI: 49%–99%) during 
the second season.28 An extension of this trial demon-
strated a sustained reduction in the number of hospi-
talizations for rotavirus disease also 3 years after vac-
cination.29 Reports from RCTs were consistent with little 
Mexique, la diminution estimative du taux de mortalité impu-
table aux diarrhées a été la plus grande chez les nourrissons âgés 
de <11 mois (baisse relative de 41% (IC à 95%: 36%-47%). Il y a 
eu aussi une baisse relative chez les enfants âgés de 12 à 23 mois 
(29%, IC à 95%: 17%-39%), mais aucune diminution significative 
n’a été observée chez les enfants de 24 à 59 mois (7%, IC à 95%: 
14%-26%).25 Au Brésil, une étude a indiqué qu’en comparaison 
avec les taux escomptés sur la base des tendances avant l’ère de 
la vaccination, les taux de mortalité imputable à la diarrhée 
étaient inférieurs de 22% (IC à 95%: 6%-44%) à ce qu’on aurait 
pu attendre. Les plus fortes diminutions de la mortalité (22%-
28%) ont été observées chez les enfants de <2 ans, qui avaient 
aussi les taux de vaccination les plus élevés. À l’inverse, des 
baisses plus faibles de la mortalité (4%, IC à 95%: 30%-29%) ont 
été enregistrées chez les enfants de 2 à 4 ans, qui avaient dépassé 
l’âge de la vaccination au cours de la période de l’étude.26 
Aucun ECR n’a été fait pour évaluer spécifiquement la mortalité 
toutes causes confondues entre les différents calendriers de 
vaccination ou entre les études faites dans les diverses strates 
de mortalité de l’OMS.20 Les données des études cas-témoins 
établissent que le RV1 et le RV5 sont plus efficaces quand le 
calendrier complet est administré, mais qu’on peut arriver à 
obtenir un certain degré de protection après des séries incom-
plètes de vaccination. Par exemple, le RV5 montre une nette 
efficacité contre la gastroentérite à rotavirus avant d’avoir 
terminé la série complète de 3 doses.20, 27 
L’interchangeabilité du RV1 et du RV5 n’a pas été étudiée.
Le RV1 et le RV5 ont une efficacité similaire contre la GERV 
sévère dans les pays où il y a une circulation concomitante 
d’une grande diversité de souches, ce qui évoque un rôle impor-
tant pour l’immunité protectrice hétérotypique. En revanche, 
des preuves indirectes tendent à indiquer que l’immunité 
homotypique pourrait également jouer un rôle dans la protec-
tion contre des rotaviroses ultérieures. La caractérisation des 
souches présentes dans l’environnement après la vaccination 
est nécessaire pour exclure la sélection de souches «d’échappe-
ment» dans les populations à cause d’une pression durable de 
l’immunité homotypique.11
Durée de la protection
Les ECR publiés n’ont pas une puissance suffisante pour 
conclure définitivement à une diminution dans le temps de 
l’efficacité du RV1 ou du RV5. Pour le RV5, un ECR ayant recruté 
des sujets dans 11 pays ont indiqué une efficacité contre la 
rotavirose sévère estimée à 98% (IC à 95%: 88%-100%) pendant 
la première saison et 88% (IC à 95%: 49%-99%) pendant la 
seconde.28 Une extension de cet essai a mis en évidence une 
diminution durable du nombre des hospitalisations pour rota-
virose également 3 ans après la vaccination.29 Les rapports des 
ECR ont concordé avec une légère diminution de l’efficacité du 
27 Wang FT et al. Effectiveness of an Incomplete RotaTeq® (RV5) Vaccination Regimen 
in Preventing Rotavirus Gastroenteritis in the United States. The Pediatric Infectious 
Disease Journal, 2012, [Epub ahead of print].
28	 Vesikari	T	et	al.	Safety	and	efficacy	of	pentavalent	human-bovine	(WC3)	reassortant	
rotavirus vaccine in preventing rotavirus gastroenteritis and reducing associated 
health care resource utilization. The New England Journal of Medicine, 2006, 
354:23–33. 
29	 Vesikari	T	et	al.	Efficacy	of	the	pentavalent	rotavirus	vaccine,	RotaTeq®,	in	Finnish	
infants up to 3 years of age: the Finnish Extension Study. European Journal of Pedia-
trics, 2010, 169: 1379–1386. 
27 Wang FT et al. Effectiveness of an Incomplete RotaTeq® (RV5) Vaccination Regimen in Preven-
ting Rotavirus Gastroenteritis in the United States. The Pediatric Infectious Disease Journal, 
2012, [Epub ahead of print].
28	 Vesikari	T	et	al.	Safety	and	efficacy	of	pentavalent	human-bovine	(WC3)	reassortant	rotavirus	
vaccine in preventing rotavirus gastroenteritis and reducing associated health care resource 
utilization. The New England Journal of Medicine, 2006, 354:23–33. 
29	 Vesikari	T	et	al.	Efficacy	of	the	pentavalent	rotavirus	vaccine,	RotaTeq®,	in	Finnish	infants	up	to	
3 years of age: the Finnish Extension Study. European Journal of Pediatrics, 2010, 169: 1379–
1386. 
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decrease in the efficacy of RV1 against severe rotavirus 
disease during the second season of follow-up, from 
83% (95% CI: 67%–92%) to 79% (95% CI: 66%–87%) in 
Latin America30 and from 96% (95% CI: 90%–99%) to 
86% (95% CI: 76%–92%) in Europe.31 A RCT of RV1 
conducted in 3 high income settings in Asia reported 
sustained efficacy against severe RVGE of 100% (95% 
CI: 67.5%–100%) during the third year of life.32
In contrast, a study of RV5 conducted in 3 countries in 
sub-Saharan Africa reported an estimated efficacy of 
39.3% (95% CI: 19.1%–54.7%) against severe RVGE over 
the full follow-up period with an estimated 64.2% (95% 
CI: 40.2%–79.4%) during the first year after vaccination 
and 19.6% (95% CI: 15.7%–44.4%) in the second year 
after vaccination.33 For RV1 in South Africa, results from 
the extended follow-up of a RCT are inconclusive given 
the lack of power in the extension study.34
There is currently insufficient evidence to make a gen-
eral recommendation on the need for a third dose of 
RV1 in the primary series. A RCT directly assessing vac-
cine efficacy against severe RVGE in South Africa and 
Malawi did not show statistically significant differences 
between 2 doses and 3 doses of RV1; 58.7%, (95% CI: 
35.7%–74%) and 63.7%, (95% CI: 42.4%–77.8%), respec-
tively.35 However, in South African children, the efficacy 
of 2 or 3 doses of RV1 against severe RVGE over 2 
consecutive rotavirus seasons was 32% (p = 0.487) and 
85% (p = 0.006), respectively, as compared to the pla-
cebo group.34 Similarly, although significant reduction 
of RVGE of any severity was observed in the 2-dose 
group (49%; p = 0.007), the reduction was lower than 
that in the 3-dose group (68%; p < 0.001). Further ad-
equately powered studies would be helpful to explore 
whether additional doses have a favourable risk/ben-
efit ratio in high mortality settings and whether par-
tial vaccination is also efficacious against severe rota-
virus diarrhoea.36
Vaccine safety and precautions
In a recent review of efficacy and safety of the current 
rotavirus vaccines that included 41 trials with 
186 263 participants, no differences were observed 
RV1 contre la rotavirose sévère lors de la deuxième saison de 
suivi: de 83% (IC à 95%: 67%-92%) à 79% (IC à 95%: 66%-87%) 
en Amérique latine30 et de 96% (IC à 95%: 90%-99%) à 86% (IC 
à 95%: 76%-92%) en Europe.31 Un ECR du RV1, mené dans 
3 milieux à haut revenu en Asie, a indiqué une efficacité durable 
contre la GERV sévère de 100% (IC à 95%: 67,5%-100%) pendant 
la troisième année de vie.32
Inversement, une étude menée sur le RV5 dans 3 pays africains 
a indiqué une efficacité estimative de 39,3% (IC à 95%: 19,1%-
54,7%) contre la GERV sévère pendant toute la période de suivi, 
avec une estimation à 64,2% (IC à 95%: 40,2%-79,4%) pendant 
la première année après la vaccination et 19,6% (IC à 95%: 
15,7%-44,4%) pendant la seconde année.33 Pour le RV1 en 
Afrique du Sud, les résultats du suivi étendu d’un ECR ne sont 
pas concluants en raison du manque de puissance de l’étude 
d’extension.34
On n’a pas pour l’instant de données suffisantes pour faire une 
recommandation générale sur la nécessité d’ajouter une troi-
sième dose à la série du RV1. Un ECR évaluant directement 
l’efficacité de la vaccination contre la GERV sévère en Afrique 
du Sud et au Malawi n’a pas révélé de différences statistiques 
significatives entre 2 et 3 doses de RV1; 58,7%, (IC à 95%: 35,7%-
74%) et 63,7%, (IC à 95%: 42,4%-77,8%), respectivement.35 En 
revanche, chez des enfants d’Afrique du Sud, l’efficacité de 2 ou 
3 doses de RV1 contre la GERV sévère sur 2 saisons consécutives 
a été de 32% (p = 0,487) et 85% (p = 0,006), respectivement, par 
rapport au groupe placebo.34 De même, bien qu’on ait observé 
une baisse significative des GERV, toutes gravités confondues, 
dans le groupe à 2 doses (49%; p = 0.007), la diminution a été 
plus faible dans le groupe à 3 doses (68%; p <0.001). D’autres 
études ayant la puissance requise seraient utiles pour examiner 
si des doses supplémentaires ont un rapport risque–avantage 
favorable dans les situations de forte mortalité et si la vaccina-
tion partielle est également efficace contre les diarrhées sévères 
à rotavirus.36
innocuité du vaccin et précautions
Lors d’un examen récent de l’efficacité et de l’innocuité des 
vaccins antirotavirus couvrant 41 essais avec 186 263 partici-
pants, aucune différence n’a été observée entre les groupes 
30	 Linhares	AC	et	al.	Efficacy	and	safety	of	an	oral	live	attenuated	human	rotavirus	
vaccine	against	rotavirus	gastroenteritis	during	the	first	2	years	of	life	in	Latin	Ame-
rican infants: a randomised, double-blind, placebo-controlled phase III study. Lan-
cet, 2008, 371:1181–1189.
31	 Vesikari	T	et	al.	Efficacy	of	human	rotavirus	vaccine	against	rotavirus	gastroenteritis	
during	 the	 first	 2	 years	 of	 life	 in	 European	 infants:	 randomised,	 double-blind	
controlled study. Lancet. 2007, 24, 370:1757–1763.
32	 Phua	KB	et	al.	Rotavirus	vaccine	RIX4414	efficacy	sustained	during	the	third	year	of	
life: a randomized clinical trial in an Asian population. Vaccine, 2012, 30:4552–
4557.
33	 Armah	GE	et	al.	Efficacy	of	pentavalent	rotavirus	vaccine	against	severe	rotavirus	
gastroenteritis in infants in developing countries in sub-Saharan Africa: a rando-
mised, double-blind, placebo-controlled trial. Lancet, 2010, 376:606–614.
34	 Madhi	SA	et	al.	Efficacy	and	immunogenicity	of	2	or	3	dose	rotavirus-vaccine	regi-
men in South African children over two consecutive rotavirus-seasons: a rando-
mized, double-blind, placebo-controlled trial. Vaccine, 2012, 30 Suppl 1:A44-51.
35 Madhi SA et al. Effect of human rotavirus vaccine on severe diarrhoea in African 
infants. New England Journal of Medicine, 2010, 362:289-298.
36	 Grading	of	scientific	evidence	–	Tables	5–6:	Is	giving	a	third	dose	of	RV1	superior	to	
the currently recommended 2-dose schedule? (Table 5); Is partial vaccination also 
efficacious	 against	 severe	 rotavirus	 diarrhoea?	 (Table	 6).	Available	 from	 http://
www.who.int/immunization/position_papers/rotavirus_grad_rv1_3rd_dose
30	 Linhares	AC	et	al.	Efficacy	and	safety	of	an	oral	live	attenuated	human	rotavirus	vaccine	against	
rotavirus	gastroenteritis	during	the	first	2	years	of	life	in	Latin	American	infants:	a	randomised,	
double-blind, placebo-controlled phase III study. Lancet, 2008, 371:1181–1189.
31	 Vesikari	T	et	al.	Efficacy	of	human	rotavirus	vaccine	against	rotavirus	gastroenteritis	during	the	
first	2	years	of	life	in	European	infants:	randomised,	double-blind	controlled	study.	Lancet. 2007, 
24, 370:1757–1763.
32	 Phua	KB	et	 al.	 Rotavirus	 vaccine	RIX4414	efficacy	 sustained	during	 the	 third	 year	of	 life:	 a	
randomized clinical trial in an Asian population. Vaccine, 2012, 30:4552–4557.
33	 Armah	GE	et	al.	Efficacy	of	pentavalent	rotavirus	vaccine	against	severe	rotavirus	gastroenteri-
tis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, place-
bo-controlled trial. Lancet, 2010, 376:606–614.
34	 Madhi	SA	et	al.	Efficacy	and	immunogenicity	of	2	or	3	dose	rotavirus-vaccine	regimen	in	South	
African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-
controlled trial. Vaccine, 2012, 30 Suppl 1:A44-51.
35 Madhi SA et al. Effect of human rotavirus vaccine on severe diarrhoea in African infants. New 
England Journal of Medicine, 2010, 362:289-298.
36	 Cotation	des	preuves	scientifiques	–	Tableaux	5-6:	L’administration	d’une	troisième	dose	de	RV1	
est-elle supérieure au calendrier de 2 doses actuellement recommandé? (Tableau 5); La vaccina-
tion	partielle	est-elle	également	efficace	contre	la	diarrhée	sévère	à	rotavirus?	(Tableau	6).	Dispo-
nible sur http://www.who.int/immunization/position_papers/rotavirus_grad_rv1_3rd_dose
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between the vaccine groups and the placebo groups in 
terms of events that required discontinuation of the 
vaccination schedule.19 
A RCT that enrolled a total of 100 HIV-positive infants 
aged 6–10 weeks in South Africa found that 3 doses of 
RV1 were tolerated well and elicited a satisfactory im-
mune response without aggravating the immunologic 
or HIV condition.37 Similarly, a RCT in Kenya showed 
no significant differences in serious or non-serious ad-
verse events between the 88 HIV-exposed RV5 recipients 
versus the 89 HIV-exposed placebo recipients who were 
vaccinated at approximately 6, 10, and 14 weeks of age.38
 
Simultaneous administration of RV1 or RV5 with other 
vaccines of the infant immunization programme, in-
cluding combined diphtheria, tetanus toxoid and acel-
lular pertussis vaccine (DTaP), inactivated poliovirus 
vaccine (IPV), H. influenzae type b conjugate (Hib), 
hepatitis B vaccine, and pneumococcal conjugate vac-
cine have been shown not to interfere significantly with 
the protective immune responses or safety profile of the 
respective vaccines.39, 40 Although OPV may have an 
inhibitory effect on the immune response to the first 
dose of both rotavirus vaccines, this interference does 
not persist after administration of subsequent doses of 
rotavirus vaccines.41
Breastfeeding and prematurity (<37 weeks’ gestation) 
do not seem to significantly impair the response to the 
rotavirus vaccines.20, 42
Contraindications for using rotavirus vaccines are se-
vere hypersensitivity to any of their components and 
severe immunodeficiency including severe combined 
immunodeficiency (SCID). Vaccination should be post-
poned in case of ongoing acute gastroenteritis or fever 
with moderate to severe illness. These vaccines are not 
routinely recommended for infants with a history of 
intussusception or intestinal malformations possibly 
predisposing for intussusception. 
In 2010, contamination of RV1 with full length DNA 
from porcine circovirus was reported and subsequently, 
low levels of DNA fragments of this virus were also 
detected in bulk lots of RV5.43 Porcine circovirus is not 
known to infect or cause disease in humans. GACVS has 
concluded that given the extensive clinical data support-
ing the safety of both RV1and RV5 and the benefits of 
vaccinés et les groupes placebo pour ce qui est des événements 
nécessitant d’interrompre le calendrier de vaccination.19 
Un ECR ayant recruté au total 100 nourrissons séropositifs pour 
le VIH et âgés de 6 à 10 semaines en Afrique du Sud a révélé 
que 3 doses de RV1 étaient bien tolérées et induisaient une 
réponse immunitaire satisfaisante sans aggraver l’état immuno-
logique ou pathologique lié au VIH.37 De même, un ECR au 
Kenya n’a pas mis en évidence de différences significatives au 
niveau des effets indésirables graves ou bénins entre 88 sujets 
ayant reçu le RV5 et exposés au VIH et 89 sujets d’un groupe 
placebo, également exposés au VIH, vaccinés aux âges d’environ 
6, 10 et 14 semaines.38
Lors de l’administration simultanée du RV1 ou du RV5 et 
d’autres vaccins du programme de vaccination infantile, parmi 
lesquels celui associant l’anatoxine diphtérique, l’anatoxine 
tétanique et le vaccin anticoquelucheux acellulaire (DTCa), le 
vaccin antipoliomyélitique inactivé (VPI), le vaccin conjugué 
contre H. influenzae type b (Hib), le vaccin anti-hépatite B et 
le vaccin antipneumococcique conjugué, on n’a pas observé 
d’interférence significative avec les réponses immunitaires de 
protection ou les profils d’innocuité des autres vaccins.39, 40 Bien 
que le VPO puisse avoir un effet inhibiteur sur la réponse 
immunitaire à la première dose des 2 vaccins antirotavirus, 
cette interférence ne persiste pas après l’administration des 
doses suivantes des vaccins antirotavirus.41
L’allaitement au sein et la prématurité (<37 semaines de gesta-
tion) ne semblent pas nuire sensiblement à la réponse aux 
vaccins antirotavirus.20, 42 
Les contre-indications à l’utilisation des vaccins antirotavirus 
sont une forte hypersensibilité à l’un de leurs constituants ou 
une immunodéficience sévère, dont le déficit immunitaire 
combiné sévère (SCID). La vaccination doit être différée en cas 
de gastroentérite aiguë en cours ou de fièvre accompagnant une 
affection modérée à grave. D’ordinaire, ces vaccins ne sont pas 
recommandés aux nourrissons avec des antécédents d’invagi-
nation ou de malformations intestinales les prédisposant à ce 
type de problème. 
En 2010, on a signalé la contamination d’un RV1 avec la 
séquence complète d’ADN d’un circovirus porcin et, ensuite, de 
faibles teneurs en fragments d’ADN de ce virus ont aussi été 
décelés dans des lots de RV5 en vrac.43 Le circovirus porcin 
n’est pas connu pour infecter l’homme ou être pathogène pour 
lui. Le Comité consultatif mondial de la Sécurité vaccinale a 
conclu que, compte tenu de la multitude des données cliniques 
37 Steele AD et al. Safety, reactogenicity, and immunogenicity of human rotavirus vac-
cine	RIX4414	 in	 human	 immunodeficiency	 virus-positive	 infants	 in	 South	Africa.	
Pediatric Infectious Disease Journal, 2011, 30:125–130. 
38 Laserson KF et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in 
Kenya, including among HIV-infected and HIV-exposed infants. Vaccine, 2012, 
30 Suppl 1:A61–70. 
39 See http://us.gsk.com/products/assets/us_rotarix.pdf 
40 See http://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf 
41 Soares-Weiser K et al. Rotavirus vaccine schedules: a systematic review of safety 
and	efficacy	from	RCTs	and	observational	studies	of	childhood	schedules	using	RV1	
and RV5 vaccines. Report to WHO/Initiative for Vaccine Research, 2012. Available 
from http://www.who.int/immunization/sage/meetings/2012/april/Soares_K_et_
al_SAGE_April_rotavirus.pdf, accessed January 2013.
42	 Goveia	MG	et	al.	Efficacy	of	pentavalent	human-bovine	(WC3)	reassortant	rotavirus	
vaccine based on breastfeeding frequency. The Pediatric Infectious Disease Journal, 
2008, 27:656–658.
43 McClenahan SD et al. Molecular and infectivity studies of porcine circovirus in vac-
cines. Vaccine, 2011,29:4745–4753.
37 Steele AD et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 
in	human	immunodeficiency	virus-positive	infants	in	South	Africa.	Pediatric Infectious Disease 
Journal, 2011, 30:125–130. 
38 Laserson KF et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, in-
cluding among HIV-infected and HIV-exposed infants. Vaccine, 2012, 30 Suppl 1:A61–70. 
39 Voir http://us.gsk.com/products/assets/us_rotarix.pdf 
40 Voir http://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf 
41 Soares-Weiser K et al. Rotavirus	vaccine	schedules:	a	systematic	review	of	safety	and	efficacy	
from RCTs and observational studies of childhood schedules using RV1 and RV5 vaccines. Rap-
port fait à l’OMS/ Initiative pour la recherche sur les vaccins, 2012. Disponible sur http://www.
who.int/immunization/sage/meetings/2012/april/Soares_K_et_al_SAGE_April_rotavirus.pdf, 
consulté en janvier 2013. [Document disponible en anglais uniquement.]
42	 Goveia	MG	et	al.	Efficacy	of	pentavalent	human-bovine	(WC3)	reassortant	rotavirus	vaccine	
based on breastfeeding frequency. The Pediatric Infectious Disease Journal, 2008, 27:656–658.
43 McClenahan SD et al. Molecular and infectivity studies of porcine circovirus in vaccines. Vac-
cine, 2011,29:4745–4753.
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rotavirus vaccination for children, the benefits of vac-
cination far outweigh any currently known risk associ-
ated with use of either rotavirus vaccine.44
the risk of intussusception
Post-licensure surveillance showed that the previously 
marketed rotavirus vaccine, RotaShield® (Wyeth- 
Lederle), carried an attributable risk of intussusception 
estimated at 1:10 000 recipients.45 Intussusception, an 
intestinal invagination resulting in obstruction, is char-
acterized clinically by intermittent severe abdominal 
pain, blood in the stools, a palpable lump in the abdo-
men, and vomiting. This serious and potentially fatal 
condition was associated primarily with the first of the 
3 oral vaccine doses and the highest attributable risk 
was found in infants >3 months of age. The pathogenic 
mechanisms involved in intussusception following 
rotavirus vaccination remain poorly defined. 
RCTs conducted so far have lacked power to rule out 
very small relative risks of association between RV1or 
RV5 and intussusception in narrow risk windows, for 
example the 1–7 day period after dose 1.20, 46 However, 
no increased risk of intussusception was detected with 
either RV1or RV5 in 2 RCTs, each of which including 
approximately 60 000–70 000 infants (30 000–35 000 re-
ceived rotavirus vaccine) and designed to detect a risk 
similar to that seen with Rotashield®.28, 47
Using self-controlled case-series and case-control meth-
ods the potential association between RV1 and intus-
susception was investigated after routine immunization 
of infants in Mexico and Brazil.48 The study included 
615 case patients (285 in Mexico and 330 in Brazil) and 
2050 controls. An increased risk of intussusception 
1–7 days after the first dose of RV1 was identified 
among infants in Mexico using both the self-controlled 
case-series method (incidence ratio, 5.3; 95% CI: 3.0– 
9.3) and the case-control method (odds ratio, 5.8; 95% 
CI: 2.6–13.0). Among infants in Brazil no significant risk 
was found after the first dose, but an increased risk by 
a factor of 1.9 to 2.6 was seen 1–7 days after the second 
dose. A combined annual excess of 96 cases of intus-
susception in Mexico (approximately 1 per 51 000 in-
fants) and in Brazil (approximately 1 per 68 000 infants) 
and of 5 deaths due to intussusception was attributable 
to RV1. 
A prospective, active surveillance study for intussuscep-
tion in infants following RV1 vaccination was per-
étayant l’innocuité du RV1 comme du RV5, ainsi que des béné-
fices de la vaccination antirotavirus pour les enfants, les avan-
tages de celle-ci dépassent de loin les risques actuellement 
connus en relation avec l’utilisation de l’un ou l’autre de ces 
2 vaccins.44
le risque d’invagination intestinale
La pharmacovigilance a mis en évidence que le RotaShield® 
(Wyeth-Lederle), un vaccin antirotavirus commercialisé aupa-
ravant, s’accompagnait d’un risque attribuable d’invagination 
intestinale estimé à 1/10 000 sujets vaccinés.45 L’invagination 
intestinale, ou intussusception, provoquant une obstruction, se 
caractérise sur le plan clinique par des douleurs abdominales 
intermittentes sévères, du sang dans les selles, une masse 
palpable dans l’abdomen et des vomissements. On a associé 
avant tout cette affection grave et potentiellement mortelle à la 
première des 3 doses orales de vaccin et l’on a trouvé le risque 
attribuable le plus élevé chez les nourrissons âgés de >3 mois. 
Les mécanismes pathogènes impliqués dans l’invagination 
intestinale postvaccinale restent mal définis. 
Les ECR menés jusqu’à présent n’ont pas eu la puissance néces-
saire pour exclure de très faibles risques relatifs d’association 
entre le RV1 ou le RV5 et l’invagination intestinale dans des 
fenêtres étroites, par exemple sur une période de 1 à 7 jours 
suivant la première dose.20, 46 Toutefois, 2 ECR n’ont pas détecté 
d’augmentation du risque d’invagination intestinale pour le 
RV1 ou le RV5; chacun d’entre eux a porté sur environ 60 à 
70 000 nourrissons (30 000-35 000 ont été vaccinés) et a été conçu 
pour déceler un risque similaire à celui observé avec le 
Rotashield®.28, 47 
À l’aide de la méthode des séries de cas auto-contrôlées et de 
la méthode cas-témoin, une enquête sur le lien potentiel entre 
le RV1 et l’invagination intestinale a été faite après la vaccina-
tion systématique des nourrissons au Mexique et au Brésil.48 
L’étude a couvert 615 cas (285 au Mexique et 330 au Brésil) et 
2050 témoins. Un risque accru d’invagination intestinale de 1 à 
7 jours après la première dose de RV1 a été repéré chez les 
nourrissons au Mexique en appliquant à la fois la méthode des 
séries de cas auto-contrôlées (ratio d’incidence, 5,3; IC à 95%: 
3,0-9,3) et la méthode cas-témoins (rapport des côtes o, 5,8; IC 
à 95%: 2,6-13,0). Chez les nourrissons au Brésil, aucun risque 
significatif n’a été mis en évidence après la première dose, mais 
un risque accru d’un facteur de 1,9 à 2,6 a été observé de 1 à 
7 jours après la deuxième dose. Un excédent annuel combiné 
de 96 cas d’invaginations intestinales au Mexique (environ 
1 pour 51 000 nourrissons) et au Brésil (environ 1 pour 
68 000 nourrissons) et de 5 décès dus à l’invagination intestinale 
a été attribué au RV1. 
Une étude prospective de surveillance active de l’invagination 
intestinale chez les nourrissons après la vaccination par le RV1 
44 See No 30, 2010, pp. 285–292.
45 Acute intussusception in infants and young children (WHO/V&B/.02.19). Geneva, 
World Health Organization, 2002. Available at http://www.who.int/vaccinesdocu-
ments/DocsPDF06/www640.pdf, accessed January 2013.
46 Buttery JP et al. Intussusception following rotavirus vaccine administration: post-
marketing surveillance in the National Immunization Program in Australia. Vaccine, 
2011, 29:3061–3066.
47	 Ruiz-Palacios	GM	et	al.	Safety	and	efficacy	of	an	attenuated	vaccine	against	severe	
rotavirus gastroenteritis. New England Journal of Medicine, 2006, 354:11–22.
48	 Patel	MM	et	al.	Intussusception	risk	and	health	benefits	of	rotavirus	vaccination	in	
Mexico and Brazil. New England Journal of Medicine, 2011, 364:2283–2292
44 Voir No 30, 2010, pp. 285-292.
45 Acute intussusception in infants and young children (WHO/V&B/.02.19). Genève, Organisation 
mondiale de la Santé, 2002. Disponible sur http://www.who.int/vaccinesdocuments/Docs-
PDF06/www640.pdf consulté en janvier 2013. [Document disponible en anglais uniquement.]
46 Buttery JP et al. Intussusception following rotavirus vaccine administration: post-marketing 
surveillance in the National Immunization Program in Australia. Vaccine, 2011, 29:3061–3066.
47	 Ruiz-Palacios	GM	et	al.	Safety	and	efficacy	of	an	attenuated	vaccine	against	severe	rotavirus	
gastroenteritis. New England Journal of Medicine, 2006, 354:11–22.
48	 Patel	MM	et	al.	Intussusception	risk	and	health	benefits	of	rotavirus	vaccination	in	Mexico	and	
Brazil. New England Journal of Medicine, 2011, 364:2283–2292
60 WEEklY EPIdEmIologIcAl REcoRd, no. 5, 1st FEBRUARY 2013
formed in Mexico during the period 2008–2010.49 The 
relative incidence of intussusception within 31 days of 
vaccination was 1.8 (95% CI: 1.2–2.5; p=0.001) post-
dose 1 and 1.1 (95% CI: 0.8–1.5; p=0.8) post-dose 2. The 
relative incidence of intussusception within 7 days of 
vaccination was 6.5 post-dose 1 (95% CI: 4. 2–10.1; 
p<0.001) and 1.3 post-dose 2 (95% CI: 0.8–2.1; p=0.3). 
The attributable risk of intussusception within 7 days 
of vaccine dose 1 was estimated at 3 to 4 additional 
cases of intussusception per 100 000 vaccinated infants.
In Australia, an excess of observed compared to ex-
pected cases of intussusception was reported for both 
RV1 and RV5 among children 1–3 months of age. With 
RV1, the relative risk was 3.5 (95% CI: 0.7–10.1) 
1–7 days after the first dose and 1.5 (95% CI: 0.4–3.9) 
1–21 days after the first dose. The corresponding fig-
ures for RV5 were 5.3 (95% CI: 1.1–15.4) and 3.5 (95% 
(CI: 1.3–7.6).46
Two large cohort studies with active follow-up assessed 
the risk of intussusception following receipt of RV5 in 
the USA. In one US study, covering the period 2006–
2010, a total of 786 725 RV5 doses, including 309 844 first 
doses, were administered to infants 4–34 weeks of age. 
Comparing the incidence of intussusception between 
rotavirus vaccine recipients and similarly aged recipi-
ents of other infant vaccines, no statistically significant 
increased risk of intussusception with RV5 was ob-
served for either comparison group following any dose 
in either the 1–7 day or 1–30 day risk window.50 The 
other US study, which compared the risk of intussuscep-
tion between 85 397 RV5 recipients and 62 820 DTaP 
recipients found 6 and 5 confirmed cases of intussus-
ception, respectively, within 30 days following either 
dose. The relative risk of intussusception was 0.8 (95% 
CI: 0.2–3.5).51
Thus, in some but not all settings, post-marketing sur-
veillance of both currently available rotavirus vaccines 
has detected a small increased risk of intussusception 
(about 1–2/100 000 infants vaccinated) shortly after the 
first dose. Where present, this risk is 5–10 times lower 
than that observed with the previously licensed 
RotaShield®, and the benefits of rotavirus vaccination 
against severe diarrhoea and death from rotavirus 
infection far exceeds the risk of intussusception.52
Administration of the first and last dose of RV1 and 
RV5 at different ages inside the recommended age win-
dow has not shown any impact on the incidence of 
serious adverse events including intussusception.53 No 
a été faite au Mexique sur la période 2008-2010.49 L’incidence 
relative de l’invagination intestinale dans les 31 jours suivant 
la vaccination a été de 1,8 (IC à 95%: 1,2-2,5; p=0,001) après la 
dose 1 et de 1,1 (IC à 95%: 0,8-1,5; p=0,8) après la dose 2. L’in-
cidence relative dans les 7 jours suivant la vaccination a été de 
6,5 (IC à 95%: 4,2-10,1; p<0,001) après la dose 1 et de 1,3 après 
la dose 2 (IC à 95%: 0,8-2,1; p=0,3). Le risque attribuable d’inva-
gination intestinale dans les 7 jours suivant la dose 1 a été 
estimé à 3 à 4 cas supplémentaires pour 100 000 enfants vacci-
nés.
En Australie, on a signalé pour le RV1 comme pour le RV5 un 
excédent des cas d’invagination intestinale observés par rapport 
au nombre attendu chez les enfants âgés de 1 à 3 mois. Avec le 
RV1, le risque relatif a été de 3,5 (IC à 95%: 0,7-10,1) de 1 à 
7 jours après la première dose et de 1,5 (IC à 95%: 0,4-3,9) de 
1 à 21 jours après la première dose. Pour le RV5, les chiffres 
correspondants ont été de 5,3 (IC à 95%: 1,1-15,4) et de 3,5 (IC 
à 95%: 1,3-7,6).46 
Deux grandes études de cohorte avec suivi actif ont évalué le 
risque d’invagination intestinale après administration du RV5 
aux États-Unis d’Amérique. Dans l’une d’entre elles, couvrant 
la période 2006-2010, au total 786 725 doses de RV5, dont 
309 844 premières doses, ont été administrées à des nourrissons 
âgés de 4 à 34 semaines. En comparant l’incidence de l’invagi-
nation intestinale entre les sujets vaccinés contre le rotavirus 
et ceux du même âge vaccinés contre d’autres maladies infan-
tiles, aucune augmentation statistiquement significative du 
risque n’a été observée pour le RV5 dans les 2 groupes de la 
comparaison, que ce soit sur la période du risque de 1 à 7 jours 
ou de 1 à 30 jours après la vaccination.50 L’autre étude améri-
caine, qui a comparé le risque d’invagination intestinale entre 
85 397 sujets vaccinés par le RV5 et 62 820 vaccinés par le DTCa, 
a mis en évidence 6 et 5 cas confirmés respectivement, dans les 
30 jours suivant l’administration, quelle que soit la dose. Le 
risque relatif d’invagination intestinale a été de 0,8 (IC à 95%: 
0,2-3,5).51
Dans certaines situations donc, mais pas toutes, la surveillance 
post-commercialisation des 2 vaccins antirotavirus actuelle-
ment disponibles a décelé une légère augmentation du risque 
d’invagination intestinale (environ 1-2/100 000 nourrissons 
vaccinés) peu après la première dose. Lorsqu’il existe, ce risque 
est inférieur de 5 à 10 fois à celui observé avec le RotaShield®, 
vaccin précédemment homologué, et les bénéfices de la vacci-
nation antirotavirus contre les diarrhées sévères et la mort par 
rotavirose dépassent de loin le risque d’invagination intesti-
nale.52 
L’administration de la première et de la dernière doses de RV1 
et de RV5 à différents âges à l’intérieur de la période recom-
mandée n’a pas eu d’impact avéré sur l’incidence des événe-
ments indésirables graves, dont l’invagination intestinale.53 On 
49 Velázquez FR et al. Postmarketing Surveillance of Intussusception Following Mass 
Introduction of the monovalent human Rotavirus Vaccine in Mexico_(UGG)_(EPI 
PLAN). The Pediatric Infectious Disease Journal, 2012, 31:736–744.
50 Shui IM et al. Risk of intussusception following administration of a pentavalent 
rotavirus vaccine in US infants. JAMA: the Journal of the American Medical Associa-
tion, 2012, 307:598–604.
51 Loughlin J et al. Postmarketing evaluation of the short-term safety of the pentava-
lent rotavirus vaccine. The Pediatric Infectious Disease Journal, 2012,31:292–296.
52 See No 6, 2012, pp. 53–60.
53	 Grade	table	7:	Is	it	safe	to	administer	the	first	dose	of	vaccine	at	different	ages?	
Available from http://www.who.int/immunization/position_papers/rotavirus_grad_
safe_first_dose_ages
49 Velázquez FR et al. Postmarketing Surveillance of Intussusception Following Mass Introduction 
of the monovalent human Rotavirus Vaccine in Mexico_(UGG)_(EPI PLAN). The Pediatric Infec-
tious Disease Journal, 2012, 31:736–744.
50 Shui IM et al. Risk of intussusception following administration of a pentavalent rotavirus vac-
cine in US infants. JAMA: the Journal of the American Medical Association, 2012, 307:598–604.
51 Loughlin J et al. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus 
vaccine. The Pediatric Infectious Disease Journal, 2012,31:292–296.
52 Voir No 6, 2012, pp. 53-60.
53 Tableau 7 de cotation: L’administration de la première dose de vaccin à différents âges est-elle 
sûre? Disponible sur http://www.who.int/immunization/position_papers/rotavirus_grad_safe_
first_dose_ages
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data are available on the possible risk of such events 
outside the recommended age window. There is limited 
information on the background rates of intussusception 
in settings of high mortality due to RVGE and no data 
on the risk of intussusception following rotavirus vac-
cination in such settings.
optimizing immunization schedules
Ideally, vaccination schedules should be designed to 
provide benefits to those at highest risk of severe dis-
ease and death. Based on pooled data from studies of 
38 populations, at least 3 of which are from each WHO 
Region, 1%, 3%, 6%, 8%, 10%, 22% and 32% of all RVGE 
events had occurred by age 6, 9, 13, 15 and 17, 26 and 
32 weeks, respectively, although with substantial hetero-
geneity between populations. Mortality was limited to 
RVGE events before 32 weeks of age.2 Although in many 
parts of the world there are relatively few admissions 
for RVGE before the scheduled first dose of the rotavi-
rus vaccine (at the age 6–12 weeks), RVGE in very young 
children is more common in low income settings. Chil-
dren in the poorest, typically rural, households with the 
highest risk of mortality seem to have the earliest ex-
posure to rotavirus and the lowest level of vaccine pro-
tection.2 
To maximize its impact, the rotavirus vaccine has to be 
given before RVGE occurs and before a sizeable propor-
tion of the target population acquires natural infection. 
The impact of rotavirus vaccination depends on 
effectiveness, timeliness and coverage. In developing 
countries where natural infection occurs early, comple-
tion of the immunization schedule early in infancy is 
desirable, though programmatically challenging.54
Previously, WHO recommended that rotavirus immuni-
zation be initiated by 15 weeks of age when background 
intussusception rates are reportedly low. However, this 
policy could exclude a substantial number of children 
from vaccination, especially in low income countries 
where delays in vaccination are common. 
A model was used to predict the number of deaths pre-
vented by rotavirus vaccination and the number of in-
tussusception deaths caused by rotavirus vaccination 
when administered on the previously recommended, 
restricted schedule (initiate by 15 weeks and complete 
by 32 weeks) versus a schedule allowing vaccination up 
to 3 years of age. Countries were grouped by WHO child 
mortality strata and the inputs were stratum-specific 
estimates of rotavirus mortality, intussusception mor-
tality, and predicted vaccination rates by week of age, 
and vaccine efficacy and vaccine-associated intussus-
ception risk.23
The model estimated that a restricted schedule would 
prevent 155 800 rotavirus deaths (5th–95th centiles, 
ne dispose pas de données sur le risque éventuel de ces mani-
festations en dehors de la tranche d’âge recommandée. Les 
informations sont limitées sur la fréquence spontanée de l’inva-
gination intestinale dans les situation de forte mortalité par 
GERV et l’on n’a pas de donnée sur le risque de cette affection 
après la vaccination antirotavirus dans ces milieux.
optimisation des calendriers de vaccination
Dans l’idéal, les calendriers de vaccination doivent être conçus 
pour bénéficier à ceux qui sont le plus exposés au risque de 
maladie grave et de mort. Sur la base des données regroupées 
d’études dans 38 populations, dont au moins 3 dans chaque 
région de l’OMS, 1%, 3%, 6%, 8%, 10%, 22% et 32% de tous les 
cas de GERV avaient eu lieu aux âges de 6, 9, 13, 15 et 17, 26 et 
32 semaines respectivement, malgré une hétérogénéité substan-
tielle des populations. La mortalité s’est limitée aux cas de 
GERV avant l’âge de 32 semaines.2 Bien que, dans de nombreuses 
régions du monde, il y ait relativement peu d’hospitalisations 
pour GERV avant la première dose de vaccin antirotavirus au 
calendrier (à l’âge de 6 à 12 semaines), cette maladie est plus 
commune chez les très jeunes enfants dans les milieux à faible 
revenu. Les enfants dans les ménages les plus pauvres, ruraux 
en général, avec le risque de mortalité le plus élevé, semblent 
avoir l’exposition la plus précoce au rotavirus et le plus faible 
niveau de protection vaccinale.2 
Pour avoir le maximum d’effet, le vaccin antirotavirus doit être 
administré avant la survenue d’une gastroentérite à rotavirus 
et avant qu’une proportion assez grande de la population n’ait 
contracté l’infection naturelle. L’impact de la vaccination dépend 
de son efficacité, du respect du calendrier et de la couverture. 
Dans les pays en développement où l’infection naturelle survient 
à un âge précoce, il est souhaitable d’achever rapidement le 
calendrier de vaccination en bas âge, bien que cela puisse 
présenter des difficultés pour les programmes.54
Auparavant, l’OMS recommandait de commencer la vaccination 
antirotavirus avant l’âge de 15 semaines au plus tard, lorsque 
la fréquence spontanée des invaginations intestinales est faible, 
selon les informations disponibles. Cette politique pourrait 
cependant exclure un grand nombre d’enfants, notamment dans 
les pays à faible revenu où les retards de vaccination sont 
courants. 
Un modèle a été utilisé pour prédire le nombre de décès évités 
par la vaccination antirotavirus et le nombre de décès par inva-
gination intestinales dus à cette vaccination lorsqu’elle est 
administrée en suivant le calendrier restreint recommandé 
précédemment (début jusqu’à l’âge de 15 semaines et fin à 
32 semaines) par rapport à un calendrier autorisant la vacci-
nation jusqu’à l’âge de 3 ans. Les pays ont été regroupés selon 
les strates de mortalité de l’OMS pour les enfants et l’on a entré 
des estimations spécifiques des strates portant sur la mortalité 
due au rotavirus, la mortalité par invagination intestinale, les 
taux prévisibles de vaccination selon l’âge en semaines, l’effica-
cité du vaccin et le risque d’invagination intestinale associé à 
la vaccination.23
Selon les estimations du modèle, un calendrier restreint évite-
rait 155 800 décès dus au rotavirus (5e-95e centile, 83 300-217 700) 
54 Cherian T et al. Rotavirus vaccines in developing countries: the potential impact, 
implementation challenges, and remaining questions. Vaccine, 2012: 30 Sup-
pl 1:A3–6.
54 Cherian T et al. Rotavirus vaccines in developing countries: the potential impact, implementa-
tion challenges, and remaining questions. Vaccine, 2012: 30 Suppl 1:A3–6.
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83 300–217 700) while causing 253 intussusception deaths 
(76–689). Vaccination without age restrictions would 
prevent 203 000 rotavirus deaths (102 000–281 500) while 
causing 547 intussusception deaths (237–1160). Thus, 
the model predicted that removing the age restrictions 
would avert an additional 47 200 rotavirus deaths 
(18 700–63 000) and cause an additional 294 (161–471) 
intussusception deaths for an incremental benefit-risk 
ratio of 154 deaths averted for every death caused by 
the vaccine. These additional deaths prevented under 
an unrestricted versus restricted schedule reflect ad-
ditional 21%–28% children who would potentially be 
eligible for rotavirus vaccination. Thus, in low and mid-
dle income countries, the additional lives saved by re-
moving age restrictions for rotavirus vaccination would 
by far outnumber the excess vaccine-associated intus-
susception deaths.22 
Cost effectiveness of vaccination against  
rotavirus infection
Estimates of the annual cost per disability-adjusted life 
year (DALY) averted and of the proportion (%) of ro-
tavirus deaths averted through introduction of rotavi-
rus vaccines vary between US$ 8 and US$ 87, and 32% 
and 44%, for Afghanistan and Bangladesh, respectively. 
For India, the country with the highest number of re-
corded deaths due to RVGE, the corresponding figures 
were US$ 57 and 34%, whereas for the Democratic 
Republic of Congo, Ethiopia, and Nigeria these figures 
varied between US$ 19–27 and 28–31%. The estimates 
are based on the expected introduction of rotavirus 
vaccination into the respective national immunization 
programmes within the next few years (2012–2018) and 
on forecasts of the vaccination coverage that can then 
be expected for a first dose administered before the age 
of 15 weeks and a second dose by age 32 weeks. 
Recent cost-effectiveness modeling in Kenya predicted 
that cumulated over the first 5 years of life, the esti-
mated prevented costs totaled US$ 1 782 761 (direct and 
indirect costs) with an associated 48 585 DALYs saved. 
Irrespective of the vaccine used, vaccination against 
rotavirus disease was found to be cost effective.55
A generic approach to the development of cost-effec-
tiveness models for rotavirus vaccines in national im-
munization programmes has been proposed.56
WHo recommendations 
Rotavirus vaccines should be included in all national 
immunization programmes and considered a priority, 
particularly in countries with high RVGE-associated fa-
tality rates, such as in south and south-eastern Asia and 
sub-Saharan Africa. 
The use of rotavirus vaccines should be part of a com-
prehensive strategy to control diarrhoeal diseases with 
tout en causant 253 décès par invagination intestinale (76-689). 
La vaccination sans restriction d’âge permettrait d’éviter 
203 000 décès dus au rotavirus (102 000-281 500) mais entraîne-
rait 547 décès par invagination intestinale (237-1160). Le modèle 
prédit donc que la levée des restrictions d’âge permettrait d’évi-
ter 47 200 décès supplémentaires dus au rotavirus (18 700-63 000) 
et provoquerait 294 décès supplémentaires par invagination 
intestinale (161-471) pour un ratio bénéfice-risque supplémen-
taire de 154 décès évité pour chaque mort due au vaccin. On 
retrouve dans ces décès supplémentaires évités avec un calen-
drier sans restriction par rapport à un calendrier restreint, les 
21% à 28% d’enfants supplémentaires qui, potentiellement, 
rempliraient les conditions pour être vaccinés contre le rotavi-
rus. Donc, dans les pays à revenu faible ou intermédiaire, les 
vies supplémentaires sauvées en levant les restrictions d’âge 
pour la vaccination antirotavirus dépasseraient de loin l’excé-
dent de mortalité par invagination intestinale due au vaccin.22 
Coût-efficacité de la vaccination contre les rotaviroses 
Les estimations du coût annuel par année de vie ajustée sur 
l’incapacité (DALY) évitée et de la proportion (%) de décès par 
rotavirose évité par l’introduction des vaccins antirotavirus 
varient entre US$ 8 et US$ 87, et entre 32% et 44%, pour l’Afgha-
nistan et le Bangladesh respectivement. Pour l’Inde, le pays 
enregistrant le plus grand nombre de décès par gastroentérite 
à rotavirus, les chiffres correspondants étaient de US$57 et 34%, 
alors qu’en Éthiopie, au Nigéria et en République démocratique 
du Congo, ils s’établissent dans des fourchettes de US$19-27 et 
28-31%. Les estimations se fondent sur l’introduction escomp-
tée de la vaccination antirotavirus dans les programmes natio-
naux de vaccination concernés au cours des prochaines années 
(2012-2018) et sur les prévisions de la couverture vaccinale à 
laquelle on peut s’attendre pour une première dose administrée 
avant l’âge de 15 semaines et une seconde dose jusqu’à l’âge de 
32 semaines. 
Une modélisation récente du rapport coût-efficacité au Kenya 
a prédit en chiffres cumulés sur les 5 premières années de la 
vie des coûts évités d’un total de US$ 1 782 761 (coûts directs 
et indirects) et 48 585 DALY associées. Quel que soit le vaccin 
utilisé, la vaccination antirotavirus s’est avérée d’un bon rapport 
coût-efficacité.55
Une approche générale pour l’élaboration de modèles de coût-
efficacité pour les vaccins antirotavirus dans les programmes 
de vaccination a été proposée.56
recommandations de l’omS
Les vaccins antirotavirus devraient être intégrés dans tous les 
programmes nationaux de vaccination et considérés comme 
prioritaires, en particulier dans les pays ayant des taux de 
mortalité par GERV élevés, comme en Asie du Sud et du Sud-
Est, ainsi qu’en Afrique subsaharienne. 
L’utilisation des vaccins antirotavirus devrait faire partie d’une 
stratégie globale de lutte contre les affections diarrhéiques, avec 
55 van Hoek AJ et al. (2012) A cost effectiveness and capacity analysis for the introduc-
tion of universal rotavirus vaccination in Kenya: Comparison between Rotarix and 
RotaTeq Vaccines. PLoS ONE, 2012, 7: e47511. 
56 Postma MJ et al. Comparative review of 3 cost-effectiveness models for rotavirus 
vaccines in national immunization programs; a generic approach applied to various 
regions in the world. BMC Medicine, 2011, 9:84. 
55 van Hoek AJ et al. (2012) A cost effectiveness and capacity analysis for the introduction of 
universal rotavirus vaccination in Kenya: Comparison between Rotarix and RotaTeq Vaccines. 
PLoS ONE, 2012, 7: e47511. 
56 Postma MJ et al. Comparative review of 3 cost-effectiveness models for rotavirus vaccines in 
national immunization programs; a generic approach applied to various regions in the world. 
BMC Medicine, 2011, 9:84. 
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the scaling up of both prevention (promotion of early 
and exclusive breastfeeding, handwashing, improved 
water supply and sanitation) and treatment packages. 
WHO/UNICEF recommend that all children receive so-
lutions of low-osmolarity ORS to prevent and treat de-
hydration due to diarrhoea. Breast milk is also an excel-
lent rehydration fluid and should be given to children 
still breastfeeding along with ORS. In addition to fluid 
replacement, children with diarrhoea should continue 
to be fed during the episode. Food intake supports fluid 
absorption from the gut into the bloodstream to pre-
vent dehydration and helps maintain nutritional status 
and ability to fight infection. Children should also si-
multaneously receive zinc treatment which reduces the 
duration and severity of diarrhoea episodes, stool vol-
ume and the need for advanced medical care.57, 58 Plans 
for introduction of rotavirus vaccines should consider 
the epidemiology of the disease by age, the coverage 
and actual age at vaccination and an evaluation of the 
estimated public health impact and potential risks. In 
addition, cost-effectiveness assessment, issues of afford-
ability of the vaccine, financial and operational impact 
on the immunization delivery system, and careful ex-
amination of current immunization practices should be 
taken into account.
Introduction of rotavirus vaccine should be accompa-
nied by measures to ensure high vaccination coverage 
and timely administration of each dose.
Following a review of new evidence on age- specific 
burden of rotavirus disease and deaths, timeliness of 
vaccination, and the safety and effectiveness of different 
immunization schedules, WHO continues to recom-
mend that the first dose of rotavirus vaccine be admin-
istered as soon as possible after 6 weeks of age, along 
with diphtheria-tetanus-pertussis (DTP) vaccination, to 
ensure induction of protection prior to natural rotavi-
rus infection. 
Although early immunization is still favoured, the man-
ufacturers’ conventional age restrictions on the first and 
last dose of rotavirus vaccines may have prevented vac-
cination of many vulnerable children in settings where 
the DTP doses are given late (i.e. after 15 weeks for 
DTP1 or after 32 weeks for DTP 2 or DTP3). By allowing 
infants to receive rotavirus vaccine together with DTP 
regardless of the time of vaccination, immunization 
programmes will be able to reach children who were 
previously excluded from the benefits of rotavirus vac-
cines. Because of the typical age distribution of RVGE, 
rotavirus vaccination of children >24 months of age is 
not recommended. 
RV1 should be administered orally in a 2-dose schedule 
at the time of DTP1 and DTP2 with an interval of at 
le renforcement des mesures de prévention (promotion de l’al-
laitement précoce et exclusif au sein, lavage des mains, amélio-
ration de l’approvisionnement en eau et de l’assainissement) et 
de traitement. L’OMS et l’UNICEF recommandent d’administrer 
à tous les enfants des solutions de SRO à osmolarité réduite 
pour prévenir et traiter la déshydratation due à la diarrhée. Le 
lait maternel est aussi un excellent liquide de réhydratation et 
doit être donné avec les SRO aux enfants qui sont encore allai-
tés. Outre le remplacement des liquides, les enfants doivent 
continuer à s’alimenter pendant l’épisode diarrhéique. L’inges-
tion d’aliments contribue à l’absorption des liquides dans l’in-
testin et à leur passage dans la circulation sanguine pour éviter 
la déshydratation; elle aide au maintien de l’état nutritionnel et 
à la capacité de combattre les infections. Il faut également 
donner en même temps à ces enfants un traitement de zinc qui 
réduit la durée et la gravité des épisodes diarrhéiques, le volume 
des selles et le besoin de recourir à des soins médicaux de 
pointe.57, 58 Les plans pour l’introduction des vaccins antirotavi-
rus doivent envisager l’épidémiologie de la maladie en fonction 
de l’âge, la couverture et l’âge véritable de la vaccination et 
évaluer les estimations de l’impact et des risques potentiels 
pour la santé publique. De plus, il faudrait aussi prendre en 
compte une évaluation du rapport coût-efficacité, les questions 
d’accessibilité économique du vaccin, les répercussions finan-
cières et opérationnelles sur le système d’administration de la 
vaccination et un examen soigneux des pratiques en usage.
L’introduction des vaccins antirotavirus devrait s’accompagner 
de mesures garantissant une forte couverture de la vaccination 
et l’administration de chaque dose en temps voulu.
Après un examen des nouvelles données factuelles sur la charge 
des rotaviroses et la mortalité selon l’âge, la ponctualité de la 
vaccination, ainsi que l’innocuité et l’efficacité des différents 
calendriers de vaccination, l’OMS continue de recommander 
l’administration de la première dose du vaccin antirotavirus 
dès que possible après l’âge de 6 semaines, en même temps que 
la vaccination contre la diphtérie, le tétanos et la coqueluche 
(DTC), pour induire la protection avant la survenue d’une rota-
virose naturelle. 
Bien que la vaccination précoce reste préférée, les limites indi-
quées typiquement par les fabricants pour l’âge à l’administra-
tion de la première et de la dernière dose des vaccins antiro-
tavirus pourraient avoir empêché la vaccination de nombreux 
enfants vulnérables dans les milieux où les doses de DTC sont 
administrées tardivement (c’est-à-dire après 15 semaines pour 
le DTC1 ou après 32 semaines pour le DTC2 ou le DTC3). En 
permettant une administration concomitante avec le DTC quel 
que soit l’âge, les programmes de vaccination pourront couvrir 
des enfants auparavant privés des bénéfices apportés par les 
vaccins antirotavirus. Compte tenu de la répartition typique de 
la GERV selon l’âge, la vaccination antirotavirus des enfants 
âgés de >24 mois n’est pas recommandée. 
Le RV1 doit être administré par voie orale en 2 doses au même 
moment que le DTC1 et le DTC2, avec un intervalle d’au moins 
57 Diarrhoea: why children are still dying and what can be done. Genève, OMS/UNICEF, 2009. 
Disponible sur http://www.who.int/maternal_child_adolescent/documents/9789241598415/
en/index.html, consulté en janvier 2013. [Document disponible en anglais uniquement.]
58 Pneumonia and diarrhoea: tackling the deadliest diseases for the world’s poorest children. New 
York,	 UNICEF,	 2012.	 Disponible	 sur	 http://www.unicef.org/media/files/UNICEF_P_D_com-
plete_0604.pdf, consulté en janvier 2013. [Document disponible en anglais uniquement.]
57 Diarrhoea: why children are still dying and what can be done. Geneva, WHO/
UNICEF, 2009. Available from http://www.who.int/maternal_child_adolescent/do-
cuments/9789241598415/en/index.html, accessed January 2013.
58 Pneumonia and diarrhoea: tackling the deadliest diseases for the world’s poorest 
children. New York, UNICEF, 2012. Available from http://www.unicef.org/media/
files/UNICEF_P_D_complete_0604.pdf,	accessed	January	2013. 
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least 4 weeks between doses. RV5 should be adminis-
tered orally in a 3-dose schedule at the time of the DTP1, 
DTP2, and DTP3 contacts, with an interval of at least 
4 weeks between doses. With both vaccines, prematurely 
born infants should follow the vaccination schedules 
recommended for their chronological age.
Rotavirus vaccinations can be administered simultane-
ously with other vaccines in the infant immunization 
programme.
Apart from a low risk of intussusception (about 1–2 per 
100 000 infants vaccinated) the current rotavirus vac-
cines are considered safe and well tolerated. 
Proper planning and training of staff to conduct phar-
macovigilance should take place before the vaccine is 
introduced. Countries should develop a strategy to in-
form relevant health staff that although the benefits 
outweigh the risks, a small potential risk of intussuscep-
tion after rotavirus vaccination remains. Countries 
should also ensure that caregivers are adequately 
counseled to recognize danger signs of dehydration or 
intussusception that should prompt immediate medical 
consultation.
Given the background rate of natural intussusception 
and the large number of children included in national 
immunization programmes, intussusception cases are 
expected to occur by chance alone following rotavirus 
vaccination. It is important to establish the baseline 
incidence of intussusception at sentinel sites and to use 
epidemiological studies, such as the self-controlled case 
series method, to assess the safety of rotavirus 
vaccines.59 
Severe allergic reaction (e.g. anaphylaxis) after a previ-
ous dose, and severe immunodeficiency including 
severe combined immunodeficiency, are contraindica-
tions for rotavirus vaccination. Precautions are neces-
sary if there is a history of intussusception or intestinal 
malformations, chronic gastrointestinal disease, and 
severe acute illness. Vaccination should be postponed 
in case of ongoing acute gastroenteritis or fever with 
moderate to severe illness. 
The epidemiological impact of rotavirus vaccination 
should be monitored. High-quality surveillance should 
be conducted in selected countries and defined popula-
tions, including high child mortality settings. However, 
lack of population-based surveillance should not be an 
impediment to the introduction of rotavirus vaccine. 
4 semaines entre les doses. Pour le RV5, le calendrier prévoit 
3 doses administrées au même moment que le DTC1, le DTC2 
et le DTC3, avec un intervalle d’au moins 4 semaines entre les 
doses. Pour les 2 vaccins, les calendriers de vaccination appli-
cables aux enfants prématurés sont ceux recommandés en fonc-
tion de leur âge chronologique.
Les vaccins antirotavirus peuvent être administrés en même 
temps que les autres vaccins du programme de vaccination 
infantile.
Mis à part le faible risque d’invagination intestinale (environ 
1-2 pour 100 000 nourrissons vaccinés), on considère que les 
vaccins antirotavirus sont sûrs et bien tolérés. 
Avant d’introduire le vaccin, il convient de mettre en place une 
planification et une formation suffisantes du personnel pour 
assurer la pharmacovigilance. Les pays devraient élaborer une 
stratégie pour informer les personnels de santé concernés qu’il 
subsiste un faible risque d’invagination intestinale après la 
vaccination antirotavirus, bien que les avantages dépassent ce 
risque. Ils devraient aussi s’assurer que les personnes s’occu-
pant des enfants reçoivent les conseils nécessaires pour recon-
naître les signes de danger de déshydratation ou d’invagination 
intestinale nécessitant de consulter immédiatement un médecin.
Compte tenu de la fréquence naturelle spontanée des invagina-
tions intestinales et du grand nombre d’enfants couverts par 
les programmes de vaccination nationaux, il faut s’attendre à 
ce que des cas d’invagination surviennent fortuitement après 
la vaccination antirotavirus. Il est important d’établir l’inci-
dence de départ de cette affection dans des sites sentinelles et 
d’utiliser des études épidémiologiques, comme les séries de cas 
auto-contrôlées, pour évaluer l’innocuité des vaccins antirota-
virus.59
Des réactions allergiques sévères (anaphylaxie par exemple) 
après une dose administrée précédemment et l’immunodéfi-
cience sévère, y compris le déficit immunitaire combiné sévère, 
sont des contre-indications aux vaccins antirotavirus, tandis 
que les précautions d’emploi comportent les antécédents d’in-
vagination ou de malformations intestinales, une affection 
gastro-intestinale chronique et une maladie aiguë sévère. La 
vaccination doit être différée en cas de gastroentérite aiguë en 
cours ou de fièvre accompagnant une affection modérée à grave. 
Il faut surveiller l’impact épidémiologique de la vaccination 
antirotavirus. Une surveillance de grande qualité sera menée 
dans certains pays et populations, y compris dans des situations 
de forte mortalité infantile. Toutefois, l’absence de surveillance 
basée dans la population ne devrait pas être considérée comme 
un obstacle à l’introduction de cette vaccination. 
59 See No 8, 2011, pp. 61–72. 59 Voir No 8, 2011, pp. 61-72.
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S1 Table. Information about the data used for new analyses 
New analysis Where and how data was collected Ethics statement 
Clinical 
syndromes of 
U5 diarrhoea 
hospitalisations 
WHO/CDC review of paediatric logbooks 
(Indonesia) and electronic discharge data 
(Rwanda and Zambia) from 50 hospitals 
included in the WHO-coordinated Global 
Sentinel Site Rotavirus Surveillance 
Network – GRSN. 
All WHO GRSN surveillance data is from 
public health surveillance records. All data 
were anonymized prior to access and analysis. 
Institutional ethical approval was granted by 
CDC for the review of logbooks and analysis 
of the GRSN database. More details about 
GRSN are available at: 
https://www.cdc.gov/mmwr/ 
preview/mmwrhtml/mm6329a5.htm  
CMC/CDC review of paediatric logbooks 
from 7 hospitals included in the Indian 
National Hospital Rotavirus Surveillance 
Network – NRSN. 
All data were available under an existing 
disease burden project approved by the 
Institutional Review Board at the Christian 
Medical College (CMC) in Vellore. All data 
were anonymized prior to access and analysis. 
All data were collected as part of the 
previously published Global Enteric 
Multicenter Study – GEMS (Kotloff K. 
Lancet 2013). Data were from 27 hospitals 
from 5 country sites included in GEMS.  
GEMS was approved by the ethics committee 
at the University of Maryland, Baltimore, 
MD, USA, and at every field site. Written 
informed consent was obtained from the 
parent or primary caretaker of each participant 
before initiation of study activities. All data 
were anonymized prior to access and analysis. 
Datasets are available upon request from: 
http://www.medschool.umaryland.edu/ 
CVD/Projects/Global-Enteric-Multicenter-
Study-GEMS/ 
Clinical 
syndromes of 
U5 diarrhoea 
deaths 
Investigation of a representative sample of 
child deaths identified in a household 
survey, including deaths in the community 
or a health facility, using the birth history 
method with follow-up questions to the 
mother or caregiver of the deceased child. 
Verbal autopsy data collected as part of 
national or multi-district verbal/social 
autopsy (VASA) studies in Cameroon 
(18,000 households in 2012), Malawi 
(24,000 households in 2012), Niger (25,000 
households in 2010) and Nigeria (40,680 
households in 2014). For more details please 
see Adewemimo A. et al (PLOS One 2017) 
http://journals.plos.org/plosone/ 
article?id=10.1371/journal.pone.0178129. 
All four VASA studies underwent ethical 
review and were approved by the Johns 
Hopkins University Institutional Review 
Board and the respective national ethical 
review committee of each study country. All 
data were anonymized prior to access and 
analysis. Nigeria data available from: 
https://doi.org/10.5281/zenodo.569864 
Niger data available upon request from the 
National Institute of Statistics (INS – Niger):  
http://www.stat-niger.org/nada  
/index.php/catalog/70#page  
=accesspolicy&tab=study-desc 
Rotavirus-
positive 
proportion in 
U5 diarrhoea 
hospitalisations 
and U5 
diarrhoea deaths 
in GEMS 
All data were collected as part of the 
previously published Global Enteric 
Multicenter Study – GEMS (Kotloff K. 
Lancet 2013). Data from 6 of the 7 country 
sites included in GEMS.  
GEMS was approved by the ethics committee 
at the University of Maryland, Baltimore, 
MD, USA, and at every field site. Written 
informed consent was obtained from the 
parent or primary caretaker of each participant 
before initiation of study activities. All data 
were anonymized prior to access and analysis. 
Datasets are available upon request from: 
http://www.medschool.umaryland.edu/ 
CVD/Projects/Global-Enteric-Multicenter-
Study-GEMS/.  The verbal autopsy data from 
GEMS are not publicly available. These data 
are collected by the site’s Demographic 
Surveillance System (DSS) and were shared 
with GEMS.  Thus the sharing, but not the 
procedure, was described in the GEMS 
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protocol. All data were anonymized prior to 
access and analysis. 
Rotavirus 
attributable 
fraction among 
rotavirus-
positive U5 
diarrhoea 
hospitalisations 
in GEMS 
All data were collected as part of the 
previously published Global Enteric 
Multicenter Study – GEMS (Kotloff K. 
Lancet 2013). Data were from 6 of the 7 
country sites included in GEMS. 
GEMS was approved by the ethics committee 
at the University of Maryland, Baltimore, 
MD, USA, and at every field site. Written 
informed consent was obtained from the 
parent or primary caretaker of each participant 
before initiation of study activities. All data 
were anonymized prior to access and analysis. 
Datasets are available upon request from: 
http://www.medschool.umaryland.edu/ 
CVD/Projects/Global-Enteric-Multicenter-
Study-GEMS/ 
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Refers to:  
Chapter 4, S1 Appendix, Further details on the comparison of rotavirus mortality estimates 
from GBD, CHERG and WHO/CDC 
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S1 Appendix. Further details on the comparison of rotavirus mortality estimates from 
GBD, CHERG and WHO/CDC 
GBD, CHERG and WHO/CDC used different methods to: 
(i)       select data points (rotavirus-positive proportions); 
(ii)       extrapolate data points to individual countries; 
(iii)      account for rotavirus vaccine coverage; 
(iv)      convert rotavirus-positive proportions to rotavirus attributable fractions; and, 
(v)       calculate uncertainty ranges. 
The following provides a fuller description of these differences: 
 
Data points (rotavirus-positive proportions) 
CHERG identified 242 data points (rotavirus-positive proportions) from 76 countries; GBD 
identified 1336 data points from 71 countries; and, WHO/CDC identified 774 data points 
from 90 countries.  110 countries were included by at least one of the three sources, and only 
42 were identified by all three. There was considerable variation in the combination of other 
countries included by each source (see Table below). 
S1 Appendix Table.  Number of countries with data points (rotavirus-positive 
proportions <5 years) included by CHERG, GBD and WHO/CDC by WHO region 
WHO 
region 
CHERG GBD WHO /CDC All three 
sources 
At least one 
source 
AFRO 15 14 20 8 25 
AMRO 10 11 18 8 19 
EMRO 11 8 16 5 16 
EURO 23 23 18 9 31 
SEARO 6 5 7 4 7 
WPRO 11 10 11 8 12 
GLOBAL 76 71 90 42 110 
 
304 
 
Where possible, GBD and WHO/CDC disaggregated studies into sub-national sites and 12-
month periods, and entered each as a separate data point.   
All three groups excluded any data points that did not represent at least 12 months of data, 
thus avoiding seasonality issues. However, the groups differed on other inclusion and 
exclusion criteria.  CHERG and WHO/CDC did not include rotavirus proportions derived 
from outpatients, but GBD included data points for both outpatients and inpatients, and made 
an explicit adjustment for inpatient status in their regression model.  33 of the 71 countries 
included by GBD had rotavirus-positive proportions for both inpatients and outpatients, 6 
countries had data points for outpatients only (Austria, Denmark, Germany, Iceland, Saudi 
Arabia, Zambia) and 32 countries had data points for inpatients only.  CHERG and GBD 
included data points from studies published from January 1990 onwards.  WHO/CDC only 
included data points with a mid-year data collection point from July 1998 onwards.  GBD and 
WHO/CDC excluded data points based on fewer than 100 tested diarrhoea samples but 
CHERG did not set a lower threshold for this. WHO/CDC only included studies that reported 
data points for the entire <5 year age range whereas both CHERG and GBD included data 
points reported for narrower age bands (e.g. <2yrs) and made adjustments to account for 
missing data.  GBD did not use GRSN data, but this was the only source of evidence used in 
20 of the 32 GRSN countries included by CHERG and 16 of the 61 GRSN countries included 
by WHO/CDC. 
CHERG found 39% rotavirus positivity in 180 single-pathogen inpatient studies compared to 
20% rotavirus-positivity in 24 inpatient studies that tested for at least 5 pathogens [1].  This 
suggests a bias associated with single-pathogen rotavirus studies. Rotavirus studies may be 
more likely to be conducted in areas with higher rotavirus prevalence, and more likely to 
exclude acute bloody and persistent diarrhoea cases, leading to inflated estimates of the 
rotavirus-positive proportion.  To allow further investigation of this bias, future estimates 
should report the number of pathogens tested for each data point used.  
The methods used by WHO/CDC and CHERG are relatively straightforward and derived 
from data points that are in general, publicly available.  WHO routinely publishes summary 
reports of the GRSN data, but it is not currently possible to download this information in an 
editable spreadsheet format.  Greater access to this information would permit its use by all 
groups in future estimates.  The methods used by GBD are more complex and include a small 
proportion of data points that are not available publicly.  In an effort to increase transparency, 
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GBD will release all of its computer codes in future GBD releases.  They do however 
acknowledge that it would be very difficult for others to replicate their estimates without 
intimate understanding of their source files and code [2].   
Recent Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) 
have recommended publication of a spreadsheet table with details about the data points used 
to inform estimates [3].  We recommend a set of minimum variables that should be included 
in future estimates (see first recommendation in main manuscript). The GATHER checklist 
also requires detailed documentation of inclusion and exclusion criteria and methods of data 
analysis, and should help to increase transparency in reporting of methods in future updates. 
Extrapolating rotavirus-positive proportions to individual 
countries 
Different methods are used to extrapolate sub-national data points to individual countries.  
WHO/CDC and GBD use regression models.  CHERG calculates a median for each region 
and then extrapolates this to all countries within each region.  Covariates used by WHO/CDC 
were the calendar year, Millennium Development Goal (MDG) region, national under-five 
mortality rate and national rotavirus vaccine coverage level.  GBD use their Dismod-MR 
regression model, a Bayesian, hierarchical, mixed-effects meta-regression model with fixed 
effects for sex, inpatient sample status and broad screening method and random effects to 
account for super-region, region, country, age and calendar year.   
All three groups assumed that sub-national data points were representative of the national 
situation.  However, most GRSN sites and most other sites reported in the published literature 
are located in major urban areas where socioeconomic conditions, environmental risks and 
access to treatment may be different to the rest of the country.  Issues of representativeness 
can be overcome if regression models include characteristics that are specific to each sub-
national data point e.g. proportion of patients from rural areas, under-five mortality rate, 
private/public hospital, secondary/tertiary hospital etc.  However, both GBD and WHO/CDC 
used national variables to define sub-national data points when constructing their respective 
regression models.  This is a reasonable approach in the absence of detailed sub-national 
information about each site.  However, where possible, groups should extract and test the 
importance of other potentially influential sub-national characteristics e.g. private/public 
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hospital, secondary/tertiary hospital, under-five mortality rate, proportion of patients from 
rural areas etc.  If it is not feasible to collect this information from all sites, then a more 
detailed review of the GRSN dataset could be informative, and would allow comparison of 
several sub-national sites within the same countries.   
WHO/CDC restricted their dataset to data points collected after July 1998 because previous 
literature reviews had shown an increase in the rotavirus-positive proportion from 22% (for 
studies published 1986-1999) to 39% (for studies published 2000-2004).  This warrants 
further scrutiny.  In particular, whether the trend is still observed after correcting for the 
improved sensitivity of testing in more recent years (e.g. rectal swabs vs EIA) and the 
increased number of single-pathogen rotavirus studies conducted in more recent years.  These 
single-pathogen studies were shown by CHERG to give a significantly higher rotavirus-
positive proportion than multiple pathogen studies.  If such a trend were to exist after 
correcting for these potential biases, then regression models could explicitly account for the 
period of data collection.  Period effects may be closely linked to the stage of economic 
development in each country, and thus may already be captured by existing covariates e.g. 
GDP per capita, under-five mortality rate etc.  However, estimates for historical years 
published by GBD (1990-2013) and WHO/CDC (2000-2013) indicate very little change in 
the proportion of U5 diarrhoea deaths caused by rotavirus each year.  This suggests the effect 
is either not observed in the datasets, or does exist, and is not appropriately captured in the 
regression models.  
Accounting for rotavirus vaccine coverage 
CHERG did not account for vaccine coverage in their 2010 estimates because very few 
countries had introduced rotavirus vaccines before that year.  For the purpose of this 
comparison exercise, the pre-vaccine rotavirus-positive proportions reported by CHERG for 
2010 were applied to pre-vaccine era U5 diarrhoea deaths estimated by CHERG for 2013, 
and no adjustment was made for the small number of countries that had introduced rotavirus 
vaccination before 2013.  To estimate U5 diarrhoea deaths in the year 2013, GBD included 
rotavirus vaccine introduction status as a binary covariate in their CODEm regression model.  
However, the rotavirus-attributable fractions used by GBD for years with rotavirus 
vaccination, were based on data points (rotavirus-positive proportions) extracted from the 
pre-vaccine era.  Vaccine-adjusted estimates of U5 diarrhoea deaths were therefore combined 
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with rotavirus-attributable fractions that had not been adjusted for rotavirus vaccine use.  
WHO/CDC included a binary covariate in their regression model used to predict the 
rotavirus-positive proportion.  This covariate was used to differentiate sites that had 
introduced rotavirus vaccines to a reasonable level of coverage (>60% coverage of children 
aged <1 year, at least 12 months after vaccine introduction).  However, the 2000-2013 
CHERG estimates of U5 diarrhoea deaths available at the time of the analysis were not 
adjusted for rotavirus vaccine use [4].  WHO/CDC therefore combined U5 diarrhoea deaths 
that had not been adjusted for vaccine use, with rotavirus-positive proportions that had been.  
In summary, both GBD and WHO/CDC estimates were adjusted for rotavirus vaccine impact 
at one level of the analysis but not both, and this may have led to over-estimation of rotavirus 
deaths in a small number of countries that had introduced rotavirus vaccination in 2013.  
Including a rotavirus vaccine coverage covariate at both levels of the analysis (U5 diarrhoea 
deaths, rotavirus-positive proportion) would partly overcome this problem.  However, if 
separate regression models or separate sources of estimates are used at each level of the 
analysis, this may lead to estimates of U5 diarrhoea deaths and U5 rotavirus deaths that are 
not internally consistent in post-vaccination years.  This could be overcome by generating a 
single estimate of the number of rotavirus deaths prevented by vaccination, and adjusting 
both the number of U5 diarrhoea deaths and the number of U5 rotavirus deaths by the same 
consistent number.  Joint WHO/UNICEF estimates of coverage have been standardised 
across countries (accounting for both household surveys and administrative data) and should 
ideally be used for these adjustments. 
Converting rotavirus-positive proportions to rotavirus 
attributable fractions  
WHO/CDC used the rotavirus-positive proportion as a direct proxy for the rotavirus 
attributable fraction, and did not make further adjustments.  
CHERG added together: (a) the median rotavirus-positive proportion, based on all included 
data points; (b) the median pathogen-positive proportions reported for all other enteric 
pathogens, based on studies that sought 5-13 pathogens (n=27); and, (c) the median 
proportion of stool samples with unknown etiology, based on 12 studies that sought at least 8 
pathogens.  The total summed to greater than 100%, so all medians were rescaled to 100%.  
Pathogen-positive proportions were therefore converted into something closer to pathogen-
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attributable fractions.  The rescaling of pathogen-positive proportions is one approach to 
attributing mixed infections to a single cause, but this does not account for differences in 
pathogenicity.  Re-analysis of diarrhoeal samples from GEMS using a pan-molecular 
approach with real-time, quantitative PCR [5, 6] suggests that the pathogenicity of different 
organisms is very different.  The low prevalence of rotavirus identified in the stools of 
healthy controls compared to diarrhoea hospitalisations in GEMS (3% vs 38% - See main 
manuscript, Table 3) suggests that rotavirus is likely to be an important cause of severe 
diarrhoea whenever it is detected.  A similar pattern (6% vs 27%) was also observed in the 
Malnutrition and Enteric Disease Study (MAL-ED) where children from 8 sites in South 
America, Africa and Asia were followed from birth until age 24 months [7].  The proportion 
of samples with unknown etiology (34%) was also included in the CHERG rescaling process, 
but this did not account for variability in the performance of the conventional tests used to 
identify each pathogen.  Retesting of stool samples from the GEMS case control study using 
the Polymerase Chain Reaction (PCR) TaqMan® array card recently found significant 
variation in test performance [8].  It should be noted that the results of the new PCR analyses 
were not available at the time the 2010 CHERG estimates were developed. 
GBD derived rotavirus-attributable fractions by multiplying rotavirus-positive proportions by 
1/(1-OR), where OR is the odds ratio derived from the GEMS case control study, and reflects 
the odds of having MSD if rotavirus is detected in the stool using the conventional EIA test.  
ORs were calculated for all enteric pathogens included in GEMS.  The average ORs of 
countries with GEMS sites in African and Asian sub-regions were applied to other countries 
in that sub-region.  The average ORs across all GEMS sites was applied to all other countries.  
The original GEMS analysis [9] first calculated odds ratios, and then adjusted for the 
presence of other pathogens using the Bruzzi correction [10].  GBD derived their own ORs 
from the GEMS dataset; these ORs did not account for socio-demographic characteristics but 
did account for inter-site variability [11].  In both the primary GEMS analysis and GBD 
reanalysis the ORs were calculated using MSD cases, which include both outpatients and 
inpatients.  GBD apply attributable fractions for each pathogen to diarrhoea deaths and any 
remaining deaths not assigned to a cause are considered to be unknown.  The number of 
diarrhoea deaths with an unknown cause was around 40% in GBD 2013 [11].   
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Uncertainty 
WHO/CDC estimates include uncertainty in the proportion of U5 diarrhoea deaths due to 
rotavirus, but not higher level uncertainty in U5 deaths and U5 diarrhoea deaths.  Both 
CHERG and GBD generate probabilistic uncertainty intervals that account for uncertainty in 
U5 deaths, the proportion due to diarrhoea, and the proportion due to rotavirus.  In addition, 
GBD includes uncertainty in the GEMS odds ratios applied to rotavirus-positive proportions.  
CHERG separately presented uncertainty that was due to parameter inputs versus specific 
methodological choices e.g. they showed deaths with and without the inclusion of single-
pathogen studies.  
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 Table W1:  Survey countries, years and sample sizes 
Year of WHO pop aged
Country survey region  < 3y (000s) < 5 < 3 BCG DPT1 DPT3 MCV
Bangladesh 2004 SEAR 11,076 6,908 4,154 1,801 1,780 1,357 965
Benin 2001 AFR 837 5,349 3,260 1,795 1,676 1,285 966
Bolivia 2003 AMR 730 10,448 6,043 4,024 3,918 2,880 2,351
Brazil 1996 AMR 10,836 5,045 3,072 1,988 1,985 1,563 1,423
Burkina Faso 2003 AFR 1,474 10,645 6,261 2,499 2,400 1,799 1,426
Cambodia 2000 WPR 987 8,834 5,054 649 622 407 364
Cameroon 2004 AFR 1,629 8,125 4,943 1,032 1,002 813 575
Chad 2004 AFR 1,074 5,635 3,340 548 585 309 271
Colombia 2005 AMR 2,715 14,621 8,806 5,875 5,667 4,526 3,563
Comoros 1996 AFR 75 1,145 1,145 645 623 475 384
Congo 2005 AFR 332 4,835 3,099 1,645 1,521 1,194 784
Côte d'Ivoire 1998 AFR 1,695 1,992 1,273 730 698 546 465
Dominican Republic 2002 AMR 657 11,362 7,070 3,166 2,847 1,903 1,986
Egypt 2005 EMR 5,094 13,851 8,453 4,916 4,668 3,953 3,671
Eritrea 2002 AFR 426 6,366 3,626 2,009 2,011 1,691 1,291
Gabon 2000 AFR 95 4,405 2,776 1,335 828 488 586
Ghana 2003 AFR 1,866 3,844 2,324 1,321 1,345 1,136 915
Guatemala 1998 AMR 1,182 4,943 3,012 1,511 1,567 1,176 1,123
Guinea 2005 AFR 911 6,364 3,952 671 602 444 314
Haiti 2000 AMR 752 6,685 4,120 1,703 2,023 1,232 1,218
Honduras 2005 AMR 563 10,800 6,528 5,053 4,967 4,200 3,224
India 2005 SEAR 76,330 51,555 30,666 8,999 9,222 7,508 5,527
Kenya 2003 AFR 3,417 5,949 3,682 1,646 1,617 1,277 880
Kyrgyz Republic 1997 EUR 304 1,127 1,127 771 718 601 439
Lesotho 2004 AFR 169 3,697 2,310 742 705 597 457
Madagascar 2003 AFR 1,825 5,415 3,245 1,370 1,318 1,114 795
Malawi 2004 AFR 1,410 10,914 6,869 3,928 4,137 3,454 2,622
Mali 2001 AFR 1,277 13,097 7,958 2,433 2,153 1,374 1,331
Mauritania 2000 AFR 261 4,764 2,865 730 696 428 366
Morocco 2003 EMR 1,796 6,180 3,669 2,436 2,300 2,037 1,574
Mozambique 2003 AFR 2,106 10,326 6,253 3,738 3,639 2,893 2,401
Namibia 2000 AFR 153 3,989 2,503 1,404 1,384 1,165 867
Nicaragua 2001 AMR 406 6,986 4,227 2,999 2,918 2,517 1,888
Niger 1998 AFR 1,516 4,798 4,798 1,308 1,196 884 686
Nigeria 2003 AFR 14,277 6,029 3,690 599 461 258 230
Peru 2004 AMR 1,714 5,168 3,134 1,144 1,095 952 613
Rwanda 2005 AFR 918 8,649 5,527 1,807 1,767 1,550 1,113
Senegal 2005 AFR 1,097 10,944 6,896 1,187 1,157 899 659
Tanzania 1999 AFR 3,932 3,215 1,980 1,181 1,151 963 733
Togo 1998 AFR 599 4,168 4,168 2,019 1,836 1,227 976
Turkey 1998 EUR 4,067 3,565 2,195 431 579 470 356
Uganda 2000 AFR 3,229 7,113 4,409 1,548 1,494 985 805
Uzbekistan 1996 EUR 1,636 1,324 1,324 1,052 1,019 904 758
Yemen 1997 EMR 2,056 12,451 7,571 1,358 1,385 1,063 839
Zambia 2001 AFR 1,196 6,877 4,329 2,550 2,475 2,000 1,754
Median country 2002 1,277 6,180 3,952 1,548 1,521 1,176 880
IQR 2000 657 4,764 3,012 1,052 1,002 813 586
2004 2,056 10,326 6,043 2,436 2,300 1,799 1,426
Sample sizes
age at interview with full valid dates of birth and vaccination
 
Table W2 gives information on the countries and dates covered by the surveys included 
in the study, together with information about sample sizes and numbers of children for 
whom the information needed to calculate age at vaccination was complete and valid. 
For MCV in Chad there were only 271 children with full data, and for DTP3 in Nigeria 
only 258, but most of the cells in tables W5 and W6 are based on imputation from at 
least 1000 vaccinations with valid ages.  
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Table W2: Variation between surveys in completeness of data 
percentiles 1 25th 50th 75th
Date of birth % invalid or incomplete 9.6 20.5 30.6
% with day of birth missing 9.6 20.5 31.3
% with month imputed by DHS 0.0 0.2 1.0
% with year imputed by DHS 0.0 0.0 0.0
If BCG given2 % with vaccination card and date 64.1 72.3 78.5
% of dates invalid or incomplete 0.2 0.9 1.9
% of dates missing day 0.1 0.3 0.5
% of dates missing month 0.0 0.3 0.9
% of dates missing year 0.1 0.9 1.9
If DTP1 given2 % with vaccination card and date 55.3 63.5 74.1
% of dates invalid or incomplete 0.2 0.5 1.2
% of dates missing day 0.1 0.1 0.2
% of dates missing month 0.1 0.3 0.8
% of dates missing year 0.2 0.5 1.2
If DTP3 given2 % with vaccination card and date 65.3 79.2 85.1
% of dates invalid or incomplete 0.1 0.4 0.9
% of dates missing day 0.0 0.1 0.2
% of dates missing month 0.0 0.3 0.7
% of dates missing year 0.1 0.4 0.9
If MCV given2 % with vaccination card and date 57.1 68.4 77.2
% of dates invalid or incomplete 0.0 0.1 0.4
% of dates missing day 0.1 0.3 0.5
% of dates missing month 0.2 0.5 0.8
% of dates missing year 0.2 0.5 0.8  
1. Percentiles indicate the variation between countries; eg the 50th percentile is the median of the 
distribution of country-specific values 
2.    According to vaccination card with date, card without date or mother’s recall 
 
Information on how the completeness of data varied between country surveys is given in 
Table W3. Dates were counted as invalid if day, month or year were missing, or if the 
date was self-contradictory (e.g. 30 February) or out of order (e.g. vaccination after 
mother’s interview).  Dates of interview were complete and valid in all cases.  
The table gives percentiles.  For example it can be seen that for the most complete 
quarter of the surveys, day of the month of birth was missing in 9.5% of the children or 
fewer, and in the least complete quarter it was missing in 31.4% or more. There were, 
however, fewer missing days of birth among children who had been vaccinated (25th 
percentile 4.4%, median 13.2%, 75th percentile 25.5%). Survey data on month and year 
of birth were almost complete.  
If the day of the month of birth was missing this was imputed as follows: if the child had 
been given BCG on a known date, and the difference between the month of birth and the 
month of BCG was less than 5, the child’s age at BCG was imputed from the 
distribution of known ages for children given BCG on the same day of the month and 
with the same difference between month of birth and month of BCG. The exact date of 
birth was then calculated from the date of BCG and imputed age at BCG. Otherwise a 
random day in the child’s first month of life was used.  
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Table W3: Distributions of regression coefficients b and p-values for Ho:b = 0  (45 
surveys) 
coefficients p-values
percentiles 25th 50th 75th 95th 5th 25th 50th 75th
DPT1 mean age (days) at vaccination in baseline group 47.8 59.2 67.2 89.1 0.00 0.00 0.00 0.00
if female 0.99 1.01 1.03 1.06 0.04 0.24 0.36 0.69
if rural 1.03 1.08 1.14 1.30 0.00 0.00 0.03 0.21
per year of mother's education (up to 13) 0.98 0.99 0.99 1.00 0.00 0.00 0.03 0.16
mother's age at birth 0.97 0.98 1.00 1.02 0.00 0.09 0.28 0.67
per place in the birth oder (up to 8) 1.01 1.02 1.03 1.05 0.00 0.01 0.11 0.42
if born in hospital, not home 0.85 0.89 0.93 1.02 0.00 0.00 0.01 0.16
if child's age at interview is 1-1.9 1.08 1.14 1.24 1.48 0.00 0.00 0.00 0.02
if child's age at interview is 2-2.9 1.11 1.22 1.38 1.90 0.00 0.00 0.00 0.01
DPT3 mean age (days) at vaccination in baseline group 125.6 135.3 166.5 208.1 0.00 0.00 0.00 0.00
if female 0.99 1.00 1.01 1.04 0.04 0.21 0.43 0.69
if rural 1.02 1.09 1.12 1.26 0.00 0.00 0.00 0.05
per year of mother's education (up to 13) 0.98 0.99 0.99 1.00 0.00 0.00 0.00 0.04
mother's age at birth 0.98 0.99 1.00 1.02 0.00 0.04 0.19 0.45
per place in the birth oder (up to 8) 1.01 1.02 1.02 1.05 0.00 0.00 0.10 0.35
if born in hospital, not home 0.90 0.93 0.97 1.04 0.00 0.00 0.01 0.08
if child's age at interview is 1-1.9 1.10 1.14 1.21 1.36 0.00 0.00 0.00 0.00
if child's age at interview is 2-2.9 1.15 1.25 1.35 1.71 0.00 0.00 0.00 0.00
 
Ages at vaccination were imputed for cases in which the evidence for vaccination was 
mother’s recall, or there was no date on the card. Separate regression analyses were carried 
out for each country to identify characteristics associated with variations in age at each 
vaccination. Then if a vaccination date was missing, an age at vaccination was sampled 
from a distribution based on known values of age at vaccination (ie values calculated from 
complete and valid dates of vaccination and dates of birth) for children in that country with 
similar characteristics.  
The upper part of Table W4 shows how the relationships between log(age at DTP1) and 
the different predictors (1,2) varied between countries. The lower part of the table does 
the same for DPT3.  It shows the median and quartile values for the 45 country-specific 
coefficients and p-values. The original coefficients b have been transformed to eb, so the 
coefficients are multiplicative, the baseline being the mean age at vaccination in the 
country in question for a firstborn boy aged less than 1 at the time of the interview who 
lived in an urban area, was born at home to a mother aged 16 or less with no years of 
education. Thus for DPT3 the figure of 1.12 for the 75th percentile of coefficients for ‘if 
rural’ indicates that in the 75% of countries for which the effect of rurality was weakest, 
the independent effect of living in a rural area was to multiply the age at DTP3 by less 
than 1.12 – so for 25% of the countries the effect was at least 1.12. The figure of 0.05 
for the 75th percentile of p-values for ‘if rural’ indicates that in the 75% of countries 
with the lowest p-values for the rurality coefficient, all the p-values were less than 0.05.  
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The effects of age at interview are mainly attributable to the different lengths of follow-
up involved, but may also be partly linked to recall and trend effects. In the imputation, 
all the factors in the table except for gender were used for all the surveys, but age at 
interview was measured in quarters of a year and all the variables were treated as 
categorical.  It can be seen that in general the effects of the different predictors were 
similar for DPT1 and DPT3. However the explanatory power of the models for each 
country was quite modest, with median adjusted R-squareds of 5% for DPT1 and 12% 
for DPT3.  
Imputation cannot address ‘complete’ under-reporting in the survey, which occurs when 
loss or disposal of the card is combined with failure of mothers’ recall.  If this is 
primarily because of loss of cards, and this in turn is associated with problems with 
vaccine delivery, the result of under-reporting is likely to be underestimated delays.  On 
the other hand if for example cards are more likely to be disposed of when vaccination is 
complete, this will lead to over-estimates.
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Table W4: Delays after target in ages at vaccination: 25th, 50th and 75th percentiles, by country 
target target target target
age(w) 25th 50th 75th IQR age(w) 25th 50th 75th IQR age(w) 25th 50th 75th IQR age(w) 25th 50th 75th IQR
Bangladesh 0 6.4 8.4 11.0 4.6 6 1.1 2.9 5.6 4.4 14 3.4 7.1 12.7 9.3 38 1.9 3.9 7.6 5.7
Benin 0 0.1 0.6 2.0 1.9 6 0.4 1.3 3.6 3.1 14 1.7 4.5 11.7 10.0 39 0.4 2.7 8.3 7.9
Bolivia 0 0.1 1.7 6.0 5.9 9 0.2 1.9 6.4 6.3 26 0.5 4.6 14.6 14.1 52 0.4 4.4 19.2 18.9
Brazil 0 2.3 4.6 7.4 5.1 9 0.2 0.7 3.2 3.0 26 1.0 3.0 9.0 8.0 39 0.6 2.0 6.4 5.9
Burkina 0 1.0 2.9 7.3 6.3 9 0.0 1.9 6.7 6.7 17 1.6 6.6 18.9 17.3 39 0.1 3.1 10.4 10.3
Cambodia 0 2.9 7.0 16.3 13.4 6 1.7 4.4 13.7 12.0 14 4.8 11.2 27.9 23.1 39 0.7 5.3 14.7 14.0
Cameroon 0 0.9 2.7 6.9 6.0 6 0.3 1.6 5.6 5.3 14 2.1 4.7 10.4 8.3 39 -0.1 2.0 6.7 6.9
Chad 0 1.7 6.3 20.1 18.4 6 1.0 8.0 20.3 19.3 14 6.4 17.8 39.5 33.1 39 -3.3 5.1 20.4 23.7
Colombia 0 0.1 0.7 3.6 3.4 9 0.2 1.0 3.7 3.6 26 0.0 2.2 7.5 7.4 52 -23.8 -16.5 1.7 25.4
Comoros 0 0.4 1.9 6.6 6.1 6 0.7 3.4 8.0 7.3 14 5.5 11.8 27.4 21.9 39 0.1 4.1 15.9 15.7
Congo 0 0.3 1.4 4.3 4.0 9 0.0 1.0 3.3 3.3 17 0.5 2.5 6.0 5.6 39 0.3 1.7 5.3 5.0
Cote d'Ivoire 0 0.4 1.4 5.4 5.0 6 0.9 3.0 8.0 7.1 14 3.1 8.2 19.5 16.4 39 0.0 2.7 12.9 12.9
Dominican R 0 0.1 0.7 3.4 3.3 9 0.3 1.2 4.4 4.1 26 -5.7 0.5 5.6 11.3 52 -24.9 -19.2 -9.9 15.0
Egypt 0 1.0 2.0 4.3 3.3 9 -0.1 0.3 1.3 1.4 26 -0.1 0.6 2.0 2.1 39 -0.1 0.6 1.9 2.0
Eritrea 0 0.3 6.6 11.6 11.3 6 0.4 2.0 6.6 6.1 14 1.7 3.8 9.8 8.1 39 -0.3 1.0 5.1 5.4
Gabon 0 0.6 2.0 6.0 5.4 6 0.7 3.0 7.9 7.1 14 3.8 8.1 17.9 14.1 39 0.1 3.0 10.1 10.0
Ghana 0 0.6 3.0 7.1 6.6 6 0.7 2.6 5.6 4.9 14 2.7 6.1 13.5 10.9 39 0.0 2.4 7.3 7.3
Guatemala 0 2.9 6.9 17.3 14.4 9 0.9 4.2 10.3 9.4 17 7.0 15.3 30.5 23.4 39 1.4 5.7 15.3 13.9
Guinea 0 0.1 1.1 3.1 3.0 6 0.6 2.0 5.9 5.3 14 2.9 6.1 12.9 10.0 39 -0.4 1.1 6.0 6.4
Haiti 0 1.0 4.1 10.3 9.3 6 1.0 3.4 9.7 8.7 14 3.9 11.4 25.8 21.9 39 0.7 5.7 23.9 23.1
Honduras 0 0.1 0.4 4.4 4.3 9 0.0 0.4 1.7 1.7 26 0.6 2.2 5.9 5.3 52 0.2 1.2 3.8 3.6
India 0 1.7 5.3 9.7 8.0 6 1.0 2.9 6.3 5.3 14 3.2 6.2 12.8 9.6 39 0.3 2.7 6.9 6.6
Kenya 0 0.7 3.0 6.7 6.0 6 0.3 1.4 4.1 3.9 14 1.1 3.2 7.5 6.4 39 -0.3 1.7 5.6 5.9
Kyrgyz 0 0.4 0.6 0.7 0.3 9 0.2 1.0 3.7 3.6 22 2.0 4.4 9.3 7.3 52 0.4 1.4 4.1 3.7
Lesotho 0 0.1 1.4 4.4 4.3 6 0.6 1.1 2.9 2.3 14 2.1 4.1 9.1 7.0 39 1.0 2.9 7.3 6.3
Madagascar 0 1.3 4.6 8.9 7.6 6 0.6 1.9 5.6 5.0 14 2.2 4.8 11.2 9.0 39 0.1 1.6 5.1 5.0
Malawi 0 2.6 6.9 12.3 9.7 6 1.1 3.1 7.1 6.0 14 3.9 8.5 16.1 12.1 39 1.0 4.4 9.0 8.0
Mali 0 1.3 3.4 13.4 12.1 6 0.6 2.9 13.1 12.6 14 3.1 8.8 26.1 23.0 39 -1.3 3.1 16.1 17.4
Mauritania 0 0.6 3.7 13.1 12.6 6 0.6 3.6 13.7 13.1 14 3.5 9.4 21.9 18.4 39 -1.2 2.4 15.1 16.3
Morocco 0 1.6 2.1 2.7 1.1 6 0.6 1.3 2.4 1.9 14 2.2 3.5 5.8 3.6 39 0.1 1.0 3.1 3.0
Mozambique 0 0.3 1.3 5.3 5.0 6 2.9 4.3 8.3 5.4 14 4.4 8.9 18.4 14.0 39 0.0 2.1 8.4 8.4
Namibia 0 0.1 0.1 1.3 1.1 6 0.1 0.7 1.9 1.7 14 1.1 2.4 6.8 5.7 39 0.1 0.9 3.4 3.3
Nicaragua 0 0.1 0.4 4.3 4.1 9 0.2 0.9 4.3 4.1 26 -6.8 -2.0 7.0 13.9 52 0.4 2.8 10.1 9.7
Niger 0 0.7 4.6 10.6 9.9 6 1.3 3.4 9.1 7.9 14 4.2 8.2 19.1 14.9 39 -4.2 3.3 11.0 15.1
Nigeria 0 0.9 2.7 7.3 6.4 6 0.3 2.4 8.9 8.6 14 1.7 5.1 13.5 11.9 39 -0.3 2.3 8.1 8.4
Peru 0 0.3 1.6 3.1 2.9 9 0.0 0.4 2.0 2.0 17 0.3 1.6 4.6 4.3 52 0.4 1.8 4.7 4.3
Rwanda 0 1.1 2.3 3.9 2.7 6 0.4 1.1 2.6 2.1 14 1.4 2.9 5.4 4.0 39 0.6 2.4 5.0 4.4
Senegal 0 1.1 3.1 6.6 5.4 6 0.6 2.6 5.3 4.7 14 2.5 6.2 11.4 8.9 39 0.1 2.7 8.0 7.9
Tanzania 0 0.3 1.9 5.3 5.0 4 1.0 3.0 6.0 5.0 12 3.4 7.3 14.3 10.9 39 0.3 2.4 6.3 6.0
Togo 0 0.7 2.1 5.9 5.1 6 0.9 2.3 6.9 6.0 14 3.1 7.5 18.7 15.6 39 -0.3 3.3 11.1 11.4
Turkey 8 0.4 1.6 3.6 3.1 8 1.6 3.6 6.9 5.3 16 4.2 7.8 13.7 9.4 39 1.0 2.9 6.9 5.9
Uganda 0 1.4 6.1 13.7 12.3 6 1.1 4.0 12.3 11.1 14 3.5 9.2 21.5 18.0 39 0.0 2.7 9.6 9.6
Uzbekistan 0.4 0.0 0.3 0.5 0.4 9 0.7 3.3 10.0 9.3 17 3.5 11.0 27.5 24.0 39 1.0 5.7 17.6 16.6
Yemen 0 4.7 7.9 14.3 9.6 6 0.7 3.0 7.1 6.4 14 3.2 7.2 13.7 10.4 39 -0.9 1.1 6.6 7.4
Zambia 0 1.6 4.9 10.1 8.6 6 2.9 5.0 9.3 6.4 14 5.4 10.7 20.4 15.0 39 0.1 2.7 8.7 8.6
Median 0.7 2.3 6.6 5.4 0.6 2.4 6.3 5.3 2.7 6.2 13.5 10.9 0.1 2.7 7.6 7.9
Lower quartile 0.3 1.4 4.3 3.4 0.3 1.2 3.7 3.6 1.4 3.5 9.0 8.0 -0.3 1.7 5.3 5.9
Upper quartile 1.3 4.6 10.3 8.6 1.0 3.3 8.3 7.1 3.5 8.5 19.1 15.6 0.4 3.1 11.0 13.9
BCG DPT1 DPT3 MCV
percentile delay (weeks) percentile delay (weeks) percentile delay (weeks) percentile delay (weeks)
 
Negative values indicate vaccination before target date.  Both Colombia and the Dominican Republic responded to local outbreaks of measles by bringing forward their vaccination programmes. 
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Appendix A – Further details about the alternative waning functions considered 
 
Equations of the alternative waning functions evaluated and Deviance Information Criteria 
We used two analyses in our study, a meta-regression to generate pooled estimates of vaccine 
efficacy, and a Poisson regression in which we investigated waning of an individual trial where we 
had weekly-follow up data. Different waning functions were compared visually, statistically 
(comparing the Deviance Information Criteria), and were assessed for biological plausibility. 
Estimated cumulative vaccine efficacies were converted to instantaneous vaccine efficacies using the 
method outlined in Appendix B.   
 
1. Pooled analysis – meta-regression 
We fitted curves estimating overall cumulative vaccine efficacy to the observed cumulative vaccine 
efficacies. We performed a Poisson regression using a hierarchical Bayesian model, where study-
specific relative risks were centred around an overall latent relative risk (RR) in each respective 
mortality stratum. 
We investigated multiple waning functions. In waning functions that are listed as bounded, the RR is 
bounded between 0 and 1. As a result, cumulative vaccine efficacy in these functions is bounded 
between 100% and 0%. Note that this does not necessarily bound the instantaneous vaccine efficacy, 
as a cumulative vaccine efficacy above 0% can still result from negative instantaneous vaccine 
efficacies in a certain period. 
The table below illustrates the functional form of the natural logarithm of the latent time-specific RR 
as fitted in each respective waning function in the meta-regression. Time specific cumulative vaccine 
efficacy was then estimated as 1 – elog(RR).  Note that the entire waning function is used in computing 
the RR, and that individual parameters in each waning function are not easily interpretable. Each 
function has up to 4 different parameters, depending on the complexity of the waning function: σ, t, α, 
and β. σ was estimated for each study separately as σi (centred around an overall latent σ, which prior 
was assigned mean 0 and standard deviation equal to the square root of the estimated between study 
variance), whereas α and β were the same across studies. t is the time-component of the function and 
refers to the months since final dose of vaccination was administered. 
The high mortality stratum was modelled three times. Once including all countries, once excluding 
India, and once for India only. Because the analysis for India only included two studies, the 
hierarchical construct of the analysis over-inflated uncertainty around our estimates. As a result, we 
removed the hierarchical component of our model from the analysis with India only, assuming exactly 
the same distribution for σ in the two studies. 
Model Log relative risk 
No waning 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 
Linear 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 + 𝛼𝛼 + log (𝑡𝑡) 
Power 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 + 𝑒𝑒𝛼𝛼log (𝑡𝑡) 
Power 2 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 + 𝛼𝛼 log (𝑡𝑡) 
Power 3 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 + 𝛼𝛼 𝑡𝑡 
Power (bounded) 𝜃𝜃(𝑡𝑡) =  𝛼𝛼 + 𝑒𝑒𝛽𝛽 log(𝑡𝑡) − log (𝑒𝑒𝜎𝜎 + 𝑒𝑒𝛼𝛼𝑡𝑡𝑒𝑒𝛽𝛽) 
Sigmoid (bounded) 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 − log(e𝜎𝜎 + e𝛼𝛼e−e𝛽𝛽𝑡𝑡) 
Gamma (bounded)* 𝜃𝜃(𝑡𝑡) = log(Г(t, 𝑒𝑒𝜎𝜎 , 𝑒𝑒𝛽𝛽))  
* Г refers to the cumulative gamma function 
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2. Head-to-head trial: Analysis of Indonesia trial/Bines 
We used the same functions (with the exception of ‘No waning’, which was purely used for 
illustrative purposes in the meta-regression) to look at data from a single trial in Indonesia (belonging 
to the high under 5 mortality stratum). The methodology and results from this trial are published 
elsewhere1. For this study, we obtained weekly follow-up data from three arms: a placebo group, a 
group vaccinated using a neonatal schedule (0-5 days, 8-10 weeks, 14-16 weeks) and a group 
vaccinated using an infant schedule (8-10 weeks, 14-16 weeks, 18-20 weeks). We used this data to 
construct cumulative hazard estimates and used the same fitting approach as in our meta-regression, 
fitting to these cumulative estimates. The functional form of the natural logarithms of each fitted RR 
is illustrated in the table below. They differ from those used in the meta-regression only in that we 
added a parameter ρ which adjusts for potential confounding between the two vaccinated schedules. 
Coefficient ρ was multiplied by an indicator variable which was set to 1 for the infant schedule and 
set to 0 for the neonatal schedule. In other words, ρ was included in the equation in estimated vaccine 
efficacy in the infant schedule but omitted in estimating vaccine efficacy in the neonatal schedule. 
The parameters in the waning function, σ, α, and β, were estimated separately and independent from 
one another in each respective schedule. 
 
Model Log relative rate 
Linear 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 + 𝛼𝛼 + log (𝑡𝑡) + ρ 
Power 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 + 𝑒𝑒𝛼𝛼log (𝑡𝑡)  + ρ 
Power 2 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 + 𝛼𝛼 log (𝑡𝑡)  + ρ 
Power 3 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 + 𝛼𝛼 𝑡𝑡 + ρ 
Power (bounded) 𝜃𝜃(𝑡𝑡) =  𝛼𝛼 + 𝑒𝑒𝛽𝛽 log(𝑡𝑡) − log (𝑒𝑒𝜎𝜎 + 𝑒𝑒𝛼𝛼𝑡𝑡𝑒𝑒𝛽𝛽) + ρ 
Sigmoid (bounded) 𝜃𝜃(𝑡𝑡) = 𝜎𝜎 − log(e𝜎𝜎 + e𝛼𝛼e−e𝛽𝛽𝑡𝑡)  + ρ 
Gamma (bounded)i 𝜃𝜃(𝑡𝑡) = log(Г(t, 𝑒𝑒𝜎𝜎 , 𝑒𝑒𝛽𝛽)) +ρ 
i. Г refers to the cumulative gamma function 
 
Comparison of alternative waning functions 
The table below gives the DIC value for each respective function in each respective stratum. DIC 
values should be compared relative to all values in each column. Although the ‘no waning’ function 
had generally good DIC values in the pooled analysis, it performed the worst in the Indonesia 
analysis. Similarly, waning Rotavirus vaccine efficacy is broadly accepted. Although we included this 
function for comparability, we determined it to be biologically unlikely. 
Deviance Information Criteria (DIC) 
Function 
Low 
mortality 
Medium 
mortality 
 
High 
mortality 
High 
mortality 
(no India) India Indonesia 
No waning 154.2 133.5 314.0 250.6 65.6 958.9 
Linear 154.9 134.6 315.4 252.9 65.7 911.6 
Power 152.6 133.8 315.6 250.5 65.5 914.2 
Power 2 152.6 134.8 315.9 250.8 66.1 913.6 
Power 3 153.0 135.0 314.9 250.5 66.4 921.5 
Power (bounded) 153.2 134.0 315.0 251.2 66 912.6 
Sigmoid (bounded) 153.1 134.3 314.9 250.8 65.7 920.7 
Gamma (bounded) 152.0 137.3 315.0 249.8 65.8 913.7 
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Visual comparison 
The plots below show, for each function, the median estimated waning of instantaneous vaccine 
efficacy by mortality strata following 2/3 doses of oral rotavirus vaccination (infant schedules only). 
The full set of plots for all other functions can be found in Appendix C (pooled analysis) and 
Appendix D (Indonesia analysis).  
 
The simple power function (Power) was used in the main paper because it had few parameters and 
goodness of fit (DIC scores) that were consistently favourable across all strata, compared to the other 
functions considered. The gamma (bounded) would be a reasonable alternative to use in high 
mortality countries, but had the worst fit in the medium mortality stratum.  
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Appendix B - Approximating instantaneous vaccine efficacy from cumulative vaccine efficacy 
Vaccine efficacy is usually defined as the reduction in the incidence rate in vaccinated compared to 
unvaccinated people, and estimated as 1 - RR, where RR is the risk or rate ratio. This works fine 
when the RR is constant over time, i.e. vaccine efficacy does not wane. However, vaccine efficacy 
that wanes over time may be overestimated if not properly accounted for. 
In our study, we have extracted the total number of severe rotavirus-positive gastroenteritis cases 
occurring at different time-points, in multiple randomized clinical trials (RCT) aiming to assess 
efficacy of rotavirus vaccines. We then used a hierarchical Bayesian meta-regression model to fit a 
number of curves through the observed number of cases over time, allowing for waning vaccine 
efficacy, in order to retrieve a curve that best explains the observed data. This curve gives an 
estimate of waning (cumulative) vaccine efficacy. 
As we will show in the equations below, the value of the cumulative vaccine efficacy at time t is 
influenced by the values of the true instantaneous vaccine efficacy prior to time t. Because 
instantaneous vaccine efficacies before time t may be higher than the instantaneous vaccine efficacy 
at time t, the cumulative vaccine efficacy at time t may overestimate the actual instantaneous 
vaccine efficacy at time t. 
This is illustrated by figure B1 below, which shows both cumulative and instantaneous vaccine 
efficacies. The left panel shows the result of simulated data in a hypothetical RCT. The cumulative 
vaccine efficacy clearly overestimates the (known) simulated instantaneous vaccine efficacy. The 
right panel shows the vaccine efficacy as modelled with a Power function in the high mortality 
stratum in our study. The cumulative vaccine efficacy is fitted to the empiric data, whilst the 
instantaneous vaccine efficacy is derived from the fitted cumulative vaccine efficacy, using the 
method we will present below. 
This document will explain the method that was used in converting cumulative vaccine efficacy to 
instantaneous vaccine efficacy. We will use a general example. The theoretical underpinning and 
steps used to do this conversion are described below, along with its assumptions and limitations. 
Figure B1. Cumulative and instantaneous vaccine efficacy 
 
The left panel shows the cumulative vaccine efficacy and true instantaneous vaccine efficacy in a simulated 
hypothetical vaccine efficacy trial. The right panel shows the cumulative vaccine efficacy of Rotavirus vaccines 
against severe rotavirus-positive gastroenteritis as modelled with a power function in the high mortality stratum 
in our study along with its corresponding approximated instantaneous vaccine efficacy. It is equivalent to Figure 
1 in our main paper. 
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Background 
 
Smith et al (1) proposed two models of vaccine efficacy considering different models of action of the 
vaccine, which Halloran, Haber, and Longini (2) later described as the leaky and all-or-nothing 
models and extended further to incorporate heterogeneity. 
Kanaan and Farrington (3) devised a framework which can be used to assess waning vaccine efficacy 
over time, and can incorporate all models described by Halloran et al (2): leaky, all-or-nothing, leaky-
or-nothing, all-or-leaky, and potentially increased heterogeneity using multiple strata of vaccine-
action in the vaccinated group. They proposed two models in which vaccine-efficacy might wane: the 
selection-model, being the with-waning extension of the all-or-nothing model, and the 
deterioration-model, being the with-waning extension of the leaky model. 
Vaccines can provide protection against actual infection after exposure to a pathogen, against the 
amount of infectiousness after infection of a pathogen, and against the development or severity of 
disease after infection with a pathogen. Here, we will assume that vaccine efficacy relates to the 
protection against development of disease. 
Figure B2 illustrates the dynamics that would occur in a hypothetical randomised controlled trial 
(RCT) under the two methods of vaccine action: all-or-nothing and leaky. Individuals are randomised 
(R), after which a proportion π will receive the vaccine, and a proportion 1 – π a placebo. 
Participants are susceptible at the start of the trial, indicated by the Su and Sv* compartments for the 
unvaccinated and vaccinated stratum respectively. Unvaccinated individuals will become infected at 
a rate λ(t), and flow to compartment Iu.  
In the all-or-nothing model of vaccine action, a proportion α of those vaccinated will be fully 
protected against the infection (compartment Sv1). As long as the vaccine is protective, they will 
never experience disease. In contrast, the vaccine provides no protection at all for a proportion 1 - α 
of those vaccinated. As a result, these individuals will become infected at the same rate as 
unvaccinated individuals. Following Kanaan and Farrington (3), in the all-or-nothing model, waning 
of vaccine efficacy may occur as a selection effect. Subsequently, vaccinated individuals will lose 
protection and flow from the protected compartment Sv1 to the unprotected compartment Sv0. The 
amount of individuals who lose protection is explained by the waning function, γ(t).  
In the leaky model of vaccine action, the vaccine is assumed to provide some level of protection for 
all vaccinated individuals. The baseline force of infection is reduced by a proportion σ. Here, waning 
may occur as a result of a deterioration effect, where the level of protection reduces over time, 
again denoted by the function γ(t) in figure B2. 
These models may be extended to incorporate more heterogeneity in vaccine response. For 
instance, the leaky model may be extended to have multiple substrata (Sv1, Sv2, Sv3, …), in the 
vaccinated individuals, where participants in different strata have different levels of protection. 
The α parameter in the all-or-nothing model is the equivalent of the relative risk of disease, whereas 
the σ parameter in the leaky model represents the relative rate. In the absence of waning vaccine 
efficacy, when γ(t) = 0, vaccine efficacy is estimated as 1 – α, or 1 – σ. In contrast, in the presence of 
waning, vaccine-efficacy at time t is estimated as 1 – αγ(t) or 1 – σγ(t). 
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Figure B2. Compartmental models for a hypothetical randomized controlled trial under 
different assumptions of the mode of vaccine action 
 
Compartmental models for the all-or-nothing mode of vaccine action and the leaky mode of vaccine action. 
 
Methods 
Estimating vaccine efficacy 
Estimation of the relative risk is straightforward: 
𝑅𝑅𝑅𝑅 = 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑟𝑟𝑖𝑖 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑟𝑟𝑖𝑖𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣
𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑟𝑟𝑖𝑖 𝑝𝑝𝑝𝑝𝑣𝑣𝑣𝑣𝑣𝑣𝑝𝑝𝑝𝑝 = 𝑣𝑣𝑣𝑣𝑟𝑟𝑣𝑣𝑟𝑟 𝑟𝑟𝑖𝑖 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑟𝑟𝑖𝑖𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 𝑣𝑣𝑝𝑝𝑣𝑣𝑣𝑣𝑝𝑝 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑟𝑟𝑖𝑖𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣�𝑣𝑣𝑣𝑣𝑟𝑟𝑣𝑣𝑟𝑟 𝑟𝑟𝑖𝑖 𝑢𝑢𝑖𝑖𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑟𝑟𝑖𝑖𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣
𝑣𝑣𝑝𝑝𝑣𝑣𝑣𝑣𝑝𝑝 𝑢𝑢𝑖𝑖𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑟𝑟𝑖𝑖𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣�  (1) 
 
Note that, when calculating risks, the numerator holds the sum of all cases accrued over the study 
period, whilst the denominator holds all individuals who were at risk of becoming a case at the start 
of the study period. When the relative risk is constant over time, equation 1 will give a good 
measure for the relative risk throughout the entire study period. However, if vaccine efficacy wanes, 
and the relative risk increases over time, the calculation in equation 1 will only give an estimation of 
the average relative risk throughout the entire time-period, i.e. the cumulative relative risk. 
To estimate the relative rate, researchers can use parametric survival analyses such as Poisson or 
Cox regression. These often make the assumption that hazards are proportional over time, meaning 
that the relative rate remains constant. This assumption is clearly violated when vaccine efficacy 
wanes. Nonparametric methods (4), such as Kaplan Meier survival estimates (5), do not make the 
assumption of proportional hazards, and may be used as an alternative. 
The Kaplan Meier Survival estimate can be estimated as 
𝑆𝑆𝐾𝐾𝐾𝐾(𝑣𝑣) = ��1 − 𝑌𝑌𝑥𝑥𝑁𝑁𝑥𝑥�𝑑𝑑𝑥𝑥𝑡𝑡𝑥𝑥=0  (2) 
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Where Yx is the number of events observed at time x and Nx is the risk set size at time x (or total 
number of people at risk at time x, accounting for censoring). These survival estimates can be used 
to estimate the cumulative hazard at any time t as follows: 
𝐻𝐻𝐾𝐾𝐾𝐾(𝑣𝑣) =  − log𝑆𝑆𝐾𝐾𝐾𝐾(𝑣𝑣) (3) 
The cumulative hazard in the vaccinated, HKM,v, and unvaccinated, HKM,u, at time t, can then be used 
to estimate θt,the cumulative hazard ratio at time t: 
𝜃𝜃(𝑣𝑣) = 𝐻𝐻𝐾𝐾𝐾𝐾,𝑣𝑣(𝑣𝑣)
𝐻𝐻𝐾𝐾𝐾𝐾,𝑢𝑢(𝑣𝑣) (4) 
 
Which can be used to estimate cumulative vaccine efficacy at time t: 
𝑉𝑉𝑉𝑉𝑣𝑣(𝑣𝑣) = 1 − 𝜃𝜃(𝑣𝑣) (5) 
 
Following equation 1, the survival estimate at time t is a result of the product of all risks in the risk 
sets up until time t. Subsequently, the cumulative vaccine efficacies as calculated in equation 5 will 
give the vaccine efficacy over the entire period up until time t, rather than the vaccine efficacy at 
time t. This is illustrated in figure B3. Again, this is a measure of the cumulative vaccine efficacy. 
Figure B3. Cumulative vaccine efficacy derived from the Kaplan-Meier method. 
  
Cumulative vaccine efficacies are derived from the infant schedule in the RV3-BB trial estimating vaccine 
efficacy against severe rotavirus gastroenteritis (6). Vaccine efficacies reported in a certain week (points on the 
right) are the average vaccine efficacies over the periods as illustrated by the solid lines. 
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In practice, researchers will usually be interested in the exact level of protection at time t, i.e. the 
instantaneous vaccine efficacy. We will now present a method to approximate instantaneous 
vaccine efficacy from cumulative vaccine efficacy, based on the Kaplan-Meier method described 
above.  
Approximating instantaneous vaccine efficacy 
For the unvaccinated arm, equation (2) can be rewritten as: 
𝑆𝑆𝐾𝐾𝐾𝐾,𝑢𝑢(𝑣𝑣) = ��1 − 𝜆𝜆𝑥𝑥𝑁𝑁𝑥𝑥𝑁𝑁𝑥𝑥 �𝑑𝑑𝑥𝑥𝑡𝑡𝑥𝑥=0  (6) 
 
Where λx is the force-of-infection at time x. Nx cancels out, so: 
𝑆𝑆𝐾𝐾𝐾𝐾,𝑢𝑢(𝑣𝑣) = �(1 − 𝜆𝜆𝑥𝑥)𝑑𝑑𝑥𝑥𝑡𝑡
𝑥𝑥=0
 
(7) 
 
As the rate ratio is the reduction (or increase) of the force of infection, in this case as a result of 
immunisation, we can rewrite equation 5 for vaccinated individuals as follows: 
𝑆𝑆𝐾𝐾𝐾𝐾,𝑣𝑣(𝑣𝑣) = �(1 − 𝜆𝜆𝑥𝑥𝜎𝜎𝑥𝑥)𝑑𝑑𝑥𝑥𝑡𝑡
𝑥𝑥=0
 
(8) 
 
Where σx is the instantaneous rate ratio at time x. Putting all these equations together, cumulative 
vaccine efficacy can be estimated as: 
𝑉𝑉𝑉𝑉𝑣𝑣(𝑣𝑣) = 1 − 𝜃𝜃(𝑣𝑣) = 1 −− log∏ (1 − 𝜆𝜆𝑥𝑥𝜎𝜎𝑥𝑥)𝑑𝑑𝑥𝑥𝑡𝑡𝑥𝑥=0
− log∏ (1 − 𝜆𝜆𝑥𝑥)𝑑𝑑𝑥𝑥𝑡𝑡𝑥𝑥=0  (9) 
 
Unfortunately, this cannot  easily be rewritten to estimate the instantaneous vaccine efficacy, σx. 
However, as λx is the force of infection, this rate is usually very small. And as a result, equation 9 can 
be approximated by: 
lim
𝜆𝜆𝑥𝑥→0
− log�(1 − 𝜆𝜆𝑥𝑥)𝑑𝑑𝑥𝑥𝑡𝑡
𝑥𝑥=0
= � 𝜆𝜆𝑥𝑥𝑣𝑣𝑑𝑑𝑡𝑡
𝑥𝑥=0
 
(10) 
  
Which is similar to the Nelson-Aalen estimator of the cumulative hazard rate (7,8). This can be used 
to rewrite equation 3, to estimate the cumulative rate ratio at time t: 
𝜃𝜃(𝑣𝑣) = ∫ 𝜆𝜆𝑥𝑥𝜎𝜎𝑥𝑥𝑣𝑣𝑑𝑑𝑡𝑡𝑥𝑥=0
∫ 𝜆𝜆𝑥𝑥
𝑡𝑡
𝑥𝑥=0
𝑣𝑣𝑑𝑑
 
(11) 
 
Ordinary survival analyses often assume proportional hazards, i.e. rate-ratios remain constant over 
time, in which case equation 11 would be: 
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𝜃𝜃(𝑣𝑣) = ∫ 𝜆𝜆𝑥𝑥𝜎𝜎𝑣𝑣𝑑𝑑𝑡𝑡𝑥𝑥=0
∫ 𝜆𝜆𝑥𝑥
𝑡𝑡
𝑥𝑥=0
𝑣𝑣𝑑𝑑
=  𝜎𝜎 (12) 
 
I.e. the cumulative rate-ratio and instantaneous rate-ratio would be the same. Following equation 
12, this is irrespective of any change in the baseline-rate λx, assuming that this rate is the same in the 
vaccinated and unvaccinated groups. Ideally, infections in the vaccinated and unvaccinated arms are 
always observed and censored after becoming a case. However, individuals may get asymptomatic 
infections which are not observed in the study, but boost immunity, especially in the unvaccinated. 
This may alter the baseline rate in the unvaccinated arm of the trial, such that rates in the vaccinated 
and unvaccinated arm are no longer similar. Eventually, this can lead to an overestimation of the 
relative rate when natural immunity in the unvaccinated arm increases, as has been shown for 
rotavirus vaccines (9). 
Because we are modelling waning vaccine-efficacy, we obviously assume that the rate-ratio does not 
remain constant over time. Assuming a time-dependent rate-ratio, equation 11 can be rewritten as: 
𝜎𝜎(𝑣𝑣) = 𝜃𝜃(𝑣𝑣) + � (𝜃𝜃(𝑣𝑣) − 𝜎𝜎(𝑑𝑑))𝑡𝑡
𝑥𝑥=0
𝜆𝜆𝑥𝑥
𝜆𝜆𝑡𝑡
𝑣𝑣𝑑𝑑 
(13) 
 
There are two issues with this equation. First, in order to retrieve instantaneous vaccine efficacy at 
time t, we need all instantaneous vaccine efficacies up until time t. Second, the change in the 
baseline-rate between time x and time t needs to be accounted for, as the cumulative rate ratio 
observed at time t is affected by the interaction between changes in the baseline-rate, and changes 
in the instantaneous relative rate. 
The first issue can be easily accounted for, as the instantaneous relative rate at the first time-point is 
the same as the cumulative relative rate at that time-point: 
𝜎𝜎1 = 𝜃𝜃1 (14) 
 
This rate can subsequently be used to estimate the instantaneous relative rate at the second time-
point, and so on.  
It is harder to account for changes in the baseline rate over time, as this is often unknown. In 
infectious disease epidemiology, we know that rates change over time. For instance, seasonal 
patterns can result from changes in the temperature or from changes in contact rates in a 
population. However, we can make the bold assumption that this rate remains stable over time. This 
assumption is often made when parametric survival analyses are used. One could aim to retrieve 
changes in the baseline rate over time, for instance by building a natural history model, but this is 
outside the scope of the methodology presented here. Making the assumption of time-independent 
rates, equation 13 can be rewritten as: 
𝜎𝜎(𝑣𝑣) = 𝜃𝜃(𝑣𝑣) + � (𝜃𝜃(𝑣𝑣) − 𝜎𝜎(𝑑𝑑))𝑡𝑡
𝑥𝑥=0
𝑣𝑣𝑑𝑑 
(15) 
 
Which can be used to retrieve the instantaneous rate ratio at time t. Eventually, this instantaneous 
rate ratio can be used to estimate instantaneous vaccine efficacy at time t: 
𝑉𝑉𝑉𝑉𝑟𝑟(𝑣𝑣) = 1 − 𝜎𝜎(𝑣𝑣) (16) 
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We will now present results of simulated data to show the success of this method. 
 
Simulations 
We simulated data following the compartmental models as illustrated in figure B2. Although our 
method would generally only work for a leaky vaccine, we will simulate data for both all-or-nothing 
and leaky vaccines. 
The following differential equations (17-25) can be used to describe transmission in the trial for the 
all-or-nothing vaccine. Note that, in contrast to mathematical transmission models, the force-of-
infection λ(t) does not depend on the number of infectious individuals in the trial. We assume that 
the individuals in the trial are part of a larger population, and that transmission mainly occurs due to 
the infections outside of this population. 
𝑣𝑣𝑆𝑆𝑢𝑢
𝑣𝑣𝑣𝑣
= −𝜆𝜆(𝑣𝑣) (17) 
 
𝑣𝑣𝐼𝐼𝑢𝑢
𝑣𝑣𝑣𝑣
= 𝜆𝜆(𝑣𝑣)𝑆𝑆𝑢𝑢 (18) 
 
𝑣𝑣𝑆𝑆𝑣𝑣0
𝑣𝑣𝑣𝑣
= −𝜆𝜆(𝑣𝑣) + 𝛾𝛾(𝑣𝑣)𝑆𝑆𝑣𝑣1 (19) 
 
𝑣𝑣𝑆𝑆𝑣𝑣1
𝑣𝑣𝑣𝑣
= −𝛾𝛾(𝑣𝑣) (20) 
 
𝑣𝑣𝐼𝐼𝑣𝑣0
𝑣𝑣𝑣𝑣
= 𝜆𝜆(𝑣𝑣)𝑆𝑆𝑣𝑣0 (21) 
 
In simulations where the vaccine wanes, we assume that waning follows a sigmoidal shape, which 
can be described as: 
𝛾𝛾(𝑣𝑣) = 11 + 5000𝑣𝑣−0.01𝑡𝑡 (22) 
 
In simulations where the vaccine does not wane, this parameter is always set to 1: 
𝛾𝛾(𝑣𝑣) = 1 (23) 
 
Similarly, in simulations where the force of infection changes over time, it is assumed to follow a 
sine-curve: 
𝜆𝜆(𝑣𝑣) = 0.004 �1 + 0.1 sin 𝑣𝑣80� (24) 
 
In simulations where this force of infection is fixed, we assume 
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𝜆𝜆(𝑣𝑣) = 0.004 (25) 
 
 
Dynamics in the leaky mode of vaccine action can be described through the following differential 
equations (26-30): 
𝑣𝑣𝑆𝑆𝑢𝑢
𝑣𝑣𝑣𝑣
= −𝜆𝜆(𝑣𝑣) (26) 
 
𝑣𝑣𝐼𝐼𝑢𝑢
𝑣𝑣𝑣𝑣
= 𝜆𝜆(𝑣𝑣)𝑆𝑆𝑢𝑢 (27) 
 
𝑣𝑣𝑆𝑆𝑣𝑣2
𝑣𝑣𝑣𝑣
= −𝜆𝜆(𝑣𝑣)𝜎𝜎(𝑣𝑣) (28) 
 
𝑣𝑣𝐼𝐼𝑣𝑣2
𝑣𝑣𝑣𝑣
= 𝜆𝜆(𝑣𝑣)𝜎𝜎(𝑣𝑣)𝑆𝑆𝑣𝑣2 (29) 
 
Where λ(t) takes on the same values as in equations 24 and 25 for simulations with or without a 
changing baseline force of infection. 
Waning vaccine efficacy is again modelled as a sine-curve, similar to that in equation 22. The 
instantaneous rate ratio, σ(t), is defined as 
σ(𝑣𝑣) = 1 − 𝜙𝜙1 + 5000𝑣𝑣−0.01𝑡𝑡 (30) 
 
Where Φ is the vaccine efficacy after administration at the start of the trial. 
In all simulations, for both methods of vaccine action, the ratio of vaccinated versus placebo is 1:1, 
i.e. π = 0.5. The total study population size, N, is set to 1000. Initial vaccine efficacy is set to 75%, so 
α = 0.75 in the all-or-nothing vaccine, and Φ is set to 0.75 in the leaky vaccine. 
We ran the model for 2000 timesteps. We estimated cumulative vaccine efficacy twice, using risk 
ratios, as in equation 1, and using cumulative hazard ratios, as in equation 5. In the all-or-nothing 
vaccine, compartments V0 and V1 were combined to calculate cumulative measures, as the individual 
level of protection would normally be unknown in a clinical trial. 
Actual instantaneous rate ratios were estimated as: 
𝑅𝑅𝑅𝑅(𝑣𝑣) = 1 𝑆𝑆𝑣𝑣0
𝑆𝑆𝑣𝑣0 + 𝑆𝑆𝑣𝑣1 + 𝑆𝑆𝑣𝑣2 + 0 𝑆𝑆𝑣𝑣1𝑆𝑆𝑣𝑣0 + 𝑆𝑆𝑣𝑣1 + 𝑆𝑆𝑣𝑣2 + σ(𝑣𝑣) 𝑆𝑆𝑣𝑣2𝑆𝑆𝑣𝑣0 + 𝑆𝑆𝑣𝑣1 + 𝑆𝑆𝑣𝑣2 (31) 
 
Which reduces to: 
𝑅𝑅𝑅𝑅(𝑣𝑣) = 𝑆𝑆𝑣𝑣0
𝑆𝑆𝑣𝑣0 + 𝑆𝑆𝑣𝑣1 (32) 
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In the all-or nothing vaccine (i.e, instantaneous rate ratios are equivalent to the proportion of 
vaccinated susceptibles that is unprotected). In the leaky vaccine, the instantaneous rate ratio is 
simply: 
𝑅𝑅𝑅𝑅(𝑣𝑣) = σ(𝑣𝑣) (33) 
 
Instantaneous risk ratios were estimated as: 
𝑅𝑅𝑅𝑅𝑝𝑝(𝑣𝑣) = 1 𝑆𝑆𝑣𝑣0 + 𝐼𝐼𝑣𝑣0
𝑆𝑆𝑣𝑣0 + 𝑆𝑆𝑣𝑣1 + 𝑆𝑆𝑣𝑣2 + 𝐼𝐼𝑣𝑣0 + 𝐼𝐼𝑣𝑣1 + 𝐼𝐼𝑣𝑣2 + 0 𝑆𝑆𝑣𝑣1 + 𝐼𝐼𝑣𝑣1𝑆𝑆𝑣𝑣0 + 𝑆𝑆𝑣𝑣1 + 𝑆𝑆𝑣𝑣2 + 𝐼𝐼𝑣𝑣0 + 𝐼𝐼𝑣𝑣1 + 𝐼𝐼𝑣𝑣2+ σ(𝑣𝑣) 𝑆𝑆𝑣𝑣2+𝐼𝐼𝑣𝑣2
𝑆𝑆𝑣𝑣0 + 𝑆𝑆𝑣𝑣1 + 𝑆𝑆𝑣𝑣2 + 𝐼𝐼𝑣𝑣0 + 𝐼𝐼𝑣𝑣1 + 𝐼𝐼𝑣𝑣2 
(34) 
 
The main difference with the formula for the instantaneous rate ratio is that infected individuals (Iv0, 
Iv1, and Iv2) are not censored when the risk ratio is estimated, whilst they are censored when the rate 
ratio is estimated. 
For the all-or-nothing vaccine, equation 34 reduces to: 
𝑅𝑅𝑅𝑅𝑝𝑝(𝑣𝑣) = 𝑆𝑆𝑣𝑣0 + 𝐼𝐼𝑣𝑣0
𝑆𝑆𝑣𝑣0 + 𝑆𝑆𝑣𝑣1 + 𝑆𝑆𝑣𝑣2 + 𝐼𝐼𝑣𝑣0 + 𝐼𝐼𝑣𝑣1 + 𝐼𝐼𝑣𝑣2 (35) 
 
Which is again equivalent to the proportion of individuals in the vaccinated group that has lost 
protection, including individuals who have been infected. 
For the leaky vaccine, this again reduces to: 
𝑅𝑅𝑅𝑅𝑝𝑝(𝑣𝑣) = σ(𝑣𝑣) (36) 
 
Indicating that the instantaneous risk ratio and instantaneous rate ratio are the same for the leaky 
vaccine. 
Instantaneous rate ratios are approximated in two ways. First, it is assumed that the baseline rates 
remain constant over time (equation 15), as will most often be the case in practice. However, as this 
is simulated data, we know exactly how baseline rates change over time. Therefore, we will also 
estimate instantaneous rate ratios adjusting for changes in the baseline rate (equation 16). We 
always use cumulative rate ratios in converting to instantaneous measures, regardless of the mode 
of vaccine action. 
We simulate four scenarios: scenario A with a fixed baseline rate and no waning vaccine efficacy; 
scenario B with a fixed baseline rate and waning vaccine efficacy; scenario C with a changing 
baseline rate but no waning vaccine efficacy; and scenario D with a changing baseline rate and 
waning vaccine efficacy. 
Results 
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Figure B4. Simulated results for scenario A. Columns show vaccine efficacies derived from, from left to right, the cumulative risk ratio, the cumulative rate ratio, the real 
instantaneous risk ratio, the real instantaneous rate ratio, and the unadjusted and adjusted approximated instantaneous rate ratio, where the cumulative rate ratio shown 
in the second column is converted.  
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Figure B5. Simulated results for scenario B. Columns show vaccine efficacies derived from, from left to right, the cumulative risk ratio, the cumulative rate ratio, the real 
instantaneous risk ratio, the real instantaneous rate ratio, and the unadjusted and adjusted approximated instantaneous rate ratio, where the cumulative rate ratio shown 
in the second column is converted. 
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Figure B6. Simulated results for scenario C. Columns show vaccine efficacies derived from, from left to right, the cumulative risk ratio, the cumulative rate ratio, the real 
instantaneous risk ratio, the real instantaneous rate ratio, and the unadjusted and adjusted approximated instantaneous rate ratio, where the cumulative rate ratio shown 
in the second column is converted. 
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Figure B7. Simulated results for scenario D. Columns show vaccine efficacies derived from, from left to right, the cumulative risk ratio, the cumulative rate ratio, the real 
instantaneous risk ratio, the real instantaneous rate ratio, and the unadjusted and adjusted approximated instantaneous rate ratio, where the cumulative rate ratio shown 
in the second column is converted.
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The results of the simulations show a number of things. First, the cumulative vaccine efficacies in 
scenario A clearly illustrate that vaccine efficacy should be estimated using a risk ratio for all-or-
nothing vaccines and using a rate-ratio for leaky vaccines. 
When a rate ratio is used to estimate vaccine efficacy of an all-or-nothing vaccine, it will appear to 
wax over time, as shown in the second column of figure B4. This effect occurs because infected 
individuals are censored when rate ratios are estimated (assuming full ascertainment of infections). 
As a result, the only susceptible individuals who remain in the cohort after follow-up are those who 
are fully protected, or whose vaccine efficacy is 100%. 
Similarly, if vaccine efficacy is estimated using a risk ratio for a leaky vaccine, vaccine efficacy will 
appear to wane, until it is 0%. Because vaccinated individuals are only partially protected against the 
infection, they will eventually all become infected, given that the trial goes on for long enough and 
the force of infection remains the same. As vaccinated individuals become infected, the entire 
vaccinated stratum (both susceptible and ever infected) will become similar to the unvaccinated 
stratum, and vaccine efficacy decreases to 0%. 
The results from scenario A also make it apparent that, in the leaky vaccine, instantaneous vaccine 
efficacy is the same as cumulative vaccine efficacy. 
Scenario B shows that the existence of waning vaccine efficacy already becomes apparent in 
estimates derived from the cumulative relative risk and the cumulative relative rate. However, as 
these vaccine efficacies reflect the average vaccine efficacies in the period between the first 
timepoint and the reported timepoint, vaccine efficacy is overestimated as time progresses. In the 
all-or-nothing vaccine, cumulative vaccine efficacy (derived from the cumulative risk ratio, first 
column) is clearly an overestimation of the real instantaneous vaccine efficacy (derived from the real 
instantaneous risk ratio, third column). The same can be observed for the leaky vaccine (second 
column compared to the fourth column). 
Scenario B also shows the success of the approximated instantaneous vaccine efficacy. As the 
baseline rate is fixed, the two approximated instantaneous vaccine efficacies (unadjusted: fifth 
column, and adjusted: sixth column) will be the same. They both retrieve the real instantaneous 
vaccine efficacy (fourth column). 
Scenario C shows that a change in the baseline rate has no effect on the correct cumulative 
measures of vaccine efficacy for the respective models, if vaccine efficacy does not wane. However, 
it becomes evident from scenario D that a change in the baseline rate does have an effect when 
vaccine efficacy wanes over time. It has a small effect on the cumulative efficacies, although it is 
nearly unobservable (because cumulative vaccine efficacies represent average vaccine efficacies). 
However, this effect becomes apparent when cumulative measures are converted to instantaneous 
measures, without adjustment for this change in baseline rates (fifth column). Although the 
unadjusted approximated instantaneous values are similar to the real instantaneous values, they 
differ from the true values. Unadjusted instantaneous efficacies will fluctuate around the true 
instantaneous efficacies, depending on the magnitude of the change in force of infection. Adjusting 
for those fluctuations (last column), true instantaneous vaccine efficacy is again successfully 
retrieved. 
This method is designed to convert cumulative rate ratios to instantaneous rate ratios, and rate 
ratios should only be used for leaky vaccines. However, note that the approximated instantaneous 
vaccine efficacies in this particular simulation were surprisingly similar to the real instantaneous 
vaccine efficacy derived from the real instantaneous risk ratio. In the simulation presented here, 
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waning of vaccine efficacy was very strong, as eventually all vaccinated individuals lost their 
protection. If waning would be less extreme, this method would become less reliable for all-or-
nothing vaccines. 
Sparse data 
Because this basically method converts a vector of all cumulative vaccine efficacies in a given time-
period, it works best when cumulative vaccine efficacy is reported as detailed as possible. Figure B8 
shows what may happen to the converted instantaneous vaccine efficacy, when cumulative vaccine 
efficacy is only available for sparser time-periods. As data on cumulative vaccine efficacy become 
less detailed (red dots), approximated instantaneous vaccine efficacy becomes less reliable. 
Researchers may overcome this issue by fitting a curve through cumulative vaccine efficacies in 
order to get detailed estimates, which can subsequently be converted to instantaneous vaccine 
efficacy. 
Figure B8. Instantaneous vaccine efficacy with sparser time-points. 
 
Cumulative vaccine efficacy is estimated based on the cumulative rate ratio for the leaky model presented in 
scenario B (no change in baseline rate, but with waning vaccine efficacy). Cumulative vaccine efficacies are 
plotted in red, whilst instantaneous vaccine efficacies are plotted in blue. Titles of the panels indicate sparsity 
of the available time-points (10 times smaller, 100 times smaller, 200 times smaller, and 400 times smaller). 
Solid lines represent vaccine efficacies when data is available for all time-points. Points represent actual data 
which is used in the approximation.  
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Limitations 
There are several limitations to the method presented here. First, it is only applicable for leaky 
vaccines, and will fail for all-or-nothing vaccines. However, one might argue how realistic an all-or-
nothing vaccine really is. In practice, all vaccines may be leaky, where there is heterogeneity in the 
level of protection the vaccine offers (i.e. the vaccine may offer full protection for a small proportion 
of vaccinated individuals, whereas a second proportion is 80% protected, and yet another only 40%). 
This protection may then gradually wane, as in the leaky vaccine presented here, rather than either 
offer full protection or no protection at all, as in the all-or-nothing vaccine presented here. 
Second, when the force of infection changes over time, which is common for infectious agents, this 
change in force of infection will interact with the waning of the vaccine efficacy, and the 
instantaneous vaccine efficacy should be appropriately adjusted. One may be able to use a dynamic 
transmission model to retrieve changes in baseline rates over time. 
Third, the calculation of instantaneous vaccine efficacy at time t is dependent on all instantaneous 
vaccine efficacies up until time t. Therefore, all cumulative vaccine efficacies up until time t must be 
known, ideally at small time-steps. Moreover, estimating all instantaneous vaccine efficacies up until 
time t may be computationally intensive. 
Researchers should also bear in mind that this method assumes that all infections are accrued and 
censored, which will not be the case in many trials for vaccines against infections where 
asymptomatic infections are common. 
However, the method presented here does seem to be effective in converting cumulative vaccine 
efficacies to instantaneous vaccine efficacies, and may assist researchers with a new way to 
investigate waning of vaccine efficacy. Ideally, approximated instantaneous vaccine efficacies would 
be compared to true instantaneous vaccine efficacies, i.e. immunological markers that provide a 
good correlate or surrogate of protection. 
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Appendix 8 
 
Refers to:  
Chapter 7, Appendix C, Waning functions for pooled analysis 
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Choose country
Choose a file location for storage of leaflets:
E:\Ana Maria Schedules Model\ROTAVIRUS MODEL\LEAFLETS\
Chad
Chile
China
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Cote d'Ivoire
Democratic People's Republic of Korea
Democratic Republic of the Congo
Djibouti
Dominica
Dominican Rep
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Egypt
3rd June 2013
Afghanistan
YES NO 
Immunization Vaccines & Biologicals  
World Health Organization  
Avenue Appia 20,  
CH 1211-Genève 27  
Immunizing children against 
rotavirus:  
Making the most of every contact 
ROTAVIRUS VACCINE SCHEDULES 
 
The WHO Strategic Advisory Group of Experts on Immunization (SAGE)  
reviewed new evidence that afforded an opportunity to avert additional 
deaths from rotavirus disease, including systematic reviews of rotavirus 
disease burden and effectiveness of different immunization schedules, 
improved estimates of the benefits in different epidemiological settings, and 
additional data on the risk of intussusception after rotavirus vaccination. 
SAGE was informed by separate reviews by both the Global Advisory 
Committee on Vaccine Safety and the Immunization Practice Advisory 
Committee.  
 
The risk benefit analysis continues to favour early immunization but the 
current age restrictions for the first dose (<15 weeks) and last dose (<32 
weeks) are preventing vaccination of many vulnerable children.  
 
By removing the age restrictions, programmes will be able to immunize 
children who are currently excluded from the benefits of rotavirus vaccines 
and this is likely to include some of the children most vulnerable to severe 
rotavirus disease. Many thousands more deaths would be averted, but with 
the possibility of a small additional increase in intussusception cases.  
 
SAGE also noted that in view of the age distribution of rotavirus disease, 
providing rotavirus vaccine to children older than 24 months of age will be of 
little benefit.  
 
Considering the above, SAGE continues to recommend that the first dose of 
rotavirus vaccine be administered along with DTP, as soon as possible after 6 
weeks of age as this maximizes protection.  
 
SAGE recognized that countries have different burdens of disease and may 
or may not have introduced rotavirus vaccines. For this reason, countries 
should develop their own plans for how the removal of age restrictions on 
vaccine administration can be introduced in a manner that supports existing 
programmes.  
 
SAGE encouraged all countries to establish or strengthen post-marketing 
surveillance which should focus on documenting any intussusception cases.  
 
SAGE also stressed that vaccination is a dynamic field that will always be 
challenged by new data.  
What are the implications  
of the new SAGE                            
recommendations  
for rotavirus vaccines? 
Countries which are  
PLANNING TO INTRODUCE 
rotavirus vaccine 
Countries which have  
ALREADY INTRODUCED 
rotavirus vaccine 
As part of your vaccine introduction 
plan and together with your NITAG, 
SELECT the immunization schedule 
with the greatest potential for 
preventing rotavirus-related disease 
and deaths.  
This includes review of: 
- the actual ages at which each dose of 
DTP/penta vaccine is given;  
- the peak age of rotavirus 
gastroenteritis cases and deaths; 
- the possible risks and  benefits of 
choosing a schedule without age 
limitation, in terms of  potential 
additional intussusception deaths  and 
additional rotavirus deaths prevented. 
 
Review progress of your introduction 
plan with your NITAG and ASSESS 
whether or not the removal of age 
restrictions would prevent additional 
rotavirus -related disease and deaths.  
This includes review of: 
- the actual ages at which  each dose of 
rotavirus vaccine is given;  
- the peak age of rotavirus 
gastroenteritis cases and deaths; 
- the possible risks and benefits of 
removing  age limitations in the 
schedule in terms of potential  
additional intussusception deaths and 
additional rotavirus deaths  prevented . 
 
Do most children receive their pentavalent or rotavirus 
vaccines doses by the recommended ages?  
Inform relevant health care staff that although the benefits outweigh the risks,  
a small potential risk of intussusception after rotavirus vaccination remains and 
ensure that caregivers are adequately counselled  on how to recognize the 
danger signs that mean a sick baby should be brought to medical attention  
immediately. 
Establish or strengthen post-marketing surveillance . 
This should focus on documenting any cases of intussusception.  
 
Deliver rotavirus vaccination at 6 weeks 
of age or soon after 
with pentavalent vaccine,  
even if delayed                       
AND 
monitor regularly to ensure  
vaccine doses  are given on time and 
high vaccination coverage is achieved 
 
Deliver rotavirus vaccine  
with pentavalent vaccine,    
even if  delayed     
                   
AND 
develop a plan to ensure  
vaccine doses are given on time and high 
vaccination coverage is achieved 
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To maximize its impact, rotavirus vaccine has to be given before Rotavirus Gastro-
Enteritis (RVGE) occurs.  
 
Protection of children through vaccination before RVGE cases occur depends on both 
the actual age at which each dose is given and on rotavirus vaccine coverage.  
 
It is critical to administer each dose of vaccine at the recommended age.  
 
Rotavirus vaccine coverage needs to be high, especially among children at higher risk 
of rotavirus death. 
 
The expected benefits of rotavirus vaccine (in terms of rotavirus deaths averted) 
outweigh the potential risks (intussusception deaths associated with rotavirus 
vaccine).  
ABOUT THIS LEAFLET 
 
Countries  should develop their own plans on how rotavirus vaccine can be introduced 
in a manner that strengthens existing immunization programmes.                                                            
To stimulate and assist this process at national level,  this leaflet contains information 
available at the global level together with estimates generated by various models. 
However, it is important that the information in this leaflet is enriched by and checked 
against other locally relevant data, and that NITAG members, decision makers at the 
national immunization programme and other key stakeholders review and discuss 
these data together with any  other available evidence.  
Additional information is available at:   
 
www.vaccine-schedules.com 
www.who.int/nuvi/rotavirus/en/index.html   
 
These data do not constitute official WHO estimates.  
Estimates are correct as of: 
 
Estimated deaths caused and prevented by rotavirus vaccination
A
A
DRVIS: vaccine-related intussusception RVGE: rotavirus gastro-enteritis
Relative risk of RVIS vs background risk = 5.5 after 1st dose and 1.7 after 2nd dose
6.  The benefits of rotavirus vaccination continue to outweigh the risks after 
accounting for uncertainty in the calculations
Each dot on the chart above represents a different combination of possible model 
parameter values.  The chart shows the result of 1000 possible combinations.  The 
orange dots are for 'unrestricted' vaccination and the blue are for 'restricted' 
vaccination.  SAGE, the principal advisory group to WHO on vaccination, has 
recommended that age restrictions be removed in settings with high rotavirus 
mortality to increase the potential number of lives that could be saved by the 
vaccine.  Note very the different scales on the two axes.
1.  To maximize its impact rotavirus vaccine has to be given before RVGE occurs.  
2.  It is critical to administer each dose of vaccine at the recommended age and to 
achieve high coverage
Rotavirus vaccine helps to prevent a leading cause of severe diarrhoea in children 
(c. 40% of hospitalizations in children aged <5 years globally).  It is estimated that 
nearly all children will be exposed to rotavirus before age 5, regardless of where 
they are born.  Children in low-income countries may acquire the infection early 
during the first year of life.  For Afghanistan, this age distribution was based on a 
global literature review and regression analysis using data from Afghanistan, Egypt, 
Iran, Iraq, Jordan, Libya, Morocco, Oman, Pakistan, Sudan, Syria, Tunisia, Yemen.  
Source: Sanderson 2012
Vaccination should be scheduled as early as possible.  This is especially important 
for rotavirus vaccine as many children will be exposed during  the first months of 
life.  Thus it is very important to ensure that each dose is given at the 
recommended age and not delayed. In Afghanistan, age-specific vaccination 
coverage was based on household surveys (DHS/MICS) or a regression analysis in 
countries without a survey.  Timeliness of vaccination was scaled to the 2011 
estimates of DTP coverage as reported by WHO. Countries with surveys in the 
relevant WHO sub-region were: Djibouti, Egypt, Iraq.  Source: Sanderson 2012
3.  It is important to use regionally appropriate estimates of vaccine efficacy
The efficacy of the rotavirus vaccine against severe disease and hospitalisation has 
been found to be lower in Africa and Asia than in other parts of the world, so it is 
important to consider whether efficacy assumptions are regionally appropriate. 
Clinical trials have reported vaccine efficacy during the first and second year of life.  
This allows the duration of clinical protection to be estimated over time.  A sigmoid 
shape is assumed.  In Afghanistan, modelling studies have used 67% efficacy 
against severe rotavirus disease (as a proxy for rotavirus mortality) based on 
studies conducted in other countries with a similar mortality profile. Source: 
Brieman Vaccine (Bang, Viet, Ghn, Ken, Mal, RV5) 
4.  Maximizing the benefits of rotavirus vaccine requires that each dose is given 
on at the recommended age and high coverage is achieved
The number of RVGE (rotavirus gastroenteritis) deaths prevented by vaccination is 
determined by: the age at which cases occur, coverage, timeliness of each dose, 
and vaccine efficacy (taking time since vaccination into account).  If rotavirus 
vaccine is given at the same visits as doses of DTP/pentavalent vaccine, a model 
estimates that the numbers of cases represented by the blue shaded area shown 
above could be prevented by the vaccine. Rotavirus vaccine will prevent many but 
not all cases and deaths of RVGE,  partly because the vaccine is not 100% effective, 
but partly because some children will get RVGE before they are vaccinated. 
Provision of the vaccine is also an opportunity to remind caregivers about other 
things they can do to prevent diarrhoea deaths, such as breast feeding, ORS, zinc 
etc.
5. The benefits of rotavirus vaccine (rotavirus deaths averted) outweigh the risks 
(rotavirus vaccine-related intussusception deaths)
In some countries (Australia, Mexico, Brazil) post-licensure data on intussusception 
(blockage of the bowel) associated with rotavirus vaccine (RVIS) suggest a low-level 
risk of RVIS of approximately 1-2 cases per 100,000 vaccinees. In other countries 
such as the US no increased risk has been documented to date, but there are 
insufficient data to exclude the possibility. All data available on RVIS are from 
vaccinees who received the 1st dose by 15 weeks of age and the last dose by 32 
weeks of age. Thus there is a very limited basis for estimating RVIS risk when the 
1st dose is given after 15 weeks of age. Natural intussusception rarely occurs 
before 3 months of age but the incidence increases ten-fold between 3 and 6 
months of age.  Health care staff should be aware of the possibility of an increased 
although very small risk of RVIS, and must be encouraged to strengthen the 
detection, reporting and  investigation of intussusception cases.
Potential RVIS deaths 
caused
Potential RVGE 
deaths averted
Risk 
benefit 
ratio
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Age un-restricted
Difference
Age restricted 2.9 4,348 1519
14.4
11.5
8,510
4,162
591
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